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ABSTRACT
Nearly 90% of cancer mortality from solid tumors is due to metastasis of malignant cells to
the distant vital organs. It is now well established that a plethora of stromal cells are present
within the tumor, and contribute in various ways to tumor initiation and progression, and
plasma membrane proteins are the mediators for tumor-stromal communications. In this
thesis, I focused on plasma membrane proteins that may contribute to tumor metastasis. I
applied quantitative mass spectrometry technology to first identify plasma proteins that are
expressed at different levels in melanoma cells with high versus low metastatic abilities.
Using SILAC (stable isotope labeling with amino acids in culture) coupled with nano-spray
tandem mass spectrometry, this work led to the discovery of Cub Domain Containing
Protein 1 (CDCP1) as one of those differentially expressed transmembrane proteins. We
found that CDCP1 is not only a surface marker for cells with higher metastatic potential, it is
also functionally engaged in enhancing tumor metastasis. When searching for the
underlying mechanisms, we found that CDCP1 is important for soft agar colony-forming
abilities, suggesting that CDCP1 might regulate the balance between cell proliferation and
anoikis. Making use of 3D Matrigel culture system, we found that CDCP1 also regulates
scattered growth of melanoma cells. We speculate these two factors may contribute to
enhanced-metastatic ability observed in mice. When investigating signaling pathways that
may mediate the functions of CDCP1, we found that overexpression of CDCP1 correlates
with hyper-activation of Src family kinases. While wild-type CDCP1 enhances SFK
activation, point mutation that abolished CDCP1 functions (in scattered growth and in
metastasis) also abolished SFK hyper-activation, suggesting that CDCP1 might function
through the activation of SFKs. Such notion was further supported since pharmacological
reagents PP2 and Dasatinib, which are two SFK inhibitors, blocked in vitro functions of
CDCP1 in scattered growth. Thus the work in this thesis has identified a novel metastasis
enhancer, CDCP1, and has gained insight into the mechanisms by which CDCP1 functions.
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Richard Hynes: Professor of Biology
Forest White: Associate Professor of Biological Engineering

Acknowledgements
ACKNOWLEDGEMENTS
This thesis would not have been possible without the help and support from many people.
First and foremost, I want to thank my thesis advisers - Richard Hynes and Forest White. I
want to thank Richard for his support and guidance, and also the independence he gave me
to pursue my scientific interests. I also want to thank him for always being patient and
calm... I sincerely appreciated his effort in ensuring the lab being a pleasant place for every
member, and I simply admire his critical yet fair judgments of science in general.
When experiments were particularly challenging at the beginning of the thesis, Forest came
and rescue me. With his experience, his eager of sharing that experience, and his laughter
and openness, he guided me through the rough spots.
I would like to thank my thesis committee members, Tyler Jacks and Michael Yaffe for their
time and advice, and for their critical evaluation of my work. I am also grateful to Michael
Hemann and Karen Cichowski for giving the time and effort to be on my defense committee.
I want to thank Richard Cook and Alla Leshinsky in the biopolymer facility. Dick generously
allowed me to learn and use their instrument for my mass spectrometry work; and Alla has
being there for me - we worked side-by-side and learned mass spectrometry step-by-step
together. I am grateful to Shao-En Ong at the Broad Institute for providing invaluable
suggestions, and for being a great person to talk to when having mass spectrometry
problems. Many thanks go to the proteomics facility as well.
It has been great pleasure working in the Hynes lab for the past years and I want to thank all
the Hynes lab members for making it such a friendly, supportive and stimulating working
environment. Many thanks to Jane, for her loving and caring for all the lab members, and
for fulfilling my requests of having bourbon sauce on all my birthday cakes. I want to thank
the past and present fellow graduate students, Sarah, Chris, Sunny, Olga, and Jeff, for
sharing the wonderful graduate school experiences. I also want to thank previous and
current Hynes lab members, Lei, Patrick, Sophie, Yueyi, Aaron, Shahin, Mariette, Myriam,
Joe, Josh, Adam and John in our side of the lab, and Kaan, Chris, Arjan, Hamid, Jessica,
and Kwabena in "the other side" of the lab, they are all fantastic people to work with.
Our Koch Institute support facilities have made many of the experiments possible. I am
particularly grateful for Denise Crowley, Charlie Whittaker, Elisa Vasile, and MIT Division of
Comparative Medicine for their help. Also, I would like to thank Dr. Donna Stoltz, Dr. James
Quigley, and Dr. Ryuichi Sakai for generously providing various reagents for my work.
Lastly, I want to thank my family - my parents for their endless support and encouragement
and giving me the freedom of pursuing my interests since I was little; my husband for his
love, patience (when are you going to get a real job?) and tolerance @; and my little David
for making me understand the simplicity of happiness, and giving me a different perspective
on almost everything, even other drivers honking me on the street!
Acknowledgements
Table of Contents
Title Page -------------------------------------------------------------------------------------- 1
Abstract ---------------------------------------------------------------------------------------- 3
Acknowledgement ---------------------------------------------------------------------------- 5
Table of Contents ---------------------------------------------- ------------------ 7
Chapter 1: Introduction ------------------------------------------------ --------------------- 9
Chapter 2: Application of Quantitative Mass Spectrometry to Identify
Membrane Proteins That are Differentially Expressed
Between Poorly and Highly Metastatic Tumor Cells ----------------- 55
Chapter 3: A Direct Test for the Role of CDCP1 in Melanoma Metastasis ------- 93
Chapter 4: Cellular Mechanisms by which CDCP1 May Function to Enhance
Metastasis -------------------------------------------------------------------- 135
Chapter 5: Molecular Mechanisms by which CDCP1 May Function to
Enhance Metastasis ----------------------------------------------------------- 171
Chapter 6: Discussions and Future Directions ---------------------------------------- 233
Appendix A: Role of Yes Associate Protein (YAP) in Melanoma Metastasis ------ 253
Appendix B: Protocols for SILAC and Mass Spectrometry ------------------------ 267
Appendix C: Proteins that were Identified by Mass Spectrometry ---------------- 273
Appendix D: Materials and Methods ---------------------------------------- --------- 293

Chapter 1
CHAPTER 1.
INTRODUCTION
The contents of this chapter were written by Hui Liu, with editing by Richard Hynes.
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Chapter 1
The Basics of Cancer Metastasis
Despite significant improvement in local treatments for cancer, many patients still succumb
to this disease. In 2008 alone, it was estimated by the American Cancer Society that
565,000 cancer-related deaths occurred. Nearly 90% of cancer mortality from solid tumors
is due to tumor metastasis to the distant organs that are resistant to conventional therapies,
begging for a more thorough understanding of this deadly disease. Indeed, the studies of
cancer metastasis began over 100 years ago, but only in the past thirty years have we seen
an explosion of research advances and started to gain insights into the mechanisms of the
fatal disease. This lag is not due to lack of effort, but rather, it reflects the complicated
nature of cancer metastasis.
It has long been observed that tumor cells metastasize to specific organs; breast cancer
cells primarily metastasize to bone, lungs, liver and brain; lung adenocarcinomas frequently
form tumors in brain, bone, adrenal gland and liver. While both colorectal and pancreatic
cancer cells tend to grow secondary tumors in the liver and lungs, prostate caner cells
almost exclusively migrate to bones and form tumors there (Hess et al., 2006; Nguyen et al.,
2009). This tissue tropism has sparked various hypotheses, and numerous experiments
have been carried out, particularly with the development of microarray technology, to
address this issue (Gupta et al., 2005; Kang et al., 2003; Muller et al., 2001), and I will focus
on this topic first. Another important feature of metastasis concerns the kinetic differences
among various types of tumors. Breast cancer recurrences are often observed after years
or decades of tumor remission, while lung cancer patients and patients with melanoma often
suffer swift and multi-organ metastasis months after initial diagnosis (Hoffman et al., 2000;
Karrison et al., 1999). This topic has just started to receive more attention and factors that
account for the temporal differences among different tumors remain obscure.
Dividing Cancer Metastasis to Three Major Steps
Tumor metastasis is a complicated process, presumably involving tumor cell detachment
and migration/invasion from the primary site (local invasion); intravasation, survival in the
circulation, arrest and sometimes extravasation from the circulation (systemic traveling); and
growth, survival and angiogenesis at the distant organ(s) (colonization) (Gupta and
Massague, 2006; Hynes, 2003; Nguyen et al., 2009; Weiss, 2000).
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It has become increasingly clear that tumor cells coordinate with environmental factors, such
as other cells (in particular, fibroblasts, macrophages, platelets and endothelial cells) and
extracellular matrix proteins to metastasize (Bissell et al., 2005; Bissell and Radisky, 2001;
Condeelis and Pollard, 2006; Fata et al., 2004; Fidler et al., 2007; Haviv et al., 2009; Kenny
and Bissell, 2003; Nelson and Bissell, 2006; Zumsteg and Christofori, 2009). In the past
decade, with the development of microarray and other large-scale profiling technologies
such as array-CGH and SNP arrays, a large number of genes/proteins have been found
contributing to various steps of metastasis; both tumor cell-intrinsic factors and components
derived from the stroma. Here I will describe three major steps through which tumor cells
progress in order to make successful metastases, and give examples of factors that are
involved in each step (see Figure 1 for an overview of these steps).
Step I - Local Migration and Invasion
The journey of cancer cell metastasis starts when cells detach from the primary tumor and
begin to invade into neighboring connective tissues and blood vessels or lymphatics.
Almost all cells have an intrinsic ability to perform some level of migration, and different cells
may utilize different forms of migration; however, such activities are greatly augmented in
invasive tumors.
Numerous in vitro studies using fibroblasts and keratinocytes migrating on 2D substrates
have established the principal events leading to effective cell migration, which have recently
been extended to migration in a 3D matrix (Friedl and Wolf, 2003; Lauffenburger and
Horwitz, 1996). Migration in general can be divided into five steps that form a continuous
cycle - 1) localized actin polymerization drives the formation of lamellipodia or filopodia,
followed by 2) integrin-mediated focal-contact formation, engaging the intracellular actin-
based cytoskeleton with extracellular matrix proteins. 3) Surface proteases such as
membrane-type I matrix metalloproteinase are recruited near focal adhesions to perform
localized matrix degradation. 4) Actin filaments engage cross-linking proteins to stabilize
actin strands, and interact with contractile proteins such as myosin II, for contracting and
shortening of actin strands. 5) Such contraction of membrane-anchored actin strands co-
ordinates with turnover of focal adhesions at the rear ends, thus generating cell
translocation along the substrate (Friedl, 2004). This type of movement is typical
mesenchymal cell movement, where integrins and matrix matalloproteases have been
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shown to play critical roles in migration (Hynes, 2002; Sabeh et al., 2004). Adhesion by
integrins to ECM proteins presents a bimodal relationship - while weak interaction between
integrins and ECM is not supportive for effective cell migration, high affinity also damps cell
migration.
This 5-step model and in vitro migration systems have helped to decipher molecular players
involved in each step of migration and have generated a large body of knowledge regarding
effective cell migration. Initially, the actin-nucleating ARP2/3 complex together with a
multifunctional adaptor protein N-WASP, are critical for the generation of actin protrusions
(Bompard and Caron, 2004; Le Clainche and Carlier, 2008; Stradal and Scita, 2006), and
phosphoinositides (PIPs) are important for both anchoring Arp2/3/WASP complexes to the
membrane, and for activation of small GTPases RAC, CDC42 and Rho through binding and
activating their activator GEFs (guanine-nucleotide exchange factors)(Kaibuchi et al., 1999).
The accumulation of membrane metalloproteases has been shown to regulate fibroblast and
tumor cell migration in 3D matrices in vitro (Friedl et al., 1997; Hotary et al., 2000; Sabeh et
al., 2004), and regulates normal mammary gland development in vivo (Bissell et al., 2005;
Fata et al., 2004).
The hypothesis that epithelial-mesenchymal transition (EMT) may play major roles during
cancer metastasis further highlighted the importance of mesenchymal migration (Thiery,
2002; Yang et al., 2004). During EMT, epithelial cells reduce expression of the cell-cell
adhesion molecule E-cadherin, acquire elongated morphology and migrate as single
spindle-shaped cells. In humans, there seems to be an inverse relationship between E-
cadherin levels and tumor grade or patient survival (Birchmeier and Behrens, 1994;
Hirohashi, 1998). In the RipTag pancreatic mouse model, a loss of E-cadherin during
adenoma-to-carcinoma transition was observed. When crossed with mice expressing E-
cadherin under the Rip-promoter, tumors that developed in double-transgenic mice were
arrested at adenoma stage; when RipTag mice were crossed with mice expressing
dominant-negative E-cadherin, more tumors progress to carcinoma, with some of them
invading to lymph nodes (Perl et al., 1998). These data are consistent with the model that
EMT has a functional role during tumor progression and metastasis. In addition,
transcription factors Twist, Snail and Slug, which induce EMT during normal development,
have been shown to induce EMT in tumor cells and render these cells highly metastatic
(Alves et al., 2009; Peinado et al., 2007; Yang et al., 2004). The importance of EMT has
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been emphasized over the past years to understand how normally non-mobile epithelial
cells become invasive.
Recently, a slightly different view of how tumor cells migrate in vivo has emerged, owing to
the development of novel imaging technologies and use of fluorophore-labeled cells in live
organisms (Sahai, 2007). Using multiphoton confocal microscopy, it has been observed
that, in vivo, the speed and character of mammary carcinoma cell motility is quite different
from what has been observed in vitro (Condeelis and Segall, 2003; Farina et al., 1998;
Wyckoff et al., 2007). In vivo, cancer cells migrate in amoeboid fashion, with velocity up to
10 times that observed in vitro. The highest velocity was observed when cells move along
linear ECM fibers, and such movement was not restricted by ECM networks in the mammary
tumors. This type of amoeboid movement is quite different from the traditional
mesenchymal movement described above. In amoeboid movement, cells make weak and
transient interactions with ECM, lack stress fibers and focalized proteolytic activity (which
are typical for mesenchymal migration), and the physical movement is generated by cortical
filamentous actin (Friedl and Wolf, 2003).
It is, perhaps, not surprising to see a different mode of migration, since several different
types of migration have long been observed during development and in human tumor
samples. Migration can be categorized as individual cell migration (such as mesenchymal
and amoeboid migration mentioned above) or collective cell migration. For example, during
mammary gland morphogenesis, cells migrate together as a column; and following closure
of the neural tube, blastoderm cells migrate as a sheet of cells (Davidson and Keller, 1999);
both are collective migrations. In tumor samples, both single-cell and collective migrations
have been observed, showing the heterogeneous nature of tumor cell migration.
In addition, tumor cells have shown great plasticity in mode of movement. In 3D collagen
matrix, HT-1080 fibrosarcoma cells or MDA-MB-231 mammary carcinoma cells display a
mesenchymal type of migration, dependent on 31 integrins and degrading matrix by MT1-
MMPs. However, when such collagen proteolysis was blocked using a range of protease
inhibitors, the cells completely changed their mode of migration and migrated in amoeboid
fashion independent of proteolysis, "elbowing" their way through the collagen matrix. This
newly adapted movement is instead dependent on the activation of ROCK (possibly by
activation of RhoA), and myosin-generated force (Wolf et al., 2003; Wyckoff et al., 2006).
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Primary melanoma tumor explants growing in collagen lattices migrate as multi-cellular
clusters, with preferential 11 integrin localization at the leading edge. When blocking
antibody was used against 131 integrins, instead of blocking cell migration, the melanoma
cells took off as individual amoeboid cells and disseminated (Hegerfeldt et al., 2002). These
observations suggest that tumor cells can use different migration patterns, depending on
what tools are available to them.
It is safe to conclude that there is no "one-size-fits-all" for cancer cell migration and invasion
in vivo. There are different modes of migration, each with different molecular requirements-
mesenchymal migration is dependent on activation of integrins, Rac and MMPs, while
amoeboid movement needs activities of Rho, and cells possess remarkable plasticity to
switch between different methods. Therefore, studying tumor cell migration in vivo or in
vivo-like 3D matrix settings will be useful to deduce common features and requirements for
migration, in the hopes to develop therapeutic reagents to block tumor cell metastasis.
But what makes some carcinoma cells more invasive than others, if all cells have intrinsic
abilities of migration? What are the factors that mobilize such migration abilities? The
answers may lie both in the microenvironment in which tumor cells reside and in the ability
of some tumor cells to activate their migration machinery more efficiently than others.
It is now well established that a plethora of stromal cells are present within the tumor, and
contribute in various ways to tumor initiation and progression (Tlsty and Coussens, 2006).
Cancer-associated fibroblasts (CAFs) have previously been shown to contribute to tumor
growth (Camps et al., 1990; Haviv et al., 2009; Olumi et al., 1999) and invasiveness of colon
cancer cells (Nakajima et al., 1990). Tumor cell interactions with fibroblasts regulate the
secretion of type IV collagenase in vitro and presumably contribute to the differential
production of this enzyme in vivo (Fabra et al., 1992). Recently, it was observed that
fibroblasts lead collective squamous cell carcinoma invasion in 3D matrix, generating
remodeled matrix tracks to enhance the carcinoma cells' invasion (Gaggioli et al., 2007).
The presence of innate immune cells, especially mast cells and macrophages, has been
documented in numerous clinical studies, and has been correlated with angiogenesis and
poor clinical outcomes (Duncan et al., 1998; Takanami et al., 2000; Talmadge et al., 2007).
In experimental models (MMTv-PyMT mammary carcinoma model, or in lung cancer cells),
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selectively deleting tumor-associated macrophages reduces tumor angiogenesis, invasion
and lung metastasis, highlighting the pivotal roles of macrophages in tumor metastasis
(Hiraoka et al., 2008; Lin et al., 2006; Lin et al., 2001; Miselis et al., 2008; Zeisberger et al.,
2006). In vivo, direct observation of primary mammary tumors revealed enhanced infiltration
of macrophages in tumors generated by highly metastatic cells relative to poorly metastatic
cells.
On the tumor side, establishing cell polarity was suggested to be one of the essential
functions for effective migration, and one important factor to differentiate tumor cells with
different metastatic potentials (Friedl, 2004). Comparing mammary carcinoma cells with
high metastatic ability (MTLn3 cells) to cells with low metastatic potential (MTC cells)
revealed interesting differences (Farina et al., 1998; Neri et al., 1982). While MTLn3 cells
migrate in a completely amoeboid manner without intrinsic polarity, once they come close to
blood vessels, these cells polarize toward them (Wyckoff et al., 2000), and MTLn3 cells only
invade blood vessels where perivascular macrophages are located (Wyckoff et al., 2007);
MTC cells have some residual polarity with partial mesenchymal movement, but they do not
respond to the blood vessel cue. Mechanistically, a paracrine loop has been identified
between macrophages and breast carcinoma cells. These macrophages have been shown
to produce epidermal growth factor (EGF), which will reorientate tumor cells expressing
EGF-receptors, and attract them toward the blood vessels. Macrophages are recruited to
the tumor site due to production of a powerful chemoattractant, colony-stimulating factor 1
(CSF-1) (Goswami et al., 2005; Wyckoff et al., 2004). Figure 2 shows the crosstalk between
tumor cells and macrophages that enhances tumor cell local invasion.
Once polarity is established, it stimulates local activation of cofilin resulting in actin
polymerization and membrane protrusion. Wyckoff et al have developed an in vivo invasion
assay where needles containing EGF were inserted into the mammary gland to collect
primary tumor cells that are actively in the process of invasion. This assay was combined
with microarray technology to profile the cells that are most invasive from the primary tumors
(Wyckoff et al., 2004). Through such analyses, the cofilin pathway was identified and shown
to be a major determinant of metastasis (Wang et al., 2007; Wang et al., 2006). Cofilin is a
small ubiquitous protein that can sever actin filaments, increasing the number of free barbed
ends for future actin polymerization (Ghosh et al., 2004; Yamaguchi et al., 2005). In
addition, cofilin can synergize with the dendritic nucleation acitivity of Arp2/3 complexes
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(Ichetovkin et al., 2002). The end result of cofilin activation is a large increase in actin
polymerization, generating protrusions at the membrane. It was shown that EGF stimulation
of mammary carcinoma cells induces phosphorylation-dependent global inactivation of
cofilin, while stimulating local phospholipase Cy-mediated activation of cofilin. Such spatial
control will direct actin polymerization toward the source of EGF, mediating directional cell
migration (Wang et al., 2007). The importance of the cofilin pathway in mammary cancer
metastasis was shown by experimentally manipulating LIM kinase 1 (LIMK1), which
negatively regulates cofilin activity by phosphorylating cofilin. Mammary tumor cells
expressing LIMK1 or kinase-dead LIMK1 have decreased or enhanced cofilin activation,
respectively, which caused proportional reduction or increase in motility (both in vitro and in
vivo), intravasation, and metastasis of tumor cells (Wang et al., 2006).
In addition, RhoC has been identified as a metastasis enhancer through microarray analysis
comparing melanoma cells with low or high metastatic ability. When poorly metastatic
melanoma cells over-express RhoC, these cells became more migratory and more
metastatic when injected intravenously. Conversely, when highly metastatic cells express
dominant-negative RhoC, there was a strong reduction in both cell migration and number of
metastasis in the lungs, supporting the hypothesis that RhoC functions to enhance motility
and metastasis (Clark et al., 2000). These experimental metastasis results were confirmed
using an endogenous mammary tumor model crossed with RhoC knockout mice - many
fewer metastases were observed when RhoC expression was abolished (Hakem et al.,
2005).
In summary, current data support the idea that there exist intrinsic differences in cell
migration machinery among tumor cells with different metastatic abilities. There also exist
differences in how various tumor cells co-ordinate with their microenvironment - how they
change the microenvironment, and how they respond to the different factors contributed by
the cells in that local community. All these factors contribute to the ability of the tumor cells
to migrate/invade through their tissue stroma to gain access to the circulation, which is the
first step toward systemic dissemination.
Step II - Systemic Traveling and Arresting
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The next hurdle tumor cells encounter before they gain access to the blood stream for
systemic dissemination is the endothelial barrier. Tumor cell migration slows down
significantly when tumor cells come near the blood vessels, possibly due to the thick
basement membrane surrounding the blood vessels. When interacting with endothelial cells
that express DARC (Duffy antigen receptor for chemokines), tumor cells may stop
proliferation and senesce if they express tetraspanin CD82 (KAI1) (Bandyopadhyay et al.,
2006). Trans-endothelial migration of tumor cells is one of the mechanisms that tumor cells
use to intravasate, and in fact, angiopoietin-like 4 produced by tumor cells in response to
TGF- has been shown to induce dissociation of endothelial cell-cell junctions to facilitate
tumor entrance to the blood stream (Padua et al., 2008). However, this is not the only
mechanism by which tumor cells gain access to the bloodstream. Work by Chang et al has
clearly shown that a high percentage of tumor vessels contain "mosaic" vessels, where part
of the vessels lack CD31/CD105 and lectin staining, and are replaced by tumor cells (Chang
et al., 2000). Although it is not clear whether the tumor cells are a functional part of the
blood vessels, these data certainly suggest that tumor cells can directly face the blood
stream without the barrier of endothelial cells, which is also in agreement with the fact that
some tumor vessels are leaky. In other cases, tumor cells are thought first to enter rather
porous lymphatics before draining into systemic circulation.
Whether or not entering the bloodstream is a rate-limiting step is still controversial, partly
due to technical difficulties of direct observation. In some situations, large numbers of tumor
cells have been observed in the blood. It has been estimated that nearly 4*10e6 cells were
released from each gram of primary tumor per day (Butler and Gullino, 1975; Glaves et al.,
1988; Weiss and Glaves, 1983). In other work, the number of tumor cells in circulation
correlates with the number of lung metastases (Wyckoff et al., 2000), and correlates with
poor prognosis (Denis et al., 1997; Racila et al., 1998), suggesting that it may be one of the
rate-limiting steps in metastasis. It was observed that 32% of poorly metastatic MTC cells
were fragmented while entering the blood stream, compared with 6% of highly metastatic
MTLn3 cells, suggesting that intravasation is at least an inefficient, if not rate-limiting, step
(Wyckoff et al., 2000). With new technology that efficiently captures circulating tumor cells
(Nagrath et al., 2007), revisiting this question will certainly provide more information.
Once in the bloodstream, tumor cells are devoid of assembled extracellular matrix proteins
with which they were familiar at the primary site, and endure shear stress that they have
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never encountered before. It is speculated that activation of Rho, and thus stronger cortical
acto-myosin contraction that promotes amoeboid movement discussed above, may
physically help the tumor cells withstand mechanical stress (Sahai, 2007). In addition,
increased expression of cytokeratin in highly metastatic cells relative to poorly metastatic
cells was also suggested to play a role in physically counteracting the shear force in the
circulation (Condeelis and Segall, 2003). Furthermore, genes involved in apoptosis
pathways may also contribute to tumor cell survival.
James Ewing suggested that blood-flow pathways between primary and secondary tumors
were sufficient to account for organ-specific metastasis (Fidler, 2003). Although it is clear
that circulatory patterns do not fully explain tissue tropism, flow patterns certainly contribute
to where tumor cells go once they are in the circulation. For example, colon cancer cells are
taken by the hepatic-portal circulatory system first to the liver and indeed, 78% of colon
cancer metastases are in liver (Hess et al., 2006). However, such blood-flow patterns
cannot explain fully the distribution of metastases (Weiss, 2000). As will be discussed later,
the tissue microenvironment where disseminated cells end up is another important
determinant.
Eventually, circulating tumor cells arrest, making contacts with endothelial cells. In some
situations, this can be a passive process - while the diameter of capillaries ranges from 3-
8pm, the sizes of most tumor cells are around 15-20pm, and tumor cells can be arrested in
the capillary due to physical constriction (Chambers et al., 2002; Ito et al., 2001).
Alternatively, tumor cells may actively adhere to endothelial cells, similar to what has been
observed for leukocytes. Selectins have been shown to be crucial for leukocyte tethering
and rolling in response to inflammatory cytokines, which is essential for subsequent integrin
activation and firm adhesion to endothelial cells (Sperandio, 2006). Tumor cells with
reduced selectin ligands were less metastatic (Witz, 2008; Zipin et al., 2004). Spontaneous
pancreatic tumors metastasize to lymph nodes when expressing L-selectin (Qian et al.,
2001). Mice lacking P- and/or L-selectins were resistant to metastasis by colon cancer cells
(Borsig et al., 2002), supporting the idea that selctin-mediated interactions with tumor cells
may be actively involved in arresting in the blood vessels. Recently, it was shown that
phage presenting metadherin home specifically to lung microvasculature and that breast
cancer cells whose metadherin was blocked using antibody or siRNA showed reduced lung
metastasis, in agreement with tumor-vasculature interaction being important for cancer cell
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metastasis (Brown and Ruoslahti, 2004). In vivo imaging showed that within the bone
marrow, there exist specialized discontinuous endothelial regions that express E-selectin
and stromal-cell-derived factor 1 (SDF-1). When tumor cells (including leukemia cells and
prostate cancer cells) were introduced to the mice through tail-vein injection, cells were
localized to these regions within 1 hour of injection, and remained there for a period of time.
Disrupting the interaction between SDF-1 and its receptor CXCR4 on the tumor cells
inhibited localization of tumor cells to these discrete sites, suggesting that tumor cells are
actively "homing" to regions in the bone marrow (Sipkins et al., 2005). These data support
the idea that tumor cells can home to specific anatomic areas via active protein-protein or
protein-carbohydrate interactions.
Several lines of evidence suggest that platelets may facilitate tumor cell metastasis through
various means. Platelets have been observed to surround tumor cells (Honn et al., 1992a;
Kitagawa et al., 1989), possibly providing physical protection and preventing attack by
immune cells(Nieswandt et al., 1999); such tumor-platelet aggregates may help in tethering
to endothelial cells, slowing down their movement, adhering to the blood vessel, and may
help facilitating growth at the site, or extravasation. In addition, platelets are a rich source of
various growth factors, such as platelet-derived growth factor (PDGF) and VEGF, which
have been shown to promote tumor cell proliferation, survival, invasion (Lip et al., 2002;
Nash et al., 2002) and angiogenesis (Sierko and Wojtukiewicz, 2004), all of which can
potentially contribute to tumor metastasis (Honn et al., 1992b; Sierko and Wojtukiewicz,
2007).
Recently an intriguing observation was reported - in mice bearing subcutaneous tumors of
either B16 melanoma or Lewis lung carcinoma (LLC), "pre-metastatic niches" were
observed in the lungs, which contain bone-marrow-derived cells that are VEGFR1- and
integrin a411- positive. In these niches, strong fibronectin expression was also reported.
This finding is surprising because such niches could apparently be detected before
individual tumor cells were seen in the lungs. In addition, conditioned media from
melanoma could re-direct LLC cells to organs to which melanomas frequently metastasize
(Kaplan et al., 2005). These results suggested that "primary" tumors can secrete factors
that mobilize bone-marrow-derived progenitor cells, which in turn dictate where the future
metastases arise. In another paper, it was shown that tumor cells secrete growth factors
such as VEGFA, TGFI, and TNFa, which stimulate endothelial cells and Macl+ myeloid
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cells to produce chemokines S100A8, S100A9. These chemokines in turn stimulate tumor
cell migration, and neutralizing antibodies reduced the colonization of tumor cells in the lung
(Hiratsuka et al., 2006). This new observation suggests that primary tumor cells
themselves, in part, determine where the future metastases arise through systemic release
of factors, although a generalization of this idea requires many more experiments. There
are many important questions unanswered. Given the systemic release of chemokines by
the growth factors, why do "pre-metastatic" niches develop in specific sites? Are these sites
that have different types of endothelial cells relative to their neighbors (Sipkins et al., 2005),
or are these sites that experience different blood flow and thus different shear forces and
respond differently to the systemic signals than do endothelial cells at other locations? Or
are these sites of spontaneous lesions constantly occurring in normal organisms that attract
platelets, which together with endothelial cells determine where these niches are? Are
these sites indeed where the future metastasis are located? What are the roles of bone-
marrow derived cells at these niches? Do they function like the macrophages in the primary
tumor to generate a permissive environment? What are the functions of the fibronectin
observed in these "pre-metastatic" niches? A deeper understanding of these questions will
have important clinical implications in terms of preventing tumor cells from lodging at distant
organs and preventing metastasis.
Step III - Colonization of Distant Organ(s)
As mentioned earlier, one of the characteristics of cancer metastasis is tissue tropism. In
1889, Stephen Paget found that out of 735 breast cancer necropsies, "241 had cancer of the
liver, only 17 had cancer of the spleen, and 30 had cancer of the kidneys or suprarenals",
and 70 had lung cancer (Weiss, 2000). Based on earlier work and ideas of Fuchs, he
proposed the "seed-and-soil" theory - "When a plant goes to seed, its seeds are carried in
all directions; but they can only live and grow if they fall on congenial soil" (Paget, 1989),
thus tumor cells cannot flourish on their own unless they encounter a suitable organ
environment. The "seed-and-soil" theory suggests that, in addition to the properties of the
"seeds", additional factors at the "soil" or target organs will contribute greatly to the growth of
metastases. I mentioned earlier the determinants of where tumor cells finally settle, which is
certainly part of where the 'seeds" go, and now I will focus on the factors that contribute to
whether these "seeds" can eventually flourish.
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Given the large body of knowledge that tissue microenvironment contributes to tumor
initiation and progression at the primary site, it is not hard to imagine similar cooperation at
work at the metastatic sites, although work has just started to elucidate these factors.
Recognizing similarities between circulating tumor cells and circulating leukocytes, Muller et
al analyzed the chemokine receptor expression levels of a panel of human breast carcinoma
cells, and found markedly enhanced expression of CXCR4 and CCR7. Their ligands (SDF-
la and CCL21, respectively) are highly enriched in lymph nodes, to which tumor cells
normally metastasize. When blocking antibody was used to disrupt SDFla - CXCR4
interactions, a significant reduction in lung and lymph node metastasis was observed, using
both an experimental metastasis model and an orthotropic implantation model, supporting
the important roles these chemokines play during mammary carcinoma metastasis (Muller
et al., 2001). Melanoma and other mammary carcinoma cells that metastasize to the bone
have been shown to express RANK (receptor), and in response to the ligand RANKL, the
cells show increased migration. In vivo, disrupting RANK-RANKL signals by over-
expression of the decoy receptor OPG on melanoma cells significantly decreased bone
metastasis. These experiments clearly showed the importance of cytokines/chemokines in
metastasis formation, although it is still not clear if these cytokines/chemokines just function
in tumor cell "homing" to a particular organ, or if they also contribute to the growth of these
cells upon their arrival (Jones et al., 2006).
Kang et al expanded the early studies by in vivo selection of mammary carcinoma cells that
traffic specifically to the bones, and analyzed the expression profiles of these cells using
microarrays, which was followed by functional evaluation of identified gene signatures (Kang
et al., 2003; Lu and Kang, 2007). Together with Yin et al and Park et al, a co-operative
network between mammary carcinoma cells and osteoclasts in the bone marrow was
suggested to facilitate osteolytic metastasis (Lu and Kang, 2007; Pantschenko et al., 2003;
Park et al., 2007; Yin et al., 1999). In this particular microenvironment, factors secreted by
tumor cells (including IL-11, TNF-a, IL-6 and parathyroid hormone-related protein (PTHRP)
stimulate the release of RANKL by osteoblasts. RANKL functions on myeloid precursor
cells, promoting maturation of osteoclasts, which degrade the bone matrix and release a
plethora of growth factors that benefit the tumor cells (Nguyen et al., 2009). Although
different players are involved compared to the invasive microenvironment at the primary
tumor site, a similar scheme is employed, involving both the tumor cells and tissue-resident
cells and crosstalk among these cells. Recently, a different gene signature was discovered
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marking mammary carcinoma cells that target specifically to the lungs (Minn et al., 2005).
Comparison between this gene set with the "bone-metastasis" gene set revealed little
commonality, suggesting that different molecules are involved in successful colonization in
different organs. Given that many of the "lung signature" genes are secreted or membrane
proteins, it is plausible that these factors invoke crosstalk between tumor cells and the lung-
resident cells, together contributing to the formation of lung metastasis, although the details
of such crosstalk await further elucidation. Figure 3 depicts such an "excited"
microenvironment where various growth factors, cytokines and chemokines produced by
tumor cells and tissue-resident cells provide a fertile "soil" for metastasis formation.
Another common site of metastasis is liver - almost all common tumors metastasize to the
liver, and in particular, uveal melanoma, pancreatic and colorectal carcinomas preferentially
form secondary tumors there. This may be partly due to the blood-flow pattern of liver -
approximately 75% of all its blood supply comes from the hepatic portal vein, which drains
from spleen and gastrointestinal tract and is rich in nutrients (Shneider 2008). It is the first
microvascular bed that gastrointestinal tumor cells encounter once they have intravasated,
and the rich nutrients in the blood could certainly help tumor survival and growth. The
anatomy of the liver sinusoid may also contribute to establishment of metastases. Liver
sinusoidal capillaries are fenestrated, lined with discontinuous endothelial cells, thus
facilitating traverse of tumor cells into the organ (Paku et al., 2000).
Kupffer cells, which are liver-resident macrophages making up almost 10-15% of all liver
cells, lining the liver sinusoids in addition to endothelial cells. As mentioned earlier,
macrophages have been shown to play pivotal roles for mammary tumor initiation,
angiogenesis and progression due to secretion of cytokines, growth factors and
metalloproteases (Joyce and Pollard, 2009). Knowing the importance of macrophages in
those circumstances, and drawing similarities here, can we speculate that Kupffer cells may
also contribute to liver metastasis by providing rich sources of growth factors and cytokines
to contribute to tumor cell colonization in the liver? There is some evidence supporting this
hypothesis - tumor cells have been shown to stimulate Kupffer cells to release TNFa and to
upregulate endothelial adhesion molecules such as E-selectin, mediating enhanced tumor-
endothelial interactions (Auguste et al., 2007; Gangopadhyay et al., 1998; Gjoen et al.,
1989; Khatib et al., 2005). A recent study suggests that Kupffer cell-derived MMP9
contributes to liver metastasis of colorectal cancer (Gorden et al., 2007). However, it was
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also argued that Kupffer cells might function to suppress metastasis formation in the liver
due to endocytosis-mediated tumor cell destruction (van der Bij et al., 2005).
These observations may sound contradictory at first, but probably reflect temporal
differences in Kupffer cell functions. In work by Timmers et al investigating the early events
of rat colon carcinoma cells injected intramesenterically into rats, they found that between 1
hr to 8 hr, about 70% of all tumor cells are in phagosomes of the Kupffer cells, which
increases to approximately 90% by 24 hours, supporting their function as first-line immune
defense at early time points. However, about 6% of all tumor cells remain untouched by
Kupffer cells (or by Natural killer cells), suggesting this might be the population of tumor
cells that persist and become metastases (Timmers et al., 2004), potentially through
stimulating Kupffer cells to produce a variety of cytokines over a period of time. It is clear
that, in order to understand why many different types tumor cells can flourish in the liver,
more work is needed to investigate tumor-liver cell interactions. One starting point might be
extending works by Kang et al and Minn et al, to isolate mammary carcinoma cells that
specifically metastasize to the liver and profile those cells for "liver signatures".
Furthermore, a more vigorous test of the function of Kupffer cells in metastasis
establishment is necessary before research can be carried out to address the mechanisms
of such involvement, if any.
Laborious approaches such as cDNA subtraction and microcell-mediated chromosomal
transfer have been applied early on to identify genes that are involved in metastasis
(Yoshida et al., 2000). Since then, new technologies such as genome sequencing and
microarray analysis have accelerated the pace by which new discoveries were made. In the
past decades, a large number of genes/proteins have been found to potentially contribute to
metastasis by functioning in the above-mentioned steps. These are both cell-intrinsic
factors (such as cofilin pathway, RhoC) and factors such as chemokines/chemokine
receptors that allow for tumor-environment crosstalk. And some of these discoveries may
open the gate toward better treatment. However, many questions still remain - in addition
to tissue tropism, another observation is that different tumors metastasize at different rates.
So what are the factors contributing to such temporal differences?
Kinetic Differences Among Different Tumor Metastases and Tumor Dormancy
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It was observed that although breast cancer and lung cancer metastasize to similar organs
(Hess et al., 2006), such as bone, liver and brain, they do so with distinct kinetics. In breast
cancer, metastasis might be manifest years or decades after the initial removal of even a
small primary tumor (Karrison et al., 1999); while for lung cancer, distant metastases can be
established within months of diagnosis (Feld et al., 1984; Hoffman et al., 2000), and similar
swift metastasis is observed in pancreatic and colorectal cancers (Fearon and Vogelstein,
1990; Nieto et al., 2008). Although early diagnosis accounts for some of the differences, the
striking temporal variability among different types of tumors suggests mechanistic
differences among the tumor cells forming metastases slowly or quickly.
One question concerning such variability is whether or not tumor cells from breast or
prostate cancer disseminate at different time points relative to lung or colorectal or intestinal
cancers? In breast and prostate cancers, it has been recently appreciated that
dissemination of tumor cells can occur early during primary tumor progression (Klein, 2008;
Riethdorf et al., 2008). This became apparent with better technology to identify
disseminated tumor cells (DTCs) or circulating tumor cells (CTCs) from the bone marrow or
the blood of cancer patients respectively, followed by single-cell genomic analysis including
CGH (comparative genomic hybridization), LOH (loss of heterozygosity), and microarray
analyses. Analyses of human DTCs have found that DTCs present different genomic
changes compared to the primary tumors, suggesting that they may have disseminated
early and evolved independently at the distant site (Schardt et al., 2005) (Schmidt-Kittler et
al., 2003). In addition, early DTCs can also be found in transgenic mice bearing a
constitutively activated HER-2 gene under control of MMTV promoter before the transition
from epithelial hyperplasia to carcinoma in situ. Investigations following DTCs in mice have
shown that they can eventually become overt metastases, supporting the idea that (at least
some) early-disseminated cells from breast cancer are indeed metastasis-competent.
These data showed that in breast cancer, tumor cells can achieve the first two steps (local
invasion and systemic traveling and landing) of metastasis early, but the competence to
colonize at the distant organ may take time to develop (Nguyen et al., 2009).
Colorectal carcinoma, on the other hand, seems to take decades to transit from colorectal
hyperplasia to adenoma to invasive carcinoma; however, when colon tumor cells invade the
underlying colonic wall, metastasis can proceed quickly. Once they become invasive, few, if
any further genetic mutations are required for them to become metastatic (Jones et al.,
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2008; Kinzler and Vogelstein, 1996). Although minimal residual disease has been observed
from some colorectal patients, it is not clear whether they disseminated from early or late
stages of tumors (Merrie et al., 1999). Currently studies to investigate DTCs in the liver for
human patients and using colorectal mouse models have not been performed to the same
extent as has been done for mammary tumors.
The temporal differences among different tumors may suggest mechanistic differences in
the way that these primary tumor cells become metastatic. Maybe, for breast cancers,
infiltration can be achieved early but the cells are kept "dormant", while for colorectal or lung
cancer cells, ability to infiltrate is gained later during tumor progression while colonization is
relatively efficient for these cells. Therefore, for breast cancer cells (and perhaps prostate
cancer cells), tumor dormancy is of particular interest, since this step may represent a
critical step amenable to clinical intervention. Identifying the capacities of different tumor
cells at various stages of tumor progression will be particularly useful to design effective
treatment, perhaps targeting the rate-limiting step(s) during metastasis for different tumor
types.
Tumor Dormancy
Metastasis is an inefficient process, and it has been estimated that approximately 0.01% of
cancer cells directly injected into circulation eventually form metastases (Fidler, 1970).
Work by Cameron et al (Cameron et al., 2000) and Luzzi et al (Luzzi et al., 1998) showed
that using an experimental metastasis assay where tumor cells were introduced into
circulation directly, the initial "trapping " of the cells was efficient, with approximately 90% of
cells observed 1 hour post injection. However, on day 3, only 2% of the cells persist as
"micrometastases" or "seeds" and by two weeks, about 0.1% of the cells grow into micro- or
macro-metastases in the liver, although a much higher percentage of solitary cells were
observed (-80% on day3 and -40% by two weeks, respectively) (Luzzi et al., 1998). Similar
results were observed when tumor cells were introduced to the lungs, although the numbers
are slightly different (Cameron et al., 2000). It was suggested that failure of these solitary
cells to initiate growth and inefficiency of micrometastasis in progressing into
macrometastasis, are the primary reasons for metastasis inefficiency.
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In fact, persistent presence of tumor cells in cancer patients has long been observed,
particularly in breast and prostate cancer patients, where 20-45% of patients will relapse
years or even decades after initial tumor removal (Karrison et al., 1999). After initial
treatments, tumor deposits that remain in the body (minimum residual disease) have been
observed for breast, prostate, colon, head and neck, neuroblastoma, melanoma, non-small
cell lung cancer, leukemia and lymphoma patients (Aguirre-Ghiso, 2007), threatening the
recurrence of tumors in the patients. The long latency between the time of initial treatment
and the manifestation of metastasis can not be explained by continuous tumor cell
proliferation (Aguirre-Ghiso, 2007), and detected circulating tumor cells after surgery are
often negative for the proliferation marker Ki67, suggesting that the state of "dormancy"
exists in human patients (Muller et al., 2005).
Does tumor dormancy exist in mouse models that are commonly used for metastasis
studies? The answer is yes. With fluorescence-marked mammary carcinoma cells, tumor
cells can be seen by microscopy as single cells in the lungs upon tail-vein injection for up to
6 months; when recovered from the lungs, these cells retain the ability to proliferate in vitro,
forming primary tumors at the subcutaneous site and in the fat pad (Goodison et al., 2003).
This is true in the liver, since poorly metastatic mammary carcinoma cells were observed to
persist in the liver as solitary cells for up to 11 weeks without proliferation (Ki67-negative),
while highly metastatic cells progress to tumors (Naumov et al., 2002). Using magnetic
resonance imaging (MRI) to track breast cancer cells in the brain and follow them overtime,
Heyn et al have shown that while some cells become sizable tumors in the brain, others
remain as single cells over the course of a month, representing a reservoir of dormant cells
(Heyn et al., 2006).
Then the important questions are: 1) Why the disseminated cells are in a dormant state? 2)
What triggers the exit from such a state?
Why disseminated tumor cells remain dormant?
It was appreciated that two types of dormancies exist - cellular dormancy as described
above, where solitary cells remain alive but withdraw from the cell cycle; and tumor mass
dormancy, when tumor cell proliferation and apoptosis are balanced, probably due to lack of
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angiogenesis (Naumov et al., 2008). They are not mutually exclusive, and can co-exist both
in mouse models and in human patients (Aguirre-Ghiso, 2007).
Currently the understanding of why individual tumor cells are dormant is still limited, and an
emerging theme seems to be the lack of proper cell-microenvironment interactions, most
notably cell-ECM (extracellular matrix protein) crosstalk. In vitro, 40% of tumorigenic T4-2
mammary cells proliferate continuously after 10-12days in Matrigel, while most non-
malignant S1 cells stopped proliferation and assumed acinar structures. When integrin 11
blocking antibody was used to interfere with tumor cell and ECM interactions, T4-2 cells
upregulated p21 c'P and withdrew from the cell cycle, which was reversible if the blocking
antibody is removed. These observations suggest that, at least in vitro, the ability of cells to
engage proper ECM is critical for cell proliferation (Weaver et al., 1997). In vivo,
concomitant deletion of 11 integrin (MMTV-131oxP/oxP) and expression of polyoma-virus
middle T oncogene (MMTV-Cre-PyMT) in mammary epithelial cells resulted in reduced
hyperplastic nodules in the mammary glands; when the hyperplastic nodules were analyzed
for 11 integrin expression, they remained positive (due to the mosaic pattern of Cre
expression, thus a mosaic pattern of 131 integrin deletion). When 131 was deleted in vitro by
infecting tumor cells with adenovirus expressing Cre, these cells failed to proliferate in vitro;
and when orthotopically implanted into the mammary fat pad, cells deleted of 131 integrins
failed to proliferate in vivo, although remaining as single cells (White et al., 2004). These
data showed that disrupting integrin and ECM interaction renders the cells dormant, both in
vitro and in vivo at the primary tumor site.
Along the same line, reduction of urokinase plasminogen activator receptor (uPAR) in
human epidermoid carcinoma cells resulted in loss of tumor growth in chick CAM, which is
probably due to much reduced cell proliferation judging by BrdU incorporation. This loss of
tumor growth can last up to 5 months before spontaneous resumption of growth occurs (Yu
et al., 1997). Work by Aguirre-Ghiso et al led to the conclusion that pPAR is involved in
activation of integrin a511, which activates the ERK (mitogenic extracellular regulated
kinase) signaling pathway. When disrupting pPAR-11 integrin interactions with blocking
peptides, activation of ERK is reduced (Aguirre Ghiso et al., 1999). Furthermore, activation
of integrin a511 promotes fibronectin fibril assembly, and results in reduced signaling
through stress-activated kinase p38 MAPK activation (Aguirre-Ghiso et al., 2001). In vivo
imaging in chick CAM and in nude mice has shown the activation of ERK or p38MAPK in
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growing or dormant tumors, respectively (Aguirre-Ghiso et al., 2004). It was proposed by
Aguirre-Ghiso et al that a balance between oncogenic activated ERK pathway and stress-
activated p3 8MAPK pathway determines whether cells enter proliferation or dormancy
(Ranganathan et al., 2006a; Ranganathan et al., 2006b).
Conceptually, it is logical to think that when disseminated tumor cells land in foreign organs,
where integrins encounter incompatible ECM, the cells may activate a "stress pathway". As
a result, the cells withdraw from cell cycle and become dormant. The above-mentioned
experiments certainly support this hypothesis. Further support of this idea came from work
by Vander Griend et al (Vander Griend et al., 2005). They found that over-expression of
JNK (c-Jun NH2-teminal kinase) - specific kinase MKK7 in prostate carcinoma cells, which
activates the JNK pathway, significantly suppressed formation of overt lung metastasis.
Lungs bearing these tumor cells formed microscopic metastasis, but could not progress to
full-blown tumors. The same metastasis-suppression was observed when MKK4 was over-
expressed, which activated both JNK and p3 8 MAPK pathways (Vander Griend et al., 2005;
Yamada et al., 2002; Yoshida et al., 1999). Recently the same group showed that, in
human ovarian cancer cell lines, activation of p38 MAPK (by MKK6) and JNK (by MKK4)
suppressed tumor metastasis in the lungs via activation of p21cip and p26kip in tumor cells
and withdrawal from cell cycle (Hickson et al., 2006; Lotan et al., 2008).
In addition to the role of tumor-ECM interactions in inducing tumor dormancy, other cells in
the microenvironment that the tumor cells encounter are likely to contribute as well. The
tetraspanin KAI1 (or CD82) has been found to be a metastasis suppressor for prostate,
breast, lung, pancreatic tumors and for melanomas and the mechanism of such suppression
has recently been elucidated after the ligand of KAI1 was found (Dong et al., 1995; Tonoli
and Barrett, 2005). It turns out the Duffy antigen receptor for chemokines (DARC) is
localized specifically on the endothelial cells, and interaction between KAI1 localized on the
tumor cells with DARC leads to inhibition of tumor proliferation and tumor cell senescence
(Bandyopadhyay et al., 2006). These data suggest that interactions between tumor cells
and endothelial cells are likely to induce tumor cell dormancy as well, although it is not clear
why KAI1 does not affect primary tumor growth and functions to suppress metastasis
specifically. One possible link is that KAI1 has been shown to regulate pPAR activities and
to interact with integrins and disrupt integrin signaling (Bass et al., 2005; Sridhar and Miranti,
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2006), reflecting the recurring theme of disrupted tumor-microenvironment communications
mentioned earlier, but the detailed mechanisms are not clear.
KiSS-1 is another metastasis suppressor gene that has been shown to suppress melanoma,
mammary and ovarian cancer metastasis, but did not affect primary tumor growth (Lee et
al., 1996; Lee and Welch, 1997; Nash and Welch, 2006). It encodes several secreted
peptides, among which is metastin, a 54-amino acid peptide that binds to G-protein-coupled-
receptor 54 (GPR54) (Kotani et al., 2001; Muir et al., 2001; Ohtaki et al., 2001). Although
the early report suggested that GRP54 mediates the metastasis-suppression function of
KISS1 in melanomas (Ohtaki et al., 2001), other reports have shown KISS-1 can still
suppress tumor metastases even when they lack GPR54 expression (Jiang et al., 2005;
Nash et al., 2007; Nash and Welch, 2006). It was found that melanoma cells expressing
KiSS1 persist in the lungs as solitary cells for up to 120 days after intravenous injection,
suggesting the induction of cellular dormancy by KISS1. Interestingly, these tumor cells do
not express the receptor GPR54, and only when KISS1 is secreted can it function as a
metastasis suppressor. In addition, such suppression is manifested in multiple organs such
as lung, eye, kidney and bones (Horak et al., 2008; Nash et al., 2007). It is possible that
other unknown receptor(s) on the tumor cells may be mediating KiSS1 functions as a
metastasis suppressor. It is also conceivable, given known tumor-microenvironment
communications, that secreted KISS1 acts on other cells in the microenvironment, which in
turn, mediate tumor cell dormancy.
The relationships between primary tumors and their metastases are complicated - on the
one hand, primary tumors have been claimed to mobilize bone marrow-derived cells to set
up "pre-metastatic niches" to facilitate future metastasis; on the other hand, primary tumors
have been shown to systemically secrete factors that keep metastases in check. Husemann
et al found that in mice bearing primary tumors, the number of DTCs is small (approximately
0.002% of the bone marrow cells). However, when transferred into naive mice, these DTCs
quickly expand into tumors and can make up to 30% of the bone marrow in the recipient
mice. This work suggested that in mice with primary tumors, the DTCs are kept in a
dormant state, which can be released experimentally by transferring DTCs to naive mice
without primary tumors (Husemann et al., 2008). Angiogenesis inhibitors secreted by the
primary tumors, such as angiostatin and endostatin, have been shown to maintain
metastases in tumor mass dormancy, with proliferation balanced by cell apoptosis due to
Chapter 1
lack of angiogenesis (Holmgren et al., 1995; Naumov et al., 2008; O'Reilly et al., 1994). A
short burst of angiogensis factors, which occurs after surgical removal of the primary tumors,
can tip such a balance and result in overt metastasis formation (Demicheli et al., 2008;
Indraccolo et al., 2006).
What wakes the cells from dormant state?
Another important question concerning tumor dormancy is what are the factors that wake up
those cells from their dormant state and restores competency to become full-blown tumors?
Unfortunately, we only have very limited knowledge on this question.
One intriguing observation though, may shed some light on this question. Work by
Podsypanina in the Varmus group showed that normal mammary epithelial cells, when
injected into the tail vein of immunocompromised mice, are able to persist in the lungs for up
to 4 months with slow proliferation. However, when these cells were induced to express
ongogenic Ras and Myc, the cells proliferate quickly and develop into ectopic mammary
tumors in the lung (Podsypanina et al., 2008). Although this scenario is different from
dormant metastasis cells in that 1) presumably clusters of mammary epithelial cells were
introduced to the lung, rather than single solitary cells and 2) the existence of a basal level
of mitosis in the cells that is lacking in dormant disseminated cancer cells, these data
suggested that acute oncogenic stimulation can quickly "wake up" the cells to become
competent for intensive proliferation. It is conceivable that for dormant disseminated tumor
cells that reside in the body, maybe a local or systemic "stimulation" can functionally fulfill
what is achieved here (by inducing K-Ras and Myc), and thus act as a switch to turn on the
proliferative competence of the dormant cells. The nature of this stimulation is not clear.
But one can speculate that changes in the microenvironment due to inflammation or aging
could be part of the "stimulus package". It was shown that induction of lung inflammation
through activation of macrophages enhanced lung metastases formation (Stathopoulos et
al., 2008); hyperoxic injury to the lung and allergen-induced pulmonary inflammation also
increased lung metastasis (Adamson et al., 1987; Taranova et al., 2008). Furthermore, cells
expressing senescent markers accumulate with age (Dimri et al., 1995; Mishima et al.,
1999; Pendergrass et al., 1999), and senescent fibroblasts have been shown to produce
inflammatory cytokines and proteases, promoting tumor cell growth (Campisi, 2005; Krtolica
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et al., 2001). These data suggest that changes in the microenvironment of tumor cells may
contribute to waking the cells from dormant state, although the mechanisms are not clear.
The ultimate goal of studying metastasis is to slow the progress of the disease, and ideally
coax tumor cells into "peaceful existence" within host organs, and the naturally-occurring
tumor dormancy offers some hope toward such a goal. It is fair to say that, although tumor
dormancy has been recognized for half a century (Hadfield, 1954), mechanistic studies of
this phenomenon have just started to yield fruit, and we still have very limited knowledge on
this subject. With currently available technologies, such as live imaging technology, in vivo
functional screening using barcoded RNAi and cDNA expression libraries, and global
expression profiling, we can expect to see an explosion of research on this topic, which will
undoubtedly extend our understanding of this intriguing phenomenon.
Outstanding questions
Despite significant enrichment of knowledge about cancer metastasis, many questions
remain and some have been outlined above. As mentioned earlier, different tumor cells
preferentially metastasize to defined sets of organs (tissue tropism), and this could be due to
preferential landing and /or preferential growth at these organs, and may often involve both
the tumor cells and other cell types such as macrophages, fibroblasts and endothelial cells
present in the distant organs. Much work has been done on mammary carcinomas to
understand metastasis toward bone and lung, but research on this front for other types of
tumors is still lacking. In addition, tissue tropism toward liver has not been extensively
studied, although almost all tumor types metastasize to this organ.
When investigating tumor-stromal interactions, many factors, most noticeably soluble factors
such as chemokines and growth factors, have been shown to contribute greatly to initial
invasion and ultimately to tumor growth at distant sites. However, research on membrane-
localized adhesion molecules has not been done to the same level. Recently "cancer stem
cells (CSC)" have been hypothesized to contribute to solid tumor initiation and maintenance
(Visvader and Lindeman, 2008), and to tumor metastasis (Brabletz et al., 2005). Adult stem
cells have been shown to exist in various tissues such as skin (Blanpain and Fuchs, 2009),
prostate, breast (Shackleton et al., 2006), lung (Kim et al., 2005), brain, and in several
cases, expansion of adult stem cells has been observed upon oncogenic stimulation (Kim et
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al., 2005; Malanchi et al., 2008; Shackleton et al., 2006), suggesting they may be the
precursors for these tumors. In vitro sorting of tumor cells based on different surface
markers (such as CD44, CD133, Thy-1, CD24, CD49) has shown that certain cell
populations marked by "stem cell markers" are more efficient at forming tumors in
immunocompromised mice (Al-Hajj et al., 2003; Bao et al., 2006; Cho et al., 2008; Fang et
al., 2005; Hermann et al., 2007; Malanchi et al., 2008; Schatton et al., 2008; Singh et al.,
2004; Wright et al., 2008; Yang et al., 2008). Although the "cancer stem cell" theory was
recently challenged (Kelly et al., 2007; Quintana et al., 2008) and the question of whether
they are real "stem cells" is still debated, it remains true that cells with certain surface
markers can initiate tumors better than cells that do not express these surface markers.
Elucidating the common roles of these "markers" may provide additional targets for cancer
treatment.
What are these "markers"? One commonly used marker is CD44 - CD44 is a receptor for
hyaluronic acid, which is a major component of extracellular matrix of most mammalian
tissues. It has been shown to be involved in adhesion and motility, cell proliferation, and cell
survival, and over-expression of CD44 variant forms has been shown to enhance metastasis
in pancreatic and mammary tumors (Gunthert et al., 1991; Klingbeil et al., 2009), potentially
through activation of c-Met (Matzke et al., 2007; Orian-Rousseau et al., 2002), Src (Lee et
al., 2008) and/or Rho-ROCK (Visvader and Lindeman, 2008). Therefore, it is possible that
CD44 expression on the "cancer stem cells" confers functional advantage for these cells to
be better equipped for tumor formation and invasion. Another routinely used "cancer stem
cell" marker is CD133, or prominin. Although not many functional studies have been done
on this molecule, recent work showed that reducing CD133 expression by siRNA in
metastatic melanoma significantly reduced lung metastasis, supporting a functional role of
this molecule during metastasis (Rappa et al., 2008). Perhaps in addition to being surface
markers, these membrane proteins are actually involved in communication with their
environment, providing selective advantages for these cells during the course of tumor
formation and metastasis.
Although many membrane adhesion molecules have been identified to be involved in cancer
metastasis (E-cadherin, ICAM, integrins etc), putting them in the context of a complicated in
vivo environment and investigating tumor cell behavior in such an environment will be one
step further toward an integrated view of metastasis formation. In particular, in the context
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of tumor dormancy when tumor cells fail to recognize the new environment, adhesion
molecules will undoubtedly be interesting targets to investigate, to understand if some of
them provide "this is home" information and allow the outgrowth of metastasis, or transduce
stress signals to retain dormancy. Currently, this research is still lacking
Finally, although I did not elaborate upon it in this review, the host immune system can both
positively and negatively affect tumor initiation, progression and metastasis, and that is
certainly an area of intensive investigation (Dunn et al., 2004; Smyth et al., 2006).
Plasma membrane proteins in melanoma metastasis
As described earlier, tumor microenvironment contributes greatly to tumor initiation,
progression and metastasis formation. Many of the genes in the "gene signature" derived
from mammary carcinoma cells metastasizing to the lungs encode secreted and membrane
proteins (Minn et al., 2005); a "metastasis signature" that correlates with clinical outcomes of
melanoma patients is also highly enriched for secreted and membrane proteins (Xu et al.,
2008). Given that these factors (secreted proteins, plasma membrane proteins) potentially
mediate the interactions between tumor cells and their microenvironment, this thesis aims to
investigate plasma membrane proteins and their roles in melanoma metastasis. The
subsequent chapters are structured in the following manner:
* In Chapter 2, I will describe a strategy that we applied to enrich for plasma
membrane proteins. I will also describe a quantitative mass spectrometry method
we applied to identify membrane proteins that are differentially expressed on
melanoma cells with high versus low metastatic potentials. Finally, I will discuss the
identification of one membrane protein - Cub domain containing protein 1 (CDCP1) -
through such a process and focus on this protein for subsequent functional analysis.
* In Chapter 3, I will provide an overview of CDCP1 and CUB domains - including
proteins containing CUB domain and CUB domain structures. I will also provide
evidence that CDCP1 is a surface marker for melanoma cells with higher metastatic
ability. I will further test the functional involvement of CDCP1 using both shRNA-
mediated knock-down, and using retrovirus-mediated over-expression. It was found,
by both methods, that CDCP1 plays a causal role to enhance melanoma metastasis.
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* In Chapter 4, I will describe our attempts to understand, at a cell biological level, the
functions of CDCP1 that contribute to its metastasis-enhancer activity. I will describe
our work with both conventional 2D assays and eventually turn to 3D Matrigel assays
to understand the roles of the CDCP1.
* In Chapter 5, I will provide an overview of activation mechanisms of Src and PKC6,
and I will describe our attempts at understanding the functions of CDCP1 at the
molecular level. I will provide evidence that Src activation possibly contributes to the
functions of CDCP1, both in vitro and in vivo.
* In Chapter 6, I will summarize the work described in this thesis, the unanswered
questions that came from this study, and possible avenues for future research that
could be undertaken to answer these questions.
Chapter 1
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Figure 1. General review of three major steps in tumor metastasis and genes/proteins that
have been shown to be involved in each step. (Adapted from Joyce JA and Pollard JW,
Nature Reviews Cancer, 2009.
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Figure 2. Crosstalk between tumor cells and macrophages that augments local
invasiveness. Primary tumor cells secrete CSF1, which attracts macrophages to the site of the
primary tumor, and are often associated with blood vessels. Macrophages in turn produce EGF,
which orientate the primary tumor cells and induce migration of tumor cells toward the blood
vessels. Tumor cells can also secrete angiopoietin-like 4 (upon stimulation by TGF3) to induce
dissociation of endothelial cell-cell junctions, facilitating tumor cell intravasation. (Adapted from
Condeelis J and Segall JE, Nature Reviews Cancer, 2003)
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Figure 3. Colonization of distant organs. Depicted here is the presence various growth
factors, cytokines, chemokines and their receptors cooperate to create an
microenvironment at the distant organs that facilitate tumor metastasis formation. In
response to tissue-enriched ligands such as SDF-1 and CXL21, tumor cells may be
"attracted" to these particular organs. Once the cells are arrested in particular organ, for
example in the bone marrow, tumor cells are capable of secreting cytokines and
chemokines such as IL6, IL11, parathyroid hormone related protein (PTHrP), which
stimulate the release of RANKL by osteoblasts. RANKL in turn promotes the maturation of
osteoclasts, resulting in bone desorption and release of growth factors embedded in the
bone marrow matrix, thus stimulating metastases formation in the bone.
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CHAPTER 2.
APPLICATION OF QUANTITATIVE MASS SPECTROMETRY
TO IDENTIFY MEMBRANE PROTEINS THAT ARE
DIFFERENTIALLY EXPRESSED BETWEEN POORLY AND
HIGHLY METASTATIC TUMOR CELLS
The work in this chapter was conceived by Hui Liu and Richard Hynes. The colloidal silica
beads were kindly provided by Dr. Stolz at University of Pittsburgh. Mass spectrometry
analyses were assisted by Richard Cook and Alla Leshinsky, and bioinformatics analysis
was assisted by Charlie Whittaker. The contents of this chapter were written by Hui Liu, with
editing by Richard Hynes.
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INTRODUCTION
As mentioned in the first chapter, although metastasis has been recognized for more than
100 years, the tools for mechanistic understanding of the contributors were just not there
until the past twenty years or so. Equipped with molecular biology technologies, various
methods have been used over the years to identify the underlying genetic and epigenetic
changes that enhance or suppress metastatic abilities in mouse models.
Experimental Mouse Models
Three basic experimental models have been applied to study metastasis in mice. The most
convenient method is introducing tumor cells directly into the circulation, the so-called
"experimental metastasis assay". Using this assay, for example, tumor cells can be injected
into mice via tail vein, and the first microvascular bed the cells encounter is the lung. Tumor
cells can also be injected intraportally to target mouse liver, or injected into the left cardiac
ventricle to target the bones. The advantage of this method is that cells can be
experimentally manipulated to over-express or down-regulate genes-of-interest and used to
test the causative relationship between particular proteins/genes and metastasis. It is the
most widely used method because of the simplicity of the experiment. However, this
method does not capture the whole metastatic process; rather, it focuses on the later steps
of metastasis (systemic traveling and arresting, and colonization as described in Chapter 1).
The other commonly used metastasis model involves implantation of primary tumor either at
an ectopic or orthotopic site, followed by analyzing the target organs to which those tumor
cells normally metastasize. This method allows researchers to investigate the whole
metastasis process, and is often used to investigate mammary and prostate metastasis.
This method suffers temporal restrictions, since sometimes the experiments have to be
stopped due to large primary tumors, and therefore primary tumor resection is required to
observe full metastasis. Such surgical removal of primary tumors may change the course of
metastasis. Nevertheless, this method is also widely used to test causality of particular
genes/proteins. Once these data are in hand, and if transgenic or knockout mice are
available for the gene/protein-of-interest, endogenous tumor models are often crossed with
the transgenic or knockout mice to confirm their functions in metastasis.
Technologies used to Identify Metastasis Enhancers and Suppressors
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Many technologies have been applied to understand metastasis, each with its own merits
and caveats. For simplicity, I will divide the techniques used into three categories, focusing
on DNA, mRNA, or protein, respectively.
Changes at DNA Level
Several techniques have been used to investigate chromosomal changes, which reveal
copy number and structural differences at the whole-genome level, as well as regional
chromosome gain or loss. Conventional banding karyotyping has been used to identify
chromosomal changes. Although suffering from poor resolution, such analysis has
narrowed one of the early-identified tumor suppressors to chromosome 11 p11.2-13
(Ichikawa et al., 1992), which eventually led to the discovery of KAI1, a metastasis
suppressor gene (Dong et al., 1995). Currently this method has largely been replaced by
molecular cytogenetic techniques, including comparative genomic hybridization (CGH),
spectral karyotyping (SKY), multicolor fluorescence in situ hybridization (FISH), and single
nucleotide polymorphism arrays (SNP arrays). Essentially FISH consists of labeling DNA
probes (usually using bacterial artificial chromosomes or BACs) with different fluorescence
(red or green) directly or indirectly, followed by hybridization on chromosomal preparations
previous fixed on slides, which will be visualized in situ by microscope (Volpi and Bridger,
2008). FISH is best suited for detecting and localizing specific DNA sequences on the
chromosomes, and identifying numerical and structural chromosomal abnormalities.
Traditionally the resolution of FISH is limited by the size of BACs, which are usually 100s of
thousands of base pairs; however currently more than 30 different types of FISH have been
developed, some with resolution down to 1000bp (Volpi and Bridger, 2008). SKY uses
optical spectroscopy and chromosomal paint to examine the orderly arrangement of all
chromosomes, a nice tool to investigate chromosomal translocations. SKY can detect DNA
fragments as small as 1.5 million base pairs and can detect the origin of extrachromosomal
fragments present in tumor cells (Rutka et al., 2009).
CGH is another molecular cytogenetic technique, which traditionally involves labeling total
genomic DNA from two samples (for example, from cells with low or high metastatic abilities)
with different fluorescence directly or indirectly (red or green), and hybridizing to pre-fixed
metaphase chromosome spreads. The results are visualized with fluorescence microscopy
- any gain or loss of genetic material will be visualized and calculated as enhanced or
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dimmed fluorescence (Gebhart, 2004). CGH has been used to examine chromosome
imbalance. Although this traditional method has quite coarse resolution and cannot detect
differences below 3-5 mega base pairs, currently an improvement of this method has been
developed, which is array-CGH. In this technique, instead of hybridizing to metaphase
spreads, the probes are incubated with glass slides that have thousands of DNA sequences
spanning all chromosomes, offering unprecedented resolution of less than 100 kilobases.
Copy number changes (deletions, gains or amplifications) can be easily detected; however,
balanced chromosome translocations and inversions cannot be detected. Another genomic
array, SNP array, is frequently used for genetic linkage analysis to map disease-
susceptibility genes, and for loss of heterozygosity (LOH) analysis due to uniparental disomy
in cancer research. Using high-density SNP arrays to analyze large collections of human
lung adenocarcinomas, 57 recurrent events including large-scale chromosome arm-copy
number gain and loss and local amplification and homozygous deletions have been
observed. Through this work, a novel putative oncogene was identified which is located at a
frequently amplified region (chromosome 14q13.3), and encodes a transcription factor
(Andersen et al., 2007; Lindblad-Toh et al., 2000; Weir et al., 2007).
Recent breakthroughs in new sequencing methods have led to the development of "next
generation" sequencing technologies, including 454, Solexa or SOLiD sequencing. The end
results of such massive sequencing are tens of gigabases of sequencing data in a single
run, allowing genome-wide screening for point mutations, copy number changes and
rearrangement in a single experiment. The power of this technology has been shown
recently - Campbell et al have found more than 100 somatic rearrangements in two lung
cancer patients, and some of those resulted in fusion transcripts that may be involved in
oncogenesis. In another paper, Hodges et al combined exon-capture arrays with deep
sequencing, and re-sequenced - 200,000 exons in a single experiment (Campbell et al.,
2008; Hodges et al., 2007).
Since the goal of genomic analysis is to identify changes that may eventually result in
functional changes (by proteins and microRNAs), and due to the prevalence of repetitive
sequences and non-coding sequences in the human genome, chromosomal changes found
at the DNA level do not always yield functional consequences. Therefore, DNA analyses
are often combined with mRNA analyses in practice.
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Changes at the mRNA Level
cDNA library construction and subsequent screening with mRNA probes from highly or
poorly metatastic cells have been used to identify cDNA clones that showed differential
hybridization. This method (although painfully tedious) has been used successfully to isolate
the first metastasis suppressor gene NM23 (Steeg et al., 1988). Subtractive hybridization,
which relies on the removal of cDNA-mRNA hybrids formed between the control and test
samples, can also be used to detect differentially expressed transcripts. Using this method,
Kiss-I, another metastasis suppressor has been identified (Lee et al., 1996).
Although these methods have been useful in identifying transcriptional alterations, a
powerful new technique emerged in the 1990s has essentially replaced them. DNA
microarrays enabled the detection of changes in the whole transcriptome in one simple
experiment, and current advances in software not only allow the identification of individual
gene-expression changes, but also allow the recognition of signaling pathways that may be
altered (Subramanian et al., 2007). Since their development, DNA microarrays have been
applied efficiently to identity numerous genes that enhance or suppress metastasis. Early
work by Clark found that a small GTPase, RhoC, is upregulated in highly metastatic
melanoma cells and shown to be functionally involved in metastasis (Clark et al., 2000).
Following that, a large number of genes have been found to be up- or down-regulated in
metastasis, involving motility, survival, proliferation and angiogenesis (Nguyen et al., 2009).
Data from microarray analyses have helped to dissect some of the molecular mechanisms
of tissue tropism of metastasis (Gupta et al., 2005), and help define molecular interactions of
tumor-cell and microenvironment interactions (Joyce and Pollard, 2009), both are
fundamental questions regarding cancer metastasis.
In addition, microarray analyses have proven valuable in the clinic; profiling of the primary
tumors has shown the presence of gene signatures that predict the clinical outcomes of the
patients, thus providing an additional tool for patient therapy decision-making (Ramaswamy
et al., 2003; van 't Veer et al., 2002; Weir et al., 2007), and cathepsin cysteine proteases
identified from array analysis have been used in mouse lung adenocarcinoma models to
image the presence and progress of lung cancers (Grimm et al., 2005). Applying laser-
capture microdissection to isolate particular regions within the tumors, researchers have
analyzed the expression profiles of heterogeneous populations of cell in a given tumor, to
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identify tumor progression genes. For example, Schuetz et al have microdissected ductal
carcinomas in situ and invasive ductal carcinoma within breast tumors and performed
microarray analysis, and identified genes that are potentially involved in invasiveness
(Schuetz et al., 2006). The versatility and flexibility of arrays have been shown in work by
Hoshida et al, where formalin-fixed, paraffin-embedded, human samples,that have been
archived for up to 24 years can be used to perform array analyses, and yielded predictive
power for disease recurrence (Hoshida et al., 2008). In fact, work has been started to take
advantage of the predictive power of the gene signatures and to use that in clinical trials in
order to select breast cancer patients who might benefit from adjuvant chemotherapy (Mook
et al., 2007).
As mentioned earlier, combination analyses of chromosomal changes and expression
profiling are often used together, and ideally, changes in chromosomes show correlative
changes in mRNA transcription. Often, this is followed by analyses of corresponding
proteins to see if changes found in the above-mentioned process result in mutation,
truncation, or alteration in expression levels of the proteins. The reason for this indirect
approach to identify protein changes is that nucleotides are much easier to manipulate
experimentally and can be analyzed at large-scale genomic levels. On the contrary,
traditional protein-sequencing using Edman degradation is not suitable for high-throughput
screening. With recent technological improvements in protein-array and mass spectrometry,
direct protein comparisons are now becoming feasible.
Changes at the Protein Level
It needs to be mentioned that researches have cleverly taken advantage of the immune
system to identify proteins that are differentially expressed (either at different quantity or in
different forms). The development of monoclonal antibodies has been an invaluable tool to
identify novel proteins, and if high specificity is confirmed, they can be used to deliver toxins
or radio-isotopes selectively to cells expressing those antigens. For example, tenascin was
found to be overexpressed by human malignant gliomas (Bourdon et al., 1985; Bourdon et
al., 1983), and when conjugated with radio-isotopes, monoclonal antibodies to tenascin
have been used in clinical trials in glioma patients with significant efficacy (Bigner et al.,
1995; Cokgor et al., 2000). Other methods, including subtractive immunization and whole-
cell panning with subtraction, have been developed to look specifically for proteins
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differentially expressed on closely related cells. When searching for proteins that may
contribute to metastasis, mice were first immunized with poorly metastatic cells and treated
with immuno-suppressant drugs, followed by immunizing with highly metastatic cells and
generation of monoclonal antibodies from those mice (subtractive immunization). Through
this work, one monoclonal antibody was found to inhibit HEp3 cell metastasis, which was
later identified to be anti-CD151 antibody (Testa et al., 1999; Zijlstra et al., 2008).
Mass Spectrometry
Mass spectrometers measure the mass-to-charge ratios (m/z) of ions; therefore the very first
step of using mass spectrometers in biological analyses is converting neutral proteins- or
peptides-of-interest usually present in liquid to gas-phase charged molecules. This can be
accomplished by electrospray ionization (ESI) or matrix-assisted laser desorption/ionization
(MALDI). Indeed, it was the development of such ionization technologies that led to the
share of the 2002 Nobel Prize in Chemistry and finally application of mass spectrometry to
efficient biological analyses (Glish and Vachet, 2003). Currently there are many different
types of mass spectrometers, each with its own advantages and drawbacks, thus better
suited for different purposes. For example, linear ion-trap mass analyzer possesses great
sensitivity and fast data acquisition, but has limited resolution and is very useful for high-
throughput protein identification. On the other hand, quadropole time-of-flight (Q-TOF)
mass spectrometer exhibits high resolution and mass accuracy, and performs well for
quantitative analysis as well as posttranslational modification analysis (Domon and
Aebersold, 2006).
The basic procedures for protein identification using linear ion-trap type of mass
spectrometry is outlined below: 1) Enzymatic digestion of protein complexes (usually by
trypsin) to reduce the sizes to peptides; 2) Separation of complex peptide mixtures to
simplify the population of peptides introduced into the mass analyzer. This is typically
achieved by loading peptide mixtures onto reverse-phase HPLC and eluting with increasing
concentrations of organics, thus peptides are separated by their hydrophobicity; 3)
Ionization of peptides using electrospray ionization (ESI), which introduces (usually) positive
charges on the peptides, allowing the subsequent analysis; 4) Peptides (ions) fly into the
mass spectrometer and are focused along the way to enter the mass analyzers, where the
m/z (molecular weight/charge) is analyzed for all peptides present in the analyzer. This step
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is called an MS scan; 5) Particular peptides (ions) are then enriched in the ion trap followed
by collision-induced-dissociation (CID), which breaks the selected peptides to smaller
fragments at peptide bonds. The m/z of these smaller ions are again analyzed, and this
step is called an MS/MS scan. MS scan and MS/MS scan are repeated thousands of times
until all peptides from the HPLC are eluted. 6) Following this data-gathering stage, the
resulting thousands of spectra (where m/z is plotted against ion intensity) are searched
against protein/nucleotide databases using computer programs. The programs take the
MS/MS spectra as input and score them against theoretical fragmentation patterns, which
are computed for peptides in the databases. If a high confidence match is found for a
particular spectrum, it will be assigned with a peptide sequence, which will be matched to a
particular protein (Nesvizhskii et al., 2007; Steen and Mann, 2004).
This basic identification process can be modified to meet quantification needs. This usually
involves chemically or metabolically labeling one population of proteins/peptides with
"heavy" isotope entities (such as 13C, 15N), while the other population remains "light" (with
12C or 14N). When these two populations are mixed and subjected to mass spectrometric
analysis, they can be separated by their m/z difference in the spectrum, thus allowing for
relative quantification (Ong and Mann, 2005).
In the past 10 years, significant technological improvements in mass spectrometers and the
completion of genomic sequencing have pushed mass spectrometry to the center stage of
protein identification and quantification at the system level. The impressive sensitivity
(attomoles of peptides can be detected), the ability to identify proteins and their
modifications, coupled with novel quantitative methods, has enabled mass spectrometry to
perform high-throughput analysis to identify and simultaneously quantify large numbers of
proteins in given cells or tissues (Andersen and Mann, 2006; Cox and Mann, 2007; Cravatt
et al., 2007; Domon and Aebersold, 2006; Han et al., 2008). To date, mass spectrometry
has been applied successfully to investigate protein-protein interactions (Burckstummer et
al., 2006; Danial et al., 2003; Drakas et al., 2005; Honey et al., 2001), to understand
organelle components and dynamic changes of organelles in response to stimulations
(Andersen et al., 2005; Andersen and Mann, 2006; de Hoog et al., 2004; Foster et al.,
2003), to investigate protein-level changes during disease progression, such as during
tumor progression and metastasis (Conn et al., 2008; Everley et al., 2006; Everley et al.,
2004; Hastie et al., 2005; Leth-Larsen et al., 2009; Lund et al., 2009; Rahbar and Fenselau,
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2004), to understand cell signaling pathways in response to particular stimulation ((Macek et
al., 2009; Nita-Lazar et al., 2008; White, 2008), and to characterize known and novel post-
translational modifications of proteins, such as ubiquitination, SUMOylation, methylation
(Denison et al., 2005; Makhnevych et al., 2009; Miranda and Sorkin, 2007; Ong et al.,
2004). Recent focus on biomarker identification from blood or tissue fluid will undoubtedly
help with early disease diagnosis in the future.
One challenge that mass spectrometry faces is that proteins are present in the cells with
much higher complexity than at the mRNA level, due to various post-translational
modifications and splice variants, and are also present with large concentration differences.
For example, the dynamic range in serum reaches 10 orders of magnitude (Wright et al.,
2005). Due to these difficulties, one-experiment-analyze-all approaches such as DNA
microarrays are not feasible using mass spectrometry. Instead, analyzing a defined subset
of proteins usually yields deeper and often more useful information. In addition, proteins
often have different functions when localized at different subcellular localizations - for
example, ErbB-1 functions as the epidermal growth factor receptor on the plasma
membrane, transducing signals to activate the MAPK signaling pathway; however, ErbB-1
bound to ligand can translocate to the nucleus and function as a transcription activator for
activation of cyclin D1, and C-terminal fragment of ErbB-4 can also translocate to the
nucleus, and regulate the transcription factor Yes-associated-protein (Aqeilan et al., 2005;
Carpenter, 2003; Komuro et al., 2003; Omerovic et al., 2004). Therefore analyzing specific
organelles not only functionally simplifies samples for mass spectrometry analyses, but also
provides information about protein localization, which is one important part of protein
function. This type of inventory analysis can be coupled with large-scale protein-protein
interaction profiling, to shed light on the complex protein networks within each organelle and
among different organelles (Andersen and Mann, 2006).
Cancer Membrane Proteomics
As mentioned in Chapter 1, membrane proteins play important roles during various stages
of tumor progression and metastasis. In a sense, they function as the 'antennae" for cells to
detect their environment and determine the cellular outcome, such as cell proliferation,
migration or apoptosis, in response to the stimuli present in the environment.
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Studying plasma membranes at the proteomics level has only been made possible by the
advances in the mass spectrometry and 2D electrophoresis fields. Using 2D
electrophoresis, two populations of complex protein mixtures can be differentially labeled
using fluorophores before electrophoresis and relative protein quantities can be detected
based on the fluorescence ratios present at each protein spot. The spots can then be
excised for identification using mass spectrometry. Such analyses have proven useful to
identify membrane proteins involved in tumor progression and metastasis (Blonder et al.,
2006; Dowling et al., 2007; Jiang et al., 2003; Roesli et al., 2008).
Using quantitative mass spectrometry, more membrane proteins have been discovered to
change expression among tumor cells (Dowling et al., 2008; Everley et al., 2006; Everley et
al., 2004; Hastie et al., 2005; Keshamouni et al., 2006; Leth-Larsen et al., 2009; Lund et al.,
2009; Patra, 2008; Rahbar and Fenselau, 2004). For example, recently the Quigley group
have isolated plasma membrane from HT-1080 fibrosarcoma cells that are highly
disseminating or poorly disseminating, and have identified 47 membrane proteins that are
differentially expressed. Among them, tissue factor (TF) has been shown to be functional
involved in tumor cell intravasation in a chick CAM (chorioallantoic membrane) metastasis
model (Conn et al., 2008).
Currently, application of quantitative mass spectrometry has yielded a large amount of
information, however, in most cases, this information remains un-validated. Very few of
these identifications have been followed up with functional tests for their actual involvement
in metastases, or followed up to test their efficacies as disease markers. However, as more
researchers become dissatisfied with merely inventorying membrane proteins, we may see
improvements over the current analyses.
EXPERIMENTAL GOALS AND APPROACHES
We are interested in understanding differences between tumor cells with high versus low
metastatic abilities. In particular, given known interactions between tumor cells and their
microenvironment, we are particularly interested in plasma membrane proteins that show
differential expression levels. We would like to focus on potential adhesion molecules, as
mentioned in Chapter 1, I believe that a better understanding of adhesion molecules (cell-
cell adhesion and cell-matrix adhesion) - their functions in metastasis formation, and the
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molecular mechanisms of such functions - should shed light on the mechanisms that tumor
cells use to communicate with their microenvironment.
With this goal in mind, I first identified membrane proteins that are present on melanoma
cells using membrane enrichment, proteolysis, followed by liquid chromatography coupled to
tandem mass spectrometry (LC-MS/MS). Then I applied newly developed quantitative mass
spectrometry methods to screen for membrane proteins that showed expression-level
differences between poorly metastatic A375 cells and highly metastatic MA2 cells. These
analyses were followed by confirming changes using other conventional methods and
eventually I focused on one particular membrane protein for functional studies, which will be
described in Chapter 3.
RESULTS
Plasma Membrane Enrichment
Previously a series of melanoma cells with different metastatic abilities have been
established in our lab (Xu et al., 2006). A375 cells are poorly metastatic when introduced
into the mice via tail-vein injection, while MA2 cells form large numbers of lung tumors using
the same assay. To enrich for plasma membrane proteins, we decided to apply a colloidal
silica method since this method introduces minimum alteration of the proteins, as compared
with surface biotinylation; and this method has been shown to remove intracellular
membranes, such as ER and Golgi membranes and to enrich for plasma membranes
specifically. Contamination by internal membranes is the major caveat for microsome
fractionation protocols that enrich for membranes.
The colloidal silica protocol was developed by the Jacobson group, which took advantage of
the electrostatic interactions between positively charged colloidal silica beads and negatively
charged plasma membranes (Chaney and Jacobson, 1983; Rahbar and Fenselau, 2004;
Sambuy and Rodriguez-Boulan, 1988; Stolz et al., 1992; Stolz and Jacobson, 1992). Briefly
A375 or MA2 cells were dissociated from the culture plates by incubating in PBS for 5-
10min, and cell numbers were determined. After coating the cells with colloidal silica beads,
the cells were over-coated with anionic polyacrylic acid to stabilize colloidal pellicles and to
minimize contaminations between exposed colloidal silica beads and cell debris. Following
resuspension in hypotonic lysis buffer, cells were lysed with a Parr nitrogen bomb and the
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cell lysate was centrifuged at low speed (900g) to remove cytosolic proteins (supernatant I
or Supt I). Pellets from this low-speed centrifugation (pellet I or PI) were loaded onto 70%
Nycodenz, and were centrifuged at 15000g to pellet plasma membranes. Membranes from
other organelles concentrate at the interface between the two layers. After removing top,
middle and bottom layers, the pellet was washed three times with basic buffer to remove
loosely associated proteins, and the final pellet (pellet II) was stored at -800C until analysis.
The membrane isolation procedure is shown in Figure 1A.
Western blot experiments were performed using a list of antibodies against different
subcellular organelle markers (Figure 1B), among which, integrin a2 was used as marker for
plasma membrane, Golgin 97 as the Golgi marker, and Sec61 3 was used as ER marker.
Images of the western blots are shown in Figure 1C, and the relative plasma membrane
enrichment was determined based on the densitometry measurements compared to the
whole cell lysate, and a 10-15 fold enrichment was routinely achieved.
Mass Spectrometry and Protein Identifications
Enriched membrane proteins were separated on 4-20% gradient gels and stained with
Coomassie blue SafeStain (Figure 2A). 30 gel slices were dissected from the sample gel,
reduced, alkylated, and in-gel digested with trypsin. Peptides were extracted and dried using
Speed-vac, and were then reconstituted in 0.1% formic acid in deionized H20. One-third of the
peptides from each gel slice were analyzed with LTQ ion-trap mass spectrometer from Thermo
Finnigan, using in-line liquid chromatography- tandem mass spectrometry (LC-MS/MS). Data
were collected by the mass spectrometer in data-dependent acquisition mode, with 10 most
abundant ions collected for MS/MS scan following a survey scan (MS scan) in each cycle.
These data were analyzed using Sequest software, and annotated for subcellular localization.
A total of 1325 proteins were identified, with 384 (37.8%) identified by one peptide, 355 (34.9%)
identified by two peptides and 586 (57.7%) proteins identified with three or more peptides
(Figure 2B). Among the 586 proteins, 56.3% were identified with 3-5 peptides, 29% were
identified with 6-10 peptides and 14.7% were identified with more than 10 peptides (Figure 2C).
Next, we analyzed the subcellular localization of identified proteins using GO term analysis
(Figure 2D). We found approximately 26% of GO-term associated proteins are plasma
membrane proteins, while -10% are cytoskeleton proteins. The significant contamination came
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from cytosol (8.8%) and nucleus (23.1%). See appendix C for the full list of proteins that were
identified in this work.
Stable Isotope Labeling by Amino Acids in cell Culture (SILAC) and Quantitative Mass
Spectrometry
SILAC was developed in the Mann group (Ong et al., 2002; Ong et al., 2003), where heavy
isotope-enriched amino acids were fed to the cells in tissue culture. After extended periods of
time, almost all proteins are labeled with "heavy" amino acids. Currently, the most commonly
used amino acids are arginine and lysine, because tryptic peptides usually contain at least one
of these two residues. Since its development, this technique has been widely applied to
measure relative protein and phospho-protein abundances (Aggelis et al., 2009; Cox et al.,
2009; Gioia et al., 2009; Ong et al., 2009; Oppermann et al., 2009; Pimienta et al., 2009).
Compared with other chemical labeling techniques, SILAC is best used for in vitro culture
systems since it requires at least five passages in the medium to ensure full incorporation of the
heavy amino acids, although recently SILAC mice have been developed - the mice were fed
with a heavy amino-acid-enriched diet and thus all cells in the mice are "heavier" than those
from littermates that were given regular diet - thus opening the door for in vivo quantification
(Kruger et al., 2008). Because SILAC labeling occurs at the protein level, differentially labeled
cells can be mixed early on before any manipulations are done, thereby minimizing errors
introduced by experimental procedure. For these reasons, we chose to use SILAC to fulfill our
quantification needs, and a schematic is outlined in Figure 3A.
To determine empirically the cut-off value for quantification, "light" and "heavy" peptides with the
same sequence were synthesized by the Biopolymer Lab at the Koch Institute. The heavy
peptides were synthesized in the presence of "heavy"-L-Leucine-N-FMOC (U-13C6, 15N -L-
leucine), therefore the molecular weights of heavy peptides are 7 daltons heavier than light
peptide. These two peptides were mixed at equal amount and 20 femtomole, 200 femtomole, or
2 picomole of the mixture were introduced into the mass spectrometer. Upon data collection
and database search, relative quantities of these two peptides were obtained using PepQuan
software, which is part of the BioWorks Browser package (Agilent). Based on this information,
we choose to define a conservative ratio 50.75 as showing decreased expression, and a ratio
>1.25 as defining enhanced expression (Figure 3B).
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Passage-matched A375 (low metastatic cells) and MA2 (high metastatic cells) were grown in
"light" (ArgO, Lys 0) and "heavy" (ArglO0, Lys 8) media, respectively; equal amounts of total cell
lysate from these two cell lines were mixed and plasma membrane preparations were made. A
total of 80pg of membrane proteins were separated on 4-20% gel and 20 gel slices were cut
and in-gel digested. Samples were analyzed with LC-MS/MS as mentioned above; with slight
modification of sample-acquisition method. Briefly, during gradient elution from the HPLC,
followed by an MS scan, zoom scan spectra and MS/MS spectra were obtained for each of the
top 5 abundant ions per data-dependent cycle. Data were analyzed using Sequest software for
identification and with PepQuan for quantification. Figure 3C and 3D show examples of the
identification and quantification of SILAC peptide pairs from EphA2. Table 1 and table 2 show
proteins that are downregulated or upregulated in highly metastatic MA2 cells relative to poorly
metastatic A375 cells, respectively. In total, we found approximately 60% of all proteins
generated quantitative information, while the relative quantities of 40% of the identified proteins
could not be determined, most likely due to their low abundance. Out of all proteins that were
quantitated, 23% have shown differential expression between A375 cells and MA2 cells.
Confirmation of Mass Spectrometry Analysis
To confirm the mass spectrometry data, western analysis and flow cytometry (FACS) analyses
were performed. Equal amounts of total protein lysates from passage-matched A375 and MA2
cells were loaded onto SDS-PAGE gels, and western analysis was carried out using antibodies
against integrin a3 and EphA2 (Figure 4A). We found reduction in integrin a3 (top panel) and
EphA2 (bottom panel) protein levels in MA2 cells relative to A375 cells. These results are in
agreement with the mass spectrometry quantifications. However, we did not observe total
protein expression change in CDCP1 using cells in vitro by western blotting (Figure 4B). We
then carried out FACS analysis to investigate specifically protein abundance at the cell
membrane, on which the mass spectrometry analyses were done. Indeed, flowcytometry
showed that surface CDCP1 is upregulated in MA2 cells compared to A375 cells, confirming the
mass spectrometry results (Figure 4C). We also found that surface expression of integrin a3 is
reduced in MA2 cells, again agreeing with mass spectrometry results (Figure 4D). To compare
in vitro and in vivo protein expression levels, we generated subcutaneous tumors using A375
cells or MA2 cells and blotted for CDCP1 and EphA2 expression using the tumor samples. In
line with the in vitro mass spectrometry data, we saw increased CDCP1 and decreased EphA2
total protein levels in the subcutaneous tumors generated from MA2 cells relative to those from
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A375 cells (Figure 4E).
DISCUSSION
Plasma membrane constitutes only about 2% of the cellular proteins, and a small percentage of
the total cellular membrane content (Kearney and Thibault, 2003). This low abundance relative
to internal membranes, its similarity to other organelle membrane components, and its
propensity to exist in different structures (open sheets, closed vesicles) have made plasma
membrane isolation a challenge to researchers (Rahbar and Fenselau, 2004). Strategically, two
methods have been developed for this purpose. One based on the density differences between
membranes and other subcellular organelles, usually achieved by (ultra)centrifugation in
sucrose gradient. Membrane preparations obtained with this method are typically heavily
contaminated with internal membranes such as mitochondria and ER membranes due to their
similarity in densities (Macher and Yen, 2007). The colloidal silica method we applied is one
step above this traditional microsome preparation, which significantly removes internal
membrane contamination (Chaney and Jacobson, 1983; Stolz et al., 1992; Stolz and Jacobson,
1992). The other method applies affinity purification with or without up-front modifications.
Lectin affinity purification has been developed based on the presence of glycosylation on
membrane proteins (Macher and Yen, 2007). Initially we tried this method early on without
much success, and also due to concerns that different lectins may selectively bind to a subset of
proteins, thus biasing our enrichment effort. Another available affinity-based method took
advantage of membrane-impermeable biotinylation followed by high-affinity biotin-avidin
interaction for purification (Conn et al., 2008; Zhang et al., 2003). We also tried this method,
which offered similar results compared to the colloidal silica method (data not shown). Due to
the same worry of selective enrichment, we decided to choose colloidal silica method as our
primary method. But I believe that surface biotinylation is a good complementary technique.
In this work, we applied a colloidal silica pellicle method to enrich for plasma membrane.
Western analysis showed significant removal of ER and Golgi proteins, as well as nuclear and
cytosolic (data not shown) proteins, while retaining plasma membrane proteins. We routinely
achieved 10-15 fold enrichment, although >20 fold enrichment has been reported (Durr et al.,
2004; Oh et al., 2004), suggesting room for improvements. As suggested in the original
publications, the caveat of this protocol is contamination by nuclear proteins, because of density
similarity of coated plasma membrane and nuclei. And this is certainly manifested in our protein
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identification results - nearly 23% of identified proteins are nuclear proteins, which comprise the
major contaminants.
We identified a large number of proteins through this work, among which 941 were mapped by
two or more peptides to that particular protein with good confidence. This confidence came
from 1) stringent search criteria - we used Sequest search software and applied cutoffs of 2, 2.5
and 3.5 for ions with charges of 1, 2, or 3; and ACn of higher than 0.1. We also applied a cutoff
p value of less than 0.0001; and 2) additional visual inspection of the spectrum when less than 3
peptides were found to match a particular protein. Recently it was suggested that probability-
determining software that provide statistical measures of confidence and estimate false
discovery rates may need to applied as well for large datasets (Nesvizhskii et al., 2007). We
would like to try such statistical software in our future analyses, to see if it offers advantage
compared with our current method.
In our quantification, we found that nearly 40% of proteins identified did not generate
quantitative information. This is probably due to low abundance of these ions in the original
spectrum - although low abundance ions can be sequenced with good confidence, believable
quantification is not feasible if they are near or below the baseline. Another reason lies in how
the quantitative information was extracted: in an MS experiment, the ion intensity of a particular
peptide can be plotted against the time when the peptide is eluted from the HPLC. Therefore
effective quantification depends on the continued presence of that ion over a period of time, and
sometimes due to the complexity of the mixtures, this is not possible (Ong and Mann, 2005). As
a result, the quantitative information could not all be extracted with high confidence. We also
noticed that the majority of the changes are less than 2 fold, in part, this may due to the intrinsic
capability (or incapability) of the particular type of instrument that we used. We used a linear
ion-trap mass spectrometer for our analyses, which is very useful for high-throughput protein
identification, but is known to have limited resolution and low dynamic range. Future work with
improved instrumentation will offer more precise quantifications.
Despite these caveats, we were pleased to identify proteins that have previously been
implicated in metastasis, such as melanoma adhesion molecule (CD146/MUC18) (Wu et al.,
2004) and CD44, a receptor for hyaluronic acid (Hill et al., 2006), as well as EphA2 (Brantley-
Sieders et al., 2005; Brantley-Sieders et al., 2008; Vaught et al., 2008) and integrin 33 (Felding-
Habermann et al., 2001; Li et al., 2001; Pecheur et al., 2002; Switala-Jelen et al., 2004).
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For reasons that will be detailed in the next chapter, I focused on a transmembrane protein
CDCP1 (cub-domain-containing protein 1) for further analysis. We found from our membrane
mass spectrometry that CDCP1 expression is increased in highly metastatic MA2 cells relative
to the parental poorly metastatic A375 cells. Investigating total expression levels using whole
cell lysates and western blotting suggested that total protein levels are not significantly changed
between these two cells lines, rather, surface expression levels are different using flow
cytometry analysis. This type of data highlights the importance of analyzing proteins at the
subcellular localizations where they are functional. Interestingly, previous microarray analysis
by Dr. Lei Xu had found that the mRNA level of CDCP1 is reduced in subcutaneous tumors
generated by MA2 cells compared with those by A375 cells. However, protein quantitation of
CDCP1 showed that it is indeed increased in tumors generated by MA2 cells. Perhaps such a
discrepancy is not unexpected, Gygi et al have shown that for low abundance
transcripts/proteins, changes in the quantity of mRNAs are not reliable indicators of protein
abundance (Gygi et al., 1999). This discrepancy indicates that translational and post-
translational regulation of CDCP1 may occur, which awaits further elucidation. We are
interested in knowing how often this kind of difference occurs and what are the characteristics of
the transcripts /proteins that present such discrepancies. For this purpose, I have carried out
microarray analysis using passage-matched A375 cells and MA2 cells (data not shown), and
systematic comparison between protein abundances and mRNA levels will be the obvious next
step.
In summary, we have applied cutting-edge quantitative mass spectrometry analysis to identify
plasma membrane proteins, but also to investigate quantitative differences between tumor cells
with low or high metastatic potentials. Out of a list of proteins that showed differential
expression, we have confirmed such changes using other conventional methods, and we are
focusing on one of these proteins, CDCP1, for functional characterization and molecular
dissection, which will be detailed in the next three chapters.
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Figure 1. Plasma membrane enrichment. (A) Schematic of colloidal silica membrane enrichment protocol.
(B) and (C) Antibodies used (B) in western blotting to show removal of intracellular membranes and cytosolic
proteins, and enrichment of plasma membrane proteins).
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Figure 2. Identification of membrane-enriched proteins. (A) The pellet that contains the enriched
membrane proteins was separated on 1D SDS-PAGE gel, cut into 20-30 gel slices and each gel slice was in-gel
digested with trypsin, and peptides were extracted. (B) Distribution of proteins identified by number of
peptides. Approximately 70% of the proteins were identified with 2 or more peptides. (C) Among the
proteins that were identified by more than 2 peptides, 56.3% were identified with 3-5 peptides, 29% were
identified with 6-10 peptides and 14.7% were found with more than 10 peptides matching a particular
protein. (D) Distribution of proteins identified in this work, categorized by their subcellular localizations.
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Figure 3. SILAC coupled with LC-MS/MS for protein quantification. (A) Schematic SILAC strategy to label
A375 and MA2 cells and subsequent sample processing for quantitative analysis. (B) Ratios of synthetic
heavy/light peptides were determined using PepQuant, and plotted against the theoretical ratio. Based on
this result, heavy/light ratios that are <0.75 or >1.25 are considered different between two samples.
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Figure 3. SILAC coupled with LC-MS/MS for protein quantification. (C) Representative zoom scan spectrum
showing SILAC peptide pair from EphA2. The peptide pair shown has a charge of 2+, giving rise to an m/z
difference of 5. (D) Tandem mass spectrum (MS/MS) of the peptide shown in C. Masses of expected b- and
y-type fragment ions are shown.
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# of
Accession protein name peptides ratio (H/L)
P29317 EPHA2 Ephrin type-A receptor 2 8 0.18
Q59H77 Chaperonin containing TCP1, subunit 3 (Gamma) variant 7 0.28
Q01650 Large neutral amino acids transporter small subunit 1 4 0.29
P32970 Tumor necrosis factor ligand superfamily member 7 (CD70) 4 0.29
Q5JWF2 Guanine nucleotide-binding protein G(s) subunit alpha isoforms 13 0.45
Q96MN4 CDNA FLJ32119 fis,similar to RNA binding protein EWS 4 0.47
Q7Z3V1 Integrn beta 1 7 0.5
Q13765 Nascent polypeptide-associated complex subunit alpha 4 0.51
Q03405 Urokinase plasminogen activator surface receptor 3 0.52
P55290 Cadherin-13 7 0.52
Q99623 Prohibitin-2 (B-cell receptor-associated protein BAP37) 6 0.55
Q15417 Calponin-3 (Calponin, acidic isoform) 4 0.55
043809 Cleavage and polyadenylation specificity factor 5 8 0.58
P35232 Prohibitin 5 0.59
P38159 Heterogeneous nuclear ribonucleoprotein G (hnRNP G) 4 0.6
Q53X65 GAPD protein 8 0.64
P23246 Splicing factor, proline- and glutamine-rich 14 0.66
P22087 rRNA 2'-O-methyltransferase fibrillarin (EC 2.1.1.-) 13 0.66
P30825 High-affinity cationic amino acid transporter 1 2 0.66
P09471 Guanine nucleotide-binding protein G(o) subunit alpha 1 6 0.67
Q14157 Ubiquitin-associated protein 2-like (Protein NICE-4) 5 0.68
P33176 Kinesin heavy chain (Ubiquitous kinesin heavy chain) (UKHC) 3 0.68
095183 Vesicle-associated membrane protein 5 (VAMP-5) 3 0.69
P00505 Aspartate aminotransferase, mitochondrial precursor 5 0.7
P05026 Sodium/potassium-transporting ATPase subunit beta-1 6 0.7
P14625 Endoplasmin precursor, Heat shock protein 90 kDa beta member 1 11 0.71
P50443 Sulfate transporter (Diastrophic dysplasia protein) 8 0.71
P26006 Integrin alpha-3 3 0.72
Q5CAQ7 Heat shock protein HSP 90-alpha 2 26 0.73
Q4LE56 MYO1C variant protein 7 0.74
Q8ND56 Protein FAM61A (Putative alpha synuclein-binding protein) 4 0.74
P54136 Arginyl-tRNA synthetase, cytoplasmic 4 0.74
Q96PD2 Discoidin, CUB and LCCL domain-containing protein 2 2 0.74
Q99832 T-complex protein 1 subunit eta (TCP-1-eta) 6 0.75
Charged multivesicular body protein 6, Vacuolar protein sorting-
Q96FZ7 associated protein 20 3 0.75
Q9Y266 Nuclear migration protein nudC 4 0.75
P31689 Heat shock 40 kDa protein 4 0.75
Q9UHX1 Ro ribonucleoprotein-binding protein 1 (SIAHBP1 protein) 5 0.75
P15880 40S ribosomal protein S2 (S4) (LLRep3 protein) 16 0.75
P51149 Ras-related protein Rab-7 5 0.75
Table I. Proteins that are down-regulated in highly metastatic MA2 cells relative to poorly
metastatic A375 cells.
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# of
Accession protein name peptides ratio (H/L)
Q6ZNL4 FLJ00279 protein 11 1.25
P62249 40S ribosomal protein S16 6 1.25
Q59GM9 Brain glycogen phosphorylase variant 8 1.26
Q5WDO Ribosomal protein 4 1.26
P60866 40S ribosomal protein S20 6 1.26
P17301 Integrin alpha-2 precursor (Platelet membrane glycoprotein 10 1.26
Q14254 Flotillin-2 (Epidermal surface antigen) (ESA) 5 1.26
P49588 Alanyl-tRNA synthetase, cytoplasmic (EC 6.1.1.7) (Alanine- 5 1.27
Q53G25 Ribosomal protein S5 variant (Fragment) 8 1.29
Plasma membrane calcium-transporting ATPase 1 (EC
P20020 3.6.3.8) 5 1.3
P42766 60S ribosomal protein L35 4 1.32
Q71U19 Histone H2AV (H2A.F/Z) 5 1.33
P01903 HLA class II histocompatibility antigen, DR alpha chain 16 1.35
Q96AG4 Leucine-rich repeat-containing protein 59 5 1.35
Q5VWA5 Dolichyl-diphosphooligosaccharde-protein glycosyltransfe 5 1.38
Plasma membrane calcium-transporting ATPase 4 (EC
P23634 3.6.3.8) 5 1.39
Q548L2 CTCL tumor antigen HD-CL-06 (Vimentin variant) 17 1.4
000161 Synaptosomal-associated protein 23 (SNAP-23) (Vesicle-mem 10 1.42
Q59GJ2 HLA class I histocompatibility antigen, A-1 alpha chain v 4 1.44
P05106 Integrin beta-3 11 1.5
Q30180 MHC class II HLA-SB-beta-1 gene (untyped), clone LC11 3 1.52
Q58J86 Elongation factor 2 16 1.54
P18085 ADP-ribosylation factor 4 4 1.55
Q6W6M8 Antigen MLAA-42 7 1.68
Q6NOB3 Hypothetical protein DKFZp686PO3159 15 1.68
Q07065 P63 protein (Cytoskeleton-associated protein 4) 4 1.73
P62826 GTP-binding nuclear protein Ran (GTPase Ran) 5 1.79
P43121 MUC18, Melanoma-associated antigen MUC18 13 1.9
Q9H5V8 CUB domain containing protein 1 (CDCP1) 2 2.03
P16070 CD44 antigen precursor (Phagocytic glycoprotein I) (PGP-1) 7 2.23
CD59 glycoprotein precursor (Membrane attack complex
P13987 inhibitor) 3 2.24
P06396 Gelsolin precursor (Actin-depolymerizing factor) 19 2.33
P47895 Aldehyde dehydrogenase 1A3 10 2.42
Protein kinase C and casein kinase substrate in neurons
Q9UKS6 protein 3, Endophilin I 5 2.52
Q96B97 SH3-domain kinase-binding protein 1 (Cbl-interacting protein) 5 2.77
Table II. Proteins that are up-regulated in highly metastatic MA2 cells relative to poorly metastatic A375
cells.
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Figure 4. Western blotting and FACS confirming quantitative results obtained from mass spectrometry. (A)
Total cell lysates were blotted using antibodies against integrin a3 and EphA2, confirming that both proteins
are downregulated in MA2 cells relative to A375 cells. (B) Anti-CDCP1 western blot showed that total CDCP1
protein levels did not change. (C) However, cell surface CDCP1 expression level on average, is enhanced in
MA2 cells, thus confirming our mass spectrometry results. (D) When subcutaneous tumors generated from
MA2 cells or A375 cells were blotted for the expression levels of CDCP1, they also showed increased
expression in MA2 cells. (E) Flow cytometry analysis of integrin a3 revealed reduced surface expression in
MA2 cells compared to A375 cells, in agreement with mass spectrometry result.
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CHAPTER 3.
A TEST FOR THE ROLE OF CDCP1 IN MELANOMA
METASTASIS
The work in this chapter is conceived by Hui Liu and Richard Hynes. The contents of this
chapter were written by Hui Liu, with editing by Richard Hynes.
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INTRODUCTION
As described in Chapter 2, we have identified proteins that are differentially expressed
between tumor cells with high versus low metastatic potentials, and we have confirmed the
changes in expression levels using conventional western blotting and flow cytometry
analyses. One of the proteins, cub-domain-containing protein 1 (CDCP1) attracted our
attention. In this chapter, I will detail the rationales of choosing CDCP1 for further functional
analyses, and summarize current knowledge on cub domains.
CUB DOMAIN CONTAINING PROTEIN 1 (CDCP1)
Early works leading to the discovery of CDCP1 - CDC1 in cell adhesion and in cancer
and cancer metastasis
CDCP1 is a type I transmembrane protein, with extracellular N-terminal signal peptide
(amino acid residuesl-29), one high score CUB domain and two low score CUB domains
(approximately residue ranges 220-350, 425-523, and 545-660), followed by a single
transmembrane domain (residues 666-691) and a cytoplasmic domain (residues 692-836)
(Figure 1A). Northern blots show that CDCP1 is expressed most highly in skeletal muscle
and colon, followed by small intestine, lung, kidney and placenta (Hooper et al., 2003).
Prostate, thyroid and tongue also express CDCP1**. Although the function of CDCP1 is
largely unclear, the works that led to the discovery of this protein may shed some light.
CDCP1 was discovered through four independent researches. In the earliest work in 1996,
Xia et. al. found that when human foreskin keratinocytes (HFK) were detached from laminin
5 using trypsin, a strongly tyrosine-phosphorylated protein band at 80kDa was detected, but
disappeared when the cells were allowed to re-adhere. This is in marked contrast to focal
adhesion kinase (FAK), which is strongly phosphorylated when HFK cells are attached, and
de-phosphorylated with cells are in suspension (Xia et al., 1996). The same group identified
p80 as CDCP1 eight years later, with a precursor at 140kDa. It was shown that Src family
kinases (SFKs) are responsible for the phosphorylation and phosphoprotein phosphatase
** Source: Genomics Institute of the Novartis Research Foundation, provided by Steve Sheng.
Chapter 3
(PTPs) are responsible for the dephosphorylation of CDCP1, but the identity of the PTP
was not clear (Brown et al., 2004). These two papers showed correlation between cell de-
adhesion and phosphorylation of CDCP1, but the cause-effect relationship was not
analyzed.
In agreement with the idea that SFKs phosphorylate CDCP1, Bhatt et al when searching for
novel Src substrates during mitosis, found that CDCP1 is in the same immuno-precipitated
complex as Yes during mitosis. In vivo phosphorylation of CDCP1 is inhibited by three
different SFK inhibitors (PP1, PD173955 and PD179483) and, in vitro, CDCP1 can be
directly phosphorylated by Src. When CDCP1 was over-expressed in adherent mammary
carcinoma MDA-468 cells, the cells detached from the plate and proliferated in a loosely
adherent suspension, suggesting a causal role of CDCP1 in cell de-adhesion (Bhatt et al.,
2005).
CDCP1 was also shown to be overexpressed in human colorectal and lung cancer by
Schweifer's group. Using representational difference analysis (RDA) together with cDNA
array technology, Scherl-Mostageer et. al. found CDCP1 is over expressed in human lung
carcinoma and colon carcinoma (Scherl-Mostageer et al., 2001). In addition, using whole-
cell panning of antibody libraries against human prostate cancer PC3 cells subtracted by
normal prostate cells, Siva et. al. identified an antibody that reacts with CDCP1, suggesting
that CDCP1 may be differentially or over- expressed on human prostate cancer cells (Siva
et al., 2008).
Hooper et al used subtractive immunization and discovered that CDCP1 is more abundantly
expressed on highly metastatic human epidermoid carcinoma cells line, M'HEp3, as
compared with the poorly metastatic parental line HEp3. SFK-dependent tyrosine
phosphorylation of CDCP1 in these cells was also confirmed. Together these studies
suggest that CDCP1 is upregulated in several different cancers relative to the normal tissue,
and over-expressed in highly metastatic cells compared with the poorly metastatic
counterpart.
These early works on CDCP1 did not assign a functional role to CDCP1 during tumor
formation or metastasis, but present it as an interesting molecule, especially in light of the
fact that proteins involved in adhesion/migration have frequently been found playing roles
Chapter 3
during metastasis. These data prompted us to select CDCP1 as one of the candidate
proteins, to test for functional involvement in melanoma metastasis.
CUB DOMAINS
As mentioned earlier, CDCP1 contains three extracellular CUB domains. Although the
functions of CDCP1 were not clear, we hoped to gain insights in this manner by knowing
what are the other proteins that contain CUB domain, and the function of CUB domain in
those proteins, and by understanding the structural features of CUB domains.
The name CUB domain comes from three proteins where the domain was originally defined
- complement proteins C1s/C1r, sea urchin protein uEGF, and bone morphogenesis protein
1 (Bork, 1991). This domain contains approximately 110 amino acids and is almost
exclusively found in membrane proteins and secreted proteins (SMART domain analysis).
At the amino acid level, the conserved features of CUB domains include 1) the presence of
four conserved cysteines, which suggests the presence of two disulfide bridges, and 2)
conserved hydrophobic and aromatic amino acids throughout the domain, which is a pattern
typical for proteins with anti-parallel beta sheets (Bork and Beckmann, 1993). It is found in
functionally diverse proteins such as a family of spermadhesins that are involved
fertilization, complement subcomponents, dorso-ventral patterning proteins Tolloids, and in
endocytic receptor cubilin, and is believed to function in protein-protein and/or
protein/carbohydrate interactions.
Proteins Containing CUB domains
Analysis of CUB domains through the PFAM database showed that more than 900 proteins
have CUB domains in their architectures (Pfam 23.0, July 2008, 10340 families). Among
those, most of the proteins are from eukaryotes, especially from metazoans.
Among all 940 metazoan proteins that contain CUB domains, we can roughly divide into four
subfamilies. The first family contains CUB domains only, ranging between one to 15 CUB
domains, with the majority of this family having one (134 out of 206 proteins). This family
includes CDCP1, as described above.
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Proteins harboring protease domains, such as trypsin/chymotrypsin-like serine protease
domain or Zn"-dependent metalloprotease domain, belong to the second family. This family
has more than 260 proteins, making up approximately 25% of all CUB-containing proteins.
The founding members of CUB domain - complement system proteins C1s/C1r and bone
morphogenesis protein 1(BMP-1) belong to this family. Proteins containing these enzymatic
domains most likely function as proteases cleaving other cellular proteins or extracellular
matrix proteins in regulated fashion.
The third family is the largest family, comprising approximately half of all CUB-containing
proteins. All of them have one or more domains known to be involved in protein-protein
interactions, such as Sushi domains (Kirkitadze and Barlow, 2001), Fibronectin III repeats
(Hynes et al., 1984), discoidin domains, and low density lipoprotein receptor domains; or
involved in protein-carbohydrate interaction such as lectin domains (Kogelberg and Feizi,
2001). Although the functions of many of these proteins are not known, they are speculated
to be involved in protein-protein interaction or protein-carbohydrate interactions. In some
cases, these interactions may transmit signals through transmembrane domains. One
example is G-protein coupled receptor 126 (GPR126). It belongs to an orphan G-protein
coupled receptor family that has exceptionally long extracellular domains N-terminal to their
seven trans-membrane segments (Bockaert et al., 2002; Oh et al., 2006). Proteins in this
orphan receptor family have recently been shown bind to tissue transglutaminase 2 and
suppresses melanoma metastasis (Xu et al., 2006).
The last family is small, with only 14 members, but unique, in that all family members
contain one growth factor domain. Platelet derived growth factor C and D (PDGF-C and -D)
are two such proteins, with a C-terminal PDGF domain and an N-terminal CUB domain,
which requires proteolytic removal before the PDGF-DD dimer can activate PDGF receptors
(LaRochelle et al., 2001; Li et al., 2000). Figure 1B shows examples for each family of
proteins containing CUB-domains.
In addition to eukaryotes, two viral proteins and several bacterial proteins from Flavobacteria
bacterium, Pseudoalteromonas atlantica, Chlorobium phaeobacteroide, and Bdellovibrio
bacteriovorus also contain CUB domains. Often these proteins contain either CUB domain
alone, or with fibronectin III repeat, laminin G domain, or in one case, repeats in polycystic
kidney disease 1 (PDK domain), suggesting adhesion-related functions.
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Functions of CUB domains
The functions of CUB domains have been attributed to protein-carbohydrate, protein-
phospholipid, protein-protein interactions and in some cases, protein trafficking and
localization.
Roles of CUB domains in protein-carbohydrate and protein-phopsholipid binding were
mostly elucidated in the spermadhesin family of proteins found on the surface of ungulate
sperm (Topfer-Petersen et al., 2008; Topfer-Petersen et al., 1998). Spermadhesins are 12-
16 kDa proteins involved in fertilization, which have a single CUB domain in each protein. In
pigs there are five members - AQN-1, AQN-3, AWN, PSP-1, PSP-II. It has been shown that
non-aggregated AWN-1 and AQN-3 are capable of interacting with phosphorylethanolamine
(Dostalova et al., 1995), and the binding region was mapped to residues 6-12 and 104-108
of the CUB domain (Ensslin et al., 1995).
Porcine spermadhesins also present diverse carbohydrate-interacting capacities. AQN-1
recognizes both a- and P- linked galactose, as well as Man al-3 (Mana 1-6) Man structure
(Ekhlasi-Hundrieser et al., 2005); AQN-3 interacts with Gal p1-3 GIcNAc and Gal p1-4
GIcNAc sequences; and AWN binds only galactose. Isolated PSP-II is capable of
interacting with Mannose-6-phopsphate and heparin(Solis et al., 1998). **
Although CUB domains can function as protein-carbohydrate, protein-phospholipid
interaction protein modules, these seem to be unique properties in spermadhesin family of
proteins. Rather, it seems more common for CUB domains to serve as protein-protein
binding domains, since this feature has been shown in a much broader range of proteins
involved in various biological functions.
** Binding of PSP-II with mannose-6-phopshpate is lost upon heterodimerization with PSP-1.
However, recently it is shown that in normal physiological Zn++ concentration, there is a decreased
PSP-1/PSP-II heterodimer stability (Campanero-Rhodes et al., 2005), suggesting the relevance of
Man-6-P binding in physiological conditions.
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With twenty-seven CUB domains, Cubilin obtained its name. Cubilin is a 460kDa
membrane glycoprotein that functions as an endocytic receptor(Christensen and Birn,
2002). Many of these CUB domains have been shown to interact with various protein
ligands, including intrinsic factor-vitamin B12 complex (Kozyraki et al., 1999; Kristiansen et
al., 1999; Seetharam et al., 1997), apolioprotein A-I (Kozyraki et al., 1999), vitamin D
(Nykjaer et al., 2001), and myeloma light chain (Batuman et al., 1998). The Kd between
CUB5-8 and intrinsic factor -vitaminB12 is in the 40nM range, suggesting high affinity
interactions (Kristiansen et al., 1999). Moreover, mutation in CUB8 has been found
responsible for Megaloblastic anaemia 1 (MAG1), a disease characterized by selective
intestinal vitamin B12 malabsorption, supporting the involvement of CUB8 in specific protein
interaction (Aminoff et al., 1999).
Mannan-binding lectin-associated serine proteases (MASP) belong to the above-mentioned
family II, which function as proteases in the carbohydrate-initiated complement system.
Carbohydrates on the surface of pathogens are recognized by oligomeric lectins, which in
turn interact with MASPs, thus initiating the complement activation cascade. Interactions
between MASPs and lectins have been mapped to the CUB domains (Feinberg et al., 2003;
Gregory et al., 2004; Stengaard-Pedersen et al., 2003; Teillet et al., 2008), and mutation in
CUB1 of MASP-2 has been shown in patients who suffer from chronic infection and
inflammatory disease(Stengaard-Pedersen et al., 2003), supporting roles of CUB domains in
protein-protein interactions.
The model that CUB domains serve as protein-protein interaction modules is further
supported by studies with tolloid metalloprotease, including Drosophila tolloid (TLC),
mammalian tolloid (mTLD) and bone morphogenesis protein 1 (BMP1). This family of
proteins plays important roles in development due to their ability to cleave transforming
growth factor 3 (TGFI3) antagonists(Dale and Wardle, 1999; Mullins, 1998). Human BMP-1
cleaves procollagen (Kessler et al., 1996), and CUB domains are responsible for substrate
binding (Sieron et al., 2000). In addition, CUB-1 domain in another metalloprotease
ADAMTS13 has been shown to bind directly with unusually large von Willebrand factor
(ULVWF) under static and flow conditions (Tao et al., 2005), CUB domain from platelet-
endothelial cell surface protein SCUBE1 are necessary for interaction with BMP (Tu et al.,
2008). Together, these data support a common role of CUB domains in protein-protein
interaction.
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In addition to the notion that CUB domains are involved in protein-substrate interaction,
domain analyses in several proteins have shown that they are also important for protein
secretion and localization. For example, CUB1 domain from BMP-1 is important for the
secretion of BMP-1. When expressed in 293-EBNA cells, BMP-1 truncated in the first CUB
domain fails to be detected in the culture medium (Hartigan et al., 2003). Mutant PDGF-D
production (without the N-terminal CUB domain) was not successful due to intracellular
retention of the protein, suggesting a role of CUB domain in protein secretion (Bergsten et
al., 2001). Furthermore, ADAMTS13 without the C-terminus CUB domains fails to be
secreted specifically from the apical face of transfected MDCK cells, and is no longer
localized to the lipid rafts in these cells (Shang et al., 2006). Mutation resulting in loss of the
second CUB domain in ADAMTS13 was detected in patients with thrombotic
thrombocytopenic purpura (TTP) condition, and secretion of the protein was severely
impaired, further supporting the role of CUB domains in protein secretion (Pimanda et al.,
2004). However, it is not clear whether CUB domains are directly involved in protein sorting
and secretion machinery, or are important for the folding and thus the integrity of the
proteins. Misfolded proteins are often retained in the ER and Golgi for degradation. It is
largely speculation that CUB domains may be involved in proper protein folding, as CUB
domain from cubillin has been shown to interact with receptor-associated protein (RAP)
(Kristiansen et al., 1999), which is a molecular chaperone. It is possible that CUB domains
are capable of recruiting molecular chaperones, which facilitate protein folding, thus
secretion. Further analysis is required to sort out among these possibilities.
Structure of CUB domains
To understand the broad interaction capability shown by different CUB domains, we have to
turn to the structure of CUB domains. The crystal structures of CUB domains have been
solved under several conditions - CUB domain alone, CUB-EGF together, and CUB-EGF-
CUB together (Feinberg et al., 2003; Gregory et al., 2003; Romero et al., 1997; Teillet et al.,
2008).
The basic structure of CUB domains was elucidated for two members of the spermadhesins,
PSP-1 and PSP-II, revealing a compact ellipsoidal structure (FigurelC). Each CUB domain
is formed by 10 i-strands arranged into a sandwich of two 5- I1 strand sheets, with all the
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hydrophobic residues buried inside the sandwich, and two disulfide bridges located on
opposite edges of the same face of the sandwich (Romero et al., 1997).
Studies of MASP2 and MASP 1/3 have shown that CUB1-EGF-CUB2 segments within
these proteins are responsible for homo-dimerization and interaction with the binding partner
MBP (mannose-binding protein). Crystal structures of CUB1-EGF-CUB2 from MASP2 and
MASP1/3 show these CUB domains have a similar R-sandwich fold with disulfide bridges as
that of spermadhesins, only that they lack the first 1 or 2 R strands. Each CUB1-EGF-CUB2
has the shape of an elongated "C" and they dimerize in head-to-tail fashion, involving the
CUB1 domain of one monomer with the EGF of its counterpart through hydrophobic
interactions. This dimerization generates a concave surface, which was proposed to be the
binding site for MBP (Feinberg et al., 2003) (Imagine two elongated "C" in mirror symmetry,
Figure 1D). In addition, highly conserved acidic amino acids (Glu, Asp) were also identified
in many CUB domains, which have been shown to co-ordinate Ca" in the loops connecting
the p strands (Blanc et al., 2007; Teillet et al., 2008). Mutation of those sites abolishes or
severely decreases interaction with MBP, suggesting they are either involved in direct
binding, or in stabilizing the CUB domain structures (Teillet et al., 2008).
From these structural studies, it appears that P-sheets are involved in homo- and hetero-
dimerization of the CUB domains. Also, it was proposed that the loop regions -loop LC, LE,
LG and LI defined in the Romero paper- are the principal regions involved in ligand
interaction. However, more structural and mutagenesis studies are necessary to further
understand the differences in binding with a variety of partners - proteins versus
carbohydrates, and pinpoint amino acids that are involved in these interactions.
Our current understanding of proteins containing CUB domains and CUB domain structures
and functions indicates that CDCP1 might function as a membrane adhesion molecule with
extracellular ligand(s), although the identity of which is not clear. These data provided
further incentives for pursuing the functions of CDCP1.
EXPERIMENTAL GOALS AND APPROACHES
Our proteomics analysis comparing membrane proteins between high versus low metastatic
melanoma cells revealed that CDCP1 is upregulated in highly metastatic MA2 cells. We
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wished to expand this work to other highly metastatic melanoma cells to see if such
elevation is a common theme. Equally importantly, we wished to establish a functional role
of CDCP1 during melanoma metastasis. Understandably, a fraction of expression level
changes we found through the proteomics screen are potentially bystander changes that are
not functionally involved. We hoped to identify the underlying differences that drive
metastasis, therefore laying a foundation for the development of potential treatment. In this
study, we used a tail-vein injection model to investigate metastatic abilities of melanoma
cells. This model gives us the flexibility to experimentally manipulate the expression levels
of CDCP1 using either shRNA-based knockdown, or retrovirus-based over-expression.
RESULTS
CDCP1 expression is significantly altered in a variety of different tumor types
Oncomine is a public database, which contains data from 28880 microarrays and from 41
cancer types. Our initial comparison of tumor versus normal samples from Oncomine
revealed that CDCP1 mRNA levels are altered in many different tumor types (Table 1). Out
of 51 studies, 20 of them showed that CDCP1 mRNA levels changed significantly, and in
most cases, is increased in cancer comparing to normal tissues, in agreement with previous
studies. In addition, comparison of CDCP1 expression levels in brain, breast and bladder
tumors showed that CDCP1 is elevated in patients with poor prognosis
(www.oncomine.org). These data are in agreement with previous reports that CDPC1 is
upregulated in lung and colorectal cancers, and provided further support for choosing
CDCP1 as a candidate to test its functions.
Melanoma cells with enhanced metastatic potential express elevated surface CDCP1
relative to cells with low metastatic ability
As discussed in the previous chapter, highly metastatic MA2 cells have enhanced CDCP1
expression levels compared to A375 cells. However, we would like to test whether this is an
isolated incidence, as we are trying to identify common proteins that are potentially involved
in cancer metastasis. For this reason, we investigated the surface expression of CDCP1 on
other melanoma cells lines that were derived through in vivo selection by Dr. Lei Xu. After 1
or 2 rounds of selection, MA1, MC1 and MA2, MC2 were generated, respectively (Figure
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2A) and all of them produce more lung metastases when intravenously injected into nude
mice (Xu et al., 2006). Early passages of MA1, MA2, MC1 and MC2 were obtained and
0.5*106 cells were analyzed by FACS to investigate the expression levels of CDCP1. All
these cells express higher surface CDCP1 compared to A375 cells (Figure 2B).
Noticeably, flow cytometry analysis of the parental A375 cells grown in vitro reveals two
subpopulations. As shown in Figure 2B and 2C, one population of A375 cells have lower
surface expression of CDCP1 (CDCP1'OW) than the other (CDCPlhigh). And this appears to
be a stable feature for the cells cultured in vitro. When parental A375 cells were
continuously passed every three days for up to four passages and surface expression of
CDCP1 was analyzed with each passage, we always observed the presence of two
subpopulations (data not shown).
However, the picture was quite different when A375 cells were passed in vivo. x1 06 A375
cells were intravenously injected into NOD/SCID mice, and five weeks later, the lungs of the
mice were dissected and tumor nodules were surgically removed, and dispersed using the
blunt end of 1ml syringes. The cells were allowed to propagate in E4Hg-10 medium, and
passed once before analyzing surface expression of CDCP1. From this experiment, we
generated HL1720-1, -2 and HL1740-1, -2, -3, a total of 5 cell lines. Surprisingly, all these
cells showed up as CDCP 1high population (Figure 2D), and have similar mean fluorescent
intensity (MFI) to MA2 cells (Figure 2E). Thus it is the CDCP1 h igh cells that generate
metastases.
CDCP1 can be used as a surface marker to select cells with higher metastatic ability
We were intrigued yet delighted at this finding since two people using two different mouse
strains (nude mice and NOD/SCID mice), at different times isolated tumor cells from the
lungs, yet all 9 cell lines (MA1, MA2, MC1, MC2, HL1720-1, -2, and HL1740-1, -2, -3)
express high CDCP1 levels. Therefore, the fact that all tumor cells derived from the lung
have higher CDCP1 expression is unlikely to be a stochastic event. Rather, it suggests that
CDCP1 might be a surface marker for cells with higher metastatic potential.
To test this hypothesis, we sorted the parental A375 cells based on CDCP1 expression
levels into CDCP1high and CDCP1'OW using flow cytometry (Figure 3A), and intravenously
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injected these two populations into NOD/SCID mice to assay for the metastatic potential of
either population. As shown in Figure 3B, indeed mice injected with CDCPlhigh cells harbor
more lung metastases than those injected with CDCP1'oW cells (p = 0.043, student t test),
supporting our hypothesis. Again, all cells derived from these lung tumors retain high
CDCP1 expression levels (Figure 3C). These data suggested that CDCP1 is a surface
marker for cells with high metastatic potential, at least in our system.
Down-regulation of CDCP1 in highly metastatic MA2 cells significantly reduces lung
metastasis while it has no effect on subcutaneous tumor growth.
To test whether CDCP1 is functionally involved in melanoma metastasis, I first tested
whether experimental down-regulation of CDCP1 in MA2 cells reduces their metastatic
potential in the tail-vein injection model using stable CDCP1 knockdown cell lines.
We chose a mir30-based shRNA knockdown system, as this system has shown greater p53
knockdown, generating cells with phenotype reminiscent of p53 null, which has not been
achieved by other knockdown systems (Hemann et al., 2003). A schematic of the vector is
shown in figure 4A, and the resulting knockdown cells are GFP' and were selected with
2.5tg/ml of puromycin. Out of four knockdown cell lines generated, we chose to work with
knockdown line 6 and 10 (MA2-KD6 and MA2-KD10, arrows), as they showed most severe
reduction of CDCP1 compared to cells expressing stable shRNA against the firefly
luciferase gene (MA2-Ctrl-KD) (Figure 4B). We found no significant difference in cell
proliferation in vitro among the cell lines (Figure 4C), and subcutaneous tumors derived from
these cells reached the same size at the end of 33 days (Figure 4D). When the cells were
dissociated at the time of dissection and analyzed for surface CDCP1 expression by FACS
analysis, they all maintained lower expression levels compared to control knockdowns
(Figure 4E).
Next, we injected 1*106 cells of each cell line intravenously into ten NOD/SCID mice, and
five weeks later, the mice were sacrificed and surface lung nodules on the left lobe were
counted in blinded fashion. As shown in figure 4F, mice injected with MA2-KD6 and MA2-
KD10 produced significantly fewer surface lung nodules (mean = 42.8±10.7 and 51.4±7.3,
respectively) compared to MA2-Ctrl-KD (mean = 110.8±7.8, p = 0.0002 and 0.0001
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respectively). These data suggest that CDCP1 is partly necessary for A375 melanoma cells
to metastasis.
Up-regulation of CDCP1 in poorly metastatic A375 cells significantly enhances lung
metastasis while it has no effect on subcutaneous tumor growth.
Conversely, we wanted to test whether overexpression of CDCP1 enhanced the metastasis
ability in poorly metastatic A375 cells. We cloned full-length CDCP1 into a retroviral vector
MIGw, and generated pools of A375 cells harboring either control virus (A375-Vector-Ctrl) or
CDCP1 virus (A375-CDCP1). GFP-positive cells were sorted using flow cytometry and
surface expression levels of CDCP1 were confirmed using FACS (Figure 5A). In vitro,
A375-CDCP1 cells proliferate more slowly in vitro than do A375-Vector- Ctrl cells. When
cells were harvested every 3 or 4 days and cell numbers were counted, A375-CDCP1 cells
on average reach 65.13% (4.95%) of A375-vector Ctrl cells (Figure 5B and a full
description of the phenotype of A375-CDCP1 cells will be described in the next chapter).
When 0.5*10e6 cells were injected at subcutaneous sites, tumors derived from both cell
types reached similar weight at the end of each experiment, although tumors from A375-
CDCP1 cells are slightly smaller than that from A375-vector Ctrl cells, but the difference was
not statistically significant (Figure 5C). We then injected 1*1 0e6 of either A375-vector Ctrl
cells or A375-CDCP1 cells into NOD/SCID mice via the tail vein and 5 weeks later, the
numbers of GFP+ nodules on all lobes of the lungs were counted under UV dissecting
microscope (Figure 5D). A375-CDCP1 cells formed significantly more metastasis (mean =
375±48.7, Figure 5F) in the lungs than did A375-vector Ctrl cells (mean = 74.9t28.4, p =
0.0011 Figure 5E). Overall, these results indicated that CDCP1 enhances melanoma
metastasis and up-regulation of CDCP1 is sufficient to increase the metastatic potential of
poorly metastatic A375 cells.
DISCUSSION
In this work, we showed that CDCP1 expression in elevated in highly metastatic melanoma
cells relative to their poorly metastatic counterparts, and that CDCP1 is a marker for cells
with higher metastatic potential. These results are in agreement with and significantly
extend the previous studies. CDCP1 has been discovered to be elevated in lung, colon, and
gastric cancer, and in metastatic squamous cell carcinomas (Hooper et al., 2003; Perry et
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al., 2007; Scherl-Mostageer et al., 2001; Siva et al., 2008) - all these cells are epithelial of
origin. Developmentally, melanoma cells are derived from neural crest cells, a completely
different cell type from epithelial cells. Our current data that CDCP1 expression is enhanced
in metastatic melanoma cells extended these earlier works, suggesting that over-expression
of CDCP1 may be a more common phenomenon than has been researched. In fact, data
mining using Oncomine has shown that levels of CDCP1 are increased in pancreatic,
ovarian, bladder, breast, lung and brain tumors compared to the normal tissues, and support
this notion. Future studies investigating these types of tumors are needed to generalize the
correlation between CDCP1 expression levels and disease states.
Using clinical samples, Awakura and Ikeda recently showed that CDCP1 is a prognostic
marker for renal cell carcinoma and lung adenocarcinoma (Awakura et al., 2008; Ikeda et
al., 2009). There is an inverse relationship between the expression levels detected by
immunohistochemical methods and the length of survival of the patients. And CDCP1 can
be used as a prognostic marker for patients. Although we showed that CDCP1 could be
used as a marker to separate melanoma cells with different metastatic abilities, which is in
agreement with these two studies, we have not yet performed immuno-histochemical
staining of human melanoma samples. Such analysis using clinical samples including
primary and metastasis melanoma is required to establish the prognostic significance of
CDCP1 in melanomas. We have obtained human tumor samples along with normal
samples, and tumors of different grades and we will use those samples for such analysis.
Tumor cells do not survive on their own; numerous studies have shown that tumor
microenvironment including different cell types such as fibroblasts (Haviv et al., 2009; Olumi
et al., 1999), macrophages (Condeelis and Pollard, 2006), endothelial cells (Nyberg et al.,
2008) to name a few, and proteins such as extracellular proteins (ECM) (Bissell et al., 2005;
Butcher et al., 2009; Xu et al., 2006) and growth factors such as TGFP (Massague, 2008)
contribute greatly to the tumor cell behaviors. In our study, we found that A375-CDCP1
cells proliferate more slowly in vitro compared to A375-Ctrl-vector cells, but subcutaneous
tumors derived from either cell type reach the same size. However, in the lungs, A375-
CDCP1 cells form significantly more metastases than do the control cells. These
differences support the notion that factors in different tissues play important roles in tumor
growth and metastasis formation. CUB domains in other proteins have been shown to be
involved in protein-protein and protein-carbohydrate interactions. It is conceivable that three
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CUB domains that CDCP1 possess are able to interact with components in the
microenvironment, therefore transmitting signals to the cells and affecting the tumor growth.
In fact, as will be detailed in chapter V (data not shown here), we have generated hybrid
CDCP1 where extracellular and transmembrane domains were replaced with those from
IL2-receptor a(Tac-CDCP1). Cells expressing hybrid CDCP1 failed to elicit the effects seen
by wild-type CDCP1, supporting our hypothesis (although we have not eliminated the
possibility that cis- or trans- interaction between CDCP1 is enough to initiate signals). It will
be of great interest to identify the ligand of CDCP1, which will shed light on the nature of
such microenvironment interactions with the tumor cells. In fact, work has been initiated in
our lab to search for CDCP1 ligand(s).
There are several obvious extensions based on our current work and work by the Sakai
group.
1) Does CDCP1 function as a metastasis enhancer in other types of tumors in addition
to melanoma, lung adenocarcinoma and gastric cancer? Oncomine is a public
database, which contains data from 28880 microarrays and from 41 cancer types.
Comparison of CDCP1 expression levels in brain, breast and bladder tumors showed
that CDCP1 is elevated in patients with poor prognosis (www.oncomine.org). It is
worth investigating the function of CDCP1 in these types of tumors to establish a
broader role during metastasis.
2) Does CDCP1 play a role in metastasis in in vivo tumor models? This is temporarily
hindered by the absence of CDCP1 knockout mice, although such mouse strain
generation is underway through the KOMP project by NIH
(WWW.knockoutmouse.org). With the generation of such a strain (or conditional
knockout strains), we will be able to evaluate the role of CDCP1 in melanoma
progression and metastasis, and in lung and gastric cancers.
3) Going back to the observation that CDCP1 expression is enhanced in several types
of tumors (Perry et al., 2007; Scherl-Mostageer et al., 2001; Siva et al., 2008) (and
Oncomine analysis), it will be interesting to test if CDCP1 confers tumorigenesity.
4) And importantly, what is the mechanism that CDCP1 function as a metastasis
enhancer in our system? We began to address this question and have started to
gain insight on this front, which will be detailed in the next two chapters.
Chapter 3
In conclusion, we have shown that CDCP1 is a surface marker for melanoma cells with high
metastatic potential. By both partial loss-of-function and gain-of-function studies, we also
showed for the first time, that CDCP1 plays a causal role in metastasis of melanoma cells. It
is very satisfying to see that proteins identified through our proteomics screen induced
causal changes, and is not simply a bystander change. In the next chapter, we will attempt
to understand the underlying mechanisms by which CDCP1 contributes to metastasis, first
at cellular biology level then at molecular biology level.
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Figure 1. CUB domain Containing protein 1 (CDCP1) expression profile and proteins with CUB domains in
their architectures. (A) Normal human tissues that express CDCP1 at mRNA level. Data were obtained from
Novartis Gene Atlas Dataset and figure was created by Steve Shen. (B) Structure outline of CDCP1. It contains
(from N-terminus to the C-terminus): signal peptide, 3 extracellular CUB domains, a transmembrane domain
and intracellular domain. Src family kinase and PKC6 have been shown interact with CDCP1 through
intracellular tyrosines. Purple ovals represent proteins interacting with CDCP1 by Co-immunoprecipitation
experiments.
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Figure 1. CUB domain Containing protein 1 (CDCP1) expression profile and proteins with CUB domains in
their architectures. (C) Examples of subfamilies of proteins that contain CUB domains as described in the
text.
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Figure 1. CUB domain Containing protein 1 (CDCP1) expression profile and proteins with CUB domains in
their architectures. (D) Crystal structure of porcine PSPI shows the overall fold of CUB domains. Loop C, E
and G are proposed to be involved in interaction with binding partners. Adapted from Romero et al, 1997.
(E) Crystal structure of MASP2. CUB1-EGF-CUB2, notice the closed orange circles indicate where the
substrates are likely to interact. Adapted from Feinberg et al, 2003
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Figure 2. CDCP1 expression levels are upregulated in highly metastatic melanoma cell lines compared to
cells with low metastatic potential, and all cells derived from lung metastasis show high CDCP1 expression
levels. (A) A schematic of in vivo derivation of MA1, MC1, MA2 and MC2 cells from parental A375 cells. All
derived cells have higher metastatic potential compared to A375 cells. (B) Flow cytometry analysis of CDCP1
expression shows CDCP1 surface levels are increased in all highly metastatic cells (MA1, MA2, MC1 and MC2)
comparing to low-metastatic parental A375. (C) Surface expression of CDCP1 on A375 cells reveals two peaks;
(D) All tumor cells derived from in vivo lung metastasis show high expression levels of CDCP1 compared to
A375 cells. (E) Mean fluorescence intensity of CDCP1 for figure 2D.
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Figure 3. CDCP1 is a surface marker for melanoma cells with higher metastatic potentials. (A) Parental
A375 cells can be sorted into CDCP1 h igh and CDCP1ow sub-populations. (B) CDCP1 high cells form more lung
metastasis when intravenously injected into NOD/SCID mice. (C) Cells isolated from lung metastasis from
mice injected with CDCPlhigh (HL1750-1,-2, HL1760-1,-2) maintain higher CDCP1 expression levels that are
equivalent to MA2 cells.
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Figure 4. Downregulation of CDCP1 in highly metastatic cells significantly reduced lung metastasis, while
having no effect on in vitro cell proliferation and subcutaneous tumor. (A) A schematic of the vector used
to generate CDCP1 knock-down MA2 cells. Gene specific shRNA sequences were cloned between Xhol and
EcoRI sites. (B) FACS plot showing down-regulation of surface CDCP1 in MA2 cells. Arrows indicate the two
knock-down lines used in our studies. (C) Reducing CDCP1 expression in MA2 cells does not affect cell
proliferation in vitro.
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Figure 4. Downregulation of CDCP1 in highly metastatic cells significantly reduced lung metastasis, while
having no effect on in vitro cell proliferation and subcutaneous tumor. (D) Subcutaneous tumors from
MA2-Ctrl-KD and MA2-KD6, 10 reach the same weight after 33 days. (E) At the time of dissection,
subcutaneous tumor cells from MA2-KD6 (data not shown here for simplicity) and MA2-KD10 maintain their
lower CDCP1 expression compared to subcutaneous tumors generated from MA2-Ctrl-KD cells.
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Figure 4. Downregulation of CDCP1 in highly metastatic cells significantly reduced lung metastasis, while
having no effect on in vitro cell proliferation and subcutaneous tumor. (F) Numbesr of surface tumors in
mice injected with MA2-KD6 and MA2-KD10 cells are significantly smaller than with MA2-Ctrl-KD cells.
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Figure 5. Overexpression of CDCP1 in poorly metastatic A375 cells decreases cell proliferation in vitro,
does not affect tumor growth at the subcutaneous site, but significantly enhances lung metastasis of the
cells. (A) A375 cells carrying MIGw-CDCP1 vector express higher surface CDCP1 than those carrying control
vectors. (B) In vitro, A375-CDCP1 typically reach 65% in cell number comparing to A375-Vector-Ctrl on day 3
when equal numbers of cells were plated on day 1. (C) Tumors derived from A375-CDCP1 cells reach the
same size as those from A375-Vector-Ctrl cells.
100
80
60
40
A375-CDCP1
250-- ------------
200
150.
3100
E ..so
A375-Vector-CtrI A375-CDCPI
A375-Vector-Ctrl A375-CDCP1
Chapter 3
132
Chapter 3
Figure 5. Overexpression of CDCP1 in poorly metastatic A375 cells decreases cell proliferation in vitro,
does not affect tumor growth at the subcutaneous site, but significantly enhances lung metastasis of the
cells. (D) Mice injected with A375-CDCPlhave significantly more lung metastasis at the end of five weeks
compared to mice injected with control cells. (E) (F) Representative image of lung from mice injected with
control cells (E) or A375-CDCP1 cells (F).
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CHAPTER 4.
CELLULAR MECHANISMS BY WHICH CDCP1
FUNCTIONS TO ENHANCE METASTASIS
The work in this chapter was conceived by Hui Liu and Richard Hynes. The contents of this
chapter were written by Hui Liu, with editing by Richard Hynes.
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As discussed in Chapter 1, metastasis is a complicated process involving multiple steps,
with each step being accomplished by various genetic and epigenetic changes of the tumor
cells and by support from the tumor microenvironment. Many membrane proteins have
been shown involved in various steps along the way, as has been discussed in Chapter 1.
The major cellular pathways that have been implicated in cancer metastasis are cell
proliferation, apoptosis resistance, cell migration /invasion, and angiogenesis.
EXPERIMENTAL GOALS AND APPROACHES
In the previous chapter, I have shown that CDCP1 is a novel metastasis enhancer, and I am
interested in further understanding the cellular pathways that CDCP1 uses to achieve such
an effect. To start addressing this question, we utilized two sets of cells used in the
metastasis assays (MA2-Ctrl-KD and MA2-KD6/10, and A375 cells and A375-CDCP1), and
asked whether we can observe differences in cell adhesion to substrates, in cell
proliferation, in anoikis-resistance, and in migration/invasion.
RESULTS
Using these two series of cells, we found that, in some situations, both series of cells yield
the same information; while in other situations, we only observed effects when CDCP1 is
overexpressed, but not when downregulated, suggesting that in these conditions CDCP1 is
sufficient but not necessary.
CDCP1 is involved in regulating the abilities of cells to form soft agar colonies - by
both over-expression and knocking-down experiments
Soft agar colony forming assay is commonly used to measure the transformed state of the
cells - normal cells fail to form colonies in soft agar due to lack of proper cell-substrate
interactions, while transformed cells can. The assay measures the combination of cell
proliferation and survival in the absence of cell-substratum anchorage. We performed soft
agar colony assay by embedding MA2-Ctrl-KD cells and MA2-KD6, -KD10 cells in 0.3%
agarose in normal growth medium (containing 10% bovine serum). The assays were
performed in blind fashion, with the plates coded by other members in the lab. Colony
numbers were recorded after a week, and MA2-KD10 (mean = 18.69 t0.64) produced
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significantly fewer colonies comparing to MA2-Ctrl-KD cells (mean =24.15±0.82, p=0.0001,
N=3, Figure 1A). Conversely, A375 cells overexpressing CDCP1 formed more soft-agar
colonies than did A375-vector-Ctrl cells (Figure 1B). These data suggested that CDCP1
might be involved in regulating the balance between cell proliferation and cell death, in favor
of cell proliferation.
CDCP1 plays a role in cell proliferation and apoptosis within the metastasis in the
lungs
To support our in vitro findings, we performed immunohistological staining using anti-Ki67
antibody, which recognizes all cells undergoing active mitosis. When comparing percent
Ki67+ cell in the mouse lungs receiving MA2-Ctrl-KD cells versus MA2-KD6 and KD10 cells,
we found that there is a significant reduction in the mitosis index comparing MA2-KD10
(mean = 3.32% - 0.94%, p=0.03) to Ctrl-KD (mean = 6.33% ± 0.89%). There is also a small
reduction comparing MA2-KD6 (mean 4.28% ± 0.86%) to Ctrl-KD, but it is not statistically
significant (p= 0.1) (Figure 2A and 2B). Next, we analyzed cell apoptosis in these lungs
using ApopTag@, which measures the presence of free DNA ends in apoptosing/dead cells
(Figure 2C). We found a very small but statistically significant increase in percent cells
undergoing apoptosis within the metastasis when comparing MA2-KD6 (mean =
1.8%±0.162%), MA2-KD10 (mean = 1.981%±0.268%) to MA2-Ctrl-KD (mean =
1.145%±0.089%) with p=0.0016 and =0.0017 respectively.
In both over-expression and knowdown systems, CDCP1 was found to regulate soft agar
colony formation, suggesting it may function to tilt the balance of proliferation and apoptosis
favoring proliferation. This idea was also supported by in vivo data, where lung metastases
generated from MA2 cells with reduced CDCP1 showed decreased proliferation index and
slightly enhanced apoptosis. Although these differences are not very impressive, over a
long period of time, these small differences may indeed contribute to tumor metastasis.
Although the aforementioned phenomena were observed using both series of cells, the
following findings are only applicable in over-expression system.
CDCP1 -overexpressing cells proliferate more slowly in vitro
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When cell proliferation was analyzed either by plating the same number of cells and
counting after 3 days, or using CellTiter 96® AQue kit from Promega, we found that A375-
CDCP1 cells proliferate more slowly than A375-Ctrl-vector cells. Cell number is usually
65.13(±4.95%) that of A375-Vector-Ctrl cells after three days in culture (Figure 3A, N=7).
However, we did not observe proliferation difference comparing MA2-Ctrl-KD cells to
CDCP1 knockdown cell lines (Figure 3B).
CDCP1-overexpressing cells are bigger in size
Cell size analysis was performed using Coulter Counter and mean diameter of A375-
CDCP1 and control cells were analyzed. A375-Ctrl-vector cells were allowed to grow to 70-
80% confluence before being detached from the plate with PBS/EDTA, while A375-CDCP1
cells were collected from suspension. Mean diameter for A375-CDCP1 is 15.6[tm
(±0.22m, N=13) while mean diameter for A375-Vector-Ctrl is 14.4tm (±0.23R m, N=14),
representing 30% increase in cell volume comparing to the control cells (Figure 3C and 3D).
Overexpression of CDCP1 in poorly metastatic A375 cells causes the cells to detach
and proliferate in suspension
To understand further the role of CDCP1 during metastasis in vitro, we overexpressed
CDCP1 in poorly metastatic A375 cells (A375-CDCP1). A375 cells are adherent cells with a
small population loosely adherent or in suspension, which presumably are cells undergoing
mitosis. When cells were infected to express CDCP1 and GFP (not as fusion proteins), we
found that on day 1, when the cells are weakly green, they remain attached to the plate.
However, on day 2, when the cells become bright green, the majority of the cells completely
detached and became free-floating suspension cells (mean = 66.6%± 10.3% of total cells,
N=5). This is not the case for cells expressing the 2A-GFP vector (A375-Ctrl-vector), where
cells remained adherent (mean = 9.5%+2.7% of total cells, N=5, Figure 4A and 4B). A375-
CDCP1 cells are alive because they are negative for trypan blue staining, negative for
Annexin V and PI staining (data not shown). Moreover, propagation of these cells was
performed by simply diluting the suspension cells into fresh culture medium from then on. In
agreement with the observations of Bhatt, CDCP1 seems to function as an anti-adhesion
molecule (Bhatt et al., 2005).
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We decided to investigate this apparent anti-adhesion function further using standard
adhesion assays. We coated 96 -well plates with common ECM proteins - fibronectin (FN),
vitronectin (VN), and with BSA as negative control, poly D-lysine as positive control. The
cells were allowed to adhere for 10min, 30min or 1 hour before being gently washed off.
Cells remaining bound to the plates were fixed and stained with Crystal Violet, which was
extracted with Triton X-100 and absorbance of A540 was analyzed. Over-expression of
CDCP1 slightly reduced cell adhesion to fibronectin over the concentration range of
2.5[g/ml to 40 g/ml (Figure 5A). However, adhesion to vitronectin over the same
concentration range was not affected by expression of CDCP1 (n=3) (Figure 5B). To our
surprise, such reduction in adhesion to FN (Figure 5C) disappeared when adhesion assays
were carried out for 1 hour (Figure 5D)(n=3).
Integrins are the major receptors involved in cell adhesion on fibronectin and vitronectin.
A375 cells express a5131, a311, aVI33 integrins. We tested the effect of CDCP1 over-
expression on the surface integrin levels using flow cytometry, and found A375-CDCP1 cells
express similar levels of integrin av33, and a small reduction (approximately 2 fold) in a5l
surface expression. We also analyzed integrin activation status using an antibody that
specifically recognizes activated integrin 131, and again, we observed a similarly small
reduction in activated 11 on the surface, corresponding the reduced expression levels
(Figure 6). These data agree with the adhesion results, that adhesion to fibronectin is
slightly affected by overexpressing CDCP1.
When investigating the cells ability to spread on fibronectin and vitronectin, we found that
A375-CDCP1 cells almost completely failed to spread. While A375-Vector-Ctrl spread
quickly on FN or VN coated glass slides with apparent membrane ruffles, A375-CDCP1 cells
remain round and appear to sit on top of the glass slides (Figure 7). We also used live
imaging to investigate further whether A375-CDCP1 cells simply have slower kinetics for
spreading. Over 6 hours of imaging, A375-CDCP1 cells remain as round cells, while A375-
Vector-Ctrl remain spread over the period of imaging (data not shown).
Our data suggest that although CDCP1 only has a small effect on cell adhesion kinetics and
on cell adhesion strength, it severely decreased the ability of the cells to spread on
extracellular matrix proteins. This may help explain the adhesion-to-suspension transition
we observed in tissue culture.
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Direct test of anoikis using melanoma cells did not reveal significant effect by CDCP1
Uekita et al reported that in lung adenocarcinoma A549 cells, decreasing CDCP1
expression has a detrimental effect on the cells' ability to resist anoikis - apoptosis induced
by lack of cell-substrate interaction (Uekita et al., 2007). The fact that CDCP1
overexpression causes the cells to lose adhesion and proliferate in suspension suggests
that CDCP1 expression may allow the cells to circumvent anchorage-dependence. In other
words, CDCP1 provides anoikis resistance. To test this idea experimentally, we performed
an anoikis-resistance test by plating 0.1*10e6 cells in poly 2-hydroxyethyl methacrylate
(polyHEMA) coated 6-well plates in serum-free medium, the cells were stained for surface
Annexin V and propidium iodide (PI), and the percentage of cells that are Annexin V-positive
but PI-negative were calculated as apoptosing cells, and percent cells that are positive for
both Annexin V and PI were calculated as dead cells. However, this direct test of anoikis
did not yield results that we expected - both cells types showed similar level of apoptosing
cells (data not shown). Noticeably, these cells formed large cell aggregates in polyHEMA-
coated plates.
We also investigated potential involvement of CDCP1 in melanoma migration and invasion
using Boyden-chamber transwell migration and invasion assays, and we did not observe
consistent effect using a series of cells (data not shown).
In conclusion, our in vitro work with CDCP1 showed that CDCP1 overexpression slightly
enhances cells' anchorage-independence growth in the soft agar, and downregulation of
CDCP1 decreases this ability, suggesting a role of CDCP1 in altering the balance between
proliferation and anoikis. And we speculate that this ability potentially contributes to
metastasis-enhancing activity seen in vivo.
A375-CDCP1 cells grow in scattered manner in 3D Matrigel with decreased N-cadherin
and-catenin at cell-cell junctions
When considering our experimental approaches, we realized that soft agar colony assay
might be the one that best mimics in vivo situation during metastasis - namely the ability of
single cells scattered in a foreign environment to grow into colonies. We reasoned that
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applying a 3-dimensional culture system (3D) using physiologically relevant substrates such
as Matrigel (matrix proteins secreted by Engelbroth-Holm-Swarm tumor cells) instead of
agarose might be a more relevant approach to understand in vivo functions of CDCP1. This
system has been used extensively in mammary gland development and carcinogenesis, but
not so with melanoma. With this idea in mind, we coated 8-well chamber glass slides with
Matrigel at 40C and allowed solidifying at 370C before single-cell suspensions of A375-
Vector-Ctrl and A375-CDCP1 were seeded on the gels. Cells were cultured with this on-top-
of Matrigel method for 6 days to 10 days and cell morphologies were analyzed. A375-
Vector-Ctrl grow into "balls" with strong N-cadherin and p-catenin at cell-cell junctions, while
A375-CDCP1 grow in a scattered fashion like "clusters-of-grapes", with reduced N-cadherin
and B-catenin at cell-cell junctions, although the total levels of these two proteins are not
changed (Figure 8A, 8B and 8C).
From these in vitro and 3D studies, we concluded that CDCP1 promotes dispersive growth
in three-dimensional extracellular matrix. Together with its role in altered balance between
proliferation and anoikis in favor of cell growth, it is conceivable that these two effects of
CDCP1 may ultimately function in enhancement of metastasis.
CDCP1 has a small effect on the early cell seeding/surviving in the lungs
In an attempt to pinpoint temporally when CDCP1 plays a major role in promoting
metastasis, we investigated if CDCP1 has any effect during early survival (in the circulation)
and seeding phase, or during tumor initiation and growth phase of metastasis.
A375-Vector-Ctrl and A375-CDCP1 cells were labeled with red or green fluorescent dyes
and mixed at 1:1 ratio before intravenous injection into NOD/SCID mice. Mice were
sacrificed at 40min, 4hr, and 5hrs, the left lobes were sandwiched between glass-bottom
dishes and cover glasses, and 10 random fields for each lobe were imaged using a
DeltaVision microscope. We found for all three time points, that there are more A375-
CDCP1 in the lungs than A375-Control-Vector cells and the difference is statistically
significant, although the difference is less than 2 fold for all time points (Figure 9A, 9B). We
also performed the same experiment using MA2-Ctrl-KD cells and MA2-KD10 cells but we
did not observe difference between the number of MA2-Ctrl-KD cells and MA2-KD10 cells at
30min, 3 hours, 4 hours, 5 hours or 6 hours (Figure 9C, 9D).
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These data suggest that although over-expression of CDCP1 has an effect on the early
retention of cells in the lung, the difference is small (less than 2 fold) and less likely by itself
to explain the large difference (5.3 fold difference in number of metastasis) we observe at
the end of five weeks. Thus, the stronger effect of CDCP1 on lung metastasis is probably
manifested later than the first several hours.
DISCUSSION
To gain insight into how CDCP1 promotes melanoma metastasis, we performed various in
vitro assays comparing MA2 cells to CDCP1 knock-downs and A375 cells to CDCP1 over-
expressers. We found that CDCP1 has no effect on migration/invasion in short-term
assays, nor does it change anoikis resistance in polyHEMA-coating assays. However,
CDCP1 does seem to have a small effect on the balance between cell proliferation and
anoikis, because it positively regulates soft-agar colony formation abilities of melanoma
cells. We found that in 3D culture, CDCP1 expression allows the cells to grow in scattered
manner. These properties, together, might contribute to the in vivo metastasis-enhancing
ability of CDCP1. This is supported by in vivo analysis of proliferation and apoptosis - when
CDCP1 expression is reduced, within the tumor, there is somewhat increased apoptosis and
reduced proliferation in the lungs.
Uekita et al have reported that downregulation of CDCP1 in lung adenocarcinoma A549
cells significantly decreased anoikis resistance in polyHEMA assay (Uekita et al., 2007).
However, we did not find the same using melanoma cells. Although polyHEMA has been
widely used to assay for anoikis in different cell types such as mammary epithelial/cancer
cells, lung cancer cells, and colon cancer cells, melanoma seems to present a particular
problem. A375 melanoma cells aggregate in polyHEMA coated culture vessels, forming
"melanospheres". It has been thought that such aggregates enhance cell survival due to
signals by cell-cell contacts and localized secretion of ECM proteins in the aggregates. In
fact, new methods have been developed specifically to address this problem (Tzukert et al.,
2008). However, our in vitro data that CDCP1 positively regulates soft agar colony
formation, and in vivo data that downregulation of CDCP1 enhanced cell apoptosis, are
broadly consistent with results from the Sakai group, supporting the idea that CDCP1 plays
some role in apoptosis resistance.
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We also found that overexpression of CDCP1 causes the cells to detach from tissue culture
plates and proliferate in suspension, a function we termed anti-adhesion. This is particularly
interesting for several reasons. First, this is consistent with its proposed function in anoikis
resistance. Normal cells require cell-substrate engagement in order to survive and
proliferate, widely known as anchorage-dependent growth. When deprived of such
substrate interactions, normal cells die from apoptosis - a process known as anoikis. The
fact that overexpression of CDCP1 allows A375 cells and mammary carcinoma cells (Bhatt
et al., 2005) to detach and proliferate in suspension suggests that CDCP1 may provide extra
signals to circumvent the requirement for cell-substrate engagement. It will be interesting to
express CDCP1 in untransformed cells to see if CDCP1 is sufficient for such anoikis
resistance in normal cells.
Secondly, understanding the mechanisms through which CDCP1 antagonizes adhesion will
provide additional information to understand the complicated process of cell adhesion, cell
spreading and processes related to these two. Almost all cells express integrin hetrodimers,
which are the major transmembrane proteins that interact with extracellular matrix proteins
(ECM), regulating cell adhesion (Hynes, 2002; Hynes, 2004). Signals from extracellular
matrix such as the identity of the ECM proteins and the physical status of ECM proteins
(assembled or not, rigidity of the ECM) regulates the activation of integrins (outside-in
signals) and signals from inside the cells such as activation of various small GTPases, the
presence of talin and kindlin (inside-out signals) regulate the activation status of integrins
(Hynes, 2004). As a result, cells precisely regulate the timing and strength of adhesion to
ECM (Cantor et al., 2008; Larjava et al., 2008). Failures in such regulations are causes of
many diseases, such as bullous pemphigoid (Dowling et al., 1996; Smith, 1993; Venning et
al., 1992) and Glanzmann thrombasthenia (Hodivala-Dilke et al., 1999). The process of
adhesion is complicated. At the cellular level, the initial adhesion is followed by subsequent
spreading. At the molecular level, the initial adhesion is mediated by integrin-ECM
interaction at the periphery of the cells, forming small and transient focal contacts. Some of
the focal contacts mature into focal adhesions, which are more stable complexes mediating
stronger interactions. Eventually stable fibrillar adhesions form in the middle of the cells in
contact with ECM. Different structural and signal proteins are present in these complexes
(van der Flier and Sonnenberg, 2001). For example, integrin avp3 is enriched in the focal
contacts and focal adhesions, but integrin c5pl31 is more abundant in the fibrillar adhesions.
A recent proteomics study found several hundreds of proteins in these complexes,
Chapter 4
presenting a daunting job trying to understand the precise spatial and temporal regulation of
these complexes (Zaidel-Bar et al., 2007). We found that CDCP1 does not affect the initial
adhesion per se, rather, it inhibits the cells from spreading, suggest that signals from/by
CDCP1 inhibit signals that are required for later steps of cell adhesion. Thus, understanding
mechanistically how CDCP1 exerts such functions will provide useful information to tease
out the complicated process mentioned above.
We found that when A375 cells overexpress CDCP1, the cells are bigger than control cells.
At this point, we do not know if this is a direct effect of CDCP1, namely if CDCP1 impinges
on cell growth pathway such as mTOR pathway (Ma and Blenis, 2009; Sarbassov et al.,
2005), or it is a secondary effect due to lack of cell-substrate interaction, which activates
RhoGTPase and controls the contractility of the cells. Further investigations are required to
tease out these possibilities.
We also observed that when introduced into the lungs of the mice via tail vein injection,
there were more A375-CDCP1 after 40min compared to the control. However, the fact that
we did not see the opposite to be true using MA2 and knock-down cells, and the increased
cell size in A375-CDCP1 suggest that this effect may be secondary to the increase in cell
diameter. The possibility remains that CDCP1 expression enhances the cells' survival in the
blood stream. Further work is required to stain for the presence of apoptotic cells at early
time points (40min) post injection.
In an attempt to understand when CDCP1 exerts its major function in vivo to enhance
metastasis, we found that the very early effect is small at best, if any. When metastasis
number and size of lung metastases derived from A375-Vector-Ctrl cells or A375-CDCP1
cells were analyzed, we noticed that the biggest difference is in the number of tumors in the
lung. When we find tumors derived from A375-vector-Ctrl, they often can grow to the same
size as tumors derived from A375-CDCP1 cells, suggesting that maybe CDCP1 function in
initiation of metastasis. However, we will need more tumors from A375-Vector-Ctrl cells for
this to be conclusive.
3D Matrigel culture is currently accepted to mimic in vivo environment. For example,
mammary epithelial cells grown in Matrigel have been shown to closely recapitulate in vivo
mammary gland morphogenesis (Mailleux et al., 2008). A large panel of mammary tumor
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cell lines were used by the Bissell group to assay their morphologies in 3D Matrigel, and it
was shown that the growth patterns of these cells correlate with their gene expression
profiles, and cells that grow in "grape" or "stellate" morphology represent more aggressive
carcinoma cells (Kenny et al., 2007). When analyzing the behavior of A375-CDCP1 and
control cells in Matrigel 3D assays, we found a dramatic difference between the growth
patterns of these cells; while the control cells grow into tight balls of cells, expression of
CDCP1 completely changes these structures. Almost all A375-CDCP1 cells look like
clusters of grapes, with much reduced cell-cell localization of N-cadherins and p-catenin,
suggesting that overexpression of CDCP1 resulted in a more aggressive phenotype.
In conclusion, we investigated at the cellular biology level, the mechanisms by which
CDCP1 may contribute to enhanced melanoma metastasis and we found that altered
balance between cell proliferation and apoptosis, and scattered proliferation pattern in in
vivo-like environment could contribute to such a function. In the next chapter, we will
present data utilizing this system to understand at the molecular level what are the signals
activated by CDCP1 and how they may contribute to the metastasis-enhancing activity of
CDCP1 in vivo.
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Figure 1. CDCP1 regulates soft agar colony formation abilities. (A) Downregulation of CDCP1 significantly
decreased the number of colonies formed by MA2 cells. (B) Over-expression of CDCP1 slightly increased the
number of colonies formed by A375 cells. N=4
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Figure 2. Downregulation of CDCP1 in vivo decreased cell proliferation index and increased apoptosis
within lung metastases. (A) Typical lung metastases sections are shown following staining with the
proliferation marker Ki67(top) or by TUNEL, using ApopTag detection kit (bottom). (B) Quantitation of
staining results for Ki67(left panel) and TUNEL (right panel) are shown for mouse lungs 5 weeks after tail vein
injection.
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Figure3. CDCP1 overexpression reduced A375 proliferation; while down-regulation of CDCP1 did not affect
proliferation in MA2 cells. (A) 1*10e6 A375-CDCP1 or A375-Vector-Ctrl cells were seeded in 10-cm plates in
E4Hg-10 medium on day0 ad cells were collected on day3. Cell numbers were counted and A375-Vector-Ctrl
were set as 100%. On average, the number of A375-CDCP1 cells reach 65.13%(±4.95%) that of A375-Vector-
Ctrl cells (N=7). (B)) MA2-Ctrl-KD and MA2-KD6, -10 cells proliferate at similar rate in vitro
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Figure 4. Overexpression of CDCP1 in poorly metastatic A375 cells causes the cells to de-adhere in culture.
(A) Two days after A375 cells were infected with either Vector-Ctrl virus or CDCP1 virus, majority of A375-
Vector-Ctrl cells remain attached, while most A375-CDCP1 cells detach from culture plate and proliferate in
suspension; (B) Quantification of percentage of total cells that are in suspension (N=5).
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Figure 5. CDCP1-overexpressing cells show time- and concentration-dependent adhesion defect on
fibronectin, but not on vitronectin. (A) A375-CDCP1 cells show a modest reduction in adhesion to
fibronectin in concentration-dependent manner. (B) Adhesion to vitronectin was not affected by CDCP1
over-expression. (C) There are less A375-CDCP1 cells adhere to Fibronectin at 30min compared to the
control cells, and this difference was resolved after lhr of adhesion (D). No difference was observed in cells
ability to adhere to vitronectin.
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Integrin a5 Integrin 01
FL4-H: APC
A375-Vector-Ctrl A375-CDCP1 percent change
Integrin (MFI) (MFI) relative to Ctrl
a5 90 46.2 -48.67%
01 76.8 49.4 -35.68%
activated 31 59.4 31.4 -47.14%
aV 287 298 3.83%
1 3 75.3 50 -33.60%
Activated 31
102
FL4-H: APC-Huts4
Figure 6. A375-CDCP1 cells express reduced surface levels in a subset of integrins relative to A375-Vector-
Ctrl cells, and such reductions correlate with adhesion defects. (A) A375-CDCP1 and A375-Vector-Ctrl cells
were incubated with antibodies specific to each integrin and analyzed using flow cytometry. Integrin a5, 01,
33 and activated 31 showed reduced levels, while aV surface level was not changed. (B) Comparison of
mean fluorescence intensity (MFI) of surface integrins and percent change relative to A375-Vector-Ctrl cells
shows that in most cases, the difference is less than 2-fold.
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Figure 7. A375-CDCP1 cells fail to spread on fibronectin or vitronectin coated surfaces. Glass coverslides
were coated with 5p1g/ml fibronectin or vitronectin at 40C overnight, and A375-Vector-Ctrl cells or A375-
CDCP1 cells were seeded on the slides and allowed to adhere for 3 hours before the cells were washed 3
times with PBS containing Ca++/Mg++. The cells were then fixed with 4% Paraformaldehyde for 15mins and
imaged.
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Figure 8. A375-Vector-Ctrl cells and A375-CDCP1 cells grow in distinctively different pattern when cultured
in 3D Matrigel, and A375-CDCP1 cells show reduced N-cadherin staining at the "invasion front" and
mislocalized 3-catenin. In Matrigel assay, 8-well glass chamber slides were coated with 45il of Matrigel at
40C, and were incubated at 370C for at least 30min to allow the gel to solidify. 3000 cells were then plated on
top of the solidified Matrigel in the presence of 2% Matrigel in E4Hg-10 medium. The cells were cultured for
6-10 days. (A) A375-Vector-Ctrl cells grow as tight balls, while A375-CDCP1 cells showed scattered growth
pattern. (B) Cell were fixed and stained with anti N-cadherin antibody (red). While A375-Vector-Ctrl cells
show strong N-cadherin at cell-cell junctions, A375-CDCP1 cells show reduced N-cadherin at the "invasion
front" (arrows), but retain N-cadherin if cells are attached (arrowheads).
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A375-Vector-Ctrl A375-CDCP1
0-catenin
Figure 8. A375-Vector-Ctrl cells and A375-CDCP1 cells grow in distinctively different pattern when cultured
in 3D Matrigel, and A375-CDCP1 cells show reduced N-cadherin staining at the "invasion front" and
mislocalized P-catenin. (C) Cells were fixed and stained with anti 0-catenin antibody (red). While 1-catenin
was localized at cell-cell junctions in A375-Vector-Ctrl cells, A375-CDCP1 cells showed mislocalization of 13-
catenin.
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Figure 9. CDCP1 has a small effect on early "seeding" of cells in the lung. When investigating early events
post intravenous injection, cells were labeled with CellTrackerTM fluorescence dyes (red or green), mixed at
equal ratio and injected into NOD/SCID mice via tail vein. At indicated time points, the mice were sacrificed
and left lobes were imaged using DeltaVision microscope. 10-15 random fields were imaged, covering
different areas of the lung. (A) More A375-CDCP1 cells (red) than A375-Vector-Ctrl cells (green) were
retained in the lungs at 40min, 3 hours and 5 hours post tail vein injection. (B) Quantification of number of
red (A375-CDCP1) and green (A375-Vector-Ctrl) cells in the lungs at different time points.
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Figure 9. CDCP1 has a small effect on early "seeding" of cells in the lung. When investigating early events
post intravenous injection, cells were labeled with CellTracker'" fluorescence dyes (red or green), mixed at
equal ratio and injected into NOD/SCID mice via tail vein. At indicated time points, the mice were sacrificed
and left lobes were imaged using DeltaVision microscope. 10-15 random fields were imaged, covering
different areas of the lung. (C) However, a five fold reduction of surface CDCP1 in MA2 cells did not affect
early retention of cells in the lungs. (D) Quantification of number of red (MA2-KD10) and green(MA2-Ctrl-
KD) cells in the lungs at different time points.
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CHAPTER 5
MOLECULAR MECHANISMS BY WHICH CDCP1
MAY FUNCTION TO ENHANCE METASTASIS
The work in this chapter was conceived by Hui Liu and Richard Hynes. Overexpression
constructs for activated Src and activated Ras were generated by and/or obtained from
Patrick Stern. The contents of this chapter were written by Hui Liu, with editing by Richard
Hynes.
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INTRODUCTION
In the previous chapters, I have described the identification of CDCP1 as a metastasis
enhancer in vivo and we have found over-expression of CDCP1 causes cells to detach in
2D culture and grow in dispersive manner in 3D Matrigel culture. I am interested in further
understanding how CDCP1 exerts such functions in vitro and in vivo, through elucidating the
signaling pathway(s) that is (are) activated by CDCP1 overexpression.
Early work by Bhatt et al has shown that tyrosine phosphorylation of CDCP1 can be blocked
using inhibitors to Src family kninases (SFKs), and that CDCP1 can be phosphorylated in
vitro by Src, suggesting the potential involvement of SFKs (Bhatt et al., 2005). Work
accomplished by others since I initially focused on CDCP1 has also provided useful
information for our studies. When working on protein kinase C6 (PKC6), the Soltoff group
found that Src, CDCP1 and PKC8 form stable signaling complexes when all are
overexpressed. Interactions of PKC6 with CDCP1 are dependant on the C2 domain of
PKC6 and the phosphorylation of CDCP1 by Src (Benes et al., 2005). Several tyrosine
residues on CDCP1 were identified and some were shown to be important for complex
formation: Y734--)F mutation sharply reduced binding of CDCP1 to Src, and Y762-)F
mutation mildly decreased CDCP1 association with PKC8. This paper built a framework on
which models can be proposed to understand the cellular functions of CDCP1 as described
in chapter 4.
Recently, Sakai's group showed that CDCP1 plays a functional role during lung
adenocarcinoma (A549 cells) and gastric Scirrhous carcinoma (44As3 cells) metastasis
(Uekita et al., 2007; Uekita et al., 2008). In agreement with Bhatt's work, they found that
CDCP1 is tyrosine phosphorylated and can be immunoprecipitated from suspension A549
cells with antibody against Fyn (another member of the SFK family). Furthermore, wild-type,
but not Y734F mutant form of CDCP1 is important for anoikis-resistance in lung carcinoma
cells. Together, these data suggested that SFKs might be involved in CDCP1 functions
(Figure 1A Summarizes all known molecules interacting with CDCP1 and their potential
cellular functions). Therefore, I will introduce SFKs and PKC6 here, and describe their
known activation mechanisms and their roles in tumor initiation and progression.
The Src family of protein tyrosine kinases
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Src family kinases (SFKs) are non-receptor protein tyrosine kinases, playing pivotal roles in
various aspects of cellular processes, such as cell adhesion, proliferation, angiogenesis,
apoptosis-resistance, differentiation, migration and invasion (Martin, 2001; Parsons and
Parsons, 2004; Thomas and Brugge, 1997). In this chapter, I will introduce the discovery of
Src and the domain architectures of Src family kinase members, and I will focus on the
activation mechanisms of SFKs and the involvement of SFKs in tumor progression and
metastasis.
Intensive investigations using Rous Sarcoma virus identified v-src as the gene that is
required for cell transformation (Lai et al., 1973; Martin et al., 1971; Wang et al., 1975) and
the gene product is a phospho-protein pp60v-src, which is a protein tyrosine kinase (Brugge
and Erikson, 1977; Collett et al., 1978; Collett et al., 1980; Hunter and Sefton, 1980;
Levinson et al., 1978; Purchio et al., 1978). A cellular homologue c-src in normal
untransfomed cells was also identified (Oppermann et al., 1979; Stehelin et al., 1976a;
Stehelin et al., 1976b). Sequence analysis comparing v-Src and c-Src revealed substantial
differences at their C-termini, where a stretch of 12 different amino acids in v-Src replaced
those of c-Src(Takeya and Hanafusa, 1983). This structural difference correlates with
functional differences: while v-Src is constitutively active and expresses transforming ability,
c-Src is less active and does not transform chicken fibroblast cells (Iba et al., 1984; Tanaka
and Fujita, 1986).
These early studies led to the identification of the Src family of kinases, which include Src,
Fyn and Yes, expressed in most tissues; and Blk, Gfr, Hck, Lck, and Lyn, predominantly in
hematopoietic cells (Bolen and Brugge, 1997). They share the same domain structures
(FigurelB), with an N-terminal unique region, an SH3 domain, an SH2 domain and the
kinase domain (SH1 domain). The kinase is kept inactive by multiple intramolecular
interactions and the activation of SFKs is achieved by disrupting those interactions, through
phosphorylation/de-phosphorylation events and/or intermolecular associations.
Three major interactions keep Src in inactive conformation (Figure 1C, center): 1)
Tyrosine530 at the C-terminus, when phosphorylated by Csk (c-Src Kinase) (Sicheri et al.,
1997; Xu et al., 1997; Yamaguchi and Hendrickson, 1996) or by CHK (CSK homologous
kinase)(Davidson et al., 1997), folds back and binds to the SH2 domain of Src (Sicheri et al.,
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1997; Xu et al., 1997; Yamaguchi and Hendrickson, 1996). Phasphatases that remove the
phosphate from Y530 can activate Src; and in fact, this is the tyrosine that is lost in v-Src,
rendering it constitutively active; 2) A loop region (with sequence: PX4PX12P) from the
kinase domain interacts with the SH3 domain, thus preventing the closing of N- and C-lobes
of the kinase domain (Xu et al., 1999). Proteins competing with such interactions can
potentially activate Src; and 3) Activation-loop with un-phosphorylated Tyr 419 forms a short
a-helix that occludes the substrate-binding site (Bjorge et al., 2000; Ingley, 2008; Xu et al.,
1999). Auto-phosphorylation of Y419 in trans will change the conformation of the a-helix
and remove it from the binding site, thus achieving full activation of Src. Therefore,
activation of SFK can be achieved by 1) disrupting intra-molecular interactions; 2)
autophosphorylation of Y419 at the activation loop; and /or 3) de-phosphorylation of pY530
at the C-terminus (Chong et al., 2005).
Numerous proteins have been identified regulating the activities of Src, which can be divided
into two sub-groups, one modulates Src activity through phosphorylation and de-
phosphorylation events (Figure 1C, right), and the other functions as binding partners and
competes with intra-molecular interactions described above (Figure 1C, left).
Kinases/phosphatases
As mentioned earlier, Csk and CHK are the major negative regulators of Src by
phosphorylating the C-terminal tyrosine (pY530). On the other hand, activation-loop Y419 is
auto-phosphorylated in trans by an identical or related SFK, and only when Y419 is
phosphorylated can kinase achieve maximal activity (Chong et al., 2005).
Several phosphatases have been identified, among them, PTPalpha (protein tyrosine
phosphatase alpha)(Ponniah et al., 1999; Su et al., 1999; Zheng et al., 1992) and SHP1
(tandem SH2 domain-containing protein tyrosine phosphatase) (Somani et al., 1997) have
been shown to be rather specific for the C-terminal pY530, thus activating SFKs. Other
phosphatases have also been identified, such as PEP (proline-enriched tyrosine
phosphatase), TCPTP (T-cell protein tyrosine phosphatase), and CD45. They have been
shown to remove phosphate from both the C-terminal site (equivalent to Y530), and the
activation loop tyrosine, thus they can both activate and inhibit SFK activity depending on
the cell types (Alexander, 2000; Bjorge et al., 2000; Ingley, 2008).
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Src binding partners and adaptor proteins
Interactions of SFK with various proteins play important roles in regulating SFK activities
and in bringing SFK to the proper subcellular locations (Bjorge et al., 2000; Thomas and
Brugge, 1997). Proteins with specific PxxP motifs and phosphorylated-YEEI and related
sequences can compete for binding to SH3 and SH2 domains, respectively, disturbing the
intra-molecular interactions and allowing for SFK activation. For example, PDGFR can bind
to the SH2 domain of Src and induce activation of Src (Alonso et al., 1995; Kypta et al.,
1990), and Sin activates Src through interaction with the SH3 domain (Alexandropoulos and
Baltimore, 1996). Recently, a class of transmembrane adaptor proteins, including Cbp and
its related molecules such as LIME and LAT, has been identified to modulate SFK activities
by complexing with other signaling molecules. In the case of Cbp, it was identified to recruit
Csk to the membrane (Kawabuchi et al., 2000), and when tyrosine-phosphorylated, Cbp
binds to both Csk and SFK (Lyn and Src), thus mediating the inactivation of SFKs. And
interestingly, Cbp has been shown to reside in the lipid raft fraction of the plasma
membranes (Ingley, 2008; Ingley et al., 2006; Oneyama et al., 2008). Recently, reversion
induced LIM (RIL) has been shown to serve as an adaptor protein and interact with both Src
and PTPL1, thus facilitating the de-phosphorylation of tyrosine at the activation loop, and
reducing Src activities (Zhang et al., 2009). It is possible that more adaptor proteins are
involved in modulating SFK activities, and identification and analysis of these adaptor
proteins will further our understanding of the regulation of SFKs.
Roles of Src in tumor progression and metastasis
Numerous studies in colorectal carcinomas have shown the important contributions of SFKs
to tumor formation and progression, and the function of SFKs have been described in many
other types of malignancies, such as lung, skin, breast, ovarian, hepatocellular, pancreatic
and gastric cancers (Biscardi et al., 1999; Frame, 2002; Ishizawar and Parsons, 2004;
Parsons and Parsons, 2004; Summy and Gallick, 2003; Yeatman, 2004).
Early data have reported increased Src activities comparing colon carcinoma cells to normal
colon (Bolen et al., 1987), adenomatous polyps to normal mucosa (Cartwright et al., 1990),
and comparing liver metastasis to primary tumors and to normal tissues (Talamonti et al.,
1993). Furthermore, it was shown that enhanced c-Src activity served as an independent
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prognosis marker at all stages of colon carcinomas (Aligayer et al., 2002). These data
suggest strong correlation between tumor formation/progression and Src activities (Russello
and Shore, 2003).
Functional studies showed that Src is involved in various processes of tumor formation and
progression. Irby et al showed that over-expression of c-Src enhanced subcutaneous tumor
growth (Irby et al., 1997), while down-regulation of c-Src using antisense oligonucleotides
slowed the tumor growth of HT29 cells (Staley et al., 1997), supporting a role of c-Src in cell
proliferation.
SFKs also contribute to tumor metastasis. For example, colon carcinoma cells
overexpressing SFK negative regulator Csk (described above) are defective in metastatic
spread, although primary tumor formation was not affected (Nakagawa et al., 2000). Many
different pathways can be activated to promote metastases. 1) SFKs have been shown to
localize to integrin-mediated focal adhesions, and play pivotal roles in cell-ECM adhesion,
spreading and cell migration (Abram and Courtneidge, 2000; Hynes, 1992; Thomas and
Brugge, 1997); 2) SFKs can also contribute to the invasiveness of colon carcinoma cells
through enhanced metalloprotease productions. Csk over-expressing cells mentioned
above migrate to the same extent relative to control cells, but are defective in invasion
through Matrigel, possibly due to diminished production of matrix metalloprotease 2 (MMP2)
(Nakagawa et al., 2000). SW480 cells with constitutively active Src showed increased
degradation of lamininl due to transcriptional induction of urokinase receptor (Allgayer et al.,
1999; Leupold et al., 2007); 3) Active Src can diminish cell-cell junctions, which could also
be partly responsible for enhanced metastatic potential. For example, in colon tumor cells
expressing constitutively active Src, there is a reduced surface N-cad expression and
disrupted N-cadherin /p-catenin association, resulting in reduced cell-cell adhesion (Irby and
Yeatman, 2002; Nam et al., 2002; Owens et al., 2000); 4) In addition, Src can also activate
anoikis-resistance pathways. (Windham et al., 2002); 5) Src may also contribute to tumor
formation and progression through elevated angiogenesis. v-Src has been shown to induce
the production of vascular endothelial growth factor (VEGF) through the activation of STAT3
(Yu et al., 1995), Src kinase inhibitor treatment in pancreatic cancer reduced tumor burden
and decreased metastasis, and inhibited endothelial cell migration and sprouting in vitro
(Ischenko et al., 2007). It is clear that SFKs elicit a variety of activities, that individually or
collectively, could contribute to tumor progression and metastasis.
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Protein kinase C6 (PKC8)
Protein kinase C is a family of nine serine/threonine kinases that regulate cell proliferation,
apoptosis, differentiation and cell motility. It can be classified into three groups, classical
PKC or cPKC (include PKCu, P1, 1311 and y), novel PKC (nPKC: PKC8, £, r~, and 0) and
atypical PKC (aPKC: PKC and PKCL), each with different requirement for activation.
Members of the cPKC group need Ca" and DAG (or phorbol esters); nPKC members are
dependent on DAG but not on Ca", while neither Ca" nor DAG activates aPKCs. Most cells
express more than one family of PKCs - PKC isoforms a~, 8 and E are most widely
expressed, while the expression of the other PKCs are largely cell-type specific.
The mechanisms involved in the activation of PKCs have been extensively studied (Griner
and Kazanietz, 2007; Jackson and Foster, 2004; Kikkawa et al., 2002; Newton, 2003;
Steinberg, 2004), and a simplified view is presented here - phospholipase Cs (y or P)
coupled to receptor tyrosine kinases (RTKs) or G-protein-coupled receptors (GPCRs) are
activated when cells are stimulated through RTKs or GPCRs, resulting in generation of
diacylglycerol (DAG) at the membrane. The increased DAG production triggers the
recruitment of cPKCs and nPKCs through the C1-domains at the regulatory region, and
conformational changes upon localizing to the membrane induce the kinase activation
(Griner and Kazanietz, 2007).
In addition to membrane-translocation, tyrosine phosphorylations have also been shown to
modulate PKC activities, in particular, PKC8 activities (Kikkawa et al., 2002; Steinberg,
2004). However, the effect of tyrosine phosphorylation on the enzymatic activity of PKC8 is
still controversial. On the one hand, activation of SFK and epidermal growth factor receptor
signaling have been shown to result in tyrosine-phosphorylation of PKC8, and a reduction in
PKC8 activities (Denning et al., 1993; Denning et al., 1996; Joseloff et al., 2002). On the
other hand, PKC8 can be phosphorylated on tyrosines in vitro or in vivo by Src, insulin
receptor or platelet derived growth factor receptor b, resulting in enhanced PKC8 activities
(Benes and Soltoff, 2001; Li et al., 1994a; Li et al., 1994b; Uekita et al., 2007). Many factors
contribute to these apparently opposite results. Different cell types were used in these
studies, and it is conceivable that the state of the cells - such as the presence and
activation status of other signaling molecules - can well vary among different cells. In
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addition, various upstream stimuli were applied to the cells, which, together, may result in
different configurations of tyrosine residues that are phosphorylated on PKC6. The precise
configuration may dictate the properties of the enzyme (Steinberg, 2004).
The cellular functions of PKC6 have been controversial as well. However, compelling
evidence from PKC6 knockout mice supports roles of PKC8 in suppressing cell proliferation
and enhancing apoptosis. Two groups generated PKC6 knockout mice, which are viable
and fertile, suggesting PKC6 is not required for normal development (Leitges et al., 2001;
Mecklenbrauker et al., 2002; Miyamoto et al., 2002). Smooth muscle cells derived from the
mice are resistant to cell death in response to various stimuli in vitro, suggesting a normal
function of PKC6 in promoting apoptosis (Leitges et al., 2001). Also shown is loss of B-cell
tolerance in PKC8 knockout mice, with enhanced B cell proliferation, and presence of auto-
reactive antibodies (Mecklenbrauker et al., 2002; Miyamoto et al., 2002). In agreement with
these studies, PKC6 has been shown to suppress cell proliferation, mediate apoptosis
(Griner and Kazanietz, 2007; Hung et al., 2008; Mhaidat et al., 2007; Perletti et al., 1999;
Sitailo et al., 2006), and function as a tumor suppressor (Aziz et al., 2006; Lu et al., 1997;
Reddig et al., 1999). However, in other cases, PKC6 was shown to suppress apoptosis and
enhance cell proliferation (Kiley et al., 1999a; Kiley et al., 1999b; Xia et al., 2009; Xia et al.,
2007). And currently the reasons for these conflicting results are still not clear, although one
can speculate that differences in cell types and the pre-existing signaling status of the cells
may contribute to these contradictions.
EXPERIMENTAL GOALS AND APPROACHES
In the previous chapter, we found that CDCP1 alters the balance between cell proliferation
and apoptosis, and allows the cells to grow in a dispersive manner; both properties
potentially contribute to the enhanced metastatic abilities of melanoma cells. In this chapter,
we will investigate the signaling pathway(s) activated by CDCP1 that contribute to such
cellular effects. We will first focus on the possible involvement of SFKs in CDCP1-mediated
metastasis and we will also try to investigate the potential function of PKC6.
RESULTS
Extracellular and transmembrane domains are necessary for CDCP1 functions
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We would like to dissect CDCP1 further to understand the structural features that are
responsible for its functions. For this purpose, we constructed chimeric CDCP1 where the
extracellular domain (including all three CUB domains) and transmembrane domain were
replaced with those of IL2-receptor a (IL2Ra), generating Tac-CDCP1 (Berrier et al., 2002;
LaFlamme et al., 1992). When A375 cells express the chimeric proteins, cells failed to
detach in 2-D culture (Figure 2A). In 3D Matrigel, cells over-expressing Tac-CDCP1
remained as ball-like structures and failed to form "cluster-of-grapes" morphology (Figure
2B), although the proteins are expressed detected by anti-CDCP1 antibody in western blot
(Figure 2C), and on the surface of the cells assayed by flow cytometry analysis using anti-
IL2Ra antibody (Figure 2D). These data suggest that removing the extracellular domain and
transmembrane domain abolished the functions associated with CDCP1, at least in vitro. It
is possible that ligand(s) interactions and/or clustering of CDCP1s are necessary for the
functions of CDCP1, and further experiments are needed to distinguish among these
possibilities.
Mutation in tyrosine at position 743, 762 and 806 did not affect CDCP1 functions in
vitro
Inspection of the cytoplasmic domain of CDCP1 reveals the presence of five tyrosines and
two poly-proline motifs with typical PXXP sequences that are presumptive binding sites for
SH3 domains. Several of the tyrosines have been reported to be phosphorylated by SFKs
and serve as docking sites for SFKs and PKC6, suggesting they may be important sites
mediating CDCP1 functions.
To test the possible involvement of tyrosines (and phosphorylation of these tyrosines), we
performed site-directed mutagenesis to obtain tyrosine-to-phenylalanine mutant forms of
CDCP1 (Y734F, Y743F, Y762F and Y806F), and generated stable A375 cell lines
expressing each of these mutants - A375-Y734F, A375-Y743F, A375-Y762F and A375-
Y806F. Surface expression levels of these mutants are similar, comparing to wild type
CDCP1 (A375-CDCP1)(Figure 3A).
In 2D culture, A375-Y743F, A375-Y762F and A375-Y806F, just like A375-CDCP1 cells, de-
adhere from tissue culture plates and proliferate in suspension (Figure 3B). When subjected
to 3D Matrigel assay, these cell lines also behave the same as A375-CDCP1 cells, forming
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"cluster-of-grapes" morphology with scattered growth pattern (Figure 3C). These mutants
also showed mislocalization of p-catenin in Matrigel (Figure 3D) and reduced N-cadherin
staining at cell-cell junction (data not shown), although total expression levels of N-cadherin
and beta-catenin are similar judging by western blotting (Figure 3E). These data indicated
that these four tyrosine-to-phenylalanine mutations did not alter the activities of CDCP1 in
our in vitro analysis.
Tyrosine 734 of CDCP1 is critical for the cell de-adhesion activities of CDCP1 in vitro,
and scattered growth in Matrigel
In contrast to the aforementioned mutants, A375 cells overexpressing the Y734F mutant
version of CDCP1 cells remain as adherent cells in tissue culture (Figure 4A). A375-Y734F
cells fail to grow in dispersive manner in Matrigel. Instead, they grow as tight balls in 3D
Matrigel just like A375-Vector-Ctrl cells (Figure 4B). Immuno-fluorescence staining revealed
that the majority of N-cadherin and p-catenin are localized at the cell-cell junctions (Figure
4C). Our data showed that in vitro, the function of CDCP1 is dependent on the presence of
tyrosine at amino acid position 734. When mutated, it completely abolished the functions of
CDCP1 observed in vitro.
Mutation of tyrosine 734 to phenylalanine in CDCP1 abolished the metastasis-
enhancing activity of CDCP1 in vivo.
With these in vitro results, we performed In vivo metastasis assays by injecting A375-Y734F,
A375-CDCP1 cells or A375-Vector-Ctrl cells into NOD/SCID mice via the tail vein. In
agreement with our in vitro work, A375-Y734F cells produced significantly reduced number
of lung metastasis as compared with WT-CDCP1 (Figure 4D). In fact, there is no difference
in number of lung metastasis formed by A375-Y734F cells or control cells, suggesting that
mutation in Tyrosine-734 completely abolished the metastasis-enhancing activity of CDCP1
in vivo (Figure 4E).
Our work dissecting the functional motifs in CDCP1 showed that the extracellular and
transmembrane domains are required for CDCP1 activities, indicating the potential
involvement of CDCP1 ligand(s). We also identified a critical amino acid Y734 in the
cytoplasmic tail of CDCP1 that mediates various functions of CDCP1, namely cell de-
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adhesion in 2D culture, scattered growth in 3D matrigel, and enhanced metastasis in vivo.
This is very interesting, especially in light of the work by Benes et al, where the same amino
acid Y734, but not other tyrosines, was identified as the docking site for Src in the triple
over-expression system (overexpress CDCP1, Src and PKC6) (Benes et al., 2005),
suggesting the potential involvement of Src family kinases in the functions of CDCP1.
Overexpression of CDCP1 enhances activation of Src family kinases (SFKs) and AKT
We next tested which Src family kinases are present in A375 melanoma cells using
antibodies specific to Src, Fyn and Yes. Although A375 cells express all three members,
Src is the most abundant (data not shown), and we decided to focus on Src.
To investigate the possible involvement of Src in the functions of CDCP1, we performed
immuno-blotting using antibody recognizing the active form of SFKs (pY416) or total Src.
We found that, in A375 cells over-expressing CDCP1, the abundance of pY416 increased
while total Src remained the same, indicating enhanced SFK activity by overexpression of
CDCP1. We also found that the serine 473-phosphorylated form of AKT (i.e. activated AKT)
is increased in these cells comparing to A375-Vector-Ctrl cells, with the same total AKT
expression (Figure 5).
Y734F mutation abolished enhanced SFK activation by CDCP
We next analyzed the activation status of SFKs and AKT in the mutant cell lines. We found
that although over-expression of WT-CDCP1, A375-Y743F and A375-Y806F caused
stronger activation of SFKs than A375-Vector-Ctrl cells (Figure 6, lower panel), even though
total expression levels remained the same (Figure 6, upper panel). Importantly, cells over-
expressing the Y734F mutant form of CDCP1 no longer showed increased SFK activation
(Figure 6). In fact, the activation levels of SFKs in A375-Y734F cells were similar to those of
A375-Vector-Ctrl cells, suggesting that higher SFK activation caused by CDCP1 is
dependent on the presence of tyrosine 734.
The coincidence between loss of function (both in vitro and in vivo) and loss of SFK
activation suggested that CDCP1 might exert its functions through hyper-activation of Src.
We further tested the involvement of Src family kinases using pharmacological treatment.
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PP 2 and Dasatinib treatment partly reverted "cluster-of-grape" growth of A375-CDCP1
cells into ball-like structures in 3D Matrigel culture
PP2 and Dasatinib are Src family kinase inhibitors, which have been widely used. The IC50
of PP2 for Lck and Fyn has been reported as 5nM in in vitro kinases assays, and as 0.55um
in T cells (Hanke et al., 1996). However, in HT29 colon carcinoma cells, it was reported that
10um of PP2 was used to reduce Src kinase activity to 75% of that in untreated cells (Nam
et al., 2002). The IC50 of dasatinib for Src in a kinase assay is 0.6nM, and in cells is at 0.1-
0.3[tM range (Lombardo et al., 2004). We treated the cells with increasing concentrations of
PP 2 (with non-functional analogue PP3 as negative controls) and Dasatinib in 3D Matrigel
culture, and colony morphologies were analyzed after 6 days. We found that when A375-
CDCP1 cells were treated with 15um of PP2, the majority of the colonies lost the scattered
pattern and reverted to ball-like structures, while treatment with 15um PP3 had no effect on
the dispersive growth (Figure 7A). When using Dasatinib, we found that only at
concentrations higher than reported (2um) did we observe such a reversion of morphology
(Figure 7B). At this concentration, the average colony size for A375-Vector-Ctrl cells (mean
diameter = 86.2±3.29) is smaller than that of control DMSO treated cells (mean diameter =
102.3±3.98, Figure 7C), indicating some reduction in cell proliferation.
Using pharmacological treatment, we have found that at concentrations similar to reported
IC50 or higher than reported, Src family kinase inhibitors effectively inhibited the ability of
A375-CDCP1 cells to grow in a scattered manner in 3D Matrigel. These data agreed with
our previous finding that enhanced SFK activation correlates with 3D growth pattern and in
vivo metastsis, further supporting our hypothesis that CDCP1 exerts its function through the
activation of Src family kinases.
Over-expression of activated Src in A375 cells partly mimics the morphologies of
A375-CDCP1 cells
To test this idea further, we expressed activated Src in A375 cells and subjected them to 3D
Matrigel assay (Figure 8), and we found the cells partially mimic the morphology of A375-
CDCP1 cells (but not cells expressing other oncogenes such as activated Ras or YAP). The
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colonies became scattered in Src over-expressing cells, although not to the same degree as
A375-CDCP1 cells, suggesting that activated Src can induce a similar change.
We also attempted to down-regulate Src expression levels using lentivirus-mediated knock-
down. For this purpose, we obtained constructs from the Schlaepfer group (Wu et al., 2008)
and subcloned them into pLentilox3.7-p. A375-CDCP1 cells were infected and selected with
puromycin. We found that the puromycin-resistant cells initially proliferated extremely
slowly, but started to proliferate after approximately 2 weeks in the presence of puromycin.
When these cells were analyzed, we did not observe reduced Src expression. Based on our
observation, we speculate that A375-CDCP1 cells may not tolerate reduced Src expression
well. Therefore, cells which escaped shRNA knock-down were eventually selected, while
cells with reduced Src were depleted in culture. At this point, we are not able to test if down-
regulation of Src in A375-CDCP1 cells will effectively suppress the scattered growth of these
cells and eventually suppress the metastases.
To summarize, we have shown 1) a CDCP1 point mutation that diminished hyper-activation
of SFK also abolished the functions of CDCP1 in vitro and in vivo; 2) SFK inhibitors partly
reverted scattered growth morphology of A375-CDCP1 cells and 3) A375 cells expressing
activated Src partially mimic the growth pattern of those over-expressing CDCP1. All these
data indicate that CDCP1 may exert its function through hyper-activation of Src family
kinases.
Y734F mutation in CDCP1 does not significantly alter interactions between CDCP1
and Src using Triton-soluble cell lysate
We are interested in understanding the mechanism(s) by which CDCP1 activates SFKs.
Tyrosine 734 of CDCP1 has been reported as a key docking site for Src, mutation of Y734
to phenylalanine severely diminished interaction between Src and CDCP1 when both were
over-expressed (Benes et al., 2005). Upon binding, Src phosphorylated Y734 and other
tyrosines of CDCP1, and phospho-Y762 was reported to be important for PKC8 recruitment.
These data suggested a model that CDCP1 functions as a membrane adaptor protein,
directly recruiting SFKs through Y734 and activating SFKs. We decided to test this model
by comparing Src-CDCP1 interaction levels between A375 cells overexpressing WT-CDCP1
versus Y734F mutants using co-immunoprecipitation assays.
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We first lysed the cells in 1% triton lysis buffer and used the triton-soluble fraction to perform
immunoprecipitation. In two out of four experiments, we found a small reduction in
interaction between CDCP1 and Src when anti-Src antibody was used (Figure 9A, upper
panel). But in the other two experiments, similar levels of interaction were observed.
However, we observed two interesting phenomena. First, the fraction of CDCP1 complexed
with Src is very small comparing to the total amount of CDCP1 expressed by the cells
(Figure 9A, lower panel), which makes the quantification unreliable. This is probably the
major reason that we did not observe consistent reduction in CDCP1-Src interaction.
Intriguingly, we also found that, although the cells express similar levels of total Src (Figure
9B, lower panel), the amount of Src that is immunoprecipitated by anti-Src antibody is
smaller in A375-CDCP1 cells relative to A375-Vector-Ctrl or A375-Y734F cells Figure 9B,
top panel). When blotted with antibody specific to phosphorylated tyrosine 416, this fraction
of Src is positive, suggesting that it is the active form of Src (Data not shown). It has long
been observed that v-Src, which is constitutively active, is resistant to non-ionic detergent
(such as Triton X-100 and NP-40) extraction in a kinase activity-dependent manner.
However Triton X-100 can easily extract c-Src, which is normally kept inactive due to
multiple intramolecular interactions (Burr et al., 1980; Fukui et al., 1991; Loeb et al., 1987).
Because of the strong activation of Src shown in A375-CDCP1 cells, we wonder if our data
reflect the activity-dependent Src solubility-change in non-ionic detergents. Further studies
will be required to answer this question.
Our data supported the hypothesis that highly activated Src is important for the function of
CDCP1. However, the exact mechanism by which CDCP1 activates Src awaits further
investigation.
Potential Involvement of PKC6
As shown by Benes et al, the C2 domain of PKC6 interacts with tyrosine-phosphorylated
CDCP1, forming stable signal complexes when all three components (Src, PKC6 and
CDCP1) are overexpressed. Such interactions are partly dependent on the presence of
tyrosine 762 in CDCP1, since Y762F mutation in CDCP1 reduced interactions with PKC6.
185
Chapter 5
We are wondering if PKC6 is in the same pathway, therefore relaying signals initiated by
CDCP1.
To test this hypothesis, we first treated A375-CDCP1 cells and vector control cells with
rottlerin at concentration approximately its IC50 (3-6um), and allowed the cells to grow in
Matrigel in the continuous presence of rottlerin for 6 days. We found that at lum rottlerin,
neither A375-CDCP1 nor A375-Vector-Ctrl cells were affected; however, both cell types
treated with 2um rottlerin stopped proliferation, suggesting either a strong dependence on
PKC6 for cell proliferation or inhibitory side-effects of rottlerin. Because of this, we are not
able to conclude whether or not PKC 6 is responsible for the scattered growth of A375-
CDCP1 cells (Data not shown). We then made Y762F point mutation of CDCP1 and
generated stable cell lines (A375-Y762F), and these cells behaved just like WT-CDCP1 -
cells detached from plates and grew in suspension in 2D and formed "cluster-of-grapes"
morphology in 3D Matrigel (Figure 3B, 3C).
Next, we generated stable PKC6 knock-down cell lines for both A375-CDCP1 cells and
A375-Vector-Ctrl cells (A375-CDCP1-PKC6 KD7, KD8; and A375-Vector-Ctrl-PKC6 KD7,
KD8 and KD10) (Figure 10A). When we grew the cells in 3D Matrigel, we did not observe
major differences in the pattern of cell growth comparing A375-CDCP1-PKC6 KD7, KD8 to
A375-CDCP1 cells expressing control knockdown construct (Figure 10B). However, A375-
Vector-Ctrl cells with reduced PKC6 expression displayed "stellate" morphology with many
"connector" cells between the balls. These "connector cells" showed mesenchymal cell
morphology, rather than the typically observed amoeboid morphology (Figure 10C).
Potential Involvement of Akt
We also observed that the activation of Akt followed the same trend as that of SFK (Figure
11A), namely cells over-expressing the Y734F mutant showed reduced Akt activation
comparing to wild-type CDCP1 and other mutants (Y743F, Y806F). In addition, A375 cells
expressing constitutively active Akt also mimic the scattered growth pattern seen by
expressing CDCP1 (Figure 11B). However, the significance of Akt activation has not been
fully exploited, and is certainly of great interest to us.
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DISSCUSSION
In this study, several lines of evidence suggest that CDCP1 functions through the activation
of Src family kinases to exert metastasis-enhancing activities. 1) Overexpression of wild-
type CDCP1 in A375 cells hyper-activates SFKs and allow the cells to grow in dispersive
manner in 3D Matrigel culture; 2) PP2 and dasatinib, which are inhibitors of SFKs, can
revert the scattered growth pattern of A375-CDCP1 cells into ball-like structures in Matrigel;
3) A375 cells expressing activated Src mimic the growth of A375-CDCP1 cells in Matrigel;
and 4) A point mutation in CDCP1 (Y734F) abolished hyper-activation of SFKs elicited by
WT-CDCP1, which coincides with loss of cell-detachment, loss of scattered growth and loss
of metastasis-enhancing abilities of WT-CDCP1. Together, our data suggest activation of
SFKs by CDCP1 is responsible for the cellular effects of CDCP1 and for the metastasis-
enhancing activity of CDCP1.
Perhaps the above results are not surprising since Src is an important player during tumor
progression (Ishizawar and Parsons, 2004; Summy and Gallick, 2003; Yeatman, 2004).
One need only look at v-Src transformed fibroblasts to draw the similarity to the phenotypes
we found with CDCP1. v-Src transformed fibroblasts round up and float in the culture
medium, just as we saw with A375-CDCP1 cells. The mechanisms by which Src affects
cell-ECM adhesion are through disassembly and turnover of focal adhesions (Chang et al.,
1995; Fincham and Frame, 1998; Yeatman, 2004). In addition, in epithelial cells, Src
disrupts adherens junctions mediated by E-cadherin by phosphorylation of E-cadherin
followed by ubiquitin-mediated proteolysis, and by disrupting E-cadherin/p-catenin
interactions (Avizienyte et al., 2002; Yeatman, 2004). A375 cells express N-cadherin as
cell-cell adhesion molecules (rather than E-cadherins), and similar phosphorylation events
have been shown for N-cadherin as well (Qi et al., 2006), in agreement with the observation
of reduced cell-cell adhesion in 3D Matrigel in A375-CDCP1 cells. Our finding further
supports the notion that Src plays pivotal roles during cancer metastasis.
In addition, our results suggest that CDCP1 is a new regulator of Src activities. We are very
interested in the mechanisms by which CDCP1 activates Src. It was shown that when
CDCP1, Src and PKC6 are overexpressed in U2-OS cells, they form stable complexes,
which are dependent on the activity of Src. The Y734F mutation in CDCP1 reduced
interactions between CDCP1 and Src (Benes et al., 2005). This paper suggested a simple
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model; that CDCP1 activates Src by directly recruiting Src through tyrosine734. Based on
this model, the Y734F mutation should decrease/diminish interactions between CDCP1 and
Src in co-immunoprecipitation experiments. However, we did not find consistent reduction
in Src-CDCP1 association comparing Y734F mutants to wild-type CDCP1. There are
several possible explanations. First, inspection of the cytoplasmic tail of CDCP1 found two
PxxP motifs, which are the consensus binding sequences for SH3 domains. It is possible
that the Y734F mutation is not sufficient to abolish the protein-protein interactions between
CDCP1 and Src, and the presence of multiple PxxP-SH3 domain interactions could
compensate for loss of Y734 binding. In addition, we found that the amount of CDCP1 that
interact with Src is very small, perhaps less than 1% of total CDCP1 levels, which
conceivably contributed to the inconsistency in our co-IP quantifications.
Furthermore, we observed a CDCP1-dependent solubility change in Src - although A375-
CDCP1 cells express similar levels of total Src relative to the A375-Y734F mutants, there
was less Src present in the 1% Triton-soluble fraction, which complicated our data analysis.
However, the last point is quite interesting - together with the result that CDCP1
overexpression causes stronger activation of SFKs, our data suggest an activity-dependent
solubility change in Src. This observation is in agreement with early results, where
constitutively active v-Src was found prominently associated with the Triton-insoluble
fraction, while less active c-Src could be solublized easily in triton X-100. The triton X-100
insoluble fraction - which includes the cytoskeleton as well as membrane subfractions such
as lipid rafts or detergent-resistant microdomains (DRMs) - is likely to play important roles in
activating and coordinating signaling events. Many signaling molecules have been found
associated with cytoskeleton or localized in detergent-insoluble membrane microdomains,
including G protein- coupled receptors, integrins, T cell receptor complexes, Cbp, and SFKs
themselves(Echarri et al., 2007; Resh, 2006; Simons and Toomre, 2000). Therefore,
maybe CDCP1-dependent solubility change in Src reflects a significant change in
localization and activation of Src.
Based on this information, we propose a model that CDCP1 functions as an adaptor protein,
interacting with SFKs directly or indirectly, recruiting SFKs to the cytoskeleton and/or to lipid
rafts/DRM fractions. Perhaps, it is in these locations that Src is activated.
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Other circumstantial evidence may provide further support for this hypothesis. 1) CUB
domains have previously been shown to be important for directing metalloprotease
ADAMTS13 (a disintegrin and mellalloprotease with thrombospondin type I repeats 13) to
lipid rafts (Shang et al., 2006); 2) CDCP1 can potentially be palmitoylated on the cysteines
immediately C-terminal of the transmembrane domain, and many palmitoylated proteins are
enriched in lipid rafts (Resh, 2006); 3) CDCP1 has been suggested to localize to the lipid
rafts/DRM fraction (Alvares et al., 2008); and 4) Another adaptor protein, Cbp, which is
localized in the lipid rafts and interacting with Src and Csk, bears similarities in its
cytoplasmic domains to those of CDCP1. Both proteins have multiple tyrosines that are
phosphorylated by Src, which can mediate phosphotyrosine-SH2 interactions (in the case of
Cbp, it has been shown to interact with SH2 domains from both Src and Csk). Both proteins
contain PxxP motifs that can mediate SH3 domain interactions (Ingley, 2008). Further
experiments inspecting localization of CDCP1 and Src in the lipid rafts/DRM fractions or the
cytoskeleton in A375 cells expressing wild-type CDCP1 or the Y734F mutant will be needed
to test this hypothesis. In addition, identification of CDCP1-interacting proteins using an
unbiased approach such as immunoprecipitation-mass spectrometry will be greatly useful.
This experiment will identify proteins differentially interacting with wild-type CDCP1 or Y734F
mutant, which will certainly shed light on the potential mechanisms CDCP1 employs to
activate Src.
When delineating the potential signaling pathways activated by CDCP1, we also attempted
to investigate the roles of PKC5 in our system. Our initial treatment with rottlerin was not
informative because proliferation in these cells was highly sensitive to rottlerin treatment. At
a concentration that is lower than reported IC50, both A375-CDCP1 cells and A375-Vector-
Ctrl cells failed completely to proliferate. However, down-regulation of PKC6 revealed some
interesting phenomena. While reduction in PKC6 expression in A375-CDCP1 cells did not
have visible effects in these cells, we found in A375 control cells (without over-expression of
CDCP1), a subset of cells harboring PKC6 knock-down constructs change cell morphology
in Matrigel, making "networks" of cells with mesenchymal-like morphology. This is
interesting since PKC5 has been shown to inhibit cell migration - mouse fibroblasts derived
from PKC5 knockout mice show enhanced motility and dominant-negative PKC5 mutants
enhanced MCF-7 cell migration(Jackson et al., 2005). In addition,mammary carcinoma cells
presenting this "stellate" morphology in Matrigel have been shown to be more aggressive
cells compared to cells with other mophologies (Kenny et al., 2007). Our observation
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suggests a potential effect of PKC6 in cell invasion and further experiments will be needed
to address this possibility.
We also observed enhanced activation of Akt when A375 cells over-express WT-CDCP1,
which was abolished by the point mutation Y734F - the same mutation that abolishes SFK
activation. Given the essential roles of the PI3K/Akt pathway in cell survival (Duronio, 2008;
Qiao et al., 2008), we are certainly interested in understanding its functions in CDCP1-
mediated activities. Preliminary data showed that when A375 cells express constitutively
active Akt, these cells also grow in scattered manner in Matrigel. We have obtained
dominant-negative Akt (DN-Akt) and it will be interesting to see whether there is any effect
on the cell morphology and growth pattern when A375-CDCP1 cells are infected to express
DN-Akt, and if so, whether such an effect translates into in vivo metastases differences. We
will also treat the A375-CDCP1 cells with P13K pathway inhibitors such as Wortmannin and
LY294002 in the 3D assays to investigate their effects on the growth patterns. This set of
experiments will be useful to understand if Akt activation is downstream of CDCP1, and
contributes to the functions of CDCP1.
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Figure 1. Schematic of the domain structures of Src family kinases (SFKs) and the potential activation
mechanism (adapted from Yeatman T.J., 2004 and Bjorge J.D. et al, 2000). (A) All SFKs have the same
domain architecture. From N-terminus to C-terminus: variable domain -SH3 domain -SH2 domain -
SH1(catalytic) domain. (B) Activation mechanisms of SFKs (see text for details). Briefly, SFKs can be activated
through phosphorylation-de phosphorylation events (right part) and/or binding to growth factors (depicted
here, on the left) and/or other adaptor proteins.
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Figure 2. Extracellular and transmembrane domains are required for CDCP1 functions. (A) A375 cells over-
expressing Tac-CDCP1 where extracellular and transmembrane domains were replaced with those from IL2
receptor-a no longer de-adhere from culture plates. (B) A375 cells over-expressing Tac-CDCP1 grow as tight
balls in Matrigel culture. (C) Tac-CDCP1 expression was confirmed by western using polyclonal antibody
against C-terminal of CDCP1. (D) Surface Tac-CDCP1 expression was detected using anti-IL2Ra antibody.
Chapter 5
A
AN-1
&
179
120
84
66
50
.C:
n
_ ;:"s;7"' W~; :; :P *.
~ -"~:;~~ - -
'""
i:e c~
o
r
Chapter 5
202
Chapter 5
Y806F
Y743F Y762F
100  101 102  103  104
FL2-H: CDCP1-PE
Figure 3. Tyrosine-to-phenylalanine mutations in Y743, Y762 and Y806 of CDCP1 have no effect on the
functions of CDCP1 in vitro. (A) Surface expression of various mutants were confirmed using flow cytometry
and compared to the expression levels of wild-type CDCP1. (B) Similar to cells over-expressing wild-type
CDCP1, A375 cells over-expressing Y743F, Y762F or Y806F mutants de-adhere in 2D culture. (C) A375 cells
over-expressing Y743F, Y762F and Y806F mutants grow in scattered manner in 3D Matrigel, just like cells
expressing wild-type CDCP1. (See next two pages for figures B and C)
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Figure 3. Tyrosine-to-phenylalanine mutations in Y743, Y762 and Y806 of CDCP1 have no effect on the
functions of CDCP1 in vitro. (D) Immunofluorescence staining in Matrigel culture revealed mislocalization of
0-catenin. (E) Western blotting shows that total expression levels of N-cadherin and 1-catenin are similar
comparing A375 cells expressing vector control, or wild-type CDCP1 or various mutants of CDCP1.
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Figure 4. Tyrosine Y734 is necessary for all functions of CDCP1 in vitro and in vivo. (A) A375 cells over-
expressing Y734F mutant form of CDCP1 no longer de-adhere from culture plates in 2D culture. (B) A375-
Y734F cells completely lose "cluster-of-grape" pattern of growth in 3D, instead, they grow as a ball of cells in
Matrigel, similar A375 cells expressing vector control.
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Figure 4. Tyrosine Y734 is necessary for all functions of CDCP1 in vitro and in vivo. (C)
Immunoflurorescence staining shows localization of 13-catenin at cell-cell junctions in A375-Y734F cells.
These data suggested that Y734 is necessary for in vitro functions of CDCP1 (D) Y734F point mutation
completely abolished metastasis-enhancing activity of CDCP1 in vivo. A375-Vector-Ctrl, A375-CDCP1 or
A375-Y734F cells were injected into NOD/SCID mice via tai vein and numbers of lung metastasis were
recorded at the end of 10 weeks. Mice injected with A375-Y734F cells harbor significantly fewer lung tumors
comparing to those injected with A375-CDCP1. There is no difference between the number of lung tumors in
mice receiving A375-Vector-Ctrl or A375-Y734F cells. (E) Representative images of the left lobes from mice
injected with A375-Vector-Ctrl cells (left), A375-Y734F cells (middle) or A375-CDCP1 cells (right).
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Figure 5. A375 cells over-expressing CDCP1 showed strong activation of SFKs and AKT, but comparable FAK
activation relative to control cells.
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Figure 6. Y734F mutation that abolishes all functions of CDCP1 also abolished over activation of SFKs.
Other point mutations (Y743F and Y806F) that have no effect on CDCP1 functions also showed no influence
on the activation status of SFKs.
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Figure 7. Inhibitors of SFKs blocked scattered growth of A375-CDCP1 cells in 3D Matrigel cultures. (A) PP2
treatment, but not PP3 treatment, reverted dispersive growth of CDCP1 over-expressing A375 cells to control
"ball-like" structures.
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Figure 7. Inhibitors of SFKs blocked scattered growth of A375-CDCP1 cells in 3D Matrigel cultures. (B)
Another SFK inhibitor - Dasatinib - also blocked the dispersive growth of CDCP1-overexpressing cells in 3D
Matrigle. (C) Dasatinib has a small effect on colony size. The colony diameters of A375-Vector-Ctrl cells
treated with Dasatinib are slightly smaller than control DMSO treated cells.
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Figure 8. A375 cells expressing constitutively active Src partially mimics the growth pattern of A375-CDCP1
cells. A375 cells expressing constitutively active Ras or YAP display different phenotype in Matrigel,
suggesting scattered growth is not a universal effect by oncogenes.
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Figure 9. Y734F mutation in CDCP1 has little effect on binding to Src. In these co-immunoprecipitation (co-
IP) experiments, equal number of cells were lysed in 1% Triton X-100 lysis buffer on ice for 30min, followed
with centrifugation at 13000rpm at 40C using table-top centrifuge. Triton- soluble fractions were collected
from each cell lysate and incubated with anti-Src antibody (or mouse IgG control (data not shown) for co-IP.
(A) Association between CDCP1 (WT and Y734F) and Src was shown by co-immunoprecipitation with anti-Src
antibody, followed by Western blot using anti-CDCP1 antibody in upper panel. Lower panel: 5% input for Co-
IP, blotted with anti-CDCP1 antibody. (B) Western blotting using anti-Src antibody revealed that there is less
soluble Src present in 1% Triton that can be immuno-precipitated using anti-Src antibody.
(IP: immunoprecipitation; WB: Western blot)
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Figure 10. In 3D Matrigel, downregulation of PKC6 did not change growth pattern of A375-CDCP1 cells, but
affected cell behavior in A375-Vector-Ctrl cells. (A) Western blot using anti-PKC6 antibody showed that
reduced PKC6 expression using KD7, KD8 and KD10 siRNA constructs in A375-CDCP1 and A375-Vector-Ctrl
cells. (B) In A375-CDCP1 over-expressing cells, reduction of PKC6 expression (KD7) did not affect scattered
growth in Matrigel (Right panels) compared to A375-CDCP1-PKC6-Ctrl-KD cells (Left panels).
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Figure 10. In 3D Matrigel, downregulation of PKC6 did not change growth pattern of A375-CDCP1 cells, but
affected cell behavior in A375-Vector-Ctrl cells. (C) A375-Vector-Ctrl cells with reduced PKC6 expression
form "Stellate" pattern with connector cells showing mesenchymal morphology in between balls of cells.
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Figure 11. A375 cells expressing constitutively active Akt behave similarly to A375-CDCP1 cells in Matrigel
and follow the same activation pattern seen with SFKs. (A) A375 cells expressing constitutively active Akt
grow in scattered pattern in Matrigel (Left), similar to A375-CDCP1 cells (Right). (B) Western blot using
antibody against activated Akt showed that A375 cells over-expressing wild-type CDCP1, Y743F or Y806F
mutants have stronger activation of Akt compared to A375-Vector-Ctrl cells or cells over-expressing Y734F
mutant.
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CHAPTER 6.
DISCUSSION AND FUTURE DIRECTIONS
The contents of this chapter were written by Hui Liu, with editing by Richard Hynes.
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Summary of Results
Nearly 90% of cancer mortality from solid tumors is due to metastasis of malignant cells to
the distant vital organs. Currently our understanding of cancer metastasis has gone beyond
observations and researchers have started to gain mechanistic insights into this devastating
disease. Now we understand that not only the intrinsic propensities of tumor cells can partly
determine their metastatic potentials, their abilities to adapt and to change their
microenvironment also contribute greatly to the formation of metastases. Plasma
membranes are situated in between tumor cells and their microenvironments, mediating the
communications between them.
We decided to focus on plasma membranes and ask:
1) What are the intrinsic differences between tumor cells that form primary tumors
equally well but have different metastatic potentials?
2) Are any of these differences functionally contributing to metastasis?
3) If so, what are the underlying mechanisms?
We began to address the first question by enriching for plasma membrane followed by
quantitative mass spectrometry. We applied an interesting technique, colloidal silica coating
of cells, to isolate plasma membrane while removing other internal organelle membranes
(Chaney and Jacobson, 1983; Stolz and Jacobson, 1992), and we routinely achieve a 10-15
fold enrichment for plasma membrane proteins using integrin a2 as a marker. We also
observe significant removal of major contaminant membranes, particularly ER membranes
based on markers for these organelles. With this result, we began to analyze the identity of
the proteins present in the plasma-membrane-enriched complex protein mixtures by
performing mass spectrometry experiments. To reduce the complexity, we first separated
the membrane-enriched protein mixture using 1D electrophoresis, followed by excision of 30
gel slices, thus reducing the complexity by 30-fold. Upon tryptic digestion, peptides from
each gel band were further separated by reverse-phase HPLC, thus achieving 2-
dimensional separation of initial membrane protein complex. As peptides were eluted from
the column, they were introduced into the mass spectrometer by ion spray ionization, and
data-dependent acquisition was performed to collect the information of the top 10 most
abundant ions during each MS-MS/MS cycle. These data were searched against a human
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database using Sequest software to elucidate the identity of these peptides and eventually
match them to their parent proteins.
This approach yielded a list of proteins that are present in the plasma-membrane-enriched
mixture. We categorized them in two ways. First, we grouped by number of peptides
matching the identified proteins - either by single peptide, or two peptides, or more than two
peptides. Although we applied stringent search criteria followed by visual inspection of the
MS/MS spectrum, this method of categorization nevertheless provides a further measure of
confidence. For proteins that were identified by more than 2 peptides (940 proteins in total),
we are confident about their presence in the initial plasma membrane-enriched sample,
while for proteins identified by a single peptide, we are not so sure. We also group these
proteins based on their subcellular localization, which effectively is a measure of the plasma
membrane isolation technique, and we found that approximately 30% of all detected
proteins are membrane proteins.
To add quantitative power to mass spectrometry analysis, the initial protein identification
was combined with differential metabolic labeling of proteins from poorly metastatic A375
cells and highly metastatic MA2 cells. We chose metabolic labeling since it is a convenient
method with minimal human-introduced errors. However, we had to adjust our data
collection method to obtain high-resolution information with our instrument, which is needed
for quantitative analysis. We inserted a slower zoom scan step in between the conventional
MS (survey) scan and MS/MS scan. This did not come without sacrifice - indeed, we
reduced the number of peptides collected and analyzed by MS/MS from 10 to 5. Therefore,
the amount of identity information we were able to extract is less than aforementioned, but
we were able to obtain quantitative information instead. We found a total of approximately
530 proteins, 60% of which provided quantitative information.
Among the proteins that changed expression levels, we were pleased to find that some of
these proteins have been shown previously to be involved in metastasis. Ultimately, we
decided to pursue further a relatively novel protein, CDCP1, on the hypothesis that it is a
potential metastasis enhancer. CDCP1 has previously been found to be unregulated in lung
and colorectal cancer (Scherl-Mostageer et al., 2001), and in highly metastatic human
epidermoid carcinoma cells relative to their poorly metastatic counterparts (Hooper et al.,
2003). The phosphorylation status of CDCP1 seems to correlate with cell de-adhesion from
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ECM substrates (Brown et al., 2004). It was also shown that CDCP1 could be tyrosine-
phosphorylated by Src family kinases (Bhatt et al., 2005). However, at the time when we
started to focus on CDCP1, it had not been shown that CDCP1 actually played any
functional role in tumors or in metastasis formation.
When investigating surface expression levels of CDCP1 in poorly metastatic A375 cells, we
noticed that two subpopulations - CDCPlow and CDCP 1 high _ co-existed in culture, but only
CDCPlhigh cells were recovered from lung metastases. This prompted us to test whether
CDCP1 can serve as a surface marker for cells with higher metastatic potential within a pool
of A375 cells. We FACS-sorted A375-CDCP1h gh and A375-CDCP1 ' w, and tested their
metastatic abilities using tail-vein injection assays. We found that mice receiving A375-
CDCPlhigh cells harbored significantly more lung tumor nodules relative to mice receiving
A375-CDCP1low cells, suggesting that CDCP1 can indeed mark cells with higher metastatic
potential.
We then began to examine the role of this protein in melanoma metastasis by
downregulating CDCP1 expression in highly metastatic MA2 cells. When injected
intravenously into NOD/SCID mice, MA2 cells expressing siRNA against CDCP1 exhibited
significantly less metastasis in the lungs relative to the controls, whereas the size of
subcutaneous tumors did not differ. We also overexpressed this protein in poorly metastatic
A375 cells, and these cells formed significantly more tumor nodules in the lungs compared
to control cells when introduced directly into the circulation. Subcutaneous tumor growth
comparing cells overexpressing CDCP1 with control cells did not yield statistically significant
change. These data showed for the first time, that CDCP1 plays a causal role in metastasis
of melanoma cells.
We were curious about the cellular pathways in which CDCP1 might be involved to promote
melanoma metastasis. Using two series of stable cell lines - MA2 cells with or without
CDCP1 knockdown constructs, and A375 cells with or without overexpressing CDCP1 - we
tested whether CDCP1 is involved in cell adhesion, migration/invasion, proliferation or soft
agar formation. We observed that down-regulation of CDCP1 somewhat reduced the
number of soft agar colony formed by MA2 cells; while overexpression of CDCP1 increased
the number of colonies formed by A375 cells. These data suggested that CDCP1 might be
involved in regulating the balance between cell proliferation and apoptosis. This finding was
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further supported by immuno-histochemical staining of lung metastases for proliferation and
apoptosis markers. Comparing lung metastases from MA2 cells harboring CDCP1
knockdown constructs to control MA2 cells, there was a small, yet statistically significant,
reduction in proliferation index and increase in apoptosis, respectively. We speculate that
altered balance by CDCP1 toward proliferation might contribute to its ability to enhance
metastasis in the long run.
The other marked effect of CDCP1 is that CDCP1 overexpression caused the cells to
detach from culture plates, and to proliferate as suspension cells - some cells are
completely in suspension, and some cells tether loosely to the culture plate. A closer
examination found that A375 cells overexpressing CDCP1 failed to spread on ECM proteins.
We then decided to adopt a 3-D Matrigel culture system that has been widely used for
analyzing mammary carcinoma cells to study cellular alterations caused by CDCP1
overexpression. We found that, while A375 cells grow in 3D matrigel as balls with strong N-
cadherin and 3-catenin staining at cell-cell junctions, overexpression of CDCP1 caused the
cells to scatter, and grow in a dispersive manner, with decreased N-cadherin and
mislocalized P-catenin. Given that mammary gland cells behave similarly in vivo and in 3D
Matrigel (Debnath and Brugge, 2005; Schmeichel and Bissell, 2003), we speculate that this
scattered growth pattern may also occur in the lungs, and contribute to the large increase in
numbers of lung metastases caused by overexpressing CDCP1.
We would like to dissect CDCP1 further to understand the structural features that are
responsible for its functions. For this purpose, we constructed chimeric CDCP1 where the
extracellular domain and transmembrane domain were replaced by those of IL2-receptor a
(IL2Ra), generating Tac-CDCP1, along with four intracellular Y-)F mutations: Y734F,
Y743F, Y762F and Y806F. We found that Tac-CDCP1 and Y734F expressing cells no
longer caused de-adhesion in 2D culture or dispersive growth in 3D Matrigel, suggesting
that the extracellular and/or transmembrane domains, and tyrosine Y734 are necessary for
CDCP1 functions. Remarkably, the Y734F mutation completely abolished the metastasis-
enhancing activity of CDCP1, indicating that all functions of CDCP1 - in vitro de-adhesion
and scattered growth, and in vivo metastasis-enhancing activity - are mediated through
tyrosine 734.
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We noticed that whenever we observed cell de-adhesion in culture, we also found scattered
growth and loss of cell-cell adhesion in 3D; and that mutations that abolish one
concomitantly remove the other; suggesting that CDCP1 may affect pathway(s) that regulate
both cell-cell and cell-substrate adhesions. What could the pathway(s) be? Several results
have provided clues to this question. Src family kinases have been reported to
phosphorylate CDCP1 on tyrosine (Bhatt et al., 2005), and Y734F has been implicated in
interacting with SFKs. Following recruitment of SFK, CDCP1 has been shown to be
tyrosine-phosphorylated and mediate recruitment of PKC6 (Benes et al., 2005). These data
point to the potential involvement of SFKs downstream of CDCP1, mediating CDCP1
functions.
We tested this hypothesis using several methods. First, we investigated signaling pathways
activated by CDCP1, and found that CDCP1 overexpression hyper-activates Src. This
enhanced activation is lost when cells express the Y734F mutant or Tac-CDCP1 mutant, but
not other mutants, indicating a strong correlation between the activity of CDCP1 and activity
of Src. Next, we grew A375 cells overexpressing CDCP1 in 3D Matrigel in the presence of
SFK inhibitors (PP2 or Dasatinib), and the morphology was observed. In this case, blocking
SFKs inhibited scattered growth of these cells. We then expressed activated Src and found
these cells mimic behaviors of cells overexpressing CDCP1. These data together
suggested that the metastasis-enhancing function of CDCP1 is mediated by activation of
Src family kinases.
Thus this thesis has answered, in part, the three questions we asked at the beginning of this
research. We identified a list of proteins that are differentially expressed between tumor
cells with high versus low metastatic abilities; we determined the functional involvement of
CDCP1, and found it to be a novel metastasis-enhancer for melanoma cells; we investigated
the cellular pathways that CDCP1 engages to promote metastasis and found that perhaps
the changed balance between cell proliferation and cell death, and maybe scattered cell
growth, contribute to enhanced metastases. We also found that CDCP1 exerts its functions,
in part, by activation of Src family kinases.
Future Work
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In many ways, the work described in this thesis remains ongoing. Mass spectrometry
technology has advanced since the start of this project, and currently we are better
equipped with high-resolution, high-accuracy instruments on-campus and around, and re-
analysis of some of the samples will undoubtedly yield higher-confidence data with
additional quantitative information. I described here a successful application of quantitative
mass spectrometry to the plasma membrane proteome, and this technology has much
broader use to study organelle proteomes - to first catalogue proteins present in each
organelle and studying their dynamic changes upon stimulations. In fact, we have initiated
investigation in secreted proteins, in particular, extracellular matrix proteins, using
quantitative mass spectrometry.
As mentioned in chapter 1, we are interested in secreted and membrane proteins in the
context of metastasis because these proteins represent interfaces between tumor-intrinsic
abilities and their engagement with their microenvironment. In our system, we found that
poorly metastatic human melanoma A375 cells proliferate at similar rate relative to highly
metastatic MA2 cells in vitro, and subcutaneous tumors grow at similar rate in vivo; yet when
introduced in the lungs via tail vein, there exist dramatic differences in their abilities to form
tumors in the lungs. Tumor cells probably encounter very different situations in these two
sites. At the subcutaneous site of the skin, a large number of tumor cells are embedded in
the adipose tissue with ample tumor cell-cell interactions; and in the lungs, solitary cells are
in contact with lung endothelium (experimental observations and personal communications
with Dr. Sobolev). Conceptually, the fact that poorly metastatic tumor cells fail to manifest
into tumors in the lung reflects lack of proliferation, and/or cell death of these cells in
isolation and in a foreign environment. In other words, they are sensitive to their
microenvironment. And conversely, highly metastatic cells are "indifferent" to their
microenvironment due to intrinsic factors that compensate for lack of proper cell-cell and/or
cell-matrix contacts (for example, increased activation of MAPK pathway for proliferation or
Pi3K pathway for apoptosis-resistance), or due to their ability to make their own "home" or
niche by secreting growth factors and extracellular matrix (ECM) proteins (by themselves or
by inducing the stromal cells), or a combination of both.
We began to address these possibilities by first investigating membrane proteins and we
found that upregulation of CDCP1 in highly metastatic cells enhances the activation of Src
family kinase and activation of AKT, supporting our aforementioned hypothesis. And work
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has been initiated to test whether highly metastatic cells are better at making their own
"home" by investigating secreted proteins, in particular, ECM proteins. Similar to what we
have accomplished in this thesis, we are interested in first cataloguing the ECM proteins that
are present in the normal lungs, then quantitatively compare lung ECM proteins generated
by highly metastatic cells to those from poorly metastatic cells. For quantification, instead of
using metabolic labeling, which suits in vitro samples the best, we will apply chemical
labeling using iTRAQ. This method is currently widely used. Another interesting question
concerning secreted proteins in tumors is, where are these secreted proteins coming from?
Are they secreted by tumor cells, or by the stromal cells? Our biological system of
introducing human cells in immunocompromised mice, and mass spectrometry technology
are particularly fit for answering these questions. Currently, microarray technology uses
short probes that typically fail to discriminate between species. However, since mass
spectrometry can tell precisely the amino acid sequence and assign the source of the
protein to human-derived (tumor-derived) or mouse-(stroma-) derived, one single amino acid
change can be detected by mass spectrometry. So even for ECM proteins that are highly
conserved (for example 90% identical) between human and mouse sequences, one amino
acid change for a 10-amino acid peptide will be easily discriminated.
Although sometimes suggested as "rivals", microarray analysis and quantitative mass
spectrometry are nevertheless complementing each other. Combination of these two with
intensive data mining should yield information not only concerning relative quantitative
differences, but may also provide information on translational and post-translational
modifications. We have recently generated microarray data using passage-matched A375
cells and MA2 cells grown in culture, and we will perform detailed comparisons between
array and proteomics data in collaboration with the bioinformatics center.
Although we have shown that one of the proteins identified through the quantitative mass
spectrometry screen is functionally involved in metastasis, many more proteins await
discovery and/or confirmation. In fact, this presents the bottleneck between high-throughput
analysis by proteomics works and (extremely) low-throughput biology confirmation for their
roles in metastasis. Although currently there is no easy solution for this problem, application
of 3D Matrigel culture might be a good middle ground. Kenny et al have used a large panel
of breast cancer cell lines in 3D Matrigel culture and found that they generally fall into one of
four categories - round, mass, grape and stellate morphologies. Interestingly, eight out of
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nine cell lines that form "grape" structures with loose cell-cell adhesions are cells isolated
from metastases; and six out of eight of the cell lines that form "Stellate" morphologies have
previously been shown highly invasive in Boyden-Chamber invasion assays (Kenny et al.,
2007). Therefore, there seems to be a correlation between the cell morphology in 3D
cultures and their invasiveness. In addition, with currently available genome-wide cDNA
libraries and siRNA libraries, this method can be easily coupled with high-throughput
imaging analysis to test proteins that were identified through our work and genes identified
from microarray studies for their involvement in metastasis. This method could effectively
function as pre-in vivo, second-round functional screen and we shall expect more studies
along this line in the next several years.
We found that CDCP1 is a surface marker for melanoma cells with high metastatic potential,
and we would like to extend this work to clinical samples to determine if CDCP1 expression
correlates with disease progression or patient survival. Currently we have obtained tissue
arrays containing tumor samples and their normal counterparts; as well as tumor samples of
different stages. Recent work by Ikeda et al has shown that in lung adenocarcinoma
patients, significant positive correlation was observed between CDCP1 expression and poor
prognosis, and there is also significant difference in disease-free survival between patients
with high CDCP1 expression and those with low CDCP1 expression, strengthening our
argument (Ikeda et al., 2009). So far, CDCP1 upregulation has been shown to be
associated with enhanced tumor metastasis in lung and stomach cancers (Uekita et al.,
2007; Uekita et al., 2008) and in melanoma (this work). These results certainly hint that
CDCP1 may regulate tumor metastasis in a broader spectrum of cancers, and work along
this line will be necessary to generalize its roles.
Using experimental metastasis assay, we found CDCP1 as a positive regulator of cancer
metastasis. How do we explain such remarkable effects on metastasis by CDCP1? Our
results from in vitro and in vivo characterization of cells with reduced or enhanced CDCP1
expression do not seem to offer a simple answer to this question; however, they provide
several possibilities.
Experiments comparing cells overexpressing CDCP1 to control cells in early tail vein
injection assays found a small yet consistent increase (less than 2 fold) in number of cells in
the lungs 40min, 3 hours and 5 hours after tumor cell injections. This could be due to better
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trapping in the lung microvescular bed, and/or due to better survival in the circulation and
upon lodging in the lungs. Both ideas are supported by our data. Given that A375 cells
overexpressing CDCP1 are bigger than control cells, it is conceivable that more CDCP1-
overexpressing cells can be trapped in the lung microvasculature. Although I have not
demonstrated a direct anoikis-resistance effect of CDCP1 in our cell system, such effects
have been reported for both lung adenocarcinoma cells and gastric cancer cells (Uekita et
al., 2007; Uekita et al., 2008). Together with our result that downregulation of CDCP1
somewhat reduces soft agar colony formation, these data support the possibility that
CDCP1-overexpressing cells survive better in the circulation and upon lodging in the lung.
This idea can be directly tested by staining cells for apoptosis shortly after tail-vein injection.
Obviously this initial less-than-2-fold difference cannot explain more than 5-fold difference in
number of lung metastases that we observed after 5 weeks. It is possible that a function of
CDCP1 in apoptosis-resistance continues to play a role between 5 hours and 5 weeks,
which offers one explanation. This idea can be tested by investigating the number of cells
undergoing apoptosis during the intermediate time points - such as after 2 days, one week,
two weeks. Alternatively, CDCP1 could have a function in metastasis initiation to provide
cells with proliferative power, which can also be tested by staining for proliferation marker
Ki67 at intermediate time points.
It is also possible that additional functions of CDCP1 may participate. We observed de-
adhesion from substrate and cell-cell dissociation in Matrigel when cells overexpress
CDCP1, and we speculate that perhaps these properties allow the tumor cells to dissociate
from the primary metastases and seed additional metastases in the lung, resulting in a
significant increase in the number of lung tumors. Direct in vivo observation of such a
process may not be feasible without long-term live imaging, but we can take advantage of
"marking" tumor cells with a pool of -100 barcodes, and assay for the presence of particular
barcodes in a particular metastasis and in its surrounding metastases. In an example
illustrated in Figure 1, the predominant tumors A and B could be dissected to test the
presence of barcodes (for simplicity, tumor A or B harbor barcode A or B, respectively).
Tumors surrounding A and B (indicated with red or blue arrows) could also be dissected and
tested for the presence of these and other barcodes. If all these surrounding tumors are
derived from individual cells initially seeded in the lung (and not by disseminating from tumor
A or B), then there should be equal probability for the presence of these 100 barcodes.
243
Chapter 6
However, if these metastases are indeed derived from A or B, barcode A or B should be
enriched relative to other 98 barcodes, suggesting the role of CDCP1 in metastasis-to-
metastasis dissemination.
In our assay, cells were artificially introduced into the circulation; therefore we test the
functions of CDCP1 in later steps of cancer metastssis. Perhaps the next logical step is to
use orthotopic models to confirm the function of CDCP1 in full metastasis. Currently a
CDCP1 knockout mouse is not available yet, although target vector construction has begun
by the NIH Knock Out Mouse Project (KOMP).
When analyzing molecular pathways that may mediate the activities of CDCP1, we found
that activation of SFKs strongly correlates with CDCP1 functions, and CDCP1
overexpression in turn activates SFKs. We are interested in knowing the underlying
mechanisms for CDCP1-mediated SFK activation. Work by Benes et al has suggested a
loss of recruitment of Src by mutant Y734F form of CDCP1, suggesting that CDCP1
functions as an adaptor protein through Y734 to directly recruit SFKs. However, we were
unable to confirm loss of interaction between Y734F mutant CDCP1 and Src, therefore we
cannot confirm this simple activation model. The question is then, how does CDCP1
activate Src?
Although the previous model suggests that CDCP1 interacts with Src directly to compete for
intramolecular SH2-phosphoTyrosine interactions that keep Src in inactive state, it is entirely
possible that CDCP1 activates Src through indirect interactions to recruit Src activators.
CDCP1 may interact with protein phosphatases such as SHP1 and PTPa through Y734.
These protein phosphatases have been shown to remove the phospho-group from tyrosine
530 at the C-terminus of Src, releasing intramolecular interactions between SH2-
phosphoTyrosine interactions, thus activating Src. To test this hypothesis, co-
immunoprecipitation experiments using cells overexpressing either wild-type or Y734F
mutant CDCP1 can be carried out. In such experiments, anti-CDCP1 antibody will be used
for IP, and the resultant immunocomplexes can be blotted using anti-SHP1 or anti-PTPa
antibodies. If indeed Y734 is involved in recruiting these Src activators, we expect to see
reduced interaction between SHP1 or PTPa and Y734F mutant CDCP1, relative to wild-type
CDCP1. Alternatively, an unbiased method is to apply SILAC-quantitative mass
spectrometry to investigate proteins that immunoprecipitate with wild-type or Y734F mutant
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CDCP1. Proteins that fail to interact with CDCP1 due to Y734F mutation will be under-
represented in mass spectrometry analysis, while proteins that are not affected or non-
specific proteins will be presented at 1:1 ratio.
As detailed in chapter 5, we found a CDCP1-dependent solubility change of Src in 1% Triton
X-100, which correlates with the activity change of Src. It was also reported that CDCP1 is
localized in lipid rafts of the plasma membrane (Alvares et al., 2008), and Src family kinases
have also been shown to reside in lipid rafts (Simons and Toomre, 2000; Stefanova et al.,
1991). These data suggest one possibility - that Src needs to localize to these triton-
insoluble fractions to be activated. Based on this hypothesis, wild-type CDCP1 may interact
with Src via direct interactions through both SH2 domain- and SH3 domain-mediated
interactions, but only activate Src when both are localized to the detergent-resistant fraction.
CDCP1 with Y734F mutation could therefore fail to activate Src because it itself fails to
localize to the detergent-insoluble fraction, rather than failing to interact with Src. This
hypothesis can be tested by 1) immunofluorescence staining of CDCP1 with Src and with
activated SFKs to investigate co-localization eg with the cytoskeleton; and 2) biochemical
fractionation of Triton X-100 lysate on sucrose gradient to test colocalization of CDCP1 with
Src in the lipid raft fraction.
One question that we have not started to address is whether activation of Src by CDCP1 is
dependent on the phosphorylation of CDCP1? This can be answered by investigating the
phosphorylation status of wild-type CDCP1 (that activates Src) and Y734F mutant form of
CDCP1 (that does not activate Src) by immunoprecipitating CDCP1 and blotting for tyrosine
phosphorylation using 4G10 antibody. If Src activation is dependent on the phosphorylation
of CDCP1, then we shall expect that tyrosine-phosphorylation in Y734F is reduced or
diminished. If this is true, then there may exist a feed-forward loop between CDCP1 and
Src - Src may mediate the initial phosphorylation of CDCP1, and upon phosphorylation,
CDCP1 may further activate Src. This idea is supported by the following observations 1)
Src has been shown to phosphorylate CDCP1 in vitro in kinase assays, and blocking SFKs
using inhibitors reduced CDCP1 tyrosine-phosphorylation in vivo, suggesting that Src could
be the initiating kinase, although that does not exclude the involvement of other kinases; 2)
We found that not all cells that overexpress CDCP1 detach in 2D culture, an observation
supported by the Bhatt's work. It was suggested by Bhatt et al that only in the tumor cells
that have intrinsically high SFK activities did they find CDCP1 able to cause cell detachment
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(Bhatt et al., 2005). Comparing the basal SFK activities in cells that detach or remain
adherent when overexpressing CDCP1 might provide some insight in this manner.
In summary, we propose a model that CDCP1 functions as an adaptor protein, interacting
with SFKs directly or indirectly in a phosphorylation-dependent manner, recruiting SFKs to
the lipid raft/DRM fraction or to the cytoskeleton. Perhaps, it is in these locations that Src is
activated. We are very interested in testing our hypothesis in the near future.
In addition to activation of SFKs, overexpressing CDCP1 in A375 cells also enhanced the
activation of Akt. This is a very interesting phenomenon since the PI3K/Akt pathway has
been shown to be involved in apoptosis resistance (Duronio, 2008), and work by the Sakai
group has shown that down-regulation of CDCP1 in lung adenocarcinoma cells reduced
their anoikis resistance (Uekita et al., 2007). We are interested to pursue this topic further to
see if, indeed, the Akt pathway is downstream of CDCP1, mediating some of the effects we
observed. We will combine pharmacological treatments with specific inactivation (by
expressing dominant negative Akt, or siRNA-mediated knockdown) to address this question.
So far, we have investigated roles of CDCP1 as a cell-intrinsic factor. However, several
lines of evidence suggest that CDCP1 may be involved in communicating with the
microenvironment in which the cells reside. First, we found that A375 overexpressing
CDCP1 proliferate more slowly in tissue culture, and the sizes of subcutaneous tumors
generated from these cells are slightly (but not significantly) smaller relative to those from
control cells. However, when intravenously introduced into the lungs of the mice, these cells
form significantly more metastases in the lungs, suggesting a tissue-specific effect of
CDCP1 in balancing between proliferation and apoptosis. Secondly, we found that cells
overexpressing Tac-CDCP1, where extracellular and transmembrane regions of CDCP1
were replaced with those from IL-2 a, no longer detach from tissue-culture plates and no
longer grow in scattered manner in 3D Matrigel. In addition, CDCP1 contains extracellular
CUB domains, which have been shown to be involved in protein-protein, or protein-
carbohydrate interactions (Sieron et al., 2000; Tao et al., 2005; Tu et al., 2008). Together,
these results indicate the potential existence of factors in the microenvironment that interact
with CDCP1, dictating the functions of CDCP1. Identification of such factors (or CDCP1
ligands) and elucidating their localization in tumors (both the subcutaneous tumors and in
the lungs where the metastases eventually arise) will be very interesting to further our
understanding of tumor-microenvironment communications.
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Concluding Remarks
The results from this thesis have contributed small pieces of knowledge to our current
understanding of the problem of cancer metastasis. We have applied a new technology to
answer an "old" question, which has yielded novel information; we have focused on one
membrane protein CDCP1 and have shown its functions as a metastasis enhancer. We
have uncovered some of the potential cellular and molecular pathways by which CDCP1
increases metastatic potential. We hope this type of research may open avenues to design
specific blocking reagents in the effort to combat cancer metastasis.
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Chapter 6
Figure 1. Proposed experiment to test the involvement of CDCP1 in seeding metastases
from metastases. Briefly, A375-CDCP1 cells will be infected with a pool of barcodes
before intravenous injection, and metastases A and B (in this example) will be dissected
to test the presence of particular barcodes (A or B, respectively), and their surrounding
tumor nodules (red and blue arrows) will also be assayed for the presence of barcodes.
Significant enrichment for barcode A or B in these tumors suggest a role of CDCP1 in
possible metastases-seeding-metastases dissemination.
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Appendix A
APPENDIX A.
ROLE OF YES-ASSOCIATED PROTEIN (YAP) IN
MELANOMA METASTASIS
The work in this chapter was conceived by Hui Liu and Richard Hynes. Overexpression
construct for YAP was generated by Dr. Patrick Stern. The content of this chapter were
written by Hui Liu, with editing by Richard Hynes.
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When trying to understand the cellular mechanisms of CDCP1, it was overexpressed in
mouse embryonic fibroblasts to generate stable cell line (MEF-CDCP1). We found that
although control mouse embryonic fibroblasts (MEFs) formed one layer of cells and failed to
proliferate when reaching confluence (contacted-inhibited cell proliferation), MEF-CDCP1
continued to proliferate, suggesting maybe CDCP1 is involved in contact-mediated inhibition
of cell proliferation (Data not shown). I was intrigued by this observation, and I obtained
construct encoding a transcription factor - Yes Associated Protein, or YAP from Dr. Stern,
and generated retroviruses. YAP (Yorkie in Drosophila) is part of the newly discovered
Hippo pathway that mediates contact-inhibited cell proliferation (Edgar, 2006; Zhao et al.,
2008; Zhao et al., 2009). Therefore, it provided a positive control to test whether CDCP1 is
involved in contact inhibition of MEFs.
Both MEFs and A375 cells were infected with YAP or control retroviruses to generate MEF-
YAP and A375-YAP cells, as well as control cells (A375-MIGw and MEF-MIGw). When
A375-YAP cells were grown in 3D Matrigel, they look dramatically different from the control
cells. A375-YAP cells showed mesenchymal morphology and by day 8, clusters of spindly-
shaped cells spreading out from the center were observed (Figure 1), indicating that A375-
YAP cells have enhanced invasive activity. Transwell migration and invasion assays
showed drastic enhancement in the cells' ability to migrate, and in their ability to invade
through Matrigel-coated wells. While very few A375- control cells migrate or invaded
through the transwell (Figure 2A, left), the whole bottom membranes were covered with
migrated/invaded A375-YAP cells (Figure 2A, right). In addition, these migrated/invaded
cells look different from the control - while control cells present amoeboid morphology,
A375-YAP cells are mesenchymal. We also tested migration using scratch-wound assays,
and we found markedly enhanced migration with A375-YAP cells relative to control cells, in
agreement with transwell results (Figure 2B). These data showed that expression of YAP
significantly enhanced the ability of cells to migrate and invade.
Next, we investigated cell proliferation in vitro. Equal numbers of cells were seeded on day
0 and harvested on day 3, and we found approximately 40% more A375-YAP cells
compared to control cells, suggesting that YAP enhanced cell proliferation (Figure 3A).
To assess tumor cell growth at a subcutaneous site, we injected 0.5*10e6 A375-YAP cells
or A375-MIGw control cells into the mice and dissected at different time points to measure
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tumor growth rate. Initially (approximately 3 weeks and 5.5 weeks), tumors generated by
A375-YAP cells are much bigger than those from control cells; however, by eight weeks,
tumors from both cell types reached the same size (Figure 3B). These data suggesting that
YAP provides a growth advantage at early time, are in agreement with in vitro proliferation
data. However, such advantage is lost at later time points, and the reasons remain obscure
at this moment.
In light of our in vitro migration/invasion and 3D culture results, we performed experimental
metastasis assays to measure the abilities of A375-YAP cells to form lung tumors
comparing to the control cells. Perhaps as expected (given the dramatic effects we
observed in vitro), YAP expression significantly enhanced cell metastatic potential. While
mice injected with 1*10e6 A375-MIGw cells on average harbored 4.3 ±1.67 lung metastasis,
mice receiving the same number of A375-YAP cells contain 62.4+14.4 lung tumors, a more
than 10-fold increase (p= 0.0004, Figure 4). In addition, we observed formation of tumors in
the diaphragm underlying the lung, suggesting that tumor cells may have disseminated from
the lung and lodged into the diaphragm.
Impressively, we also observed numerous green tumor cells disseminated from
subcutaneous tumors generated by A375-YAP cells. We have found tumor cells in the
lungs that were disseminated from the subcutaneous tumors as early as 3 weeks. Visual
inspection using UV-dissecting microscope at the time of mouse dissection found that the
number of tumor cells in the lungs seem to increase over time. At an early time point (3
weeks), we only see solitary cells in the lungs, and later (5 weeks), small clusters of green
tumor cells could be found, indicating that these cells are proliferating. A thorough
evaluation of the number of disseminated cells in the lungs remains to be carried out.
In summary, we have identified a gene that seems to posses "super metastatic" power.
YAP has been mapped to 9qA1 region in mouse chromosome, which is frequently amplified
in liver cancer, and has been shown to be a novel oncogene contributing to rapid tumor
growth (Zender et al., 2006). Furthermore, work by Overholtzer et al showed that YAP
functions as a potential oncogene in mammary epithelial cells, enhances colony formation in
soft agar and induces epithelial-to-mesenchymal transition (Overholtzer et al., 2006). These
studies have shown that YAP is a new oncogene. Our results suggest that YAP also
contributes to tumor metastasis. In fact, we have never seen any single gene so "virulent" in
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promoting melanoma migration/invasion in vitro and promoting metastasis from
subcutaneous tumors in vivo. We are very interested in the mechanisms by which YAP
functions to augment metastatic ability, and have started to gain insight by investigating the
potential pathways that are important for YAP functions.
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Figure 1. YAP-expressing A375 cells grow in markedly different pattern compared with A375 control cells in
3D Matrigel. While control cells grow as tight balls in Matrigel, A375-YAP cells showed stellate morphology.
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Figure 2. YAP significantly enhanced A375 cell migration and invasion. (A) Representative picture of the
invasion assay (top) and migration assay (bottom) showed dramatically increased number of cells that
invaded or migrated in transwell assays. (B) Scratch wound migration assay showed that A375-YAP cells
migrate faster than A375-MIGw cells.
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Figure 3. YAP significantly increases A375 cell proliferation and provides early advantage for tumor growth
at the subcutaneous site. (A) Equal numbers of cells were seeded on day 0 and numbers of cells were
counted on day3, and plotted as percent control cells. (8) 0.5*10e6 cells were injected at the subcutaneous
site, and mice were dissected at indicated time points, and tumors were weighed. At 23 days and 39 days,
tumors from A375-YAP cells are significantly bigger than those from control cells. However, by 8 weeks,
tumor sizes are no longer different.
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Figure 4. YAP significantly enhances lung metastasis and. NOD/SCID mice were injected with 1*10e6 cells
via tail-vein and numbers of lung tumors were counted under UV dissecting microscope. YAP-expression
significantly increased numbers of tumor nodules in the lung compared to control cells.
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APPENDIX B.
METHODS USED FOR MASS SPECTROMETRY
SAMPLE PREPARATION AND SAMPLE ANALYSIS
The content of this chapter were written by Hui Liu, with editing by Richard Hynes.
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APPENDIX B. SILAC AND MASS SPECTROMETRY PROTOCOLS
SILAC medium was custom-made using the following formula:
10L (mg)
L-Cystine 478.4
Glycine 300.0
L-histidine. HCI 382.0
L-phenylalanine 660.0
L-Serine 420.0
L-threonine 950.0
L-Tryptophan 160.0
L-Tyrosine 720.0
L-Valine 940.0
Isoleucine 1050.0
10 L (g)
D-glucose 45
CaCI2 2
Fe(N03)3. 9H20 0.001
KCI 4
MgSO4. 7H20 2
NaCI 64
NaH2PO4.H20 1.24
Na Bicarbonate 22
Phenol Red 0.15
MEM vitamin stock 400ml
Adjust pH with concentrated HCI to 7.15
Filter to sterilize and store in dark at 40C.
Add the following before using
Glutamine (100x)
Leucine (60x: 6.3mg/ml )  Final
Methionine (100x: 3mg/mi)
Arginine (100x: 8.4mg/mi)
Lysine (14.6mg/ml) Final 3.6mg/100ml
Dialyzed serum to 10%
Sodium Pyrovate (100x)
Pen/Strep (100x)
Membrane Enrichment using Colloidal Silica beads
Reagents:
HBSS/5mMEDTA: 50ml HBSS + 0.5ml 0.5M stock. (warm up to 370C before use)
PMCB: 20mM MES/280mM Sorbitol/l 150mM NaCI, pH to 5.0-5.5
1% colloidal silica in PMCB: dilute from 30% provided by Dr. Donna Storz.
1mg/ml of polyacrytic acid (Sigma) in PMCB
Lysis buffer: 2.5mM imidazole (add protease inhibitor cocktail (Roche) before use)
100% Nycodenz (Sigma) : 10g in 5.5ml of lysis buffer containing protease inhibitors.
70% Nycodenz; dilute from 100%: 7ml 100% in 3ml lysis buffer, mix well.
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Protocol:
1) Harvest cells
a. Wash with 5ml of 370c HBSS/5mM EDTA. Rinse for the first two washes, and for
the last wash, leave in 370C incubator for 7 min.
b. Harvest A375 cells first by banning the plate with 5ml of HBSS/5mM EDTA, the
cells should dislodge easily. Rinse with 5ml of HBSS/5mM EDTA and pool. MA2
cells do not dislodge as easily as A375, use 5ml glass pipette and pipette up and
down gently to remove the cells. Again, rinse and pool.
c. Before spinning down, take 10ul and count live and dead cells. Then spin
1100rpm for 3 min in the tissue culture room centrifuge.
d. Place cells on ice for several minutes.
2) Coat cells with colloidal silica and polyacrytic acid (Do everything ON ICE).
a. Resuspend cells in PMCB buffer to 1xl0'/ml, keep on ice.
b. In 50ml Falcon tube, add 5ml cold 1% colloidal silica. Use P1000, add cell
suspension drop wise to the colloidal silica solution, swirl gently after each drop.
Rock at 4C for 10-15 min. Then add 14ml of PMCB, mix gently once or twice.
Repeat for the other cell line.
c. Spin 1100rpm for 3min using the centrifuge in the chemical room at 40C.
Aspirate the supernatant (Supt.)- milky white at this time. Shake the tube to
dislodge the pellet before adding 35ml of PMCB, spin again and the supt. should
be clear.
d. Resuspend the cells in 1 ml of PMCB, and keep on ice.
e. In 50ml Falcon tube, add 5ml of 1mg/mI polyacy. Again, use P1000 to add cell
suspension drop wise to the PAA solution, swirl gently after each drop. Then add
14ml of PMCB, mix gently.
f. Spin 2000rpm for 3min using the centrifuge in the chemical room at 40C. Wash
the pellet two more times with 20ml of PMCB at 2000rpm for 3min at 40C,
aspirate the supernatant.
NOTE: Use 5ml 1% colloidal silica solution for every 10x10e6 cells.
3) Lyse cells (on ice).
a. To each 10ml of lysis buffer (2.5mM Imidazole), add 1 tabelet of protease
inhibitor cocktail (Roche), let dissolve and leave on ice.
b. Add 0.5ml of lysis buffer to 0.5 x106 cells, leave on ice for 10-30min to swell.
c. Transfer cells to pre-chilled parr bomb and increase pressure to 1500psi. Let the
parr bomb sit on ice for 15min before releasing pressure to lyse the cells. Check
cell lysis using trypan blue staining.
4) Fractionate cell lysate (all solutions 40C)
a. Spin in the chemical room centrifuge at 2000rpm for 10mn at 40C. Take Supt,
b. Resuspend pellet in same volume of lysis buffer as previous, save 50ul as Pellet
I, pass through 26G needle to break up the clumps.
c. To each 15ml Cortex glass centrifuge tube, add 2ml of 70% Nycodenz. Lay
pellet from previous spin on top of Nycodenz, and centrifuge the solution at
28000rcf for 30min at 40C.
d. After spinning, carefully take the top layer, middle layer (white), and bottom layer.
Remove bottom layer as much as possible.
e. Add iml of lysis buffer (containing protease inhibitors)t o collect the pellet and
transfer into 1.5ml Eppendorf tube.
f. Wash 4x with 2.5mM imidazole, pH7.0 (with protease inhibitors) in eppendorf
tubess;
g. Wash 3x with 100mM Na2CO3, pH11.4 (with protease inhibitor); Centrifuge at
13000rpm in the tabletop centrifuge in the cold room for 5min to pellet. Freeze
the final pellet with liquid nitrogen and store at -800C till use.
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Sample Preparation and In-Gel Digestion
Thaw pellets collected from membrane preparation described above, and add 30pl of 2x SDS
sample buffer (with p-mercaptoethanol). After heating at 950C for 5min with vortexing, the
samples were loaded onto 4-20% gradient gel (Invitrogen) and electrophoresed at 150V till the
front dye runs off. The gels were transferred to clean container, rinsed with autoclaved water and
stained with SafeStain (Invitrogen), and 20-30 slices were cut from the gel. Following these
steps, in-gel digestion was performed as described below.
1. Excision of protein bands from polyacrylamide gels
a. Wash gel 2 with ddH20 ten minutes each
b. Excise the band of interest. Cut as close to the protein band as possible to
reduce the amount of "background" gel. Cut into 1mm x 1mm cubes and place in
0.65 ml tube (do not crush or clog pipet tips)
2. Washing gel pieces
a. Wash the gel pieces with -400pl of water,15 min.
b. Wash with water/Acetonitrile 1:1, 15 min (vortex) (200pl+ 200 pl)
c. Remove liquid, add acetonitrile to cover gel pieces (vortex)
d. After pieces shrink and turn sticky white, remove acetonitrile
e. Rehydrate in 100 mM NH4HCO 3, vortex
f. After 5 min, add equal volume of acetonitrile (to get 1:1 ratio) (vortex)
g. Incubate 15 minutes then remove solvent
h. Dry down in speed-vac
i. Reduction and alkylation
j. Rehydrate in 20mM DTT in 100 mM NH4 HCO 3
k. Incubate at 650C for 30 min (vortex)
I. Remove solvent, replace with same volume of 55 mM (10 mg/ml) iodoacetamide
in 100 mM NH4HCO 3
m. Incubate 20 minutes at 370C in the dark
n. Remove solvent
o. Wash with NH4HCO 3and Acetonitrile as in step 2e.
p. All the Coomassie blue stain should be removed at this time. If residual
Coomassie still remains, repeat wash with NH4HCO 3/Acetonitrile (1:1) until no
longer see blue color
q. Gel pieces should be dried completely in speed-vac
3. In-gel Digestion
a. Dilute 20 ug of Promega sequencing grade modified trypsin in 200 ul of 50 mM A
NH4HCO 3 (0.1 ug/ul) (trypsin solution)
b. Dilute trypsin solution 1:10 in 50 mM AMBIC (10 ng/ul trypsin solution)
c. Add 60 ul of 10 ng/ul trypsin solution to gel pieces and leave on ice for 1 hour.
Check every 15min to make sure the solution is enough to cover the gel pieces.
d. Incubate at 370C overnight
4. Extraction of Peptides (never let the supernatant go dry, just concentrate (-10Opl)
a. Transfer the supt. Into a clean (low-binding) 0.6ml tube, dry in the speed-vec;
b. Rinse with 50mM NH4HCO 3, pool into the speed-vacing tube
c. Add 100pl 50% acetonitrile /5% formic acid, vortex at R.T. for 30min, collect and
pool into the tube in speed-vec;
d. Rehydrate with 50xl 50mM NH4HCO 3, vortex 10min, then add 1001l 50%
MeCN/5%Formic acid, vortex at RT for 30min, collect supt and pool
e. Rehydrate in minimum volume of 50mM AMBIC, vortex 10min, then add excess
100% acetonitrile, vortex for 20min, collect supt and pool;
f. Dry down to -5-10 1, and reconstitute with 0.1% formic acid in ddH 2O.
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Mass spectrometry analysis of digested peptides
One-third peptides from each gel slice were analyzed using liquid chromatography tandem mass
spectrometry (LC-MS/MS) with the LTQ ion-trap mass spectrometer from Thermo Finnigan.
Each sample was loaded onto a 50 um (i.d.) byl0 cm (length) fused silica C18 microcapillary
column (New Objective, MA) using an Agilent 1100 (Agilent Corporation, CA) series binary HPLC
pump with auto-sampler and nanoflow cell with an in-line flow splitter to achieve approximately
100nl/min flow at the tip of the column. Peptides were eluted with a 120min linear gradient as the
following: 2% to 37.5% buffer B from 0 to 75 min, 37.5% to 75% buffer B from 75min to 105min,
and 75% to 98% B from 105 min to 120 min (buffer B: 0.1% formic acid, 80% acetonitrile). Eluted
peptides were introduced to LTQ mass spectrometer via electrospray ionization and data-
dependent acquisition was performed, with exclusion list activated and top 10 ions are selected
for fragmentation to obtain peptide sequence information.
Data collected by mass spectrometer were analyzed using Sequest software, searched against
human database, which is maintained by the biopolymer lab at Koch Institute. When search
peptides, we used filter of ACn >0.1, and Xcorr value of 2, 2.5, 3.5 for peptides with +1, +2, or +3
charges, respectively and p<0.0001. We also visually inspected the spectrum when there were
less than 3 peptides matched to the proteins.
SILAC and Identification of Proteins that are differentially expressed
Passage-matched A375 (low metastatic cells) and MA2 (high metastatic cells) were grown in
"light" (ArgO, Lys 0) and "heavy" (ArglO0, Lys 8) respectively, equal amount of total cell lysate from
these two cell lines were mixed and plasma membrane preparations were made (Figure 3). A
total of 80pg of membrane proteins were separated on 4-20% gel and 20 gel slices were cut and
in-gel digested. Samples were analyzed with LC-MS/MS as mentioned above; with slight
modification of sample-acquire method. Briefly, during gradient elution, following a MS scan,
zoom scan spectrum and MS/MS spectrum were obtained for each of the top 5 abundant ions per
data-dependent cycle. The zoom scan spectrum was included to get a high-resolution spectrum,
which can be used by quantification software (PepQuan) to quantify peptides/proteins. Data were
analyzed with Sequest for protein identification, and with PepQuan for protein quantification.
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APPENDIX C.
PROTEINS IDENTIFIED THROUGH MASS
SPECTROMETRY ANALYSIS
The work in The content of this chapter were written by Hui Liu.
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Accession Reference MW Peptide (Hits) P (prol
AOAVT1 UBA6 HUMAN (AOAVT1) Ubiquitin-like modifier-activating enzyme 6 OS=Homo sapiens GN=UBA6 PE=1 SV= 117895.2 2 (2 0 0 0 0) 1.65E-07
AOFGR8 ESYT2 HUMAN (AOFGR8) Extended synaptotagmin-2 OS=Homo sapiens GN=FAM62B PE=1 SV=1 102294.1 1 (1 00 0 0) 2.95E-07
A1L3U3 A1L3U3 HUMAN (A1L3U3) ABCA8 protein OS=Homo sapiens GN=ABCA8 PE=2 SV=1 183585.3 2 (2 0 0 0 0) 6.57E-09
A2A2L6 SERA HUMAN (043175) D-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4 26057.7 1(1 0 00 0) 2.12E-05
A2BF29 A2BF29 HUMAN (A2BF29) Major histocompatibility complex class I B (Fragment) OS=Homo sapiens GN=HL 27751.5 2 (11 00 00) 1.47E-07
A4DOW6 A4DOW6 HUMAN (A4DOW6) Similar to ribosomal protein L18; 60S ribosomal protein L18 OS=Homo sapiens 24907.0 1(0 1 000) 1.88E-06
A4DOW6 A4DOW6 HUMAN (A4DOW6) Similar to ribosomal protein L18; 60S ribosomal protein L18 OS=Homo sapiens 24907.0 1 (0 1 0 0 0) 2.22E-06
A4DOY7 A4DOY7 HUMAN (A4DOY7) Similar to 40S ribosomal protein S2 OS=Homo sapiens GN=LOC392781 PE=3 S 21055.3 5 (5 0 0 0) 3.78E-09
A4D1G5 A4D1G5 HUMAN (A4D1G5) Ribosomal protein S27 OS=Homo sapiens GN=LOC392748 PE=3 SV=1 16866.6 4 (4 0 0 00) 9.18E-08
A4D1Q5 A4D1Q5 HUMAN (A4D1Q5) Ribosomal protein L15 OS=Homo sapiens GN=LOC136321 PE=3 SV=1 23754.9 4 (4 0 000) 6.61E-11
A4D2PO A4D2PO HUMAN (A4D2PO) cDNA FLJ77333, highly similar to Homo sapiens ras-related C3 botulinum toxin s 23452.3 7 (7 0 0 0 0) 9.30E-09
A4URH5 A4URH5 HUMAN (A4URH5) MHC class I antigen (Fragment) OS=Homo sapiens GN=HLA-A PE=3 SV=1 31240.9 1 (1 0 0 0 0) 1.09E-09
A5D8X1 A5D8X1 HUMAN (A5D8X1) FLJ45422 protein OS=Homo sapiens GN=FLJ45422 PE=2 SV=1 18590.3 1 (0 1 00 0) 7.11E-06
A5JGZ4 A5JGZ4 HUMAN (A5JGZ4) Non-functional aryl hydrocarbon receptor interacting protein (Fragment) OS=Hom 40737.8 9(9 0 0 0 0) 2.61E-08
A5JGZ4 A5JGZ4 HUMAN (A5JGZ4) Non-functional aryl hydrocarbon receptor interacting protein (Fragment) OS=Hom 40737.8 2 (2 0 0 0 0) 5.32E-08
A5YKK6 CNOT1 HUMAN (A5YKK6) CCR4-NOT transcription complex subunit 1 OS=Homo sapiens GN=CNOT1 PE= 266765.7 2 (2 0 0 0 0) 1.97E-06
A6NBZ8 A6NBZ8 HUMAN (A6NBZ8) Putative uncharacterized protein ALB OS=Homo sapiens GN=ALB PE=4 SV=2 71657.7 3 (3 0 0 0 0) 7.58E-12
A6NDU1 A6NDU1 HUMAN (A6NDU1) Putative uncharacterized protein ENSP00000364356 (Fragment) OS=Homo sap 32767.3 1 (1 0 0 0 0) 1.82E-08
A6NDZ9 A6NDZ9 HUMAN (A6NDZ9) Putative uncharacterized protein PELP1 OS=Homo sapiens GN=PELP1 PE=4 S 110017.4 1 (1 00 0 0) 4.17E-09
A6NE05 A6NE05 HUMAN (A6NE05) Putative uncharacterized protein RPL26P6 OS=Homo sapiens GN=RPL26P6 PE 18243.2 4 (4 0 0 0 0) 4.50E-05
A6NECO A6NECO HUMAN (A6NECO) Putative uncharacterized protein MAGOHB OS=Homo sapiens GN=MAGOHB P 12947.7 2(2 0 0 0 0) 1.92E-05
A6NG51 A6NG51 HUMAN (A6NG51) Putative uncharacterized protein SPTAN1 OS=Homo sapiens GN=SPTAN1 PE= 284770.7 4 (23 1 000) 5.45E-13
A6NGR5 A6NGR5 HUMAN (A6NGR5) Putative uncharacterized protein ENSP00000353405 OS=Homo sapiens PE=3 31277.3 2 (2 0 0 0 0) 2.73E-08
A6NGR5 A6NGR5 HUMAN (A6NGR5) Putative uncharacterized protein ENSP00000353405 OS=Homo sapiens PE=3 31277.3 4 (4 0 0 0) 2.15E-07
A6NHL2 TBAL3 HUMAN (A6NHL2) Tubulin alpha chain-like 3 OS=Homo sapiens GN=TUBAL3 PE=1 SV=2 49876.8 2 (2 0 0 0 0) 2.52E-10
A6NHQ2 FBRLL HUMAN (A6NHQ2) rRNAltRNA 2'-O-methyltransferase fibrillarin-like OS=Homo sapiens PE=3 SV=1 34654.0 1 (1 0 0 0 0) 9.59E-07
A6NK82 A6NK82 HUMAN (A6NK82) Putative uncharacterized protein COL4A1 OS=Homo sapiens GN=COL4A1 PE= 160642.1 4 (4 0 0 0) 2.46E-11
A6NN38 A6NN38 HUMAN (A6NN38) Coactivator-associated arginine methyltransferase 1, isoform CRA b OS=Homo 65811.5 3 (30000) 1.76E-08
A6NNZ2 TBB8B HUMAN (A6NNZ2) Tubulin beta-8 chain B OS=Homo sapiens PE=3 SV=1 49540.7 4 (4 0 0 0 0) 1.85E-09
A6XMH5 A6XMH5 HUMAN (A6XMH5) Beta-2-microglobulin OS=Homo sapiens PE=4 SV=1 10392.4 2 (20000) 1.14E-07
A7YDY3 A7Y DY3 HUMAN (A7YDY3) BolA homolog 2 (E. coil) OS=Homo sapiens GN=BOLA2 PE=2 SV=I 16921.8 1 (1 0 0 00) 2.59E-07
A8K8Z5 A8K8Z5 HUMAN (A8K8Z5) cDNA FLJ76682, highly similar to Homo sapiens v-Ki-ras2 Kirsten rat sarcoma vir 21410.9 1 (1 0 0 00) 1.32E-05
A8MQ38 A8MQ 38 HUMAN (A8MQ38) Putative uncharacterized protein NOL1 OS=Homo sapiens GN=NOL1 PE=4 SV 93925.4 5 (5 0 0 0 0) 2.39E-08
A8MSK1 A8MSK1 HUMAN (A8MSK1) Lysyl-tRNA synthetase OS=Homo sapiens GN=KARS PE=3 SV=1 71451.6 1(1 0 0 00) 5.87E-07
A8MT02 A8MTO2 HUMAN (A8MTO2) Putative uncharacterized protein SNRPB OS=Homo sapiens GN=SNRPB PE=4 29851.2 2 (20000) 2.35E-08
A8MT80 A8MT80 HUMAN (A8MT80) Ribosomal protein L15 OS=Homo sapiens PE=3 SV=1 21971.5 2 (20000) 1.20E-07
A8MTF2 A8MTF2 HUMAN (A8MTF2) Putative uncharacterized protein ENSP00000382149 (Fragment) OS=Homo sapi 32818.3 1 (1 00 00 3.04E-05
A8MTH6 A8MTH6 HUMAN (A8MTH6) Putative uncharacterized protein SRI (Fragment) OS=Homo sapiens GN=SRI PI 23627.7 2 (20000) 2.81E-06
A8MTN7 A8MTN7 HUMAN (A8MTN7) Putative uncharacterized protein NACA OS=Homo sapiens GN=NACA PE=4 SV 23367.7 2 (1 0 1 0 0) 4.91E-08
A8MUM5 A8MUM5 HUMAN (A8MUM5) Putative uncharacterized protein TORIAIP1 OS=Homo sapiens GN=TOR1AIP 66279.4 3 (3 0 0 0 0) 6.89E-10
A8MUS3 A8MUS3 HUMAN (A8MUS3) Putative uncharacterized protein RPL23A OS=Homo sapiens GN=RPL23A PE= 21902.5 2 (12 0 0 0 0) 1.67E-08
A8MUS3 A8MUS3 HUMAN (A8MUS3) Putative uncharacterized protein RPL23A OS=Homo sapiens GN=RPL23A PE= 21902.5 2 (2 0 0 0 0 6.61E-08
A8MUT7 A8MUT7 HUMAN (A8MUT7) Putative uncharacterized protein ENSP00000380341 OS=Homo sapiens PE=3 , 44789.3 3 (2 1 00 0) 3.40E-07
A8MUW5 A8MUW5 HUMAN (A8MUW5) Putative uncharacterized protein FAM98B OS=Homo sapiens GN=FAM98B PE 45518.6 2 (2 0 00 0) 4.43E-07
A8MVJ4 A8MVJ4 HUMAN (A8MVJ4) Proteasome subunit alpha type (Fragment) OS=Homo sapiens GN=PSMA1 PE= 30147.3 2 (2 0 0 0 0) 2.07E-07
A8MWM6 A8MWM6 HUMAN (A8MWM6) Putative uncharacterized protein ENSP00000383763 (Fragment) OS=Homo s 44849.5 1 (1 0 0 0 0) 1.09E-06
A8MWY5 A8MWY5 HUMAN (A8MWY5) Putative uncharacterized protein ENSP00000382197 OS=Homo sapiens PE=3 12651.0 3 (3 0 000 5.21E-05
A8MXB0 MGN3 HUMAN (A8MXB0) Putative protein mago nashi homolog 3 0S=Homo sapiens GN=MAGOHP PE=5 S 17333.8 2 (2 0 0 0) 2.48E-07
A8MY04 A8MY04 HUMAN (A8MYO4) Putative uncharacterized protein ENSP00000381447 (Fragment) OS=Homo sapi 32398.2 2 (2 0 0 0 0) 5.14E-07
A8MYKI A8MYK1 HUMAN (A8MYK1) Putative uncharacterized protein MRPL23 OS=Homo sapiens GN=MRPL23 PE= 21828.7 1 (1 0 0 00) 3.81E-04
A9R9N7 A9R9N7 HUMAN (A9R9N7) Major histocompatibility complex, class I, A OS=Homo sapiens GN=HLA-A PE=3 41423.5 4 (4 0 0 0 0) 2.72E-07
BOQYKO BOQYKO HUMAN (BOQYKO) Ewing sarcoma breakpoint region 1 O0S=Homo sapiens GN=EWSR1 PE=4 SV= 64889.0 2 (2 0 0 0 0) 2.46E-08
BOYIW6 BOYIW6 HUMAN (BOYIW6) Coatomer subunit delta variant 2 (Archain 1, isoform CRA a) OS=Homo sapiens 61587.4 4 (4 00 0 0) 5.13E-08
B1AHD1 B1AHD1 HUMAN (B1AHD1) NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae) OS=Homo sapier 14617.9 2(20000) 4.69E-07
B1AK40 B1AK40 HUMAN (B1AK40) Fumarylacetoacetate hydrolase domain containing 1 OS=Homo sapiens GN=FAF 27110.9 5(5000 0) 1.26E-07
B1AM21 B1AM21 HUMAN (B1AM21) Guanine nucleotide binding protein (G protein), q polypeptide (Fragment) OS=Hc 19668.8 2 (2 0 0 0 0) 3.32E-10
B1AP13 B1AP13 HUMAN (B1AP13) CD55 molecule, decay accelerating factor for complement (Cromer blood group) ( 49306.7 1 (1 0 0 0 0) 1.12E-06
B1B5Y2 B1B5Y2 HUMAN (B1B5Y2) Tyrosine-protein kinase receptor (Fragment) OS=Homo sapiens GN=IGF1R PE=4 155746.4 1 (1 0 0 00) 6.70E-08
B1PS43 B1PS43 HUMAN (B1PS43) Myosin heavy chain 11 smooth muscle isoform OS=Homo sapiens GN=MYH11 P 234090.7 2 (2 00 0 0) 2.45E-05
B2C153 B2C153 HUMAN (B2C153) Solute carrier family 4 sodium bicarbonate cotransporter member 7 OS=Homo sapi 127278.0 7 (7 0 0 0) 1.07E-11
B2RAR6 B2RAR6 HUMAN (B2RAR6) cDNA, FLJ95068, highly similar to Homo sapiens eukaryotic translation elongati 71406.3 2 (2 00 0 0) 6.37E-08
B2RBK5 B2RBK5 HUMAN (B2RBK5) cDNA, FLJ95559, Homo sapiens dynactin 2 (p50) (DCTN2), mRNA OS=Homo s 44792.2 2(2 0 0 00) 1.67E-11
B2RDW1 B2RDW1 HUMAN (B2RDW1) cDNA, FLJ96793, Homo sapiens ribosomal protein S27a (RPS27A), mRNA (Ri 17953.5 3(30000) 6.64E-08
B2REA7 B2REA7 HUMAN (B2REA7) Ribosomal protein L36a OS=Homo sapiens GN=RPL36A PE=4 SV=1 13219.1 2 (20000) 1.46E-05
B2RWP9 B2RWP9 HUMAN (B2RWP9) MYH10 protein OS=Homo sapiens GN=MYH10 PE=2 SV=1 229887.5 6 (26 0 0 0 0) 7.08E-13
B2ZZ91 B2ZZ91 HUMAN (B2ZZ91) Golgin B1 OS=Homo sapiens GN=GOLGB1 PE=2 SV=1 376889.9 1 (1 0 0 0 0) 2.77E-05
B3KML9 B3KML9 HUMAN (B3KML9) cDNA FLJ11352 fis, clone HEMBA1000020, highly similar to Tubulin beta-2C che 44573.6 8 (17 0 1 0 0) 1.58E-12
B3KNY2 B3KNY2 HUMAN (B3KNY2) cDNA FLJ30723 fis, clone FCBBF4000282, highly similar to Homo sapiens electi 37411.0 5 (50000) 2.97E-10
B3KPJ9 B3KPJ9 HUMAN (B3KPJ9) cDNA FLJ31884 fis, clone NT2RP7002906, highly similar to Homo sapiens heat s 98051.4 4 (3 0 0 0 1) 6.94E-10
B3KPU1 B3KPU1 HUMAN (B3KPU1) cDNA FLJ32188 fis, clone PLACE6002056, highly similar to Guanine nucleotide- 25914.1 2(20000) 1.45E-05
B3KQ79 B3KQ79 HUMAN (B3KQ79) cDNA FLJ33051 fis, clone TRACH1000063, highly similar to B-cell receptor-asso 34730.3 7 (7 0 0 00 1.13E-05
B3KRQ1 SSRA HUMAN (P43307) Translocon-associated protein subunit alpha OS=Homo sapiens GN=SSR1 PE=1 S 20919.5 2 (12 0 0 00) 4.65E-08
B3KSQ1 B3KSQ1 HUMAN (B3KSQ1) cDNA FLJ36768 fis, clone ADIPS1000064, highly similar to Synaptic glycoproteii 37442.6 2 (2 0 0 0 0) 2.82E-05
B3KSQ6 B3KSQ6 HUMAN (B3KSQ6) cDNA FLJ36801 fis, clone ADRGL2007810, highly similar to NADPH:adrenodoxi 41483.7 2 (200 0) 4.68E-11
B3KSR7 B3KSR7 HUMAN (B3KSR7) cDNA FLJ36831 fis, clone ASTRO2010615, highly similar to Calpain-5 (EC 3.4.2 64005.6 4 (4 0 0 00 6.87E-10
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B3KT15 B3KT15 HUMAN (B3KT15) cDNA FLJ37456 fis, clone BRAWH2011096, highly similar to 26S proteasome nor 42915.1 2 (10 2 0 0 0) 1.77E-12
B3KTZ0 B3KTZO HUMAN (B3KTZO) cDNA FLJ38980 fis, clone NT2RI2004884, highly similar to Guanine nucleotide-bi 38712.1 6 (6 0 00 1.77E-09
B3KUY2 B3KUY2 HUMAN (B3KUY2) cDNA FLJ40895 fis, clone UTERU2002294, highly similar to Prostaglandin E syn 19436.2 2 (2 0 0 0 0) 1.21E-07
B3KX11 B3KX11 HUMAN (B3KX11) cDNA FLJ44436 fis, clone UTERU2019706, highly similar to T-complex protein 1 57909.1 6(60000) 6.33E-06
B3KXN4 B3KXN4 HUMAN (B3KXN4) cDNA FLJ45763 fis, clone N1ESE2000698, highly similar to WD repeat protein 1 62077.8 1 (1 0 0 0 0) 3.13E-06
B3KXY9 B3KXY9 HUMAN (B3KXY9) cDNA FLJ46359 fis, clone TEST14049786, highly similar to Hexokinase-1 (EC 2.7 106183.4 2 (2 0 0 0 0) 1.36E-05
B3KY95 B3KY95 HUMAN (B3KY95) cDNA FLJ16143 fis, clone BRAMY2038516, highly similar to Protein disulfide-iso 53255.9 6 (6 0 0 0 0 2.28E-10
B4DDR3 B4DDR3 HUMAN (B4DDR3) cDNA FLJ52148, highly similar to Apoptosis inhibitor 5 OS=Homo sapiens PE=2 37484.7 1 (1 0 0 0 0) 9.58E-06
B4DE31 B4DE31 HUMAN (B4DE31) cDNA FLJ54957, highly similar to Transketolase (EC 2.2.1.1) OS=Homo sapiens 68698.3 2 (120000) 1.41E-09
B4DEA8 B4DEA8 HUMAN (B4DEA8) cDNA FLJ56425, highly similar to Very-long-chain specific acyl-CoAdehydrogena 75162.9 5 (50000) 2.11E-10
B4DEH1 B4DEH1 HUMAN (B4DEH1) cDNA FLJ60436, highly similar to Homo sapiens dolichyl-phosphate mannosyltr 18346.9 4 (4 0 0 0 0) 2.37E-08
B4DEZ3 B4DEZ3 HUMAN (B4DEZ3) cDNA FLJ57958, highly similar to NADH dehydrogenase (ubiquinone) 1 alpha su 14076.3 3 (3 0 00 0 1.59E-09
B4DF76 B4DF76 HUMAN (B4DF76) cDNA FLJ59191, highly similar to NADH dehydrogenase (ubiquinone) 1 alpha sut 24865.8 2 (2 0 0 0 0) 4.80E-06
B4DFX8 B4DFX8 HUMAN (B4DFX8) cDNA FLJ56065, highly similar to Pyruvate kinase isozyme M1 (EC 2.7.1.40) OS 65888.9 7 (170000 4.65E-12
B4DGE8 B4DGE8 HUMAN (B4DGE8) cDNA FLJ55467, highly similar to Septin-2 OS=Homo sapiens PE=2 SV=1 45432.3 6 (6 0 0 0 0) 1.36E-09
B4DGP8 B4DGP8 HUMAN (B4DGP8) cDNA FLJ55574, highly similar to Calnexin OS=Homo sapiens PE=2 SV=1 71458.0 8 (8 0 0 0 0) 2.06E-12
B4DGY2 B4DGY2 HUMAN (B4DGY2) cDNA FLJ59683, highly similar to Homo sapiens malignant T cell amplified sequ 20536.8 4 (4 0 0 0 0 1.91E-06
B4DHQ3 B4DHQ3 HUMAN (B4DHQ3) cDNA FLJ56437, highly similar to Phosphoserine aminotransferase (EC 2.6.1.5, 45326.5 3 (3 0 0 0 0 8.06E-07
B4DI54 B4DI54 HUMAN (B4DI54) cDNA FLJ56386, highly similar to Heat shock 70 kDa protein 1L OS=Homo sapien 77513.3 6 (6 0 0 0 0) 2.10E-09
B4DIMO B4DIMO HUMAN (B4DIMO) cDNA FLJ56442, highly similar to ATP-citrate synthase (EC 2.3.3.8) OS=Homo sa 125057.5 4 (14 0 0 0 0) 5.76E-10
B4DJ30 B4DJ30 HUMAN (B4DJ30) cDNA FLJ61290, highly similar to Neutral alpha-glucosidase AB OS=Homo sapien 112854.8 0(10 0 0 0 0) 1.49E-09
B4DJ60 B4DJ60 HUMAN (B4DJ60) cDNA FLJ55072, highly similar to Succinate dehydrogenase (ubiguinone) flavopro 67207.0 2 (2 0 0 0 0) 1.24E-07
B4DJQ5 B4DJQ5 HUMAN (B4DJQ5) cDNA FLJ59211, highly similar to Glucosidase 2 subunit beta OS=Homo sapiens 60096.3 2 (2 00 0 0) 3.27E-08
B4DJV9 B4DJV9 HUMAN (B4DJV9) cDNA FLJ60607, highly similar to Acyl-protein thioesterase 1 (EC 3.1.2.-) OS=Hoi 28260.3 2 (2 0 0 0 0) 1.78E-07
B4DKSO B4DKSO HUMAN (B4DKSO) cDNA FLJ53381, highly similar to Monocarboxylate transporter 1 OS=Homo sapi 51802.8 2 (2 0 0 0 0) 5.70E-08
B4DKW1 B4DKW1 HUMAN (B4DKW1) cDNA FLJ55703, highly similar to Solute carrier family 2, facilitated glucose tran 47789.2 4 (4 0 0 0 0) 5.34E-09
B4DLO7 B4DL07 HUMAN (B4DL07) cDNA FLJ53353, highly similar to ATP-binding cassette sub-family D member 3 0 78410.0 1 (1 0 0 0 0) 3.94E-07
B4DL12 B4DL12 HUMAN (B4DL12) cDNA FLJ53754, highly similar to Transmembrane emp24 domain-containing prot 20046.5 5 (5 0 0 0 0) 3.49E-09
B4DLCO B4DLCO HUMAN (B4DLCO) cDNA FLJ58476, highly similar to Poly(rC)-binding protein 2 OS=Homo sapiens 32144.4 4 (4 0 0 0) 8.10E-11
B4DLU5 B4DLU5 HUMAN (B4DLU5) cDNA FLJ60675, highly similar to ATP-dependent RNA helicase DDX3X (EC 3.6. 58737.6 1 (1 0 0 0 0) 2.83E-05
B4DLV7 B4DLV7 HUMAN (B4DLV7) cDNA FLJ60299, highly similar to Rab GDP dissociation inhibitor beta OS=Homo 51121.3 1 (1 00 0) 2.74E-07
B4DM70 B4DM70 HUMAN (B4DM70) cDNA FLJ54451, highly similar to Stress-induced-phosphoprotein 1 OS=Homo s 59769.0 4 (4 0 0 0 0) 1.04E-06
B4DM97 B4DM97 HUMAN (B4DM97) cDNA FLJ55002, highly similar to Alpha-centractin OS=Homo sapiens PE=2 SV= 38250.7 2 (2 0 0 0 0) 2.04E-11
B4DMB1 B4DMB1 HUMAN (B4DMB1) cDNA FLJ53358, highly similar to Heterogeneous nuclear ribonucleoprotein R 0 66966.3 5(50000) 2.22E-08
B4DMH5 B4DMH5 HUMAN (B4DMH5) cDNA FLJ55107, highly similar to Cell division control protein 42 homolog OS=- 26562.4 4 (40 0 0 0) 1.14E-05
B4DMJ2 B4DMJ2 HUMAN (B4DMJ2) cDNA FLJ50994, moderately similar to 60S ribosomal protein L4 OS=Homo sapi 27046.2 5(5 0 0 0 0) 1.21E-08
B4DMJ5 B4DMJ5 HUMAN (B4DMJ5) cDNA FLJ53012, highly similar to Tubulin beta-7 chain OS=Homo sapiens PE=2 27289.9 9 (8 1 0 0 0 1.35E-11
B4DMU8 B4DMU8 HUMAN (B40MU8) cDNA FLJ53063, highly similar to Tubulin beta-7 chain OS=Homo sapiens PE=: 35897.4 2 (2 0 0 0 0) 3.00E-08
B4DNA3 B4DNA3 HUMAN (B4DNA3) cDNA FLJ53068, highly similar to Adenylyl cyclase-associated protein 1 OS=Ho 47091.3 1 (1 0 0 0 0) 1.27E-07
B4DNCO B4DNCO HUMAN (B4DNCO) cDNA FLJ61141, highly similar to Ras-related protein Rab-34 OS=Homo sapien 30596.7 3(3 0 0 0 0) 1.19E-09
B4DNH8 B4DNH8 HUMAN (B4DNH8) cDNA FLJ59138, highly similar to Annexin A2 OS=Homo sapiens PE=2 SV=1 21656.1 0 (10 0 0 0 0) 9.82E-11
B4DNK3 B4DNK3 HUMAN (B4DNK3) cDNA FLJ52127, highly similar to Multisynthetase complex auxiliary component 29726.8 4 (4 000  0 0)4.20E-08
B4DNK4 84DNK4 HUMAN (B4DNK4) cDNA FLJ53368, highly similar to Pyruvate kinase isozymes MI/M2 (EC 2.7.1.4( 49866.0 1 (1 0 0 0 0) 5.68E-05
B4DNL8 B4DNL8 HUMAN (B4DNL8) cDNA FLJ58851, highly similar to Galactosylgalactosylxylosyl protein 3-beta-gluc 34633.3 1 (1 0 0 0 0) 2.15E-09
B4DNV4 B4DNV4 HUMAN (B4DNV4) cDNA FLJ53071, highly similar to Heat shock 70 kDa protein 1 OS=Homo sapie 25262.9 1 (1 00 0) 7.69E-07
B4DNX1 B4DNX1 HUMAN (B4DNX1) cDNA FLJ53752, highly similar to Heat shock 70 kDa protein 1 OS=Homo sapie 45099.1 2(2 0 0 0 0) 2.39E-09
B4DP54 B4DP54 HUMAN (B4DP54) cDNA FLJ52712, highly similar to Tubulin beta-6 chain OS=Homo sapiens PE=2 46671.6 2 (1 0 0 1 0) 6.67E-06
B4DP82 B4DP82 HUMAN (B4DP82) cDNA FLJ51018, highly similar to 60S ribosomal protein L4 OS=Homo sapiens P 16561.4 2 (20000) 1.39E-07
B4DPJ2 B4DPJ2 HUMAN (B4DPJ2) cDNA FLJ51518, highly similar to Annexin All OS=Homo sapiens PE=2 SV=1 45569.3 1 (1 0 0 0 0) 3.19E-06
B4DPZ4 B4DPZ4 HUMAN (B4DPZ4) cDNA FLJ60782, highly similar to Rho-GTPase-activating protein 1 OS=Homo sa 52722.6 1 (1 0 0 0 0) 1.41E-06
B4DQU4 B4DQU4 HUMAN (B4DQU4) cDNA FLJ60809, highly similar to Homo sapiens cytokeratin type II (K6HF), mR 65321.0 2 (0 2 0 0 0) 1.47E-06
B4DR52 B4DR52 HUMAN (B4DR52) cDNA FLJ56787, highly similar to Histone H2B type 2-F OS=Homo sapiens PE=: 18029.7 2 (2 0 0 0 0) 1.01E-06
B4DR52 B4DR52 HUMAN (B4DR52) cDNA FLJ56787, highly similar to Histone H2B type 2-F OS=Homo sapiens PE=: 18029.7 3 (3 0 0 0 0) 1.05E-05
B4DR61 B4DR61 HUMAN (B4DR61) cDNA FLJ59739, highly similar to Protein transport protein Sec61 subunit alpha i. 52915.0 1 (1 0 0 0 0) 2.85E-05
B4DRJ2 B4DRJ2 HUMAN (B4DRJ2) cDNA FLJ61353, highly similar toApoptosis inhibitor 5 OS=Homo sapiens PE=2 58968.0 1 (1 0 0 0 0) 2.14E-05
B4DRS6 B4DRS6 HUMAN (B4DRS6) cDNA FLJ58980, highly similar to Sideroflexin-3 OS=Homo sapiens PE=2 SV=1 36326.9 3 (3 0 0 0 0) 1.05E-10
B4DRT2 B4DRT2 HUMAN (B4DRT2) cDNA FLJ54536, highly similar to Mitochondrial 28S ribosomal protein S27 OS=- 49119.1 1 ( 00 0 0) 4.47E-09
B4DRY3 B4DRY3 HUMAN (B4DRY3) cDNA FLJ52228, highly similar to Mps one binder kinase activator-like 1A OS=H( 25482.8 1 (1 0 0 00) 1.29E-04
B4DS71 B4DS71 HUMAN (B4DS71) cDNA FLJ57081, moderately similar to WD repeat protein 1 OS=Homo sapiens P 22409.6 2 (2 0 0 0 0) 2.68E-09
B4DS84 B4DS84 HUMAN (B4DS84) cDNA FLJ59747, highly similar to Ubiquitin carboxyl-terminal hydrolase 10 (EC 3. 87477.1 2 (2 00 0 0) 3.04E-05
B4DSR4 B4DSR4 HUMAN (B4DSR4) cDNA FLJ59973, highly similar to Elongation factor 1-gamma OS=Homo sapien 18479.3 1 (1 0 0 0 0) 3.39E-07
B4DT29 B4DT29 HUMAN (B4DT29) cDNA FLJ51082, highly similar to Actin-like protein 3 O0S=Homo sapiens PE=2 S\ 40673.7 1 (1 0 0 0 0) 6.31E-07
B4DTE6 B4DTE6 HUMAN (B4DTE6) cDNA FLJ56243, highly similar to Melanoma-associated antigen 4 OS=Homo sa 37810.3 2 (2 0 0 0 0) 1.91 E-06
B4DTG2 B4DTG2 HUMAN (B4DTG2) cDNA FLJ56389, highly similar to Elongation factor 1-gamma OS=Homo sapien 56114.4 2(2 0 0 0 0) 1.60E-09
B4DUJ2 84DUJ2 HUMAN (B4DUJ2) cDNA FLJ54063, highly similar to Homo sapiens CD74 antigen, transcrpt variant 16659.2 1 (1 0 0 0 0) 1.17E-10
B4DUQ1 B4DUQ1 HUMAN (B4DUQ1) cDNA FLJ54552, highly similar to Heterogeneous nuclear ribonucleoprotein K O 48480.2 5(50000) 4.58E-10
B4DUT2 B4DUT2 HUMAN (B4DUT2) cDNA FLJ53206 OS=Homo sapiens PE=2 SV=1 88141.6 1 (1 00 0) 6.53E-06
B4DVX2 B4DVX2 HUMAN (B4DVX2) cDNA FLJ55373, highly similar to Isoleucyl-tRNA synthetase, cytoplasmic (EC 6. 87692.8 3 (3 0 0 0 0) 4.76E-09
B4DW28 B4DW28 HUMAN (B4DW28) cDNA FLJ58953, highly similar to 40S ribosomal protein S20 OS=Homo sapien 15995.4 6 (60000) 5.19E-08
B4DW52 B4DW52 HUMAN (B4DW52) cDNA FLJ55253, highly similar to Actin, cytoplasmic 1 O0S=Homo sapiens PE=2 38608.2 2 (2 0 0 0 0) 3.58E-09
B4DW52 AT1B3 HUMAN (P54709) Sodium/potassium-transporting ATPase subunit beta-3 OS=Homo sapiens GN=ATP 38608.2 2 (11 0 0) 5.08E-09
B4DW52 B4DW52 HUMAN (B4DW52) cDNA FLJ55253, highly similar to Actin, cytoplasmic 1 OS=Homo sapiens PE=2 38608.2 1 (0 1 000) 2.49E-05
B4DW74 B4DW74 HUMAN (B4DW74) cDNA FLJ50711, moderately similar to Ras-related protein Rap-lb OS=Homo st 16023.3 6 (60000) 2.01E-07
B4DWB5 B4DWB5 HUMAN (B4DWB5) cDNA FLJ53931, highly similar to Bifunctional 3'-phosphoadenosine5'-phospho, 69987.9 5 (5 0 0 0 0) 9.97E-08
B4DWQ5 B4DWQ5 HUMAN (B4DWQ5) cDNA FLJ51655, highly similar to Actin-like protein 2 OS=Homo sapiens PE=2 34485.9 1 1 0 0 0 0) 2.08E-07
B4DWW4 B4DWW4 HUMAN (B4DWW4) cDNA FLJ55599, highly similar to DNA replication licensing factor MCM3 (MCI 95848.4 3 (3 0 0 0 0) 6.68E-09
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B4DX78 B4DX78 HUMAN (B4DX78) cDNA FLJ55484, highly similar to ATP-dependent RNA helicase DDX39 (EC 3.6. 53662.4 5 (50 00 0) 1.33E-06
B4DXJ1 B4DXJ1 HUMAN (B4DXJ1) cDNA FLJ56334, highly similar to SEC13-related protein OS=Homo sapiens PE= 40720.8 2 (20000) 3.11E-06
B4DXL5 K2C1 HUMAN (P04264) Keratin, type 10 cytoskeletal I OS=Homo sapiens GN=KRT1 PE=1 SV=5 37475.9 1 (1 0 0 0 0) 9.75E-06
B4DZ53 B4DZ53 HUMAN (B4DZ53) cDNA FLJ59643, highly similar to Neutral alpha-glucosidase AB OS=Homo sapie 96467.2 2 (2 0 0 0 0) 1.85E-07
B4DZA5 B4DZA5 HUMAN (B4DZA5) cDNA FLJ57678, highly similar to Transmembrane protein 16F OS=Homo sapien 107961.2 11 0000) 1.46E-07
B4EO40 B4E040 HUMAN (B4E040) cDNA FLJ55177, highly similar to Ras-related protein Ral-B OS=Homo sapiens PI 25950.3 2 (2 0 0 0 0) 4.26E-05
B4E132 B4E132 HUMAN (B4E132) cDNA FLJ53122, highly similar to ATP-dependent RNA helicase DDX3Y (EC 3.6.1 44813.9 3 (3 0 0 0 0) 4.66E-06
B4E1T7 B4E1T7 HUMAN (B4E1T7) cDNA FLJ58665, highly similar to Serine/threonine-protein phosphatase 2A 55 kD 52966.2 2 (2 0 0 0 0) 3.22E-05
B4E299 B4E299 HUMAN (B4E299) cDNA FLJ54574, highly similar to Staphylococcal nuclease domain-containing pro 99616.5 4 (4 0 0 0 0) 6.56E-08
B4E2P2 B4E2P2 HUMAN (B4E2P2) cDNA FLJ52061, highly similar to Translocon-associated protein subunit gamma ( 22595.9 1 1 0 0 0 0) 1.48E-05
B4E3AO B4E3AO HUMAN (B4E3A0) cDNA FLJ54253, highly similar to Ras-related protein Rab-34 OS=Homo sapiens 26703.6 2 (2 0 0 0 0) 4.56E-08
B4E3A0 B4E3AO HUMAN (B4E3AO) cDNA FLJ54253, highly similar to Ras-related protein Rab-34 OS=Homo sapiens 26703.6 2 (2 00 000 1.13E-07
B5BU72 B5BU72 HUMAN (B5BU72) Phosphatidylinositol-binding clathrin assembly protein isoform 2 OS=Homo sapie; 66351.9 1 (1 0 0 0 0) 7.79E-08
B5MDF5 B5MDF5 HUMAN (B5MDF5) Putative uncharacterized protein RANP1 OS=Homo sapiens GN=RANP1 PE=4 26207.5 1 (11 0 0 0 0) 2.76E-08
B5ME97 B5ME97 HUMAN (B5ME97) Putative uncharacterized protein SEPT10 (Fragment) OS=Homo sapiens GN=SE 59750.3 2 (02000) 4.11E-06
B5MEC5 B5MEC5 HUMAN (B5MEC5) Putative uncharacterized protein SLC38A1 OS=Homo sapiens GN=SLC38A1 PI 58729.6 1 (1 0000) 5.31E-06
000116 ADAS HUMAN (000116)Alkyldihydroxyacetonephosphate synthase, peroxisomal OS=Homo sapiens GN=AG 72865.9 5(50000) 1.27E-08
000154 BACH HUMAN (000154) Cytosolic acyl coenzyme A thioester hydrolase OS=Homo sapiens GN=ACO17 PE= 41769.4 5 (150000) 1.34E-10
000161 SNP23 HUMAN (000161) Synaptosomal-associated protein 23 OS=Homo sapiens GN=SNAP23 PE=1 SV=1 23339.5 0 (10 0 0 0 0) 7.63E-10
000186 STXB3 HUMAN (000186) Syntaxin-binding protein 3 0S=Homo sapiens GN=STXBP3 PE=2 SV=2 67720.9 3(30000) 1.83E-11
000232 PSD12 HUMAN (000232) 26S proteasome non-ATPase regulatory subunit 12 OS=Homo sapiens GN=PSMD 52870.6 0 (10 0 0 0 0) 2.94E-08
000425 1F2B3 HUMAN (000425) Insulin-like growth factor 2 mRNA-binding protein 3 0S=Homo sapiens GN=IGF2BP 63680.7 1 (1 0 0 0 0) 4.63E-05
000461 GOLI4 HUMAN (000461) Golgi integral membrane protein 4 OS=Homo sapiens GN=GOLIM4 PE=1 SV=1 81831.2 1 (1 0000) 1.73E-05
000483 NDUA4 HUMAN (000483) NADH dehydrogenase [ubiguinone] 1 alpha subcomplex subunit 4 OS=Homo sapi 9363.9 5 (5 0 0 0 0) 1.36E-07
000487 PSDE HUMAN (000487) 26S proteasome non-ATPase regulatory subunit 14 OS=Homo sapiens GN=PSMD1 34554.6 2 (20000) 1.65E-08
000487 TBA1A HUMAN (Q71U36) Tubulin alpha-1A chain OS=Homo sapiens GN=TUBA1A PE=1 SV=1 34554.6 2 (2 0 0 0 0) 1.93E-08
000541 PESC HUMAN (000541) Pescadillo homolog 1 OS=Homo sapiens GN=PES1 PE=1 SV=1 67960.1 2 (2 0 0 00 2.64E-05
000567 NOL5A HUMAN (000567) Nucleolar protein 5A OS=Homo sapiens GN=NOL5A PE=1 SV=4 66008.8 3 (3 0 0 0 0) 2.66E-07
000592 PODXL HUMAN (000592) Podocalyxin-like protein 1 OS=Homo sapiens GN=PODXL PE=2 SV=1 55561.6 1 (1 0 0 0 0) 2.53E-05
000625 PIR HUMAN (000625) Pirin OS=Homo sapiens GN=PIR PE=1 SV=1; GDPD1 HUMAN (Q8N9F7) Glyceroph 32093.3 2 (20000) 1.03E-06
014521 DHSD HUMAN (014521) Succinate dehydrogenase [ubiquinonel cytochrome b small subunit, mitochondrial C 17031.9 1 (1 0000) 7.56E-06
014657 PSDE HUMAN (000487) 26S proteasome non-ATPase regulatory subunit 14 OS=Homo sapiens GN=PSMD1 37954.8 11 000 0) 1.65E-08
014660 014660 HUMAN (014660) GARS-AIRS-GART (Fragment) OS=Homo sapiens PE=2 SV=1 10725.8 2 (2 0 0 0 0) 6.16E-10
014662 STX16 HUMAN (014662) Syntaxin-16 OS=Homo sapiens GN=STX16 PE=2 SV=3; FBRLL HUMAN (A6NH 37008.3 2 (11 0 0 0) 8.89E-07
014672 ADA10 HUMAN (014672)ADAM 10 OS=Homo sapiens GN=ADAM10 PE=1 SV=I 84087.7 5 (50000) 1.43E-08
014735 CDIPT HUMAN (014735) CDP-diacylglycerol--inositol 3-phosphatidyltransferase OS=Homo sapiens GN=CDI 23523.1 1 (1 0 00 0) 3.66E-07
014744 ANM HUMAN (014744) Protein arginine N-methyltransferase 5 OS=Homo sapiens GN=PRMT5 PE=1 SV=4 72637.7 4 (4 00 00) 6.51E-10
014763 TR10B HUMAN (014763) Tumor necrosis factor receptor superfamily member 10B OS=Homo sapiens GN=T 47819.7 3 (30000) 8.18E-10
014818 PSA7 HUMAN (014818) Proteasome subunit alpha type-7 OS=Homo sapiens GN=PSMA7 PE=1 SV=1 27869.6 1 (1 00 0) 2.50E-06
014828 SCAM3 HUMAN (014828) Secretory carrier-associated membrane protein 3 O0S=Homo sapiens GN=SCAMP 38262.4 3 (3 0 0 0 0) 2.22E-08
014908 GIPC1 HUMAN (014908) PDZ domain-containing protein GIPC1 OS=Homo sapiens GN=GIPC1 PE=1 SV=2 36026.7 2 (2 0 0 0 0) 4.83E-11
014949 QCR8 HUMAN (014949) Cytochrome b-c1 complex subunit 8 OS=Homo sapiens GN=UQCRQ PE=1 SV=4 9900.1 2 (2 00 0 0) 5.21E-06
014979 HNRDL HUMAN (014979) Heterogeneous nuclear ribonucleoprotein D-like OS=Homo sapiens GN=HNRPDL 46409.0 1(0 1 0 0 0) 6.49E-05
014980 XPO1 HUMAN (014980) Exportin-10S=Homo sapiens GN=XPO1 PE=1 SV=1 123306.1 2(2 0 0 0) 3.71E-07
015031 PLXB2 HUMAN (015031) Plexin-B2 OS=Homo sapiens GN=PLXNB2 PE=1 SV=3 204996.1 8(80000) 1.09E-10
015143 ARC1B HUMAN (015143)Actin-related protein 2/3 complex subunit 1B OS=Homo sapiens GN=ARPC1B PE 40923.4 1 (1 0 0 0 0) 7.32E-06
015145 ARPC3 HUMAN (015145) Actin-related protein 2/3 complex subunit 3 OS=Homo sapiens GN=ARPC3 PE=1 20533.4 4 (4 0 0 0 0) 3.00E-08
015160 RPAC1 HUMAN (015160) DNA-directed RNA polymerases I and III subunit RPAC1 OS=Homo sapiens GN=P 39225.1 3 (3 0 0 0 0) 1.91E-09
015260 SURF4 HUMAN (015260) Surfeit locus protein 4 OS=Homo sapiens GN=SURF4 PE=1 SV=3 30373.8 2 (2 00 0 0) 3.77E-08
015305 PMM2 HUMAN (015305) Phosphomannomutase 2 0S=Homo sapiens GN=PMM2 PE=1 SV=1 28064.2 4 (40000) 1.50E-07
015327 INP4B HUMAN (015327) Type II inositol-3,4-bisphosphate 4-phosphatase OS=Homo sapiens GN=INPP4B P 104671.5 1 (1 0 0 0 0) 3.03E-06
015400 STX7 HUMAN (015400) Syntaxin-7 OS=Homo sapiens GN=STX7 PE=1 SV=4 29797.3 1(1 0 0 00) 1.15E-06
015439 MRP4 HUMAN (015439) Multidrug resistance-associated protein 4 OS=Homo sapiens GN=ABCC4 PE=1 SV 149431.6 2 (2 0 0 00) 1.22E-06
015498 YKT6 HUMAN (015498) Synaptobrevin homolog YKT6 OS=Homo sapiens GN=YKT6 PE=1 SV=1 22403.4 1 (1 0 0 0 0) 8.30E-06
043143 DHX15 HUMAN (043143) Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 OS=Hom, 90875.3 9(9 0 0 0 0) 1.56E-08
043157 PLXB1 HUMAN (043157) Plexin-B1 OS=Homo sapiens GN=PLXNB1 PE=1 SV=3 232148.9 2 (2 0 0 0 0) 3.63E-09
043169 CYB5B HUMAN (043169) Cytochrome b5 type B OS=Homo sapiens GN=CYB5B PE=1 SV=2 16322.0 1 (1 0 00 0) 5.49E-07
043175 SERA HUMAN (043175) D-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4 56614.5 8 (8 0 0 0) 2.56E-08
043175 SERA HUMAN (043175) D-3-phosphoglycerate dehydrogenase OS=Homo sapiens GN=PHGDH PE=1 SV=4 56614.5 1 (1 0 0 0 0) 3.53E-08
043242 PSMD3 HUMAN (043242) 26S proteasome non-ATPase regulatory subunit 3 OS=Homo sapiens GN=PSMD: 60939.6 4 (4 0 0 0 0) 2.23E-08
043252 PAPS1 HUMAN (043252) Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthetase 1 OS=Homo sapie 70787.8 2 (2 0 0 0 0) 3.79E-06
043399 TPD54 HUMAN (043399) Tumor protein D54 OS=Homo sapiens GN=TPD52L2 PE=1 SV=2 22224.3 4 (4 0 0 0 0) 5.14E-06
043633 CHM2A HUMAN (043633) Charged multivesicular body protein 2a OS=Homo sapiens GN=CHMP2A PE=1 S 25087.9 1 (1 0 0 0 0) 3.10E-07
043676 NDUB3 HUMAN (043676) NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 OS=Homo sapie 11394.7 1 (1 00 0) 3.60E-06
043684 BUB3 HUMAN (043684) Mitotic checkpoint protein BUB3 OS=Homo sapiens GN=BUB3 PE=1 SV=1 37131.2 5(50000) 5.08E-08
043752 STX6 HUMAN (043752) Syntaxin-6 OS=Homo sapiens GN=STX6 PE=1 SV=1 29157.8 1 (1 0 0 0 0) 5.77E-08
043776 SYNC HUMAN (043776) Asparaginyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=NARS PE=1 SV 62902.6 2 (2 0 0 0 0) 9.36E-08
043809 CPSF5 HUMAN (043809) Cleavage and polyadenylation specificity factor subunit 5 OS=Homo sapiens GN=I 26210.7 6 (6 0 0 0 0) 2.53E-08
043837 IDH3B HUMAN (043837) Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial OS=Homo sapiens GN 42156.6 1 (1 0 0 0 0) 2.98E-09
060262 GBG7 HUMAN (060262) Guanine nucleotide-binding protein G(I)/G(S)/G(0) subunit gamma-70S=Homo sa 7517.0 2(2 0 0 0 0) 1.01E-11
060462 NRP2 HUMAN (060462) Neuropilin-2 OS=Homo sapiens GN=NRP2 PE=1 SV=2 104792.0 3 (3 00 000 6.99E-08
060506 HNRPQ HUMAN (060506) Heterogeneous nuclear ribonucleoprotein Q OS=Homo sapiens GN=SYNCRIP PE 69559.6 8 (80000) 7.21E-10
060645 EXOC3 HUMAN (060645) Exocyst complex component 3 O0S=Homo sapiens GN=EXOC3 PE=1 SV=2 86789.9 1 (1 00 0 0) 4.00E-05
060669 MOT2 HUMAN (060669) Monocarboxylate transporter 2 0S=Homo sapiens GN=SLC16A7 PE=2 SV=1 52152.2 1(1 00 0 0) 9.48E-07P"A7A7 II III -
i initiation factor lb OS=Homo sapiens GN=EIF1B PE=1 SV=21 12815.71 2 (2 0 0 0 0)1 2.95E-0
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060749 SNX2 HUMAN (060749) Sorting nexin-2 OS=Homo sapiens GN=SNX2 PE=1 SV=2 58434.8 2 (2 0 0 0 0) 7.32E-08
060941 DTNB HUMAN (060941) Dystrobrevin beta OS=Homo sapiens GN=DTNB PE=1 SV=1 71309.7 1 (1 0 000) 6.86E-07
075044 FNBP2 HUMAN (075044) SLIT-ROBO Rho GTPase-activating protein 2 OS=Homo sapiens GN=SRGAP2 PE 120804.7 2 (2 0 0 0 0) 2.94E-08
075056 SDC3 HUMAN (075056) Syndecan-3 OS=Homo sapiens GN=SDC3 PE=2 SV=2 45469.4 1 10 0 0 0) 1.45E-05
075116 ROCK2 HUMAN (075116) Rho-associated protein kinase 2 OS=Homo sapiens GN=ROCK2 PE=1 SV=3 160810.9 2 (2 0 0 0 0) 5.93E-08
075165 DJC13 HUMAN (075165) DnaJ homolog subfamily C member 13 OS=Homo sapiens GN=DNAJC13 PE=1 S 254266.4 1 (1 0 0 0 0) 5.28E-06
075352 MPU1 HUMAN (075352) Mannose-P-dolichol utilization defect 1 protein OS=Homo sapiens GN=MPDU1 PE= 26620.5 3 (3 0 00 0) 4.34E-06
075367 H2AY HUMAN (075367) Core histone macro-H2A.1 OS=Homo sapiens GN=H2AFY PE=1 SV=4 39592.5 2(2 0 0 0 0) 1.01E-08
075369 FLNB HUMAN (075369) Filamin-B OS=Homo sapiens GN=FLNB PE=1 SV=1 278018.3 3 (3 0 00 0) 1.02E-08
075396 SC22B HUMAN (075396) Vesicle-trafficking protein SEC22b OS=Homo sapiens GN=SEC22B PE=1 SV=3 24724.8 8 (8000 0 3.16E-10
075431 MTX2 HUMAN (075431) Metaxin-2 OS=Homo sapiens GN=MTX2 PE=1 SV=1 29744.1 2(20000) 1.28E-06
075436 VP26A HUMAN (075436) Vacuolar protein sorting-associated protein 26A OS=Homo sapiens GN=VPS26A P 38145.8 1 (1 0 0 0) 3.30E-06
075475 PSIP1 HUMAN (075475) PC4 and SFRS1-interacting protein OS=Homo sapiens GN=PSIP1 PE=1 SV=1 60066.7 1 (1 00 00) 2.42E-05
075477 ERLN1 HUMAN (075477) Erlin-1 OS=Homo sapiens GN=ERLIN1 PE=2 SV=1 38901.4 6(60000) 9.71E-08
075487 GPC4 HUMAN (075487) Glypican-4 OS=Homo sapiens GN=GPC4 PE=1 SV=4 62371.8 2 (2 0 0 0 0) 1.60E-06
075489 NDUS3 HUMAN (075489) NADH dehydrogenase [ubiquinonel iron-sulfur protein 3, mitochondrial OS=Homo 30222.7 8 (8 0 0 00) 9.05E-10
075506 HSBP1 HUMAN (075506) Heat shock factor-binding protein 1 O0S=Homo sapiens GN=HSBP1 PE=1 SV=1 8538.2 1 (1 0 0 0 0) 1.93E-04
075683 SURF6 HUMAN (075683) Surfeit locus protein 6 OS=Homo sapiens GN=SURF6 PE=1 SV=3 41425.7 1 (1 0 0 0 0) 2.74E-07
075694 NU155 HUMAN (075694) Nuclear pore complex protein Nup155 OS=Homo sapiens GN=NUP155 PE=1 SV= 155099.8 2 (2 00 00) 1.10E-07
075695 XRP2 HUMAN (075695) Protein XRP2 OS=Homo sapiens GN=RP2 PE=1 SV=4 39615.5 2 (2 0 0 0 0) 6.72E-07
075746 CMC1 HUMAN (075746) Calcium-binding mitochondrial carrier protein Aralarl OS=Homo sapiens GN=SLC2 74715.0 7(60 1 00) 4.49E-07
075821 EIF3G HUMAN (075821) Eukaryotic translation initiation factor 3 subunit G OS=Homo sapiens GN=EIF3G PE 35588.9 3 (3 0 0 0 0) 4.19E-09
075923 DYSF HUMAN (075923) Dysferlin OS=Homo sapiens GN=DYSF PE=1 SV=1 237142.3 1 (1 0 0 0 0) 1.21E-08
075934 SPF27 HUMAN (075934) Pre-mRNA-splicing factor SPF27 OS=Homo sapiens GN=BCAS2 PE=1 SV=1 26115.0 3(3 0 0 0 0) 3.14E-07
075947 ATP5H HUMAN (075947) ATP synthase subunit d, mitochondrial OS=Homo sapiens GN=ATP5H PE=1 SV=3 18479.5 9(90000) 6.93E-07
075955 FLOTi HUMAN (075955) Flotillin-1 OS=Homo sapiens GN=FLOT1 PE=1 SV=3 47325.7 3 (3 0 0 0 0) 4.16E-07
075964 ATP5L HUMAN (075964) ATP synthase subunit g, mitochondrial OS=Homo sapiens GN=ATP5L PE=1 SV=3 11421.2 2(12 0 0 0 0) 3.78E-10
076021 RL1D1 HUMAN (076021) Ribosomal L1 domain-containing protein 1 OS=Homo sapiens GN=RSL1D1 PE=1 54939.0 9 (9 0 0 0 0) 9.04E-09
076021 RL1D1 HUMAN (076021) Ribosomal L1 domain-containing protein 1 OS=Homo sapiens GN=RSL1D1 PE=1 54939.0 1 (1 0 0 00) 1.37E-05
076094 SRP72 HUMAN (076094) Signal recognition particle 72 kDa protein OS=Homo sapiens GN=SRP72 PE=1 S 74560.1 1 (1 0 0 0 0) 1.65E-13
094788 AL1A2 HUMAN (094788) Retinal dehydrogenase 2 O0S=Homo sapiens GN=ALDH1A2 PE=2 SV=3 56688.0 2 (2 0 0 0 0) 2.12E-08
094832 MYO1D HUMAN (094832) Myosin-ld OS=Homo sapiens GN=MYO1D PE=1 SV=2 116128.6 1 (1 0 0 0 0) 1.97E-05
094905 ERLN2 HUMAN (094905) Erlin-2 OS=Homo sapiens GN=ERLIN2 PE=1 SV=1 37815.5 4(4 0 0 0 0) 9.74E-09
094910 LPHN1 HUMAN (094910) Latrophilin-1 O0S=Homo sapiens GN=LPHN1 PE=1 SV=l 162612.9 2 (2 0 0 0 0) 2.72E-07
094911 ABCA8 HUMAN (094911)ATP-binding cassette sub-familyA member 8 OS=Homo sapiens GN=ABCA8 PE= 179128.9 4 (4 0 0 0 0) 5.14E-09
095183 VAMP5 HUMAN (095183) Vesicle-associated membrane protein 5 O0S=Homo sapiens GN=VAMP5 PE=1 SV 12796.7 2 (2 0 00 0) 6.10E-08
095202 LETM1 HUMAN (095202) LETM1 and EF-hand domain-containing protein 1, mitochondrial OS=Homo sapien 83302.0 1 (1 0 0 0 0) 9.64E-08
095232 CROP HUMAN (095232) Cisplatin resistance-associated overexpressed protein OS=Homo sapiens GN=CRC 51435.1 1 (1 0 0 0 0) 1.58E-08
095292 VAPB HUMAN (095292) Vesicle-associated membrane protein-associated protein B/C OS=Homo sapiens G 27211.1 2 (2 00 0 0) 5.87E-07
095295 SNAPN HUMAN (095295) SNARE-associated protein Snapin OS=Homo sapiens GN=SNAPIN PE=1 SV=1 14864.9 2(2 0 0 0 0) 1.40E-08
095297 MPZLI HUMAN (095297) Myelin protein zero-like protein 1 0S=Homo sapiens GN=MPZL1 PE=1 SV=1 29064.0 1 (1 0 0 0 0) 2.29E-05
095298 NDUC2 HUMAN (095298) NADH dehydrogenase [ubiquinone] 1 subunit C2 OS=Homo sapiens GN=NDUFC; 14178.4 2 (2 00 00) 6.00E-07
095486 SC24A HUMAN (095486) Protein transport protein Sec24A OS=Homo sapiens GN=SEC24A PE=1 SV=2 119673.9 2 (2 0 0 0 0) 4.37E-09
095571 ETHEl HUMAN (095571) Protein ETHEl, mitochondrial OS=Homo sapiens GN=ETHE1 PE=1 SV=2 27855.1 5(50000) 1.93E-09
095573 ACSL3 HUMAN (095573) Long-chain-fatty-acid--CoAligase 3 O0S=Homo sapiens GN=ACSL3 PE=1 SV=3 80368.3 2(20000) 1.41E-12
095747 OXSR1 HUMAN (095747) Serine/threonine-protein kinase OSR1 OS=Homo sapiens GN=OXSR1 PE=1 SV= 57986.2 2 (2 0 0 0 0) 9.42E-10
095747 OXSR1 HUMAN (095747) Serine/threonine-protein kinase OSR1 OS=Homo sapiens GN=OXSR1 PE=1 SV= 57986.2 1 (1 0 0 0 0) 3.53E-06
095831 AIFM1 HUMAN (095831)Apoptosis-inducing factor 1, mitochondrial OS=Homo sapiens GN=AIFM1 PE=1 SV 66859.0 2 (20000) 5.16E-07
095837 GNA14 HUMAN (095837) Guanine nucleotide-binding protein subunit alpha-14 OS=Homo sapiens GN=GNA 41544.2 1 (0 1 000) 1.25E-07
096000 NDUBA HUMAN (096000) NADH dehydrogenase (ubiquinonel 1 beta subcomplex subunit 10 OS=Homo sapi 20763.2 4 (4 00 0 0) 6.48E-07
096008 TOM40 HUMAN (096008) Mitochondrial import receptor subunit TOM40 homolog OS=Homo sapiens GN=TO 37869.2 4 (4 0 0 0 0) 1.88E-07
096011 PX11B HUMAN (096011) Peroxisomal membrane protein 11B OS=Homo sapiens GN=PEX11B PE=1 SV=1 28413.2 7 (7 0 0 0 0) 9.01E-09
P00338 LDHA HUMAN (P00338) L-lactate dehydrogenase A chain OS=Homo sapiens GN=LDHA PE=1 SV=2 36665.4 5 (5 0 0 0 0) 3.60E-10
P00387 NBSR3 HUMAN (P00387) NADH-cytochrome b5 reductase 3 OS=Homo sapiens GN=CYB5R3 PE=1 SV=3 34212.7 2 (2 0 0 0 0) 3.20E-07
P00403 COX2 HUMAN (P00403) Cytochrome c oxidase subunit 2 OS=Homo sapiens GN=MT-C02 PE=1 SV=1 25548.2 5 (5 0 0 0 0) 4.36E-07
P00492 HPRT HUMAN (P00492) Hypoxanthine-guanine phosphoribosyltransferase OS=Homo sapiens GN=HPRT1 P 24563.6 1 (1 0 0 0 0) 6.71E-10
P00505 AATM HUMAN (P00505)Aspartate aminotransferase, mitochondrial OS=Homo sapiens GN=GOT2 PE=1 SV 47445.3 1 (11 0 0 0 0) 7.97E-09
P00533 EGFR HUMAN (P00533) Epidermal growth factor receptor OS=Homo sapiens GN=EGFR PE=1 SV=2 134190.2 1 (1 0 00 0) 1.33E-08
P00558 PGKI HUMAN (P00558) Phosphoglycerate kinase 1 OS=Homo sapiens GN=PGK1 PE=1 SV=3 44586.2 0 (10 0 0 0 0) 2.79E-09
P01111 RASN HUMAN (P01111) GTPase NRas OS=Homo sapiens GN=NRAS PE=1 SV=l 21215.5 1 (1 00 0 0) 3.65E-05
P01112 RASH HUMAN (P01112) GTPase HRas OS=Homo sapiens GN=HRAS PE=1 SV=1 21284.6 8(8 0 0 0 0) 1.41E-08
P01116 RASK HUMAN (P01116) GTPase KRas OS=Homo sapiens GN=KRAS PE=1 SV=1 21642.0 3 (3 0 0 0 0) 2.09E-06
P01903 2DRA HUMAN (P01903) HLA class II histocompatibility antigen, DR alpha chain OS=Homo sapiens GN=HLA 28588.7 8(80000) 2.58E-11
P01908 HA21 HUMAN (P01908) HLA class II histocompatibility antigen, DQ(1) alpha chain OS=Homo sapiens PE=2 28087.4 2 (20000) 9.88E-10
P02533 K1C14 HUMAN (P02533) Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=3 51589.5 5 (50000) 3.52E-08
P02538 K2C6A HUMAN (P02538) Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3 60008.3 2 (20000) 1.85E-05
P02545 LMNA HUMAN (PO2545) Lamin-A/C OS=Homo sapiens GN=LMNA PE=1 SV=1 74094.8!3 (23 0 0 0 0) 2.51E-09
P02647 APOA1 HUMAN (P02647) Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 30758.9 2 (2 0 0 0 0) 5.22E-08
P02786 TFR1 HUMAN (P02786) Transferrin receptor protein 10S=Homo sapiens GN=TFRC PE=1 SV=2 84818.0 1 (1 00 0) 9.55E-09
P03928 ATP8 HUMAN (P03928)ATP synthase protein 8 OS=Homo sapiens GN=MT-ATP8 PE=1 SV=1 7986.2 3(30000) 1.31E-05
P04004 VTNC HUMAN (P04004) Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 54271.2 1 (1 0000) 2.32E-08
P04075 ALDOA HUMAN (P04075) Fructose-bisphosphate aldolase A OS=Homo sapiens GN=ALDOA PE=1 SV=2 39395.3 4(40000) 1.74E-08
P04083 ANXA1 HUMAN (P04083) Annexin Al OS=Homo sapiens GN=ANXA1 PE=1 SV=2; 38690.0 6 (16 0 0 0 0) 7.09E-12
P04156 PRIO HUMAN (P04156) Major pnon protein OS=Homo sapiens GN=PRNP PE=1 SV=1 27643.2 3 (3 0 0 0 0) 1.02E-07
P04179 SODM HUMAN (P04179) Superoxide dismutase [Mn], mitochondrial OS=Homo sapiens GN=SOD2 PE=1 SV 24706.6 2 (2 0 0 0 0) 1.31E-06
P04183 KITH HUMAN (P04183) Thymidine kinase, cytosolic OS=Homo sapiens GN=TK1 PE=1 SV=2 25452.0 1 (1 0 0 0 0) 7.38E-05
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P04233 HG2A HUMAN (P04233) HLA class II histocompatibility antigen gamma chain OS=Homo sapiens GN=CD74 33493.7 1 (1 0 0 00) 1.15E-07
P04264 K2C1 HUMAN (P04264) Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=5 65977.9 6 (36 0 0 0 0) 1.18E-11
P04406 G3P HUMAN (P04406) Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 36030.4 9 (9 0 0 0 0) 6.00E-09
P04792 HSPB1 HUMAN (P04792) Heat shock protein beta-I OS=Homo sapiens GN=HSPB1 PE=1 SV=2 22768.5 8 (8 0 0 0 0) 2.38E-08
P04843 RPN1 HUMAN (P04843) Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 OS=Homo 68526.9 2 (22 0 00 0) 5.86E-13
P04844 RPN2 HUMAN (P04844) Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 OS=Homo 69241.1 4 (4 0 0 0 0) 1.31E-06
P05023 AT1Al HUMAN (P05023) Sodium/potassium-transporting ATPase subunit alpha-1 OS=Homo sapiens GN=AT 112824.1 7(270000) 4.09E-13
P05026 AT1B1 HUMAN (P05026) Sodium/potassium-transporting ATPase subunit beta-1 OS=Homo sapiens GN=ATF 35038.9 5 (50000) 1.43E-09
P05106 ITB3 HUMAN (P05106) Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2 87000.4 1(11 00 0 0) 5.45E-07
P05109 S10A8 HUMAN (P05109) Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1 SV=1 10827.7 2(2 0 0 0 0) 1.31E-05
P05198 IF2A HUMAN (P05198) Eukaryotic translation initiation factor 2 subunit 1 OS=Homo sapiens GN=EIF2S1 PE= 36089.4 4 (4 0 0 0 0) 1.36E-08
P05362 ICAM1 HUMAN (P05362) Intercellular adhesion molecule 1 OS=Homo sapiens GN=ICAM1 PE=1 SV=2 57789.0 1 (1 0 0 0 0) 1.04E-08
P05386 RLA1 HUMAN (P05386) 60S acidic ribosomal protein P1 OS=Homo sapiens GN=RPLP1 PE=1 SV=1 11506.7 2 (2 0 00 0) 2.10E-07
P05387 RLA2 HUMAN (P05387) 60S acidic ribosomal protein P2 OS=Homo sapiens GN=RPLP2 PE=1 SV=1 11657.9 2 (2 0 0 0) 9.01E-08
P05556 ITB1 HUMAN (P05556) Integdn beta-1 OS=Homo sapiens GN=ITGB1 PE=1 SV=2 88357.0 4 (4 0 0 0 0) 8.27E-08
P05787 K2C8 HUMAN (P05787) Keratin, type II cytoskeletal 8 OS=Homo sapiens GN=KRT8 PE=1 SV=7 53671.2 2 (0 2 0 0 0) 1.90E-05
P06213 INSR HUMAN (P06213) Insulin receptor OS=Homo sapiens GN=INSR PE=1 SV=2 156206.1 2 (2 00 0 0) 6.14E-07
P06396 GELS HUMAN (P06396) Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 85644.3 0 (10 0 0 0 0) 7.00E-11
P06576 ATPB HUMAN (P06576) ATP synthase subunit beta, mitochondrial OS=Homo sapiens GN=ATP5B PE=1 SV= 56524.7 1 (11 0 00 0) 2.85E-13
P06733 ENOA HUMAN (P06733)Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2 47139.4 (21 11 00 0) 5.88E-14
P06737 PYGL HUMAN (P06737) Glycogen phosphorylase, liver form OS=Homo sapiens GN=PYGL PE=I SV=4 97087.1 2 (2 0 0 0 0) 2.41E-07
P06744 G6PI HUMAN (P06744) Glucose-6-phosphate isomerase OS=Homo sapiens GN=GPI PE=1 SV=4 63107.3 3 (3 0 0 0) 2.17E-09
P06748 NPM HUMAN (P06748) Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2 32554.9 2 (2 0 0 0 0) 4.72E-08
P06756 ITAV HUMAN (P06756) Integrin alpha-V OS=Homo sapiens GN=ITGAV PE=1 SV=2 115964.5 7 (17 0 0 0 0) 7.43E-09
P07195 LDHB HUMAN (P07195) L-lactate dehydrogenase B chain OS=Homo sapiens GN=LDHB PE=1 SV=2 36615.2 0 (10 0 0 0 0) 1.49E-09
P07203 GPX1 HUMAN (P07203) Glutathione peroxidase 1 OS=Homo sapiens GN=GPX1 PE=1 SV=3 31782.1 2 (2 0 0 0 0) 1.65E-08
P07305 H10 HUMAN (P07305) Histone HI.0 OS=Homo sapiens GN=H1FO PE=1 SV=3 20850.2 4(4 0 0 0 0) 1.73E-07
P07477 TRY1 HUMAN (P07477) Trypsin-1 OS=Homo sapiens GN=PRSS1 PE=1 SV=1 26541.1 1 10 0 0 0) 7.37E-04
P07686 HEXB HUMAN (P07686) Beta-hexosaminidase subunit beta OS=Homo sapiens GN=HEXB PE=1 SV=3 63071.3 1 (1 0 0 0 0) 1.07E-04
P07737 PROF1 HUMAN (P07737) Profilin-1 OS=Homo sapiens GN=PFN1 PE=1 SV=2 15044.6 1 (1 0 0 0 0) 1.03E-07
P07741 APT HUMAN (P07741)Adenine phosphoribosyltransferase OS=Homo sapiens GN=APRT PE=1 SV=2 19595.4 2 (2 0 0 0 0) 1.71E-07
P07814 SYEP HUMAN (P07814) Bifunctional aminoacyl-tRNA synthetase OS=Homo sapiens GN=EPRS PE=1 SV=3 170539.3 2 (12 0 0 0 0) 4.90E-10
P07910 HNRPC HUMAN (P07910) Heterogeneous nuclear ribonucleoproteins C1/C2 OS=Homo sapiens GN=HNRNF 33649.6 6(60000) 1.41E-07
P07942 LAMB1 HUMAN (P07942) Laminin subunit beta-1 OS=Homo sapiens GN=LAMB1 PE=1 SV=1 197935.7 5(5 0 0 0 0) 1.74E-10
P07954 FUMH HUMAN (P07954) Fumarate hydratase, mitochondrial OS=Homo sapiens GN=FH PE=1 SV=3 54602.2 1 (1 0 0 0 0) 1.73E-05
P08183 MDR1 HUMAN (P08183) Multidrug resistance protein 1 OS=Homo sapiens GN=ABCB1 PE=1 SV=2 141373.3 1 (1 0 0 0 0) 2.24E-06
P08195 4F2 HUMAN (P08195) 4F2 cell-surface antigen heavy chain OS=Homo sapiens GN=SLC3A2 PE=1 SV=2 57909.0 7 (17 0 0 0 0) 9.50E-13
P08238 HS90B HUMAN (P08238) Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 83212.2 5(50000) 1.25E-08
P08240 SRPR HUMAN (P08240) Signal recognition particle receptor subunit alpha OS=Homo sapiens GN=SRPR PE 69767.4 1 (1 0 0 0 0) 4.49E-05
P08572 C04A2 HUMAN (PO8572) Collagen alpha-2(IV) chain OS=Homo sapiens GN=COL4A2 PE=1 SV=4 167448.4 2 (2 0 0 0 0) 2.29E-05
P08582 TRFM HUMAN (P08582) Melanotransferrin OS=Homo sapiens GN=MFI2 PE=1 SV=1 80190.5 9 (19 0 0 0 0) 6.78E-11
P08670 VIME HUMAN (P08670) Vimentin OS=Homo sapiens GN=VIM PE=I SV=4 53619.2 6 (15 0 0 0 1) 3.08E-08
P08708 RS17 HUMAN (P08708) 40S ribosomal protein S17 OS=Homo sapiens GN=RPS17 PE=1 SV=2 15540.4 5 (5 0 0 0 0) 4.76E-06
P09211 GSTP1 HUMAN (P09211) Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 23341.0 1 (1 0 0 0 0) 4.94E-05
P09382 LEG1 HUMAN (P09382) Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 14706.2 2 (2 0 0 0 0) 9.09E-08
P09417 DHPR HUMAN (P09417) Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 25773.0 1 (1 0 0 00) 1.08E-05
P09429 HMGB1 HUMAN (P09429) High mobility group protein B1 OS=Homo sapiens GN=HMGB1 PE=1 SV=3 24878.2 3 (30 0 0 0) 6.16E-10
P09471 GNAO HUMAN (P09471) Guanine nucleotide-binding protein G(o) subunit alpha OS=Homo sapiens GN=GNI 40024.9 6 (6 0 0 0 0) 2.55E-10
P09543 CN37 HUMAN (P09543) 2',3'-cyclic-nucleotide 3'-phosphodiesterase OS=Homo sapiens GN=CNP PE=1 SV= 47548.7 7 (70000) 1.83E-07
P09651 ROA1 HUMAN (P09651) Heterogeneous nuclear ribonucleoproteinAl OS=Homo sapiens GN=HNRNPA1 PE 38822.1 4 (4000 0 5.01E-10
P09661 RU2A HUMAN (P09661) U2 small nuclear ribonucleoprotein A' OS=Homo sapiens GN=SNRPA1 PE=1 SV=2 28398.1 1 (1 0 0 0 0) 3.43E-05
P09874 PARP1 HUMAN (P09874) Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 SV=4 113012.4 3 (13 0 0 0 0 9.70E-11
POC7M2 RA1L3 HUMAN (POC7M2) Putative heterogeneous nuclear ribonucleoprotein Al-like protein 3 OS=Homo sap 34202.3 5 (5 0 0 0 0) 2.05E-09
POC7M2 RA1L3 HUMAN (POC7M2) Putative heterogeneous nuclear ribonucleoprotein Al-like protein 3 OS=Homo sap 34202.3 1 (1 0 0 0 0) 9.56E-06
POC7P4 UCRIL HUMAN (POC7P4) Cytochrome b-c1 complex subunit Rieske-like protein 1 OS=Homo sapiens GN=U( 30796.1 2 (2 0 0 0) 9.15E-06
P10114 RAP2A HUMAN (P10114) Ras-related protein Rap-2a OS=Homo sapiens GN=RAP2A PE=1 SV=1 20602.3 3(2 1 000) 1.10E-07
P10301 RRAS HUMAN (P10301) Ras-related protein R-Ras OS=Homo sapiens GN=RRAS PE=1 SV=1 23465.9 2 (2 0 0 0) 7.20E-07
P10515 ODP2 HUMAN (P10515) Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenas 68953.3 4(40000) 1.79E-10
P10599 THIO HUMAN (P10599) Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=3 11729.7 5(50000) 3.63E-09
P10606 COX5B HUMAN (P10606) Cytochrome c oxidase subunit 58, mitochondrial OS=Homo sapiens GN=COX5B 13686.9 2 (20000) 7.90E-07
P10809 CH60 HUMAN (P10809) 60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV= 61016.5 5 (5 0 000 0) 1.17E-09
P11047 LAMC1 HUMAN (P11047) Laminin subunit gamma-1 OS=Homo sapiens GN=LAMCl PE=1 SV=2 177491.8 6 (60000) 3.13E-11
P11142 HSP7C HUMAN (Pl1142) Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 70854.4 4 (14 0 0 0 0) 1.14E-10
P11172 PYR5 HUMAN (P1172) Uridine 5'-monophosphate synthase OS=Homo sapiens GN=UMPS PE=1 SV=1 52188.7 5(50000) 1.83E-11
P11177 ODPB HUMAN (P11177) Pyruvate dehydrogenase El component subunit beta, mitochondrial OS=Homo sapi 39208.1 2(2 0 0 00) 1.01E-06
P11217 PYGM HUMAN (P11217) Glycogen phosphorylase, muscle form OS=Homo sapiens GN=PYGM PE=1 SV=6 97030.8 2 (2 0 0 0) 8.25E-08
P11233 RALA HUMAN (P11233) Ras-related protein Ral-A OS=Homo sapiens GN=RALA PE=1 SV=1 23552.0 6 (6 0 0 0 0) 1.60E-10
P11233 RALA HUMAN (P11233) Ras-related protein Ral-A OS=Homo sapiens GN=RALA PE=I SV=1 23552.0 2 (2 0 0 0 0) 3.24E-09
P11498 PYC HUMAN (P11498) Pyruvate carboxylase, mitochondrial OS=Homo sapiens GN=PC PE=1 SV=2 129551.6 1 (1 0 0 0 0) 7.91E-07
P11586 CITC HUMAN (P11586) C-1-tetrahydrofolate synthase, cytoplasmic OS=Homo sapiens GN=MTHFD1 PE=1 101495.6 2 (2 0 0 0 0) 1.30E-10
P11766 ADHX HUMAN (P11766) Alcohol dehydrogenase class-3 OS=Homo sapiens GN=ADH5 PE=I SV=4 39698.4 2 (2 0 0 0 0) 1.25E-09
P12235 ADT1 HUMAN (P12235)ADP/ATP translocase 1 OS=Homo sapiens GN=SLC25A4 PE=1 SV=4 33043.2 6(5 1 000) 2.50E-09
P12270 TPR HUMAN (P12270) Nucleoprotein TPR OS=Homo sapiens GN=TPR PE=1 SV=3 267129.4 5(50000) 1.83E-07
P12814 ACTN1 HUMAN (P12814) Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 102992.7 4 (4 0 0 0 0) 3.78E-10
P12956 KU70 HUMAN (P12956)ATP-dependent DNA helicase 2 subunit 1 OS=Homo sapiens GN=XRCC6 PE=1 SV= 69799.2 4 (14 0 0 0 0) 1.00E-08
P13010 KU86 HUMAN (P13010)ATP-dependent DNA helicase 2 subunit 2 OS=Homo sapiens GN=XRCC5 PE=1 SV= 82652.4 8(80000) 6.85E-12
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P13073 COX41 HUMAN (P13073) Cytochrome c oxidase subunit 4 isoform 1, mitochondrial OS=Homo sapiens GN=C 19564.1 6 (6 0 0 0 0) 6.78E-09
P13164 IFMI HUMAN (P13164) Interferon-induced transmembrane protein 1 OS=Homo sapiens GN=IFITM1 PE=1 S 13955.3 3 (3 0 0 0 0) 4.36E-10
P13591 NCAM1 HUMAN (P13591) Neural cell adhesion molecule 1 OS=Homo sapiens GN=NCAM1 PE=1 SV=3 94515.2 3 (3 0 0 0 0) 2.21E-06
P13639 EF2 HUMAN (P13639) Elongation factor 2 OS=Homo sapiens GN=EEF2 PE=1 SV=4 95277.1 6(16 0 0 0 0) 2.12E-08
P13645 KIC10 HUMAN (P13645) Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=4 59474.8 0 (200 0 0) 6.58E-12
P13646 K1C13 HUMAN (P13646) Keratin, type I cytoskeletal 13 OS=Homo sapiens GN=KRT13 PE=1 SV=3 49555.5 8 (80000) 6.72E-08
P13647 K2C5 HUMAN (P13647) Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRTS PE=1 SV=3 62340.0 1 (1 0 0 0 0) 5.92E-07
P13647 K2C5 HUMAN (P13647) Keratin, type 11 cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 62340.0 2 (2 0 00 0) 2.93E-06
P13761 2B17 HUMAN (P13761) HLA class II histocompatibility antigen, DRB1-7 beta chain OS=Homo sapiens GN=H 29803.0 5(50000) 7.73E-07
P13807 GYS1 HUMAN (P13807) Glycogen [starch] synthase, muscle OS=Homo sapiens GN=GYS1 PE=1 SV=2 83732.5 1 (1 0 0 0 0) 7.57E-07
P13984 T2FB HUMAN (P13984) General transcription factor IIF subunit 2 OS=Homo sapiens GN=GTF2F2 PE=1 SV= 28362.9 1 (1 0 0 00) 6.01E-06
P13987 CD59 HUMAN (P13987) CD59 glycoprotein OS=Homo sapiens GN=CD59 PE=1 SV=1 14167.8 4 (4000 0) 4.83E-07
P14136 GFAP HUMAN (P14136) Glial fibrillary acidic protein OS=Homo sapiens GN=GFAP PE=1 SV=1 49849.7 2 (0 2 0 0 0) 1.40E-07
P14174 MIF HUMAN (P14174) Macrophage migration inhibitory factor OS=Homo sapiens GN=MIF PE=1 SV=4 12468.2 1 (1 00 0) 5.25E-04
P14406 CX7A2 HUMAN (P14406) Cytochrome c oxidase polypeptide 7A2, mitochondrial OS=Homo sapiens GN=CO) 9390.1 3 (3 0 0 0 0) 7.67E-08
P14625 ENPL HUMAN (P14625) Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 92411.2 9 (9 0 0 0 0) 8.11E-07
P14649 MYL68 HUMAN (P14649) Myosin light chain 6B OS=Homo sapiens GN=MYL6B PE=1 SV=1 22749.7 3 (3 0 0 0 0) 3.30E-07
P14866 HNRPL HUMAN (P14866) Heterogeneous nuclear ribonucleoprotein L OS=Homo sapiens GN=HNRNPL PE= 64092.4 3 (3 0 0 0 0) 3.34E-06
P14868 SYDC HUMAN (P14868) Aspartyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=DARS PE=1 SV=2 57100.1 2 (20000) 4.71E-06
P15151 PVR HUMAN (P15151) Poliovirus receptor OS=Homo sapiens GN=PVR PE=1 SV=2 45273.9 2(2 0 0 0) 2.59E-08
P15559 NQO1 HUMAN (P15559) NAD(P)H dehydrogenase [quinone] 1 OS=Homo sapiens GN=NQO1 PE=1 SV=1 30848.0 2 (2 0 0 0 0) 2.28E-08
P16070 CD44 HUMAN (P16070) CD44 antigen OS=Homo sapiens GN=CD44 PE=1 SV=2 81503.4 5(50000) 1.32E-08
P16152 CBR1 HUMAN (P16152) Carbonyl reductase [NADPH] 1 OS=Homo sapiens GN=CBR1 PE=1 SV=3 30355.9 1 (1 0 0 0 0) 2.44E-08
P16401 H15 HUMAN (P16401) Histone H1.5 OS=Homo sapiens GN=HIST1H1B PE=1 SV=3 22566.5 7 (70000) 1.89E-07
P16403 H12 HUMAN (P16403) Histone H1.2 OS=Homo sapiens GN=HIST1H1C PE=1 SV=2 21351.8 7 (70000) 8.36E-08
P16615 AT2A2 HUMAN (P16615) Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 OS=Homo sapiens GN=AT 114682.7 9 (90000) 2.31E-10
P17066 HSP76 HUMAN (P17066) Heat shock 70 kDa protein 6 OS=Homo sapiens GN=HSPA6 PE=1 SV=2 70984.4 4(40000) 1.29E-08
P17096 HMGA1 HUMAN (P17096) High mobility group protein HMG-I/HMG-Y OS=Homo sapiens GN=HMGA1 PE=1 11669.2 2 (20000) 2.86E-10
P17301 ITA2 HUMAN (P17301) Integrin alpha-2 OS=Homo sapiens GN=ITGA2 PE=1 SV=1 129213.8 5 (50000) 1.78E-07
P17612 KAPCA HUMAN (P17612) cAMP-dependent protein kinase catalytic subunit alpha OS=Homo sapiens GN=P 40564.0 2 (20000) 2.63E-08
P17661 DESM HUMAN (P17661) Desmin OS=Homo sapiens GN=DES PE=1 SV=3 53503.2 3 (30000) 6.44E-05
P17813 EGLN HUMAN (P17813) Endoglin OS=Homo sapiens GN=ENG PE=1 SV=2 70533.2 3 (3 00 0 0) 4.73E-09
P17844 DDX5 HUMAN (P17844) Probable ATP-dependent RNA helicase DDX5 OS=Homo sapiens GN=DDX5 PE=1 69104.8 9 (9 0 0 0 0) 7.09E-08
P17980 PRS6A HUMAN (P17980) 26S protease regulatory subunit 6A OS=Homo sapiens GN=PSMC3 PE=1 SV=3 49172.5 4 (4 0 0 0 0) 7.02E-11
P17987 TCPA HUMAN (P17987) T-complex protein 1 subunit alpha OS=Homo sapiens GN=CCT1 PE=1 SV=1 60305.7 1 (1 00 0 0) 6.19E-05
P18077 RL35A HUMAN (P18077) 60S ribosomal protein L35a OS=Homo sapiens GN=RPL35A PE=1 SV=2 12529.8 2 (20000) 3.11E-05
P18084 ITB5 HUMAN (P18084) Interin beta-5 OS=Homo sapiens GN=ITGB5 PE=2 SV=1 87996.2 1 (1 00 0 0) 7.80E-05
P18085 ARF4 HUMAN (P18085) ADP-dbosylation factor 4 OS=Homo sapiens GN=ARF4 PE=1 SV=3 20497.7 7 (70 0 0 0) 2.82E-07
P18206 VINC HUMAN (P18206) Vinculin OS=Homo sapiens GN=VCL PE=1 SV=4 123721.9 5(50000) 9.61E-09
P18621 RL17 HUMAN (P18621) 60S ribosomal protein L17 OS=Homo sapiens GN=RPL17 PE=1 SV=3 21383.3 8 (80000) 1.53E-10
P18669 PGAM1 HUMAN (P18669) Phosphoglycerate mutase 1 OS=Homo sapiens GN=PGAM1 PE=1 SV=2 28785.9 7 (7 00 0 0) 3.64E-10
P19013 K2C4 HUMAN (P19013) Keratin, type II cytoskeletal 4 OS=Homo sapiens GN=KRT4 PE=1 SV=4 57249.9 5(50000) 3.07E-09
P19022 CADH2 HUMAN (P19022) Cadherin-2 OS=Homo sapiens GN=CDH2 PE=1 SV=4 99747.4 1 (1 0 0 0) 3.54E-08
P19256 LFA3 HUMAN (P19256) Lymphocyte function-associated antigen 3 OS=Homo sapiens GN=CD58 PE=1 SV=1 28128.9 1 (1 0000) 2.44E-07
P19338 NUCL HUMAN (P19338) Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 76568.5 1(11 0 0 0 0) 1.82E-11
P19525 E2AK2 HUMAN (P19525) Interferon-induced, double-stranded RNA-activated protein kinase OS=Homo sapie 62055.7 1 (1 0 0 0 0) 1.20E-06
P20020 AT2B1 HUMAN (P20020) Plasma membrane calcium-transporting ATPase 1 OS=Homo sapiens GN=ATP2B1 138667.9 5(15 0 0 0 0) 4.23E-10
P20042 IF2B HUMAN (P20042) Eukaryotic translation initiation factor 2 subunit 2 OS=Homo sapiens GN=EIF2S2 PE= 38364.4 1 (1 0 0 0 0) 3.21E-06
P20309 ACM3 HUMAN (P20309) Muscarinic acetylcholine receptor M3 OS=Homo sapiens GN=CHRM3 PE=1 SV=1 66085.9 2 (2 0 0 0 0) 5.57E-07
P20339 RAB5A HUMAN (P20339) Ras-related protein Rab-5A OS=Homo sapiens GN=RAB5A PE=1 SV=2 23643.8 8(80000) 1.91E-07
P20340 RAB6A HUMAN (P20340) Ras-related protein Rab-6A OS=Homo sapiens GN=RAB6A PE=1 SV=3 23577.9 5 (5 0 0 0 0) 1.65E-07
P20618 PSB1 HUMAN (P20618) Proteasome subunit beta type-1 OS=Homo sapiens GN=PSMB1 PE=1 SV=2 26472.4 4 (4 0 0) 1.02E-08
P20645 MPRD HUMAN (P20645) Cation-dependent mannose-6-phosphate receptor OS=Homo sapiens GN=M6PR P 30973.4 2 (2 0 0 0 0) 1.11E-11
P20648 ATP4A HUMAN (P20648) Potassium-transporting ATPase alpha chain 1 OS=Homo sapiens GN=ATP4A PE=e 114045.4 1 10 0 0 0) 4.35E-06
P20674 COX5A HUMAN (P20674) Cytochrome c oxidase subunit SA, mitochondrial OS=Homo sapiens GN=COX5A F 16751.7 4(40000) 1.57E-08
P20700 LMNB1 HUMAN (P20700) Lamin-B1 OS=Homo sapiens GN=LMNB1 PE=1 SV=2 66367.7 3 (23 0 0 0 0) 1.18E-09
P21283 VATC1 HUMAN (P21283) V-type proton ATPase subunit C 1 OS=Homo sapiens GN=ATP6V1C1 PE=1 SV=4 43914.0 1 (1 0000) 4.34E-05
P21291 CSRP1 HUMAN (P21291) Cysteine and glycine-dch protein 1 OS=Homo sapiens GN=CSRP1 PE=1 SV=3 20553.8 7 (7 0 0 0 0) 1.27E-09
P21333 FLNA HUMAN (P21333) Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 280561.4 1 10 0 0 0) 1.14E-10
P21589 5NTD HUMAN (P21589) 5'-nucleotidase OS=Homo sapiens GN=NT5E PE=1 SV=1 63327.6 3 (23 0 0 0 0) 2.97E-12
P21796 VDAC1 HUMAN (P21796) Voltage-dependent anion-selective channel protein 1 OS=Homo sapiens GN=VDA 30753.6 9 (54000) 6.18E-10
P21860 ERBB3 HUMAN (P21860) Receptor tyrosine-protein kinase erbB-3 OS=Homo sapiens GN=ERBB3 PE=1 SV= 148002.2 1 (1 0 0 0 0) 2.61E-08
P21926 CD9 HUMAN (P21926) CD9 antigen OS=Homo sapiens GN=CD9 PE=1 SV=4 25399.0 2 (20000) 1.17E-05
P21964 COMT HUMAN (P21964) Catechol O-methyltransferase OS=Homo sapiens GN=COMT PE=1 SV=2 30017.6 2 (2 00 00 8.51E-06
P22061 PIMT HUMAN (P22061) Protein-L-isoaspartate(D-aspartate) 0-methyltransferase OS=Homo sapiens GN=PC 24634.6 1 (1 0 0 0 0) 3.57E-09
P22087 FBRL HUMAN (P22087) rRNA2'-O-methyltransferase fibrillarin OS=Homo sapiens GN=FBL PE=1 SV=2 33763.4 2 (12 0 0 0 0) 2.02E-11
P22307 NLTP HUMAN (P22307) Non-specific lipid-transfer protein OS=Homo sapiens GN=SCP2 PE=1 SV=2 58955.7 5 (5 0 0 0 0) 1.07E-06
P22314 UBA1 HUMAN (P22314) Ubiquitin-like modifier-activating enzyme 1 OS=Homo sapiens GN=UBA1 PE=1 SV= 117774.5 3 (3 0 0) 5.64E-08
P22626 ROA2 HUMAN (P22626) Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens GN=HNRNPA, 37406.7 7 (7 0 0 0 0) 2.72E-10
P22695 QCR2 HUMAN (P22695) Cytochrome b-c1 complex subunit 2, mitochondrial OS=Homo sapiens GN=UQCRC 48412.9 2 (2 0 00 0) 3.58E-08
P23193 TCEA1 HUMAN (P23193) Transcription elongation factor A protein 1 OS=Homo sapiens GN=TCEA1 PE=1 S\ 33948.0 2 (2 0 0 0 0) 2.58E-08
P23246 SFPQ HUMAN (P23246) Splicing factor, proline- and glutamine-nch OS=Homo sapiens GN=SFPQ PE=1 SV= 76101.8 1 (1 0 0 0 0) 6.40E-06
P23284 PPIB HUMAN (P23284) Peptidyl-prolyl cis-trans isomerase B OS=Homo sapiens GN=PPIB PE=1 SV=2 23727.5 0 (10 0 0 0 0) 1.98E-05
P23396 RS3 HUMAN (P23396) 40S ribosomal protein S3 OS=Homo sapiens GN=RPS3 PE=1 SV=2 26671.4 4 (14 0 0 0 0) 3.26E-11
P23470 PTPRG HUMAN (P23470) Receptor-type tyrosine-protein phosphatase gamma OS=Homo sapiens GN=PTPF 161926.0 1 (1 0 0 0 0) 1.79E-06
P23528 COF1 HUMAN (P23528) Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3 18490.7 8 (8 0 00) 4.24E-08
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P23634 AT2B4 HUMAN (P23634) Plasma membrane calcium-transporting ATPase 4 OS=Homo sapiens GN=ATP2B4 137832.9 6 (60000) 2.41E-10
P23919 KTHY HUMAN (P23919) Thymidylate kinase OS=Homo sapiens GN=DTYMK PE=1 SV=4 23804.5 1 (1 0 0 0 0) 4.79E-05
P24539 AT5F1 HUMAN (P24539) ATP synthase subunit b, mitochondrial OS=Homo sapiens GN=ATP5F1 PE=1 SV=2 28890.3 8 (8 0 0 0 0) 4.85E-09
P24752 THIL HUMAN (P24752)Acetyl-CoA acetyltransferase, mitochondrial OS=Homo sapiens GN=ACAT1 PE=1 SV 45170.7 7 (70000) 3.71E-09
P24941 CDK2 HUMAN (P24941) Cell division protein kinase 2 OS=Homo sapiens GN=CDK2 PE=1 SV=2 33908.0 1 (1 0 0 0 0) 5.96E-06
P25398 RS12 HUMAN (P25398) 40S ribosomal protein S12 OS=Homo sapiens GN=RPS12 PE=1 SV=2 14516.5 5 (5000 0 3.56E-06
P25685 DNJB1 HUMAN (P25685) DnaJ homolog subfamily B member 1 OS=Homo sapiens GN=DNAJB1 PE=1 SV=, 38020.4 2 (2 0 0 0 0) 1.45E-06
P25705 ATPA HUMAN (P25705)ATP synthase subunit alpha, mitochondrial OS=Homo sapiens GN=ATP5A1 PE=1 S) 59713.7 2 (12 0 0 0 0) 1.47E-10
P25787 PSA2 HUMAN (P25787) Proteasome subunit alpha type-2 OS=Homo sapiens GN=PSMA2 PE=1 SV=2 25882.3 3 (3 0 0 0 0) 4.04E-10
P25789 PSA4 HUMAN (P25789) Proteasome subunit alpha type-4 OS=Homo sapiens GN=PSMA4 PE=1 SV=1 29465.2 2 (2 0 0 0 0) 3.79E-06
P26006 ITA3 HUMAN (P26006) Integrin alpha-3 OS=Homo sapiens GN=ITGA3 PE=1 SV=3 118622.2 9 (9 0 0 0 0) 5.31E-12
P26368 U2AF2 HUMAN (P26368) Splicing factor U2AF 65 kDa subunit OS=Homo sapiens GN=U2AF2 PE=1 SV=4 53467.3 1 (1 0 0 0 0) 8.48E-06
P26373 RL13 HUMAN (P26373) 60S ribosomal protein L13 OS=Homo sapiens GN=RPL13 PE=1 SV=4 24246.5 4 (40000) 3.09E-06
P26447 S10A4 HUMAN (P26447) Protein S100-A4 OS=Homo sapiens GN=S100A4 PE=1 SV=1 11720.7 4 (4 00 0 0) 7.73E-06
P26639 SYTC HUMAN (P26639) Threonyl-tRNAsynthetase, cytoplasmic OS=Homo sapiens GN=TARS PE=1 SV=3 83382.0 1 (1 0 0 0 0) 5.05E-08
P27105 STOM HUMAN (P27105) Erythrocyte band 7 integral membrane protein OS=Homo sapiens GN=STOM PE=1 31710.7 6 (60000) 1.81E-07
P27144 KAD4 HUMAN (P27144) Adenylate kinase isoenzyme 4, mitochondrial OS=Homo sapiens GN=AK3L1 PE=I 25252.2 2 (2 0 0 0 0) 2.25E-07
P27348 1433T HUMAN (P27348) 14-3-3 protein theta OS=Homo sapiens GN=YWHAQ PE=1 SV=I 27746.8 2 (2 0 0 0 0) 8.54E-08
P27348 1433T HUMAN (P27348) 14-3-3 protein theta OS=Homo sapiens GN=YWHAQ PE=1 SV=1 27746.8 1 (1 0 0 0 0) 4.72E-06
P27695 APEX1 HUMAN (P27695) DNA-(apurinic or apyrimidinic site) lyase OS=Homo sapiens GN=APEX1 PE=1 SV- 35532.2 7 (70000) 1.10E-07
P27708 PYR1 HUMAN (P27708) CAD protein OS=Homo sapiens GN=CAD PE=1 SV=3 242827.1 6 (6 0 0 0 0) 5.48E-10
P27816 MAP4 HUMAN (P27816) Microtubule-associated protein 4 OS=Homo sapiens GN=MAP4 PE=1 SV=2 120944.1 3 (3 0 0 0 0) 2.18E-09
P28066 PSA5 HUMAN (P28066) Proteasome subunit alpha type-5 OS=Homo sapiens GN=PSMA5 PE=1 SV=3 26394.2 5(5 0 0 0 0) 1.79E-09
P28072 PSB6 HUMAN (P28072) Proteasome subunit beta type-6 OS=Homo sapiens GN=PSMB6 PE=I1 SV=4 25341.5 2 (2 0 0 0 0) 3.76E-07
P28074 PSB5 HUMAN (P28074) Proteasome subunit beta type-5 OS=Homo sapiens GN=PSMB5 PE=1 SV=3 28462.2 4 (4 0 0 0 0) 2.83E-07
P28482 MK01 HUMAN (P28482) Mitogen-activated protein kinase 1 OS=Homo sapiens GN=MAPK1 PE=1 SV=3 41363.3 6 (4 2 00 0) 4.98E-10
P28838 AMPL HUMAN (P28838) Cytosol aminopeptidase OS=Homo sapiens GN=LAP3 PE=1 SV=3 56130.9 1(1 0 00 0) 3.93E-08
P29317 EPHA2 HUMAN (P29317) Ephrin type-Areceptor 2 OS=Homo sapiens GN=EPHA2 PE=1 SV=1 108184.8 7 (17 0 0 0 0) 2.61E-13
P29320 EPHA3 HUMAN (P29320) Ephrin type-A receptor 3 OS=Homo sapiens GN=EPHA3 PE=1 SV=2 110060.2 7 (7 0 0 0 0) 2.77E-10
P29323 EPHB2 HUMAN (P29323) Ephrin type-B receptor 2 OS=Homo sapiens GN=EPHB2 PE=1 SV=5 117416.9 4 (4 0 0 0 0) 3.52E-07
P29992 GNAll HUMAN (P29992) Guanine nucleotide-binding protein subunit alpha-11 OS=Homo sapiens GN=GNA1 42096.6 6 (6 0 0 0 0) 7.97E-10
P30041 PRDX6 HUMAN (P30041) Peroxiredoxin-6 OS=Homo sapiens GN=PRDX6 PE=1 SV=3 25019.2 2 (2 00 0 0) 7.66E-05
P30042 ES1 HUMAN (P30042) ES1 protein homolog, mitochondrial OS=Homo sapiens GN=C21orf33 PE=1 SV=3 28152.7 4 (40 0 0 0) 4.88E-09
P30044 PRDX5 HUMAN (P30044) Peroxiredoxin-5, mitochondrial OS=Homo sapiens GN=PRDX5 PE=1 SV=3 22012.5 4(40000) 1.41E-08
P30048 PRDX3 HUMAN (P30048) Thioredoxin-dependent peroxide reductase, mitochondrial OS=Homo sapiens GN= 27675.2 2 (2 0 00 0) 6.31E-06
P30084 ECHM HUMAN (P30084) Enoy-CoA hydratase, mitochondrial OS=Homo sapiens GN=ECHS1 PE=1 SV=4 31367.1 9(9 0 0 0 0) 5.11E-09
P30101 PDIA3 HUMAN (P30101) Protein disulfide-isomerase A3 OS=Homo sapiens GN=PDIA3 PE=1 SV=4 56746.8 2 (2 0 0) 9.22E-07
P30461 1813 HUMAN (P30461) HLAclass I histocompatibility antigen, B-13 alpha chain OS=Homo sapiens GN=HLA 40449.1 8 (8 0 0 0 0) 3.98E-08
P30519 HMOX2 HUMAN (P30519) Heme oxygenase 2 OS=Homo sapiens GN=HMOX2 PE=1 SV=2 36009.9 2 (2 0 0 0 0) 3.14E-08
P30711 GSTT1 HUMAN (P30711) Glutathione S-transferase theta-i OS=Homo sapiens GN=GSTT1 PE=1 SV=4 27317.6 1(1 0 0 0 0) 1.04E-09
P30825 CTR1 HUMAN (P30825) High affinity cationic amino acid transporter 1 OS=Homo sapiens GN=SLC7A1 PE=1 67594.3 4(40000) 1.00E-07
P31689 DNJA1 HUMAN (P31689) DnaJ homolog subfamily A member 1 OS=Homo sapiens GN=DNAJA1 PE=1 SV=, 44839.5 2(2 0 0 0 0) 5.52E-07
P31930 QCR1 HUMAN (P31930) Cytochrome b-c1 complex subunit 1, mitochondrial OS=Homo sapiens GN=UQCRC 52612.5 2 (2 0 0 00) 7.22E-06
P31939 PUR9 HUMAN (P31939) Bifunctional purine biosynthesis protein PURH OS=Homo sapiens GN=ATIC PE=1 1 64575.5 3 (30000) 1.10E-08
P31942 HNRH3 HUMAN (P31942) Heterogeneous nuclear ribonucleoprotein H3 OS=Homo sapiens GN=HNRNPH3 36903.0 2 (2 0 00 0) 3.78E-06
P31943 HNRH1 HUMAN (P31943) Heterogeneous nuclear ribonucleoprotein H OS=Homo sapiens GN=HNRNPH1 PE 49198.4 4 (4 00 000 4.02E-09
P31946 1433B HUMAN (P31946) 14-3-3 protein beta/alpha OS=Homo sapiens GN=YWHAB PE=1 SV=3 28064.8 6 (60000) 1.58E-08
P31949 S10AB HUMAN (P31949) Protein S100-All OS=Homo sapiens GN=S100A11 PE=1 SV=2 11732.8 3 (3 00 0 0) 4.05E-07
P32119 PRDX2 HUMAN (P32119) Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1 SV=5 21878.2 0 (10 0 0 0 0) 2.32E-10
P32969 RL9 HUMAN (P32969) 60S ribosomal protein L9 OS=Homo sapiens GN=RPL9 PE=1 SV=I 21849.8 7 (70000) 1.64E-11
P32970 CD70 HUMAN (P32970) CD70 antigen OS=Homo sapiens GN=CD70 PE=1 SV=2 21104.9 1(1 0000) 1.21E-07
P33176 KINH HUMAN (P33176) Kinesin-1 heavy chain OS=Homo sapiens GN=KIF5B PE=1 SV=1 109616.9 7 (17 0 0 0 0) 4.54E-11
P33527 MRP1 HUMAN (P33527) Multidrug resistance-associated protein 1 OS=Homo sapiens GN=ABCC1 PE=1 SV 171450.5 3 (3 0 0 0 0) 2.90E-09
P33992 MCM5 HUMAN (P33992) DNA replication licensing factor MCM5 OS=Homo sapiens GN=MCM5 PE=1 SV=5 82233.3 2 (2 0 0 0 0) 2.89E-07
P34741 SDC2 HUMAN (P34741) Syndecan-2 OS=Homo sapiens GN=SDC2 PE=1 SV=2 22146.2 2 (2 0 00 0) 6.93E-07
P34897 GLYM HUMAN (P34897) Serine hydroxymethyltransferase, mitochondrial OS=Homo sapiens GN=SHMT2 PE 55957.8 5 (5 0 0 0 0) 1.65E-08
P34932 HSP74 HUMAN (P34932) Heat shock 70 kDa protein 4 OS=Homo sapiens GN=HSPA4 PE=1 SV=4 94271.1 1 (1 0 0 0 0) 1.26E-06
P35030 TRY3 HUMAN (P35030) Trypsin-3 OS=Homo sapiens GN=PRSS3 PE=1 SV=2 32508.0 1 (1 0 0 0 0) 7.29E-06
P35052 GPCI HUMAN (P35052) Glypican-1 OS=Homo sapiens GN=GPC1 PE=1 SV=1 61611.1 1 (1 0 0 0 0) 2.43E-09
P35221 CTNA1 HUMAN (P35221) Catenin alpha-1 OS=Homo sapiens GN=CTNNA1 PE=1 SV=I 100008.6 0 (10 0 0 0 0) 2.82E-09
P35222 CTNB1 HUMAN (P35222) Catenin beta-1 OS=Homo sapiens GN=CTNNB1 PE=1 SV=1 85442.3 7 (7 0 0 0 0) 1.29E-08
P35232 PHB HUMAN (P35232) Prohibitin OS=Homo sapiens GN=PHB PE=1 SV=1 29785.9 7 (7 0 0 0 0) 9.28E-08
P35249 RFC4 HUMAN (P35249) Replication factor C subunit 4 OS=Homo sapiens GN=RFC4 PE=1 SV=2 39656.9 1 (1 0 0 0 0) 3.22E-08
P35250 RFC2 HUMAN (P35250) Replication factor C subunit 2 OS=Homo sapiens GN=RFC2 PE=1 SV=3 39132.1 4 (4 0 0 0 0) 4.16E-07
P35268 RL22 HUMAN (P35268) 60S ribosomal protein L22 OS=Homo sapiens GN=RPL22 PE=1 SV=2 14777.8 2(20000) 1.64E-07
P35268 RL22 HUMAN (P35268) 60S ribosomal protein L22 OS=Homo sapiens GN=RPL22 PE=1 SV=2 14777.8 1 (1 0 0 0 0) 2.70E-05
P35270 SPRE HUMAN (P35270) Sepiapterin reductase OS=Homo sapiens GN=SPR PE=1 SV=1 28030.8 4 (4 0 0 0) 4.44E-11
P35527 KIC9 HUMAN (P35527) Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=2 62091.8 5 (14 1 0 0 0) 1.44E-10
P35579 MYH9 HUMAN (P35579) Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4 226390.6 4 (43 0 0 0 1) 4.33E-14
P35613 BASI HUMAN (P35613) Basigin OS=Homo sapiens GN=BSG PE=1 SV=2 42174.1 0 (10 0 0 0 0) 2.80E-12
P35659 DEK HUMAN (P35659) Protein DEK OS=Homo sapiens GN=DEK PE=1 SV=1 42648.0 2 (2 0 0 0 0) 3.86E-07
P35908 K22E HUMAN (P35908) Keratin, type 11 cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=1 65825.4 0 (19 1 0 0 0) 2.60E-13
P36404 ARL2 HUMAN (P36404)ADP-ribosylation factor-like protein 2 OS=Homo sapiens GN=ARL2 PE=1 SV=4 20864.9 1 (1 0 0 0 0) 7.66E-05
P36405 ARL3 HUMAN (P36405) ADP-ribosylation factor-like protein 3 OS=Homo sapiens GN=ARL3 PE=1 SV=2 20442.8 1 (1 0 0 0 0) 2.15E-06
P36551 HEM6 HUMAN (P36551) Coproporphyrinogen III oxidase, mitochondrial OS=Homo sapiens GN=CPOX PE=1 50120.1 4 (4 0 0 0 0) 7.81E-08
P36957 OD02 HUMAN (P36957) Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydr 48698.6 2 (2 0 0 0 0) 1.18E-08
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P37108 SRP14 HUMAN (P37108) Signal recognition particle 14 kDa protein OS=Homo sapiens GN=SRP14 PE=1 SV 14560.8 1 (1 0 0 0) 1.33E-08
P37198 NUP62 HUMAN (P37198) Nuclear pore glycoprotein p62 OS=Homo sapiens GN=NUP62 PE=1 SV=3 53222.5 2 (2 0 0 0 0) 1.28E-06
P37802 TAGL2 HUMAN (P37802) Transelin-2 O0S=Homo sapiens GN=TAGLN2 PE=1 SV=3 22377.2 7 (7 0 0 0 0) 5.03E-08
P38159 HNRPG HUMAN (P38159) Heterogeneous nuclear ribonucleoprotein G OS=Homo sapiens GN=RBMX PE=1 42306.3 1 (1 00 0) 1.79E-05
P39023 RL3 HUMAN (P39023) 60S ribosomal protein L3 OS=Homo sapiens GN=RPL3 PE=1 SV=2 46079.8 8 (8 0 0 0 0) 2.24E-08
P39060 COIA1 HUMAN (P39060) Collagen alpha-1(XVIII) chain OS=Homo sapiens GN=COL18A1 PE=1 SV=5 178076.4 1 (1 00 0) 4.08E-07
P40121 CAPG HUMAN (P40121) Macrophage-capping protein OS=Homo sapiens GN=CAPG PE=1 SV=1 38493.6 2(2 0 0 0 0) 1.39E-07
P40227 TCPZ HUMAN (P40227) T-complex protein 1 subunit zeta OS=Homo sapiens GN=CCT6A PE=1 SV=3 57987.7 4 (4 0 0 0 0) 9.94E-07
P40616 ARL1 HUMAN (P40616)ADP-ribosylation factor-like protein 1 OS=Homo sapiens GN=ARL1 PE=1 SV=1 20404.5 3(3 0 0 0 0) 1.78E-05
P40763 STAT3 HUMAN (P40763) Signal transducer and activator of transcription 3 OS=Homo sapiens GN=STAT3 PE 88011.4 2(20000) 2.44E-07
P40926 MDHM HUMAN (P40926) Malate dehydrogenase, mitochondrial OS=Homo sapiens GN=MDH2 PE=1 SV=3 35480.7 3 (3 0 0 0 0) 1.09E-05
P41219 PERI HUMAN (P41219) Periphedn OS=Homo sapiens GN=PRPH PE=1 SV=2 53618.5 3(20 1 00) 3.18E-07
P41240 CSK HUMAN (P41240)Tyrosine-protein kinase CSK OS=Homo sapiens GN=CSK PE=1 SV=1 50671.8 2(20 0 0) 5.81E-07
P42126 D3D2 HUMAN (P42126) 3,2-trans-enoy-CoA isomerase, mitochondrial OS=Homo sapiens GN=DCI PE=1 SV 32795.2 2 (2 0 0 0 0) 5.46E-08
P42765 THIM HUMAN (P42765) 3-ketoacyl-CoA thiolase, mitochondrial OS=Homo sapiens GN=ACAA2 PE=1 SV=2 41897.7 1 (1 0 0 0 0) 1.40E-08
P42766 RL35 HUMAN (P42766) 60S ribosomal protein L35 OS=Homo sapiens GN=RPL35 PE=1 SV=2 14542.6 2 (2 0 0 0 0) 3.92E-06
P43007 SATT HUMAN (P43007) Neutral amino acid transporter A OS=Homo sapiens GN=SLC1A4 PE=1 SV=1 55687.8 4 (4 0 0 0 0) 3.35E-08
P43034 LIS1 HUMAN (P43034) Platelet-activating factor acetylhydrolase IB subunit alpha OS=Homo sapiens GN=PAI 46608.2 5 (5 0 0 0) 9.47E-10
P43121 MUC18 HUMAN (P43121) Cell surface glycoprotein MUC18 OS=Homo sapiens GN=MCAM PE=I SV=2 71562.7 2 (12 0 0 0 0) 7.97E-09
P43243 MATR3 HUMAN (P43243) Matrin-3 OS=Homo sapiens GN=MATR3 PE=1 SV=2 94564.7 2 (2 0 0 0 0) 4.46E-09
P43304 GPDM HUMAN (P43304) Glycerol-3-phosphate dehydrogenase, mitochondrial OS=Homo sapiens GN=GPD2 80782.6 8 (8 0 0 0 0) 1.26E-09
P43307 SSRA HUMAN (P43307) Translocon-associated protein subunit alpha OS=Homo sapiens GN=SSR1 PE=I S 32215.4 4 (4 0 0 0 0) 4.65E-08
P43362 MAGA9 HUMAN (P43362) Melanoma-associated antigen 9 OS=Homo sapiens GN=MAGEA9 PE=2 SV=1 35066.0 1 1 00 00) 1.61E-06
P43487 RANG HUMAN (P43487) Ran-specific GTPase-activating protein 0S=Homo sapiens GN=RANBP1 PE=1 SV= 23295.6 3 (3 0 0 0 0) 4.36E-07
P43490 NAMPT HUMAN (P43490) Nicotinamide phosphoribosyltransferase OS=Homo sapiens GN=NAMPT PE=1 S, 55486.6 1 (1 0 0 0 0) 5.76E-04
P43686 PRS6B HUMAN (P43686) 26S protease regulatory subunit 6B OS=Homo sapiens GN=PSMC4 PE=1 SV=2 47336.6 3 (30000) 6.18E-11
P45880 VDAC2 HUMAN (P45880) Voltage-dependent anion-selective channel protein 2 O0S=Homo sapiens GN=VDA( 31546.5 6 (60000) 4.15E-08
P46063 RECQ1 HUMAN (P46063) ATP-dependent DNA helicase Q1 OS=Homo sapiens GN=RECQL PE=1 SV=3 73410.0 1 (1 0 00 0) 3.33E-05
P46776 RL27A HUMAN (P46776) 60S ribosomal protein L27a OS=Homo sapiens GN=RPL27A PE=1 SV=2 16551.0 2 (2 0 0 0 0) 9.28E-06
P46781 RS9 HUMAN (P46781) 40S dbosomal protein S9 OS=Homo sapiens GN=RPS9 PE=1 SV=3 22577.6 3 (3 0 0 0 0) 2.48E-05
P46782 RS5 HUMAN (P46782) 40S dbosomal protein S5 OS=Homo sapiens GN=RPS5 PE=1 SV=4 22862.1 7 (7 0 0 0 0) 5.60E-08
P46934 NEDD4 HUMAN (P46934) E3 ubiquitin-protein ligase NEDD4 OS=Homo sapiens GN=NEDD4 PE=1 SV=2 114864.9 1 (1 0 0 0 0) 2.43E-05
P46939 UTRO HUMAN (P46939) Utrophin OS=Homo sapiens GN=UTRN PE=1 SV=2 394219.4 7 (70000) 6.01E-08
P46940 IQGA1 HUMAN (P46940) Ras GTPase-activating-like protein IQGAP1 OS=Homo sapiens GN=IQGAP1 PE=1 189132.9 1 (11 00 0 0) 4.41E-11
P47755 CAZA2 HUMAN (P47755) F-actin-capping protein subunit alpha-2 OS=Homo sapiens GN=CAPZA2 PE=1 SV 32928.6 2 (2 0 0 0 0) 2.82E-11
P47756 CAPZB HUMAN (P47756) F-actin-capping protein subunit beta OS=Homo sapiens GN=CAPZB PE=I SV=4 31330.8 2 (20 0 0 0) 1.32E-05
P47895 AL1A3 HUMAN (P47895) Aldehyde dehydrogenase family 1 member A3 OS=Homo sapiens GN=ALDH1A3 P 56072.9 0 (10 0 0 0 0) 8.64E-11
P47897 SYQ HUMAN (P47897) Glutaminyl-tRNA synthetase OS=Homo sapiens GN=QARS PE=1 SV=1 87743.0 3 (13 0 0 0 0) 8.59E-10
P48047 ATPO HUMAN (P48047)ATP synthase subunit 0, mitochondrial OS=Homo sapiens GN=ATP5O PE=1 SV=1 23262.7 3 (3 0 0 0 0) 1.44E-07
P48059 LIMS1 HUMAN (P48059) LIM and senescent cell antigen-like-containing domain protein 1 OS=Homo sapiens 37225.9 2 (2 0 0 0 0) 3.32E-08
P48643 TCPE HUMAN (P48643) T-complex protein 1 subunit epsilon OS=Homo sapiens GN=CCT5 PE=1 SV=I 59632.9 3 (3 0 0 0 0) 8.21E-09
P48735 IDHP HUMAN (P48735) Isocitrate dehydrogenase [NADPI, mitochondrial OS=Homo sapiens GN=IDH2 PE=1 50876.9 1 (0 1 000) 1.11E-04
P49023 PAXI HUMAN (P49023) Paxillin OS=Homo sapiens GN=PXN PE=1 SV=2 64491.9 1 (1 0 0 0 0) 4.77E-07
P49207 RL34 HUMAN (P49207) 60S ribosomal protein L34 OS=Homo sapiens GN=RPL34 PE=1 SV=3 13284.5 2 (2 0 0 0 0) 6.67E-06
P49257 LMAN1 HUMAN (P49257) Protein ERGIC-53 OS=Homo sapiens GN=LMAN1 PE=1 SV=2 57513.1 1 (1 0000) 5.91E-06
P49411 EFTU HUMAN (P49411) Elongation factor Tu, mitochondrial OS=Homo sapiens GN=TUFM PE=1 SV=2 49510.2 6 (6 00 0 0) 1.24E-08
P49419 AL7A1 HUMAN (P49419)Alpha-aminoadipic semialdehyde dehydrogenase OS=Homo sapiens GN=ALDH7A 55331.5 3 (30000) 1.02E-06
P49588 SYAC HUMAN (P49588) Alanyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=AARS PE=1 SV=2 106743.3 2 (2 0 0 0 0) 2.57E-06
P49720 PSB3 HUMAN (P49720) Proteasome subunit beta type-3 OS=Homo sapiens GN=PSMB3 PE=1 SV=2 22933.5 3 (2 1 0 0 0) 2.14E-09
P49721 PSB2 HUMAN (P49721) Proteasome subunit beta type-2 OS=Homo sapiens GN=PSMB2 PE=1 SV=1 22821.7 10 (90 0 1 0) 4.73E-09
P49770 EI2BB HUMAN (P49770) Translation initiation factor elF-2B subunit beta OS=Homo sapiens GN=EIF2B2 PE= 38964.9 2 (2 0 0 0 0) 9.43E-06
P49773 HINT1 HUMAN (P49773) Histidine triad nucleotide-binding protein 10S=Homo sapiens GN=HINT1 PE=1 SV 13793.1 5(5 0 0 0 0) 6.82E-06
P49790 NU153 HUMAN (P49790) Nuclear pore complex protein Nup153 OS=Homo sapiens GN=NUP153 PE=1 SV=, 153842.5 1 (1 000 0) 4.11E-06
P49792 RBP2 HUMAN (P49792) E3 SUMO-protein ligase RanBP2 OS=Homo sapiens GN=RANBP2 PE=1 SV=2 357972.3 2 (2 0 0 0 0) 2.55E-08
P49795 RGS19 HUMAN (P49795) Regulator of G-protein signaling 19 OS=Homo sapiens GN=RGS19 PE=1 SV=1 24619.6 4(40000) 2.56E-07
P49902 5NTC HUMAN (P49902) Cytosolic purine 5'-nucleotidase OS=Homo sapiens GN=NT5C2 PE=1 SV=1 64928.4 1 (1 0 0 0 0) 5.28E-08
P49915 GUAA HUMAN (P49915) GMP synthase [qlutamine-hydrolyzinl 0OS=Homo sapiens GN=GMPS PE=1 SV=1 76667.1 7 (70000) 6.25E-11
P50213 IDH3A HUMAN (P50213) Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial OS=Homo sapiens Gt 39566.1 1 (1 0000) 5.36E-07
P50402 EMD HUMAN (P50402) Emedn OS=Homo sapiens GN=EMD PE=1 SV=1 28975.9 1 (1 0000) 1.79E-05
P50443 S26A2 HUMAN (P50443) Sulfate transporter OS=Homo sapiens GN=SLC26A2 PE=1 SV=1 81597.0 9 (90 0 0 0) 3.55E-07
P50454 SERPH HUMAN (P50454) Serpin Hi OS=Homo sapiens GN=SERPINH1 PE=I SV=2 46411.3 1 (1 0000) 6.09E-06
P50479 PDLI4 HUMAN (P50479) PDZ and LIM domain protein 4 0S=Homo sapiens GN=PDLIM4 PE=1 SV=2 35375.7 4 (4 0 0 0 0) 5.59E-09
P50502 F10A1 HUMAN (P50502) Hsc70-interacting protein OS=Homo sapiens GN=ST13 PE=1 SV=2 41305.5 1 10 0 0 0) 3.86E-10
P50570 DYN2 HUMAN (P50570) Dynamin-2 O0S=Homo sapiens GN=DNM2 PE=1 SV=2 98003.3 2 (2 0 0 0 0) 8.46E-10
P50750 CDK9 HUMAN (P50750) Cell division protein kinase 9 OS=Homo sapiens GN=CDK9 PE=1 SV=3 42750.2 1 (1 0 0 0 0) 1.65E-06
P50895 LU HUMAN (P50895) Lutheran blood group glycoprotein OS=Homo sapiens GN=BCAM PE=1 SV=2 67362.7 7(7 0 0 00) 2.55E-10
P50991 TCPD HUMAN (P50991) T-complex protein 1 subunit delta OS=Homo sapiens GN=CCT4 PE=1 SV=4 57887.9 4(40000) 9.25E-11
P50991 TCPD HUMAN (P50991) T-complex protein 1 subunit delta OS=Homo sapiens GN=CCT4 PE=1 SV=4 57887.9 2 (20000) 7.53E-10
P51148 RAB5C HUMAN (P51148) Ras-related protein Rab-5C OS=Homo sapiens GN=RABSC PE=1 SV=2 23467.8 7 (7 0 0 0 0) 6.67E-09
P51149 RAB7A HUMAN (P51149) Ras-related protein Rab-7a OS=Homo sapiens GN=RAB7A PE=I SV=1 23474.9 2 (12 0 0 0 0) 5.47E-11
P51159 RB27A HUMAN (P51159) Ras-related protein Rab-27A OS=Homo sapiens GN=RAB27A PE=1 SV=3 24852.3 1 (1 0 0 0 0) 3.91E-08
P51648 AL3A2 HUMAN (P51648) Fatty aldehyde dehydrogenase OS=Homo sapiens GN=ALDH3A2 PE=1 SV=1 54813.0 4 (40 0 0 0) 2.88E-09
P51665 PSD7 HUMAN (P51665) 26S proteasome non-ATPase regulatory subunit 7 OS=Homo sapiens GN=PSMD7 37002.5 1 (1 00 0) 2.41E-06
P51668 UB2D1 HUMAN (P51668) Ubiquitin-conjugating enzyme E2 D1 OS=Homo sapiens GN=UBE2D1 PE=1 SV=1 16591.4 1 (10000) 1.42E-05
P51690 ARSE HUMAN (P51690)Arylsulfatase E OS=Homo sapiens GN=ARSE PE=1 SV=2 65626.2 1 (1 0 0 0 0) 8.08E-07
P51812 KS6A3 HUMAN (P51812) Ribosomal protein S6 kinase alpha-3 OS=Homo sapiens GN=RPS6KA3 PE=1 SV= 83683.1 4 (40000) 3.34E-11
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P51970 NDUA8 HUMAN (P51970) NADH dehydrogenase fubiquinone] 1 alpha subcomplex subunit 8 OS=Homo sapi 20092.1 1 (1 0 0 0 0) 5.01E-05
P52209 6PGD HUMAN (P52209) 6-phosphogluconate dehydrogenase, decarboxylating OS=Homo sapiens GN=PGD 53106.0 1 (1 0 0 0 0) 2.72E-05
P52272 HNRPM HUMAN (P52272) Heterogeneous nuclear ribonucleoprotein M OS=Homo sapiens GN=HNRNPM PI 77464.3 8 (80000) 1.02E-07
P52564 MP2K6 HUMAN (P52564) Dual specificity mitogen-activated protein kinase kinase 6 OS=Homo sapiens GN= 37468.2 1 (1 0 0 0 0) 1.98E-10
P52907 CAZA1 HUMAN (P52907) F-actin-capping protein subunit alpha-10 S=Homo sapiens GN=CAPZA1 PE=1 SV 32902.3 3 (3 0 0 0 0) 2.03E-08
P52943 CRIP2 HUMAN (P52943) Cysteine-rich protein 2 OS=Homo sapiens GN=CRIP2 PE=1 SV=1 22478.0 2 (2 0 0 0 0) 1.14E-11
P53582 AMPM1 HUMAN (P53582) Methionine aminopeptidase 1 OS=Homo sapiens GN=METAP1 PE=1 SV=2 43187.3 1 (1 0000) 3.81E-06
P53597 SUCA HUMAN (P53597) Succinyl-CoAligase [GDP-forming] subunit alpha, mitochondrial OS=Homo sapiens 35025.3 2 (2 0 0 0 0) 1.04E-06
P53621 COPA HUMAN (P53621) Coatomer subunit alpha OS=Homo sapiens GN=COPA PE=1 SV=2 138257.8 4 (4 0 0 0 0) 8.49E-07
P53794 SC5A3 HUMAN (P53794) Sodium/myo-inositol cotransporter OS=Homo sapiens GN=SLC5A3 PE=2 SV=2 79641.4 3 (3 0 0 0 0) 2.28E-10
P53985 MOT1 HUMAN (P53985) Monocarboxylate transporter 1 OS=Homo sapiens GN=SLC16A1 PE=1 SV=2 53922.9 2 (2 0 0 0 0) 1.39E-07
P53992 SC24C HUMAN (P53992) Protein transport protein Sec24C OS=Homo sapiens GN=SEC24C PE=1 SV=2 118239.2 1 (1 0 0 0) 2.36E-06
P54136 SYRC HUMAN (P54136)Arginyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=RARS PE=1 SV=2 75331.0 7 (16 01 0 0) 3.10E-09
P54577 SYYC HUMAN (P54577) Tyrosyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=YARS PE=I1 SV=4 59106.2 1 (1 0 0 0 0) 7.04E-07
P54652 HSP72 HUMAN (P54652) Heat shock-related 70 kDa protein 2 OS=Homo sapiens GN=HSPA2 PE=1 SV=1 69978.0 5 (13 2 0 0 0) 4.63E-13
P54707 AT12A HUMAN (P54707) Potassium-transporting ATPase alpha chain 2 OS=Homo sapiens GN=ATP12A PE= 115437.2 3 (3 0 0 0 0) 1.73E-09
P54709 AT1B3 HUMAN (P54709) Sodium/potassium-transporting ATPase subunit beta-3 OS=Homo sapiens GN=ATF 31492.1 0 (100000) 3.67E-09
P54753 EPHB3 HUMAN (P54753) Ephrin type-B receptor 3 OS=Homo sapiens GN=EPHB3 PE=1 SV=2 110259.3 4(4 0 0 0 0) 8.58E-13
P54760 EPHB4 HUMAN (P54760) Ephrin type-B receptor 4 OS=Homo sapiens GN=EPHB4 PE=1 SV=2 108201.5 1 (1 0 0 0 0) 1.08E-07
P54762 EPHB1 HUMAN (P54762) Ephrin type-B receptor 1 OS=Homo sapiens GN=EPHB1 PE=1 SV=1 109814.6 1 (1 0 00 0) 9.71E-06
P54819 KAD2 HUMAN (P54819) Adenylate kinase isoenzyme 2, mitochondnal OS=Homo sapiens GN=AK2 PE=1 SV 26460.8 4(40000) 5.75E-08
P54886 P5CS HUMAN (P54886) Delta-1-pyrroline-5-carboxylate synthetase OS=Homo sapiens GN=ALDH18A1 PE= 87247.7 3 (3 00 0 0) 4.91E-08
P55011 S12A2 HUMAN (P55011) Solute carrier family 12 member 2 OS=Homo sapiens GN=SLC12A2 PE=1 SV=1 131363.9 2 (12 0 0 0 0) 6.11E-14
P55039 DRG2 HUMAN (P55039) Developmentally-regulated GTP-binding protein 2 OS=Homo sapiens GN=DRG2 PE 40720.4 4 (4 0 0 0 0) 2.58E-07
P55060 XPO2 HUMAN (P55060) Exportin-2 OS=Homo sapiens GN=CSE1L PE=1 SV=3 110346.5 2(20000) 1.11E-12
P55072 TERA HUMAN (P55072) Transitional endoplasmic reticulum ATPase OS=Homo sapiens GN=VCP PE=1 SV= 89265.9 2 (2 0 0 0 0) 5.67E-09
P55290 CAD13 HUMAN (P55290) Cadherin-13 OS=Homo sapiens GN=CDH13 PE=1 SV=1 78238.1 1 1 0 0 00) 6.55E-06
P55789 ALR HUMAN (P55789) FAD-linked sulfhydryl oxidase ALR OS=Homo sapiens GN=GFER PE=1 SV=2 23434.1 1 (1 0 0 0 0) 5.12E-05
P55884 EIF3B HUMAN (P55884) Eukaryotic translation initiation factor 3 subunit B OS=Homo sapiens GN=EIF3B PE 92423.8 0 (10 0 0 0 0) 3.33E-14
P56134 ATPK HUMAN (P56134) ATP synthase subunit f, mitochondrial OS=Homo sapiens GN=ATP5J2 PE=2 SV=3 10910.7 2(20000) 7.93E-08
P56192 SYMC HUMAN (P56192) Methionyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=MARS PE=1 SV= 101052.0 9(9 0 0 0 0) 5.13E-09
P56537 IF6 HUMAN (P56537) Eukaryotic translation initiation factor 6 OS=Homo sapiens GN=EIF6 PE=1 SV=1 26582.2 1 (1 0 0 0 0) 6.88E-05
P57088 TMM33 HUMAN (P57088) Transmembrane protein 33 OS=Homo sapiens GN=TMEM33 PE=1 SV=2 27959.8 3 (3 0 0 0 0) 5.10E-06
P57105 SYJ2B HUMAN (P57105) Synaptoianin-2-binding protein OS=Homo sapiens GN=SYNJ2BP PE=1 SV=2 15918.2 1 (1 0 0 0 0) 6.02E-07
P57721 PCBP3 HUMAN (P57721) Poly(rC)-binding protein 3 OS=Homo sapiens GN=PCBP3 PE=2 SV=1 35915.6 1 (1 0 0 0 0) 8.35E-09
P59665 DEFI HUMAN (P59665) Neutrophil defensin 1 OS=Homo sapiens GN=DEFA1 PE=I SV=1 10194.2 4(40000) 1.44E-05
P59768 GBG2 HUMAN (P59768) Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit amma-2 OS=Homo sa 7845.0 3 (3 0 0 0 0) 7.89E-09
P59998 ARPC4 HUMAN (P59998) Actin-related protein 2/3 complex subunit 4 OS=Homo sapiens GN=ARPC4 PE=1 19654.3 3 (3 0 0 0 0) 1.75E-06
P60174 TPIS HUMAN (P60174) Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=2 26652.7 2 (2 0 0 0) 3.35E-05
P60468 SC61B HUMAN (P60468) Protein transport protein Sec61 subunit beta OS=Homo sapiens GN=SEC61B PE= 9968.1 1 (1 00 00) 4.19E-06
P60660 MYL6 HUMAN (P60660) Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 16919.1 2 (2 0 00 0) 2.73E-06
P60842 IF4A1 HUMAN (P60842) Eukaryotic initiation factor 4A-1 OS=Homo sapiens GN=EIF4A1 PE=1 SV=I 46124.6 0 (10 0 0 0 0) 3.50E-10
P60900 PSA6 HUMAN (P60900) Proteasome subunit alpha type-6 OS=Homo sapiens GN=PSMA6 PE=1 SV=1 27381.8 4 (4 0 0 0 0) 4.05E-10
P60903 S10AA HUMAN (P60903) Protein S100-A10 OS=Homo sapiens GN=S100A10 PE=1 SV=2 11195.5 2 (2 0 0 0) 6.72E-06
P60953 CDC42 HUMAN (P60953) Cell division control protein 42 homolog OS =Homo sapiens GN=CDC42 PE=1 SV= 21296.9 1(10 0 0 0) 9.15E-05
P60981 DEST HUMAN (P60981) Destrin OS=Homo sapiens GN=DSTN PE=1 SV=3 18493.5 2 (20000) 3.11E-08
P61006 RAB8A HUMAN (P61006) Ras-related protein Rab-8A OS=Homo sapiens GN=RAB8A PE=1 SV=1 23653.2 5(50000) 1.05E-09
P61009 SPCS3 HUMAN (P61009) Signal peptidase complex subunit 3 OS=Homo sapiens GN=SPCS3 PE=2 SV=1 20300.5 4 (40 0 0 0) 2.81E-07
P61019 RAB2A HUMAN (P61019) Ras-related protein Rab-2A OS=Homo sapiens GN=RAB2A PE=1 SV=1 23530.8 9 (90000) 2.19E-09
P61020 RAB5B HUMAN (P61020) Ras-related protein Rab-58 OS=Homo sapiens GN=RAB5B PE=1 SV=I 23691.9 6 (6 0 0 0 0) 8.54E-08
P61026 RAB10 HUMAN (P61026) Ras-related protein Rab-10 OS=Homo sapiens GN=RAB10 PE=1 SV=1 22526.6 6(50 01 0) 1.83E-07
P61081 UBC12 HUMAN (P61081) NEDD8-conjugating enzyme Ubc12 OS=Homo sapiens GN=UBE2M PE=1 SV=1 20886.7 7 (7 0 0 0 0) 3.54E-07
P61106 RAB14 HUMAN (P61106) Ras-related protein Rab-14 OS=Homo sapiens GN=RAB14 PE=1 SV=4 23881.9 0 (10 0 0 00) 1.06E-09
P61221 ABCE1 HUMAN (P61221)ATP-binding cassette sub-family E member 1 OS=Homo sapiens GN=ABCE1 PE= 67271.1 4 (40000) 8.34E-10
P61247 RS3A HUMAN (P61247) 40S ribosomal protein S3a OS=Homo sapiens GN=RPS3A PE=1 SV=2 29925.8 2 (2 0 0 0 0) 8.21E-05
P61513 RL37A HUMAN (P61513) 60S ribosomal protein L37a OS=Homo sapiens GN=RPL37A PE=1 SV=2 10268.5 2 (2 0 0 0) 3.27E-06
P61586 RHOA HUMAN (P61586) Transforming protein RhoA OS=Homo sapiens GN=RHOA PE=1 SV=1 21754.1 8(80000) 6.95E-10
P61604 CH10 HUMAN (P61604) 10 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPE1 PE=1 SV= 10924.9 1(1 0 0 0 0) 8.53E-08
P61758 PFD3 HUMAN (P61758) Prefoldin subunit 3 OS=Homo sapiens GN=VBP1 PE=1 SV=3 22643.5 1 (1 0 0 0 0) 2.40E-09
P61803 DAD1 HUMAN (P61803) Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit DAD1 OS= 12488.6 2 (2 00 0 0) 2.31E-06
P61964 WDR5 HUMAN (P61964) WD repeat-containing protein 5 OS=Homo sapiens GN=WDR5 PE=1 SV=1 36565.5 2 (2 0 0 00) 5.71E-08
P61981 1433G HUMAN (P61981) 14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 SV=2 28284.9 4(4 0 0 0 0) 1.45E-09
P62070 RRAS2 HUMAN (P62070) Ras-related protein R-Ras2 OS=Homo sapiens GN=RRAS2 PE=1 SV=1 23384.7 4(4 0 0 0 0) 1.11E-06
P62081 RS7 HUMAN (P62081) 40S ribosomal protein S7 OS=Homo sapiens GN=RPS7 PE=1 SV=1 22113.3 4 (40000) 2.48E-09
P62140 PP1B HUMAN (P62140) Serine/threonine-protein phosphatase PP1-beta catalytic subunit OS=Homo sapiens 37162.6 6 (6 0 0 00) 3.18E-07
P62191 PRS4 HUMAN (P62191) 26S protease regulatory subunit 4 OS=Homo sapiens GN=PSMC1 PE=1 SV=1 49153.8 1 (1 0 0 0 0) 1.09E-06
P62241 RS8 HUMAN (P62241) 40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 24190.2 2 (12 0 0 0 0) 2.91E-09
P62244 RS15A HUMAN (P62244) 40S ribosomal protein S15a OS=Homo sapiens GN=RPS15A PE=1 SV=2 14830.0 5 (5 0 0 0 0) 3.37E-11
P62249 RS16 HUMAN (P62249) 40S ribosomal protein S16 OS=Homo sapiens GN=RPS16 PE=1 SV=2 16435.0 3 (3 00 0 0) 4.23E-07
P62258 1433E HUMAN (P62258) 14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 29155.4 2 (2 0 0 0 0) 1.13E-08
P62263 RS14 HUMAN (P62263) 40S ribosomal protein S14 OS=Homo sapiens GN=RPS14 PE=1 SV=3 16262.5 4(40000) 9.24E-08
P62266 RS23 HUMAN (P62266) 40S ribosomal protein S23 OS=Homo sapiens GN=RPS23 PE=1 SV=3 15797.7 4(40000) 1.75E-07
P62269 RS18 HUMAN (P62269)40S ribosomal protein S18 OS=Homo sapiens GN=RPS18 PE=1 SV=3 17707.9 3(3 0 0 0 0) 1.19E-05
P62277 RS13 HUMAN (P62277) 40S ribosomal protein S13 OS=Homo sapiens GN=RPS13 PE=1 SV=2 17211.7 1 (10000) 5.45E-06
P62280 RS11 HUMAN (P62280) 40S ribosomal protein S11 OS=Homo sapiens GN=RPS11 PE=1 SV=3 18419.0 2(20000) 1.26E-07
P62314 SMD1 HUMAN (P62314) Small nuclear ribonucleoprotein Sm D1 OS=Homo sapiens GN=SNRPD1 PE=1 SV= 13273.4 5 (5 0 00 0) 2.87E-07
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P62316 SMD2 HUMAN (P62316) Small nuclear ribonucleoprotein Sm D2 OS=Homo sapiens GN=SNRPD2 PE=1 SV= 13518.2 3 (30000 5.80E-05
P62318 SMD3 HUMAN (P62318) Small nuclear ribonucleoprotein Sm D3 OS=Homo sapiens GN=SNRPD3 PE=1 SV= 13907.3 2 (2 0 0 0 0) 4.49E-07
P62333 PRS10 HUMAN (P62333) 26S protease regulatory subunit S10OB OS=Homo sapiens GN=PSMC6 PE=1 SV=1 44145.2 7 (7 0 0 0 0 2.64E-09
P62424 RL7A HUMAN (P62424) 60S ribosomal protein L7a OS=Homo sapiens GN=RPL7A PE=I SV=2 29977.0 5(50000) 5.55E-12
P62495 ERF1 HUMAN (P62495) Eukaryotic peptide chain release factor subunit 1 OS=Homo sapiens GN=ETF1 PE= 49000.2 9(90000) 2.61E-12
P62701 RS4X HUMAN (P62701) 40S ribosomal protein S4, X isoform OS=Homo sapiens GN=RPS4X PE=1 SV=2 29579.1 6(6000 0) 2.54E-07
P62736 ACTA HUMAN (P62736) Actin, aortic smooth muscle OS=Homo sapiens GN=ACTA2 PE=1 SV=I 41981.8 4 (4 0 0 0 0) 2.28E-07
P62753 RS6 HUMAN (P62753) 40S ribosomal protein S6 OS=Homo sapiens GN=RPS6 PE=I SV=I 28663.0 10 (9 0 1 0 0) 1.00E-10
P62805 H4 HUMAN (P62805) Histone H4 OS=Homo sapiens GN=HIST1H4A PE=l SV=2 11360.4 5(25 0 0 0 0) 4.88E-09
P62820 RAB1A HUMAN (P62820) Ras-related protein Rab-lA OS=Homo sapiens GN=RAB1A PE=1 SV=3 22663.4 2 (2 0 0 0 0) 7.20E-07
P62829 RL23 HUMAN (P62829) 60S ribosomal protein L23 OS=Homo sapiens GN=RPL23 PE=1 SV=1 14856.1 7 (5 20 00) 2.77E-07
P62834 RAP1A HUMAN (P62834) Ras-related protein Rap-1A OS=Homo sapiens GN=RAPIA PE=i SV=1 20973.7 7 (7 0 0 0 0) 1.32E-08
P62847 RS24 HUMAN (P62847) 40S ribosomal protein S24 OS=Homo sapiens GN=RPS24 PE=1 SV=1 15413.4 3 (30000) 2.10E-07
P62851 RS25 HUMAN (P62851) 40S ribosomal protein S25 OS=Homo sapiens GN=RPS25 PE=1 SV=1 13733.7 4 (4 0 0 0 0) 5.18E-06
P62857 RS28 HUMAN (P62857) 40S ribosomal protein S28 OS=Homo sapiens GN=RPS28 PE=1 SV=1 7836.2 3 (3 0 0 0 0) 2.34E-06
P62861 RS30 HUMAN (P62861) 40S ribosomal protein S30 OS=Homo sapiens GN=FAU PE=1 SV=1 6643.8 3 (3 0 0 0 0) 4.77E-07
P62873 GBB1 HUMAN (P62873) Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 OS=Homo sapien 37353.0 2 (2 0 0 0 0) 2.97E-08
P62873 GBB1 HUMAN (P62873) Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 OS=Homo sapien 37353.0 1 (1 0 0 0 0) 1.29E-05
P62888 RL30 HUMAN (P62888) 60S ribosomal protein L30 OS=Homo sapiens GN=RPL30 PE=I SV=2 12775.7 1 (1 0 0 0 0) 1.19E-06
P62899 RL31 HUMAN (P62899) 60S ribosomal protein L31 OS=Homo sapiens GN=RPL31 PE=1 SV=1 14453.9 1 (1 0 00 0) 7.61E-09
P62906 RL10A HUMAN (P62906) 60S ribosomal protein L10a OS=Homo sapiens GN=RPL10A PE=I SV=2 24815.5 9(81 00 0) 7.21E-07
P62913 RL11 HUMAN (P62913) 60S ribosomal protein Lll OS=Homo sapiens GN=RPL11 PE=1 SV=2 20239.7 6 (6 0 0 0 0) 6.42E-09
P62917 RL8 HUMAN (P62917) 60S ribosomal protein L8 OS=Homo sapiens GN=RPL8 PE=1 SV=2 28007.3 2 (2 0 0 0 0) 2.47E-06
P63096 GNAlI HUMAN (P63096) Guanine nucleotide-binding protein G(i), alpha-1 subunit OS=Homo sapiens GN=Gt 40335.3 7 {7 0 0 0 0) 2.29E-07
P63096 BXDC1 HUMAN (Q9H7B2) Brix domain-containing protein 1 OS=Homo sapiens GN=BXDC1 PE=1 SV=2 40335.3 4 (4 0 0 0 0) 9.07E-07
P63104 1433Z HUMAN (P63104) 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 27727.7 3 (3 0 0 0 0) 3.25E-08
P63167 DYL1 HUMAN (P63167) Dynein light chain 1, cytoplasmic OS=Homo sapiens GN=DYNLL1 PE=1 SV=1 10359.1 2 (2000 ) 2.04E-07
P63173 RL38 HUMAN (P63173) 60S ribosomal protein L38 OS=Homo sapiens GN=RPL38 PE=1 SV=2 8212.7 8(8 0 0 0 0) 2.62E-08
P63208 SKP1 HUMAN (P63208) S-phase kinase-associated protein 1 O0S=Homo sapiens GN=SKP1 PE=1 SV=2 18646.3 4 (4 0 0 0 0) 2.09E-08
P63218 GBG5 HUMAN (P63218) Guanine nucleotide-binding protein G(I)/G(S)/G(O ) subunit amma-5 O0S=Homo sap 7313.8 1 (0 1 000) 2.64E-06
P63220 RS21 HUMAN (P63220) 40S ribosomal protein S21 OS=Homo sapiens GN=RPS21 PE=1 SV=1 9105.6 1 (1 0 0 0 0) 4.74E-07
P63241 IFSA1 HUMAN (P63241) Eukaryotic translation initiation factor 5A-1 OS=Homo sapiens GN=EIF5A PE=1 SV= 16821.4 1 (1 0 0 0 0) 1.53E-07
P63244 GBLP HUMAN (P63244) Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo sapiens GN=GN 35054.6 7 (7 00 0 0) 2.15E-08
P68871 HBB HUMAN (P68871) Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 15988.3 1 (1 0 0 0 0) 1.06E-04
P69905 HBA HUMAN (P69905) Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 15247.9 2 (2 0 0 0 0) 2.12E-08
P78347 GTF21 HUMAN (P78347) General transcription factor I1-1 OS=Homo sapiens GN=GTF21 PE=1 SV=2 112346.2 1(1 0000) 1.53E-07
P78358 CTG1B HUMAN (P78358) Cancer/testis antigen 1 OS=Homo sapiens GN=CTAG1A PE=1 SV=1 17981.0 2 (2 000 0 ) 1.00E-08
P78371 TCPB HUMAN (P78371) T-complex protein 1 subunit beta OS=Homo sapiens GN=CCT2 PE=1 SV=4 57452.3 5(5 0 0 0 0) 1.69E-11
P78386 KRT85 HUMAN (P78386) Keratin, type 11 cuticular Hb5 OS=Homo sapiens GN=KRT85 PE=l SV=1 55766.5 2 (2 0 0 0 0) 3.30E-05
P78527 PRKDC HUMAN (P78527) DNA-dependent protein kinase catalytic subunit OS=Homo sapiens GN=PRKDC P 468786.9 0 (20 0 0 0 0) 3.72E-11
P82650 RT22 HUMAN (P82650) 28S ribosomal protein S22, mitochondrial OS=Homo sapiens GN=MRPS22 PE=1 Sv 41254.4 2 (2 0 00 0) 8.69E-09
P82650 IF2A HUMAN (P05198) Eukaryotic translation initiation factor 2 subunit 1 OS=Homo sapiens GN=EIF2S1 PE= 41254.4 2(2 0 0 0 0) 1.36E-08
P83731 RL24 HUMAN (P83731) 60S ribosomal protein L24 OS=Homo sapiens GN=RPL24 PE=1 SV=1 17767.9 1 (11 0 0 0 0) 3.46E-09
P83916 CBX1 HUMAN (P83916) Chromobox protein homolog 10S=Homo sapiens GN=CBX1 PE=1 SV=1 21404.6 1 (1 0 0 0 0) 1.16E-07
P84077 ARF1 HUMAN (P84077) ADP-dbosylation factor 1 OS=Homo sapiens GN=ARF1 PE=1 SV=2 20683.7 6 (6 0 0 0 0) 8.55E-09
P84098 RL19 HUMAN (P84098) 60S ribosomal protein L19 OS=Homo sapiens GN=RPL19 PE=1 SV=I 23451.3 1 (11 0 0 00 8.99E-14
P84103 SFRS3 HUMAN (P84103) Splicing factor, arginine/serine-nch 3 OS=Homo sapiens GN=SFRS3 PE=1 SV=1 19317.9 1 (1 00 0 0) 3.65E-07
P98160 PGBM HUMAN (P98160) Basement membrane-specific heparan sulfate proteoglycan core protein OS=Homo 468501.1 8 (8 00 0 0) 1.60E-10
Q00325 MPCP HUMAN (Q00325) Phosphate carrier protein, mitochondrial OS=Homo sapiens GN=SLC25A3 PE=l S' 40068.8 2 (2 0 0 0 0) 1.03E-07
Q00610 CLH1 HUMAN (000610) Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 191491.7 8(80000) 1.91E-08
Q00839 HNRPU HUMAN (000839) Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE 90457.0 4(40000) 1.23E-10
Q01082 SPTB2 HUMAN (Q01082) Spectrin beta chain, brain 1 OS=Homo sapiens GN=SPTBN1 PE=l SV=2 274437.2 2(12 0 0 00) 5.32E-11
Q01518 CAP1 HUMAN (Q01518) Adenylyl cyclase-associated protein 1 0S=Homo sapiens GN=CAP1 PE=1 SV=4 51822.8 4 (40000) 5.04E-07
Q01546 K220 HUMAN (Q01546) Keratin, type II cytoskeletal 2 oral OS=Homo sapiens GN=KRT76 PE=2 SV=l 65830.1 1 (000 01 1 .75E-04
Q01650 LAT1 HUMAN (Q01650) Large neutral amino acids transporter small subunit 1 OS=Homo sapiens GN=SLC71 54974.4 4 (40000) 6.14E-13
Q01813 K6PP HUMAN (Q01813) 6-phosphofructokinase type C OS=Homo sapiens GN=PFKP PE=1 SV=2 85541.6 3 (30 00 0) 7.66E-08
Q02127 PYRD HUMAN (Q02127) Dihydroorotate dehydrogenase, mitochonddal OS=Homo sapiens GN=DHODH PE = 42841.0 5(50 0 0 0) 1.22E-13
Q02539 H11 HUMAN (Q02539) Histone H1.1 OS=Homo sapiens GN=HIST1H1A PE=l SV=3 21828.9 2(20000) 1.13E-07
Q02543 RL18A HUMAN (Q02543) 60S dbosomal protein L18a OS=Homo sapiens GN=RPL18A PE=1 SV=2 20748.9 6 (6 0 0 0 0) 5.43E-07
Q02978 M20M HUMAN (Q02978) Mitochondrial 2-oxoglutarate/malate carrier protein OS=Homo sapiens GN=SLC25, 34039.9 3(3 0 0 0 0) 4.92E-11
Q03113 GNA12 HUMAN (Q03113) Guanine nucleotide-binding protein subunit alpha-12 OS=Homo sapiens GN=GNA 44251.5 2 (0 2 000) 2.26E-06
Q03252 LMNB2 HUMAN (Q03252) Lamin-B2 OS=Homo sapiens GN=LMNB2 PE=1 SV=3 67647.6 3 (3 0 0 0 0) 8.98E-07
Q04837 SSB HUMAN (Q04837) Single-stranded DNA-binding protein, mitochonddal OS=Homo sapiens GN=SSBP1 F 17249.0 2 (2 0 0 0 0) 1.34E-07
Q04941 PLP2 HUMAN (Q04941) Proteolipid protein 2 O0S=Homo sapiens GN=PLP2 PE=1 SV=1 16679.7 2(20000) 5.14E-08
Q05193 DYN1 HUMAN (005193) Dynamin-10S=Homo sapiens GN=DNM1 PE=1 SV=2 97347.1 1 (1 0 0 0 0) 9.41E-05
Q05519 SFRl, HUMAN (Q05519) Splicing factor, arginine/serine-rich 11 OS=Homo sapiens GN=SFRS11 PE=1 SV=1 53510.2 2 (2 0 0 0 0) 9.90E-07
Q05639 EF1A2 HUMAN (Q05639) Elongation factor 1-alpha 2 O0S=Homo sapiens GN=EEF1A2 PE=I SV=1 50438.4 6 (16 0 0 0 0) 5.97E-09
Q06210 GFPT1 HUMAN (Q06210) Glucosamine--fructose-6-phosphate aminotransferase [isomerizing] 1 OS=Homo s 78756.4 1 (1 0 0 00) 1.13E-06
Q06830 PRDX1 HUMAN (Q06830) Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=1 22096.3 1 (11 0 0 0 0) 2.46E-07
Q07020 RL18 HUMAN (Q07020) 60S ribosomal protein L18 OS=Homo sapiens GN=RPL18 PE=1 SV=2 21621.1 7 (7 0 0 0 0) 3.70E-09
Q07065 CKAP4 HUMAN (007065) Cytoskeleton-associated protein 4 OS=Homo sapiens GN=CKAP4 PE=1 SV=2 65982.9 0 (20 0 0 0 0) 1.10E-11
Q07666 KHDR1 HUMAN (Q07666) KH domain-containing, RNA-binding, signal transduction-associated protein 1 S= 48197.2 1 (1 0000 5.86E-08
Q07954 LRP1 HUMAN (Q07954) Prolow-density lipoprotein receptor-related protein 1 O0S=Homo sapiens GN=LRP1 P 504243.2 1 (1 0 0 0 0) 2.85E-05
Q07955 SFRS1 HUMAN (Q07955) Splicing factor, arginine/sene-rich 1 O0S=Homo sapiens GN=SFRS1 PE=1 SV=2 27727.8 2 (2 0 0 0 0) 6.35E-06
Q08170 SFRS4 HUMAN (Q08170) Splicing factor, arginine/sedne-rich 4 OS=Homo sapiens GN=SFRS4 PE=1 SV=2 56645.3 1 (1 00 0 0) 5.79E-07
Q08211 DHX9 HUMAN (Q08211)ATP-dependent RNA helicase A OS=Homo sapiens GN=DHX9 PE=1 SV=4 140868.9 4 (4 0 0 0 0) 2.40E-07
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Q08945 SSRP1 HUMAN (Q08945) FACT complex subunit SSRP1 OS=Homo sapiens GN=SSRP1 PE=1 SV=1 81024.3 1(1 0 0 0 0) 1.80E-06
Q08AM6 VAC14 HUMAN (Q08AM6) Protein VAC14 homolog OS=Homo sapiens GN=VAC14 PE=1 SV=1 87916.8 1 (1 0 0 0 0) 6.00E-06
Q08J23 NSUN2 HUMAN (Q08J23) tRNA (cytosine-5-)-methyltransferase NSUN2 OS=Homo sapiens GN=NSUN2 PE- 86415.9 1(1 0 0 0 0) 1.26E-05
Q09028 RBBP4 HUMAN (Q09028) Histone-binding protein RBBP4 OS=Homo sapiens GN=RBBP4 PE=1 SV=3 47626.1 3 (3 0 00 0) 2.59E-10
Q09666 AHNK HUMAN (Q09666) Neuroblast differentiation-associated protein AHNAK OS=Homo sapiens GN=AHNA 628705.2 6 (15 0 1 00) 7.63E-10
QOIIN1 QOIIN1 HUMAN (QOIIN1) Keratin 77 OS=Homo sapiens GN=KRT77 PE=2 SV=1 61764.4 1 (01 000) 1.26E-04
QOVAB1 QOVAB1 HUMAN (QOVAB1) Translocase of inner mitochondrial membrane 50 homolog (S. cerevisiae) OS=H( 50447.2 5(5 0 0 0 0) 3.43E-11
Q10567 AP1B1 HUMAN (Q10567) AP-1 complex subunit beta-1 OS=Homo sapiens GN=AP1B1 PE=1 SV=1 104540.3 2 (2 0 0 0 0) 1.17E-04
Q12788 TBL3 HUMAN (Q12788) WD repeat-containing protein SAZD OS=Homo sapiens GN=TBL3 PE=1 SV=1 56011.4 2 (2 0 0 0 0) 2.53E-07
Q12792 TWF1 HUMAN (Q12792) Twinfilin-1 OS=Homo sapiens GN=TWF1 PE=1 SV=2 42182.6 6(60000) 1.74E-09
Q12800 TFCP2 HUMAN (Q12800)Alpha-globin transcription factor CP2 OS=Homo sapiens GN=TFCP2 PE=1 SV=2 57219.8 1(1 0 0 0 0) 1.25E-07
Q12840 KIF5A HUMAN (Q12840) Kinesin heavy chain isoform 5A OS=Homo sapiens GN=KIF5A PE=1 SV=2 117305.4 5(5 0 0 0 0) 2.59E-08
Q12846 STX4 HUMAN (Q12846) Syntaxin-4 OS=Homo sapiens GN=STX4 PE=1 SV=2 34158.9 2(2 0 0 0) 6.27E-06
Q12905 ILF2 HUMAN (Q12905) Interleukin enhancer-binding factor 2 OS=Homo sapiens GN=ILF2 PE=1 SV=2 43035.2 4 (4 0 0 0 0) 3.03E-11
Q12906 ILF3 HUMAN (Q12906) Interleukin enhancer-binding factor 3 OS=Homo sapiens GN=ILF3 PE=1 SV=3 95279.22 2 (120000) 1.99E-10
Q12907 LMAN2 HUMAN (Q12907) Vesicular integral-membrane protein VIP36 OS=Homo sapiens GN=LMAN2 PE=1 40203.1 2 (2 0 0 0 0) 6.14E-06
Q12929 EPS8 HUMAN (Q12929) Epidermal growth factor receptor kinase substrate 8 OS=Homo sapiens GN=EPS8 F 91824.5 2 (20000) 6.34E-11
Q12931 TRAP1 HUMAN (012931) Heat shock protein 75 kDa, mitochondrial OS=Homo sapiens GN=TRAP1 PE=1 S\ 80059.8 2 (12 0 0 0 0) 4.40E-10
Q12955 ANK3 HUMAN (012955) Ankyrin-3 OS=Homo sapiens GN=ANK3 PE=1 SV=1 480106.0 3 (30000) 2.69E-07
Q12965 MYO1E HUMAN (Q12965) Myosin-le OS=Homo sapiens GN=MYO1E PE=1 SV=2 126982.0 2 (20000) 2.42E-06
Q12979 ABR HUMAN (Q12979) Active breakpoint cluster region-related protein OS=Homo sapiens GN=ABR PE=1 S\ 97635.3 1 (1 00 0 0) 4.31E-07
Q12981 SEC20 HUMAN (Q12981) Vesicle transport protein SEC20 OS=Homo sapiens GN=BNIP1 PE=1 SV=3 26115.9 1 (1 0 0 0 0) 4.40E-05
Q13011 ECH1 HUMAN (Q13011) Delta(3,5)-Delta(24)-dienoyl-CoA isomerase, mitochondrial OS=Homo sapiens GN= 35793.4 1 (1 0 0 0 0) 1.00E-07
Q13077 TRAF1 HUMAN (Q13077) TNF receptor-associated factor 1 OS=Homo sapiens GN=TRAF1 PE=1 SV=1 46134.0 4(40000) 9.03E-07
Q13151 ROAO HUMAN (013151) Heterogeneous nuclear nbonucleoproteinAO OS=Homo sapiens GN=HNRNPA0 PE 30821.8 4 (40000) 3.27E-10
Q13155 MCA2 HUMAN (Q13155) Multisynthetase complex auxiliary component p38 OS=Homo sapiens GN=JTV1 PE 35326.3 5 (50000) 4.15E-08
Q13185 CBX3 HUMAN (Q13185) Chromobox protein homolog 3 O0S=Homo sapiens GN=CBX3 PE=1 SV=4 20798.4 3 (3 0 0 0 0) 2.48E-09
Q13263 TIF1B HUMAN (Q13263) Transcription intermediary factor 1-beta OS=Homo sapiens GN=TRIM28 PE=1 SV= 88493.5 2 (20000) 4.22E-05
Q13283 G3BP1 HUMAN (Q13283) Ras GTPase-activating protein-binding protein 1 0S=Homo sapiens GN=G3BP1 P 52132.1 4 (2 0 2 0 0) 1.34E-12
Q13308 PTK7 HUMAN (Q13308) Tyrosine-protein kinase-like 7 OS=Homo sapiens GN=PTK7 PE=1 SV=2 118316.9 1 (1 00 0) 1.06E-08
Q13347 EIF31 HUMAN (Q13347) Eukaryotic translation initiation factor 3 subunit I OS=Homo sapiens GN=EIF31 PE=1 36478.6 6 (60000) 7.52E-06
Q13363 CTBP1 HUMAN (Q13363) C-terminal-binding protein 1 OS=Homo sapiens GN=CTBP1 PE=1 SV=2 47505.6 2 (2 0 0 0) 5.52E-06
Q13418 ILK HUMAN (Q13418) Integrin-linked protein kinase OS=Homo sapiens GN=ILK PE=1 SV=2 51386.0 4 (40 0 0 0) 3.93E-06
Q13425 SNTB2 HUMAN (Q13425) Beta-2-syntrophin OS=Homo sapiens GN=SNTB2 PE=1 SV=1 57913.1 2 (20000) 1.09E-06
Q13428 TCOF HUMAN (013428) Treacle protein OS=Homo sapiens GN=TCOF1 PE=1 SV=2 152013.1 4 (4 0 0 0 0) 1.05E-05
Q13449 LSAMP HUMAN (Q13449) Limbic system-associated membrane protein OS=Homo sapiens GN=LSAMP PE= 37370.2 2 (20000) 5.83E-07
Q13557 KCC2D HUMAN (Q13557) Calcium/calmodulin-dependent protein kinase type II delta chain OS=Homo sapien 56333.6 2 (2 0 0 0 0) 1.66E-08
Q013601 KRR1 HUMAN (013601) KRR1 small subunit processome component homolog OS=Homo sapiens GN=KRR 43637.7 1 (1 0 0 0 0) 1.04E-06
Q13618 CUL3 HUMAN (Q13618) Cullin-3 0S=Homo sapiens GN=CUL3 PE=1 SV=2 88873.5 2 (2 0 0 0) 7.68E-08
Q13637 RAB32 HUMAN (Q13637) Ras-related protein Rab-32 OS=Homo sapiens GN=RAB32 PE=1 SV=3 24981.7 1 (1 0 0 0 0) 4.08E-06
Q13724 GCS1 HUMAN (Q13724) Mannosyl-oligosaccharide glucosidase OS=Homo sapiens GN=GCS1 PE=1 SV=5 91860.9 4 (4 0 0 0 0) 4.87E-09
Q13740 CD166 HUMAN (Q13740) CD166 antigen OS=Homo sapiens GN=ALCAM PE=1 SV=2 65061.2 1 (1 0 0 0 0) 2.25E-04
Q13838 UAP56 HUMAN (Q13838) Spliceosome RNA helicase BAT1 OS=Homo sapiens GN=BAT1 PE=1 SV=1 48960.01 (11 0 0 00) 6.07E-08
Q13868 EXOS2 HUMAN (Q13868) Exosome complex exonuclease RRP4 OS=Homo sapiens GN=EXOSC2 PE=1 SV 32768.1 1 (1 0 0 0 0) 6.14E-05
Q14008 CKAP5 HUMAN (014008) Cytoskeleton-associated protein 5 OS=Homo sapiens GN=CKAP5 PE=1 SV=3 225350.5 9 (9 0 0 0 0) 4.86E-08
Q14019 COTL1 HUMAN (014019) Coactosin-like protein OS=Homo sapiens GN=COTL1 PE=1 SV=3 15935.0 1 (1 0 0 0 0) 1.35E-04
Q14103 HNRPD HUMAN (014103) Heterogeneous nuclear ribonucleoprotein DO OS=Homo sapiens GN=HNRNPD P 38410.3 2(20000) 1.89E-07
Q14118 DAG1 HUMAN (Q14118) Dystroglycan OS=Homo sapiens GN=DAG1 PE=1 SV=1 97519.9 6 (6 0 0 0 0) 3.16E-08
Q14152 EIF3A HUMAN (Q14152) Eukaryotic translation initiation factor 3 subunit A OS=Homo sapiens GN=EIF3A PE 166467.5 1 (1 0 0 0 0) 7.85E-08
Q14156 EFR3A HUMAN (Q14156) Protein EFR3 homolog A OS=Homo sapiens GN=EFR3A PE=1 SV=2 92865.0 2 (20000) 2.64E-07
014160 LAP4 HUMAN (Q14160) Protein LAP4 OS=Homo sapiens GN=SCRIB PE=1 SV=3 174823.4 1 (1 0 0 0 0) 1.90E-06
Q14165 MLEC HUMAN (Q14165) Malectin OS=Homo sapiens GN=MLEC PE=1 SV=1 32213.6 1(1 0 00 0) 2.20E-05
Q14204 DYHC1 HUMAN (Q14204) Cytoplasmic dynein 1 heavy chain 1 OS=Homo sapiens GN=DYNC1H1 PE=1 SV= 532071.8 4(4 0 0 0 0) 2.21E-09
Q14232 EI2BA HUMAN (014232) Translation initiation factor elF-28B subunit alpha OS=Homo sapiens GN=EIF2B1 PE 33690.8 5(50000) 9.21E-07
Q14247 SRC8 HUMAN (Q14247) Src substrate cortactin OS=Homo sapiens GN=CTTN PE=1 SV=2 61548.6 6(3 3 0 0 0) 1.44E-09
Q14254 FLOT2 HUMAN (Q14254) Flotillin-2 OS=Homo sapiens GN=FLOT2 PE=1 SV=1 41659.3 5(50000) 1.08E-10
Q14254 FLOT2 HUMAN (Q14254) Flotillin-2 OS=Homo sapiens GN=FLOT2 PE=1 SV=1 41659.3 1 (1 0 0 0 0) 4.24E-06
Q14331 FRG1 HUMAN (Q14331) Protein FRGI OS=Homo sapiens GN=FRG1 PE=1 SV=1 29154.1 1 1 0 0 0 0) 3.21E-06
014344 GNA13 HUMAN (Q14344) Guanine nucleotide-binding protein subunit alpha-13 OS=Homo sapiens GN=GNA 44021.7 2 (12 0 0 0 0) 1.59E-09
Q14376 GALE HUMAN (Q14376) UDP-qlucose 4-epimerase OS=Homo sapiens GN=GALE PE=1 SV=2 38257.3 1 (1 0 0 0 0) 4.24E-07
Q14376 ARMC1 HUMAN (Q9NVT9) Armadillo repeat-containing protein 1 0S=Homo sapiens GN=ARMC1 PE=1 SV= 38257.3 1 (1 0 0 0 0) 4.59E-07
Q14444 CAPR1 HUMAN (Q14444) Caprin-1 0S=Homo sapiens GN=CAPRIN1 PE=1 SV=2 78318.2 1(1 0 0 0) 5.92E-07
Q14498 RBM39 HUMAN (Q14498) RNA-binding protein 39 OS=Homo sapiens GN=RBM39 PE=1 SV=2 59342.8 1(0 1 000) 1.22E-08
Q14532 K1H2 HUMAN (Q14532) Keratin, type I cuticular Ha2 OS=Homo sapiens GN=KRT32 PE=1 SV=2 50286.2 1 (1 00 0) 2.73E-06
Q14533 KRT81 HUMAN (Q14533) Keratin, type II cuticular Hbl OS=Homo sapiens GN=KRT81 PE=1 SV=2 54935.8 5 (5 0 0 0 0) 1.31E-05
Q14627 113R2 HUMAN (Q14627) Interleukin-13 receptor alpha-2 chain OS=Homo sapiens GN=IL13RA2 PE=2 SV=1 44147.8 3 (3 00 0 0) 2.82E-07
Q14690 RRP5 HUMAN (Q14690) Protein RRP5 homolog 0 S =Homo sapiens GN=PDCD11 PE=1 SV=3 208569.2 1 (1 0 0 0 0) 2.85E-05
Q14692 BMS1 HUMAN (Q14692) Ribosome biogenesis protein BMS1 homolog OS=Homo sapiens GN=BMS1 PE=1 145715.5 1 (1 0 0 0 0) 1.56E-09
Q14847 LASP1 HUMAN (Q14847) LIM and SH3 domain protein 1 O0S=Homo sapiens GN=LASP1 PE=1 SV=2 29698.2 3 (30 0 0 0) 6.02E-08
Q14964 RB39A HUMAN (Q14964) Ras-related protein Rab-39A OS=Homo sapiens GN=RAB39 PE=2 SV=2 24990.7 1 (00 1 00) 4.27E-06
Q14974 IMB1 HUMAN (Q14974) Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 SV=2 97108.2 7(7 0 0 00) 1.77E-09
Q14CN4 K2C72 HUMAN (Q14CN4) Keratin, type II cytoskeletal 72 OS=Homo sapiens GN=KRT72 PE=1 SV=2 55842.5 1 (0 1 00 0) 2.63E-06
Q15005 SPCS2 HUMAN (Q15005) Signal peptidase complex subunit 2 OS=Homo sapiens GN=SPCS2 PE=2 SV=3 24986.7 5 (5 0 0 0 0) 8.15E-06
Q15020 SART3 HUMAN (Q15020) Squamous cell carcinoma antigen recognized by T-cells 3 OS=Homo sapiens GN= 109865.3 1 (1 0 0 0 0) 4.19E-07
Q15029 U5S1 HUMAN (Q15029) 116 kDa U5 small nuclear ribonucleoprotein component OS=Homo sapiens GN=EF1 109366.4 6 (60000) 1.17E-08
Q15041 AR6P1 HUMAN (015041)ADP-ribosylation factor-like protein 6-interacting protein 10S=Homo sapiens GN=) 23347.4 1 (1 0 0 0 0) 4.26E-05
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Q15056 IF4H HUMAN (Q15056) Eukaryotic translation initiation factor 4H OS=Homo sapiens GN=EIF4H PE=1 SV=5 27368.4 1 (1 0 0 0 0) 1.68E-06
Q15057 ACAP2 HUMAN (Q15057) ARFGAP with coiled-coil, ANK repeat and PH domain-containing protein 2 0S=Ho 87973.2 1 (1 0000) 7.63E-10
Q15075 EEA1 HUMAN (Q15075) Early endosome antigen 1 0S=Homo sapiens GN=EEA1 PE=1 SV=1 162366.4 2(2 0 0 0 0) 2.11E-06
Q15149 PLEC1 HUMAN (015149) Plectin-1 OS=Homo sapiens GN=PLEC1 PE=1 SV=3 531465.9 8 (18 0 0 0 0) 1.28E-10
Q15233 NONO HUMAN (Q15233) Non-POU domain-containing octamer-binding protein OS=Homo sapiens GN=NON 54197.4 2(2 0 0 0 0) 3.90E-06
Q15286 RAB35 HUMAN (Q15286) Ras-related protein Rab-35 OS=Homo sapiens GN=RAB35 PE=1 SV=1 23010.8 8(7 1 000) 2.36E-10
Q15323 K1H1 HUMAN (015323) Keratin, type I cuticular Hal OS=Homo sapiens GN=KRT31 PE=1 SV=3 47207.1 7 (70000) 1.09E-06
Q15363 TMED2 HUMAN (Q15363) Transmerane emp24 domain-containing protein 2 O0S=Homo sapiens GN=TME 22746.4 3(3 0 0 0 0) 1.03E-06
Q15365 PCBP1 HUMAN (Q15365) Poly(rC)-binding protein 1 OS=Homo sapiens GN=PCBP1 PE=l SV=2 37474.0 8(80000) 2.96E-13
Q15369 ELOC HUMAN (015369) Transcription elongation factor B polypeptide 1 0S=Homo sapiens GN=TCEB1 PE= 12465.0 2 (20000) 8.54E-09
Q15370 ELOB HUMAN (015370) Transcription elongation factor B polypeptide 2 OS=Homo sapiens GN=TCEB2 PE= 13124.6 2(20000) 4.12E-08
Q15459 SF3A1 HUMAN (Q15459) Splicing factor 3 subunit 1 OS=Homo sapiens GN=SF3A1 PE=1 SV=1 88830.8 1 (1 000 0) 4.68E-06
Q15738 NSDHL HUMAN (Q15738) Sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating OS=Homo sapiens 41873.6 3 (3 0 0 0 0) 6.69E-10
Q15813 TBCE HUMAN (Q15813) Tubulin-specific chaperone E OS=Homo sapiens GN=TBCE PE=1 SV=1 59309.1 3 (30000) 1.56E-06
Q15836 VAMP3 HUMAN (Q15836) Vesicle-associated membrane protein 3 OS=Homo sapiens GN=VAMP3 PE=1 SV= 11302.0 3 (30000) 1.52E-10
Q15907 RB11B HUMAN (Q15907) Ras-related protein Rab-11B OS=Homo sapiens GN=RAB11B PE=1 SV=4 24473.5 1 (11 0 0 00) 1.83E-10
Q15907 RB11B HUMAN (015907) Ras-related protein Rab-11B OS=Homo sapiens GN=RAB11B PE=1 SV=4 24473.5 4 (4 0 0 0 0) 2.85E-07
Q16181 SEPT7 HUMAN (Q16181) Septin-7 0S=Homo sapiens GN=SEPT7 PE=1 SV=2 50648.0 6 (60000) 1.42E-09
Q16401 PSMD5 HUMAN (016401) 26S proteasome non-ATPase regulatory subunit 5 OS=Homo sapiens GN=PSMD 56160.5 1 (1 0 0 0 0) 2.13E-06
Q16527 CSRP2 HUMAN (Q16527) Cysteine and glycine-rich protein 2 OS=Homo sapiens GN=CSRP2 PE=1 SV=3 20939.9 3(3 0 0 0 0) 3.11E-09
016543 CDC37 HUMAN (Q16543) Hsp90 co-chaperone Cdc37 OS=Homo sapiens GN=CDC37 PE=1 SV=1 44440.1 2 (2 0 0 0 0) 5.62E-05
Q16630 CPSF6 HUMAN (Q16630) Cleavage and polyadenylation specificity factor subunit 6 OS=Homo sapiens GN=C 59173.5 1 (1 0 0 0 0) 3.18E-07
Q16666 IF16 HUMAN (Q16666) Gamma-interferon-inducible protein 1f-16 OS=Homo sapiens GN=IFI16 PE=1 SV=3 88199.5 3 (3 0 0 0 0) 1.46E-04
Q16718 NDUA5 HUMAN (Q16718) NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 OS=Homo sapi 13450.2 2 (20000) 1.04E-05
Q16719 KYNU HUMAN (Q16719) Kynureninase OS=Homo sapiens GN=KYNU PE=1 SV=1 52318.3 2 (2 0 0 0) 2.50E-12
Q16795 NDUA9 HUMAN (Q16795) NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial C 42482.6 3(30000) 1.32E-06
Q16822 PPCKM HUMAN (Q16822) Phosphoenolpyruvate carboxykinase [GTP], mitochondrial OS=Homo sapiens GN 70591.7 1 (1 0000) 1.51E-08
Q16890 TPD53 HUMAN (Q16890) Tumor protein D53 OS=Homo sapiens GN=TPD52L1 PE=1 SV=l 22435.1 2 (2 0 0 0 0) 1.46E-06
Q16891 IMMT HUMAN (016891) Mitochondrial inner membrane protein 0S=Homo sapiens GN=IMMT PE=1 SV=1 83626.5 9 (90000) 2.13E-13
Q1KMD3 HNRL2 HUMAN (Q1KMD3) Heterogeneous nuclear ribonucleoprotein U-like protein 2 0S=Homo sapiens GN 85052.2 3 (30000) 3.13E-07
Q2KHP4 Q2KHP4 HUMAN (Q2KHP4) HSPA5 protein OS=Homo sapiens GN=HSPA5 PE=2 SV=1 72377.6 2 (2 0 0 0 0) 1.89E-07
Q2M389 K1033 HUMAN (Q2M389) UPFO681 protein KIAA1033 OS=Homo sapiens GN=KIAA1033 PE=1 SV=1 136330.2 1 (1 0 0 0 0) 1.26E-07
Q2VIR3 IF2GL HUMAN (Q2VIR3) Eukaryotic translation initiation factor 2 subunit 3-like protein OS=Homo sapiens PE 51196.3 4(40000) 1.86E-08
Q2YOW8 S4A8 HUMAN (Q2YOW8) Electroneutral sodium bicarbonate exchanger 1 OS=Homo sapiens GN=SLC4A8 P 122858.3 1 (0 0 1 0 0) 2.84E-06
Q30154 2B51 HUMAN (Q30154) HLA class II histocompatibility antigen, DRB5 beta chain OS=Homo sapiens GN=HL 30037.0 1 (1 0 0 0 0) 4.82E-04
Q31612 1B73 HUMAN (Q31612) HLA class I histocompatibility antigen, B-73 alpha chain OS=Homo sapiens GN=HLA 40410.0 2 (20000) 1.66E-05
Q32P44 EMAL3 HUMAN (Q32P44) Echinoderm microtubule-associated protein-like 3 OS=Homo sapiens GN=EML3 F 95137.6 2 (2 0 0 0 0) 7.56E-05
Q32014 Q32Q14 HUMAN (Q32Q14) NDUFA7 protein (Fragment) OS=Homo sapiens GN=NDUFA7 PE=2 SV=l 13502.2 1 (1 000 0) 4.51E-08
Q32Q82 Q32Q82 HUMAN (Q32Q82) PCBP2 protein OS=Homo sapiens GN=PCBP2 PE=2 SV=l 35324.2 1 (1 0 0 0 0) 1.66E-07
Q3LXA3 DHAK HUMAN (Q3LXA3) Dihydroxyacetone kinase OS=Homo sapiens GN=DAK PE=2 SV=1 58940.2 3 (30000) 4.15E-09
Q3MHD2 LSM12 HUMAN (Q3MHD2) Protein LSM12 homolog OS=Homo sapiens GN=LSM12 PE=1 SV=2 21687.1 3 (30000) 9.97E-09
Q3SY84 K2C71 HUMAN (Q3SY84) Keratin, type II cytoskeletal 71 OS=Homo sapiens GN=KRT71 PE=1 SV=2 57214.0 2 (0 2 0 0 0) 1.12E-06
Q3SY84 K2C71 HUMAN (Q3SY84) Keratin, type II cytoskeletal 71 OS=Homo sapiens GN=KRT71 PE=1 SV=2 57214.0 1 (0 1 000) 1.77E-06
Q3ZCU9 Q3ZCU9 HUMAN (Q3ZCU9) STIP1 protein OS=Homo sapiens GN=STIP1 PE=2 SV=l 68003.3 2 (2 0 0 0 0) 2.28E-08
Q49A26 NP60 HUMAN (Q49A26) Nuclear protein NP60 OS=Homo sapiens GN=NP60 PE=1 SV=2 60509.1 1 (0 1 00 0) 440E-05
Q49AP7 Q49AP7 HUMAN (Q49AP7) Clorf212 protein OS=Homo sapiens GN=Clorf212 PE=4 SV=1 10732,6 3 (30000) 6.65E-05
Q4LE56 Q4LE56 HUMAN (Q4LE56) MYOIC variant protein (Fragment) OS=Homo sapiens GN=MYO1C variant protei 124977.9 7 (16 1 0 0 0) 9.10E-09
Q4LE64 Q4LE64 HUMAN (Q4LE64) NUMA1 variant protein (Fragment) OS=Homo sapiens GN=NUMA1 variant protei 238712.5 4 (14 0 0 0 0) 1.34E-11
Q4LE83 04LE83_HUMAN (Q4LE83) FASN variant protein (Fragment) OS=Homo sapiens GN=FASN variant protein PE 277192.9 7 (17 0 0 0 0) 4.39E-11
Q504R6 Q504R6 HUMAN (Q504R6) RAB13 protein (Fragment) OS=Homo sapiens GN=RAB13 PE=2 SV=1 27181.9 4 (40000) 7.90E-09
Q53GF9 Q53GF9 HUMAN (Q53GF9) Full-length cDNA 5-PRIME end of clone CSODF013YM24 of Fetal brain of Homo 25620.3 2 (2 00 00) 1.54E-08
Q53GL6 Q53GL6 HUMAN (Q53GL6) RNA binding protein (Autoantigenic, hnRNP-associated with lethal yellow) long is 32530.7 2 (2 0 0 0 0) 3.46E-06
Q53GQ0 DHB12 HUMAN (Q53GQ0) Estradiol 17-beta-dehydrogenase 12 OS=Homo sapiens GN=HSD17B12 PE=1 S' 34302.2 2 (20000) 4.88E-08
Q53GS9 SNUT2 HUMAN (Q53GS9) U4/U6.U5 tri-snRNP-associated protein 2 O0S=Homo sapiens GN=USP39 PE=1 S 65339.8 1 (1 0 0 0 0 9.50E-06
Q53H29 Q53H29 HUMAN (Q53H29) Nucleoporin 54kDa variant (Fragment) OS=Homo sapiens PE=2 SV=1 55529.5 2 (2 0 0 0 0) 4.76E-08
Q546F9 Q546F9 HUMAN (Q546F9) Mitochondrial aspartate-glutamate carrier protein OS=Homo sapiens GN=SLC25 74256.9 6 (6 0 0 0 0) 3.46E-08
Q562R1 ACTBL HUMAN (Q562R1) Beta-actin-like protein 2 OS=Homo sapiens GN=ACTBL2 PE=1 SV=2 41976.0 1 (1 0000 1.87E-05
Q58FF7 H90B3 HUMAN (Q58FF7) Putative heat shock protein HSP 90-beta-3 OS=Homo sapiens GN=HSP90AB3P P 68282.0 1 (1 0 0 0 0) 6.26E-06
Q58FF8 H90B2 HUMAN (Q58FF8) Putative heat shock protein HSP 90-beta 2 OS=Homo sapiens GN=HSP90AB2P P 44321.1 6 (0 6 000) 1.20E-08
Q58FF8 H90B2 HUMAN (Q58FF8) Putative heat shock protein HSP 90-beta 2 OS=Homo sapiens GN=HSP90AB2P P 44321.1 2 0 0 0 0) 4.83E-07
Q58FGO HS905 HUMAN (Q58FGO) Putative heat shock protein HSP 90-alpha A5 OS=Homo sapiens GN=HSP90AA5F 38713.8 4 (4 0 0 0 0) 1.14E-06
Q58FG1 HS904 HUMAN (Q58FG1) Putative heat shock protein HSP 90-alpha A4 OS=Homo sapiens GN=HSP90AA4F 47682.2 2 2 0 0 0) 2.44E-08
Q58FG1 HS904 HUMAN (Q58FG1) Putative heat shock protein HSP 90-alpha A4 OS=Homo sapiens GN=HSP90AA4F 47682.2 3 (0 3 0 0 0) 2.80E-07
Q59E85 Q59E85 HUMAN (Q59E85) Caveolin (Fragment) OS=Homo sapiens PE=2 SV=l 25053.1 2 (2 0 0 0 0) 8.34E-06
Q59E93 Q59E93 HUMAN (Q59E93) Membrane alanine aminopeptidase variant (Fragment) OS=Homo sapiens PE=2 110523.4 2 (12 0 0 0 0) 5.09E-08
Q59EI9 Q59EI9 HUMAN (Q59EI9) ADP,ATP carrier protein, liver isoform T2 variant (Fragment) OS=Homo sapiens PE 35360.6 2(2 0 0 00) 4.17E-08
Q59EL4 EL4HUMAN (Q59EL4) PRPF4 protein variant (Fragment) OS=Homo sapiens PE=2 SV=1 59984.3 3 (30000 3.61E-07
Q59EP1 Q59EP1 HUMAN (Q59EP1) Annexin All variant (Fragment) OS=Homo sapiens PE=2 SV=1 54858.4 1 (10 0 0 0) 5.14E-04
Q59ES3 Q59ES3 HUMAN (Q59ES3) Solute carrier family 1 (Neutral amino acid transporter), member 5 variant (Frag 57353.9 7 (7 0 0 0 0) 4.62E-09
Q59EV6 Q59EV6 HUMAN (Q59EV6) Carrier family 6 , member 8 variant (Fragment) OS=Homo sapiens GN=PPGB PE 56083.9 1 (1 0 0 0 0) 9.80E-06
Q59F66 Q59F66 HUMAN (Q59F66) DEAD box polypeptide 17 isoform p82 variant (Fragment) OS=Homo sapiens PE= 81016.9 1 (1 0 0 00) 8.71E-09
Q59F99 Q59F99 HUMAN (Q59F99) Staufen isoform b variant (Fragment) OS=Homo sapiens PE=2 SV=1 64705.8 2 0 0 0 0) 1.77E-07
Q59FFO Q59FFO HUMAN (Q59FF0) EBNA-2 co-activator variant (Fragment) OS=Homo sapiens PE=2 SV=1 107366.4 1 (1 0 0 0 0) 5.69E-04
Q59G24 Q59G24 HUMAN (Q59G24) Activated RNApolymerase II transcription cofactor 4 variant (Fragment) OS=Horn 15125.8 1 (1 0 0 0 0 2.83E-05
Q59GB4 Q59GB4 HUMAN (Q59GB4) Dihydropyrimidinase-like 2 variant (Fragment) OS=Homo sapiens PE=2 SV=1 68141.6 1 (1 0 0 0 0) 1.40E-05
Q59GD6 Q59GD6 HUMAN (Q59GD6) Transducin beta-like 3 variant (Fragment) OS=Homo sapiens PE=2 SV=l 91180.7 2 (2 0 0 00) 2.32E-06
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Q59GK9 HUMAN (Q59GK9) Ribosomal protein L21 variant (Fragment) OS=Homo sapiens PE=2 SV=1 18879.3 3 (3 0 0 0 0) 1.12E-11
059GM9 HUMAN (Q59GM9) Phosphorylase (Fragment) OS=Homo sapiens PE=2 SV=1 98766.8 9 (19 0 0 0 0) 1.00E-11
Q59GW5 59GW5 HUMAN (Q59GW5) Tripartite motif-containing 25 variant (Fragment) OS=Homo sapiens PE=2 SV= 72203.4 2 (2 0 0 0 0) 6.44E-07
Q59GX6 Q59GX6 HUMAN (Q59GX6) DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3 variant (Fragment) OS=Homo 74532.8 2 (2 0 0 0 0) 4.47E-09
Q59GX9 059GX9 HUMAN (Q59GX9) Ribosomal protein L5 variant (Fragment) OS=Homo sapiens PE=2 SV=1 35181.3 1(1 00 00) 3.81E-08
Q59GY2 Q59GY2 HUMAN (Q59GY2) Ribosomal protein L4 variant (Fragment) OS=Homo sapiens PE=2 SV=1 48965.2 2 (2 0 0 0 0) 4.22E-08
Q59HH3 Q59HH3 HUMAN (Q59HH3) Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synth 112067.5 4 (4 0 00 0) 4.61E-09
Q5HY50 Q5HY50 HUMAN (Q5HY50) Ribosomal protein L10 (Fragment) OS=Homo sapiens GN=RPL10 PE=2 SV=1 26575.9 5 (5 0 0 0 0) 1.69E-07
Q5HYE4 Q5HYE4 HUMAN (Q5HYE4) Putative uncharacterized protein DKFZp686F1612 OS=Homo sapiens GN=DKF 94577.8 2 (2 0 0 0 0) 1.37E-06
Q5HYI7 MTX3 HUMAN (Q5HYI7) Metaxin-3 OS=Homo sapiens GN=MTX3 PE=2 SV=2 35071.3 2 (2 0 0 0 0) 1.75E-11
Q5HYN5 CT451 HUMAN (Q5HYN5) Cancer/testis antigen 45-1 OS=Homo sapiens GN=CT45-1 PE=2 SV=1 21259.0 6 (6 0 0 0 0) 1.01E-07
Q5JNZ5 RS26L HUMAN (Q5JNZ5) Putative 40S ribosomal protein S26-like 1 OS=Homo sapiens GN=RPS26L1 PE=5 12994.0 5(50000) 6.13E-08
Q5JPE7 NOMO2 HUMAN (Q5JPE7) Nodal modulator 2 OS=Homo sapiens GN=NOMO2 PE=1 SV=1 139351.0 1 (1 0 0 0) 4.81E-05
Q5JVF3 PCID2 HUMAN (Q5JVF3) PCI domain-containing protein 2 0S=Homo sapiens GN=PCID2 PE=1 SV=2 45999.9 1 (1 0 0 0 0) 4.69E-10
Q5JWF2 GNAS1 HUMAN (Q5JWF2) Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas OS=Homo 110955.6 6(6000 0) 1.13E-08
Q5M7Z5 Q5M7Z5 HUMAN (Q5M7Z5) GRHPR protein (Fragment) OS=Homo sapiens GN=GRHPR PE=2 SV=1 36801.0 5 (5 0 0 0 0) 1.92E-08
Q5RI15 FA36A HUMAN (Q5RI15) Protein FAM36A OS=Homo sapiens GN=FAM36A PE=2 SV=2 13282.8 2 (2 0 0 00) 8.35E-09
Q5RKV6 EXOS6 HUMAN (Q5RKV6) Exosome complex exonuclease MTR3 OS=Homo sapiens GN=EXOSC6 PE=1 S) 28217.7 1 (1 00 00 2.78E-05
Q5SQP8 Q5SQP8 HUMAN (Q5SQP8) C-terminal binding protein 2 OS=Homo sapiens GN=CTBP2 PE=3 SV=1 56066.6 1 (1 0 0 0 0) 4.89E-06
Q5T1C6 THEM4 HUMAN (Q5T1C6) Thioesterase superfamily member 4 OS=Homo sapiens GN=THEM4 PE=1 SV=1 27111.6 1 (1 0 0 0 0) 3.34E-06
Q5T1D1 Q5T1D1 HUMAN (Q5T1D1) Novel protein similar to ribosomal protein L29 RPL29 (Fragment) OS=Homo sapi 18700.4 2 (2 0 0 0 0) 2.25E-08
Q5T4L4 Q5T4L4 HUMAN (Q5T4L4) Ribosomal protein S27 (Metallopanstimulin 1) OS=Homo sapiens GN=RPS27 PE 7351.7 2 (2 0 0 0 0) 4.62E-07
Q5T7Y6 Q5T7Y6 HUMAN (Q5T7Y6) S100 calcium binding protein Al (S100 calcium binding proteinAl, isoform CRA 15884.7 2(20000) 2.59E-08
Q5T9B7 Q5T9B7 HUMAN (Q5T9B7) Adenylate kinase 1 OS=Homo sapiens GN=AK1 PE=2 SV=1 23396.1 2 (2 0 0 0 0) 9.94E-07
Q5VTR2 BRE1A HUMAN (Q5VTR2) E3 ubiquitin-protein ligase BRE1A OS=Homo sapiens GN=RNF20 PE=1 SV=2 113592.1 1 (1 0 0 0 0) 1.72E-09
Q5WLV Q5WL5 HUMAN (Q5WL5) RNA terminal phosphate cyclase domain 1 (RNA terminal phosphate cyclase don 40683.2 2(20000) 8.95E-07
Q5VW36 K1797 HUMAN (Q5VW36) Uncharacterized protein KIAA1797 OS=Homo sapiens GN=KIAA1797 PE=2 SV=1 199942.4 1 (1 00 0) 2.69E-09
Q5VWZ2 LYPL1 HUMAN (Q5VWZ2) Lysophospholipase-like protein 1 OS=Homo sapiens GN=LYPLAL1 PE=1 SV=3 26299.4 4(40000) 1.49E-05
Q5VYJ4 RUEL1 HUMAN (Q5VYJ4) Putative small nuclear ribonucleoprotein polypeptide E-like protein 1 OS=Homo sa 10671.5 3 (3 0 0 0 0) 1.23E-06
Q5W9G2 Q5W9G2 HUMAN (Q5W9G2) LAR (Fragment) OS=Homo sapiens GN=LAR PE=2 SV=1 213832.9 1 (1 0 00 0) 7.59E-05
Q66LE6 2ABD HUMAN (Q66LE6) Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B delta isoform 52009.6 2 (2 0 0 0 0) 5.16E-09
Q68CP5 Q68CP5 HUMAN (Q68CP5) Putative uncharacterized protein DKFZp781K1922 OS=Homo sapiens GN=DKF2 20230.8 7 (70000) 1.17E-08
Q6DN03 H2B2C HUMAN (Q6DN03) Putative histone H2B type 2-C OS=Homo sapiens GN=HIST2H2BC PE=5 SV=3 21458.2 2 (2 0 0 0 0) 3.10E-06
Q6GMV3 CB079 HUMAN (Q6GMV3) Uncharacterized protein C2orf79 OS=Homo sapiens GN=C2orf79 PE=1 SV=1 15795.3 1 (1 0 0 0 0) 1.02E-06
Q61BSO TWF2 HUMAN (Q61BSO) Twinfilin-2 OS=Homo sapiens GN=TWF2 PE=1 SV=2 39523.3 5 (50 0 0 0) 3.12E-09
Q61PH7 Q61PH7 HUMAN (Q61PH7) RPL14 protein OS=Homo sapiens GN=RPL14 PE=2 SV=1 23772.2 8 (8 0 0 0 0) 2.67E-09
Q61Q22 RAB12 HUMAN (Q61Q22) Putative Ras-related protein Rab-12 OS=Homo sapiens GN=RAB12 PE=5 SV=3 27231.1 2 (2 0 0 00) 3.03E-04
Q6LAP8 Q6LAP8 HUMAN (Q6LAP8) Mitochondrial citrate transport protein (Fragment) OS=Homo sapiens PE=2 SV=1 34765.5 3 (3 0 0 0 0) 7.03E-06
Q6NT97 Q6NT97 HUMAN (Q6NT97) Regulator of chromosome condensation 1 OS=Homo sapiens GN=RCC1 PE=2 r 48115.1 6 (6 0 0) 2.67E-09
Q6NUS1 Q6NUS1 HUMAN (Q6NUS1) PDCD6IP protein OS=Homo sapiens GN=PDCD61P PE=1 SV=1 96757.6 1 (1 0 0 00) 2.81E-08
Q6NVCO Q6NVCO HUMAN (Q6NVCO) SLC25A5 protein (Fragment) OS=Homo sapiens GN=SLC25A5 PE=2 SV=1 35271.4 3 (30000) 1.33E-08
Q6NWI R13AX HUMAN (Q6NW1) Putative 60S ribosomal protein L13a-like MGC87657 OS=Homo sapiens PE=5 S\ 12126.9 2 (2 0 00 0) 5.37E-09
Q6NXE6 ARMC6 HUMAN (Q6NXE6)Armadillo repeat-containing protein 6 OS=Homo sapiens GN=ARMC6 PE=1 SV= 54107.5 1 (1 00 0 0 4.69E-09
Q6NZI2 PTRF HUMAN (Q6NZI2) Polymerase I and transcript release factor OS=Homo sapiens GN=PTRF PE=1 SV= 43449.9 1 (1 0000) 3.01E-08
Q6P1X6 CH082 HUMAN (Q6P1X6) UPF0598 protein C8orf82 OS=Homo sapiens GN=C8orf82 PE=2 SV=2 23874.1 2 (20000) 1.53E-07
Q6P2Q9 PRP8 HUMAN (Q6P2Q9) Pre-mRNA-processing-splicing factor 8 OS=Homo sapiens GN=PRPF8 PE=1 SV=, 273424.6 2 (2 0 0 0 0) 2.32E-09
Q6P4Q7 CNNM4 HUMAN (Q6P4Q7) Metal transporter CNNM4 OS=Homo sapiens GN=CNNM4 PE=1 SV=2 86651.1 1 (1 0 0 0 0) 1.75E-07
Q6PI48 SYDM HUMAN (Q6PI48) Aspartyl-tRNAsynthetase, mitochondrial OS=Homo sapiens GN=DARS2 PE=1 SV= 73516.3 1 (1 0 0 00) 1.34E-05
Q6S8J3 A26CA HUMAN (Q6S8J3)ANKRD26-like family C member 1A OS=Homo sapiens GN=A26C1A PE=I SV=3 121285.6 5(5 0 0 00) 1.41E-10
Q6U841 S4A10 HUMAN (Q6U841) Sodium-driven chloride bicarbonate exchanger OS=Homo sapiens GN=SLC4A10 F 125865.8 2 (2 0 0 00) 9.80E-07
Q6U8A4 Q6U8A4 HUMAN (Q6U8A4) Ubiquitin carboxyl-terminal hydrolase (Fragment) OS=Homo sapiens PE=2 SV=1 128921.8 2(20000) 8.21E-08
Q6UVK1 CSPG4 HUMAN (Q6UVK1) Chondroitin sulfate proteoglycan 4 OS=Homo sapiens GN=CSPG4 PE=1 SV=I 250339.4 9 (19 0 0 0 0) 2.03E-11
Q6UWEO LRSM1 HUMAN (Q6UWEO) E3 ubiquitin-protein ligase LRSAM1 OS=Homo sapiens GN=LRSAM1 PE=1 SV= 83541.1 2 (2 0 0 0 0) 8.58E-07
Q6YHK3 CD109 HUMAN (Q6YHK3) CD109 antigen OS=Homo sapiens GN=CD109 PE=1 SV=2 161586.8 5(50000) 1.39E-12
Q6ZMR3 LDH6A HUMAN (Q6ZMR3) L-lactate dehydrogenase A-like 6A OS=Homo sapiens GN=LDHAL6A PE=2 SV=1 36484.2 2 (2 0 0 0 0) 9.12E-09
Q6ZRM8 Q6ZRM8 HUMAN (Q6ZRM8) cDNA FLJ46245 fis, clone TEST14020596, highly similar to Homo sapiens calpa 77259.8 6 (6 0 00 0) 3.47E-10
Q6ZTT1 Q6ZTT1 HUMAN (Q6ZTT1i cDNA FLJ44241 fis, clone THYMU3008436, highly similar to 6-phosphofructokina 93160.6 1 (1 00 0) 5.28E-06
Q6ZUX7 LHPL2 HUMAN (Q6ZUX7) Lipoma HMGIC fusion partner-like 2 protein OS=Homo sapiens GN=LHFPL2 PE=: 24469.3 2 (2 0 0 0 0) 1.70E-05
Q71U36 TBA1A HUMAN (Q71U36) Tubulin alpha-lA chain OS=Homo sapiens GN=TUBA1A PE=1 SV=1 50103.7 7 (7 0 0 00 1.54E-11
Q71U36 TBA1A HUMAN (Q71U36)Tubulin alpha-lAchain OS=Homo sapiens GN=TUBA1A PE=1 SV=1 50103.711111 0 0 0) 5.12E-11
Q71U19 H2AV HUMAN (Q71UI9) Histone H2A.V OS=Homo sapiens GN=H2AFV PE=1 SV=3 13500.5 4 (4 0 0 0 0) 2.86E-09
Q7KZS6 Q7KZS6 HUMAN (Q7KZS6) Tubulin, beta, 4 OS=Homo sapiens GN=hCG 2042771 PE=2 SV=1 88324.5 4 (2 0 2 0 0) 1.05E-09
Q7LOY3 MRRP1 HUMAN (Q7LOY3) Mitochondrial ribonuclease P protein 1 OS=Homo sapiens GN=RG9MTD1 PE=1 47316.7 2(2 0 0) 1.38E-05
Q7L2E3 DHX30 HUMAN (Q7L2E3) Putative ATP-dependent RNA helicase DHX30 OS=Homo sapiens GN=DHX30 PE 133854.7 1(1 0 0 00 3.40E-05
Q7L2H7 EIF3M HUMAN (Q7L2H7) Eukaryotic translation initiation factor 3 subunit M OS=Homo sapiens GN=EIF3M P 42475.8 0(100000) 1.48E-08
Q7L576 CYFP1 HUMAN (Q7L576) Cytoplasmic FMR1-interacting protein 1 O0S=Homo sapiens GN=CYFIP1 PE=1 SV 145088.6 7 (6 1 0 0 0) 9.06E-09
Q7Z406 MYH14 HUMAN (Q7Z406) Myosin-14 OS=Homo sapiens GN=MYH14 PE=1 SV=1 227861.2 7(52000) 4.74E-07
Q7Z434 MAVS HUMAN (Q7Z434) Mitochondrial antiviral-signaling protein OS=Homo sapiens GN=MAVS PE=1 SV=2 56493.2 1 (1 0 0 0 0) 5.27E-08
Q7Z460 CLAP1 HUMAN (Q7Z460) CLIP-associating protein 1 OS=Homo sapiens GN=CLASP1 PE=1 SV=1 169345.6 2 (20000) 1.48E-12
Q7Z4V5 HDGR2 HUMAN (Q7Z4V5) Hepatoma-derived growth factor-related protein 2 OS=Homo sapiens GN=HDGFF 74272.3 2 (2 0 0 00) 1.39E-08
Q7Z5G4 GOGA7 HUMAN (Q7Z5G4) Golgin subfamily A member 7 OS=Homo sapiens GN=GOLGA7 PE=1 SV=2 15814.0 4(40000) 1.09E-09
Q7Z6Z7 HUWE1 HUMAN (Q7Z6Z7) E3 ubiquitin-protein ligase HUWE1 OS=Homo sapiens GN=HUWE1 PE=1 SV=3 481588.9 1(1 0 0 00) 1.20E-05
Q7Z7H5 TMED4 HUMAN (Q7Z7H5) Transmembrane emp24 domain-containing protein 4 OS=Homo sapiens GN=TME 25926.4 3 (2 10 0 0) 1.69E-05
Q86SE5 RALYL HUMAN (Q86SE5) RNA-binding Raly-like protein OS=Homo sapiens GN=RALYL PE=2 SV=2 32310.6 2 (0 2 0 0 0) 7.84E-07
Q86SE5 RALYL HUMAN (Q86SE5) RNA-binding Raly-like protein OS=Homo sapiens GN=RALYL PE=2 SV=2 32310.6 1 (01 000) 1.18E-06
Q86UK7 ZN598 HUMAN (Q86UK7) Zinc finger protein 598 OS=Homo sapiens GN=ZNF598 PE=1 SV=1 98575.4 1 (1 0 0 0 0) 4.73E-07
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Q86UP2 KTN1 HUMAN (Q86UP2) Kinectin OS=Homo sapiens GN=KTN1 PE=1 SV=1 156178.8 2 (2 0 0 0 0) 4.17E-09
Q86UU1 PHLB1 HUMAN (Q86UU1) Pleckstrin homology-like domain family B member 1 OS=Homo sapiens GN=PHLI 151067.9 1 (1 0 0 0 0) 3.76E-06
Q86V81 THOC4 HUMAN (Q86V81) THO complex subunit 4 OS=Homo sapiens GN=THOC4 PE=1 SV=3 26871.6 1 (1 0 0 0 0) 6.24E-04
Q86VP6 CAND1 HUMAN (Q86VP6) Cullin-associated NEDD8-dissociated protein 1 OS=Homo sapiens GN=CAND1 P 136288.8 4 (14 0 0 0 0) 4.48E-10
Q86VX2 COMD7 HUMAN (Q86VX2) COMM domain-containing protein 7 OS=Homo sapiens GN=COMMD7 PE=1 SV= 22525.6 1 (1 0 0 0 0 5.95E-05
Q86W42 THOC6 HUMAN (Q86W42) THO complex subunit 6 homolog OS=Homo sapiens GN=THOC6 PE=2 SV=1 37511.1 2 (2 0 0 0 0) 6.56E-06
Q86XC7 Q86XC7 HUMAN (Q86XC7) Importin 5 OS=Homo sapiens GN=IPO5 PE=2 SV=1 125506.8 1 (1 0 0 0 0) 7.74E-06
Q86Y38 XYLT1 HUMAN (Q86Y38) Xylosyltransferase 1 OS=Homo sapiens GN=XYLT1 PE=1 SV=1 107501.6 1 (1 0 0 0 0) 1.40E-04
Q86Y39 NDUAB HUMAN (Q86Y39) NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11 OS=Homo sa 14842.5 3 (3 0 0 0 0) 9.37E-07
Q86Y46 K2C73 HUMAN (Q86Y46) Keratin, type II cytoskeletal 73 OS=Homo sapiens GN=KRT73 PE=1 SV=1 58886.8 2 (2 0 0 0 0) 4.88E-07
Q86Y56 HEAT2 HUMAN (Q86Y56) HEAT repeat-containing protein 2 OS=Homo sapiens GN=HEATR2 PE=1 SV=2 93474.2 1 (1 0 0 0 0) 1.54E-05
Q86Y82 STX12 HUMAN (Q86Y82) Syntaxin-12 OS=Homo sapiens GN=STX12 PE=1 SV=1 31622.3 2 (2 0 0 00 3.52E-08
Q86YB8 ERO1B HUMAN (Q86YB8) ERO1-like protein beta OS=Homo sapiens GN=EROtLB PE=1 SV=2 53509.2 1 (1 00 0) 7.65E-05
Q81U81 12BP1 HUMAN (Q81U81) Interferon regulatory factor 2-binding protein 1 OS=Homo sapiens GN=IRF2BP1 PE 61649.1 5 (50000 4.10E-11
Q81VF7 FMNL3 HUMAN (Q81VF7) Formin-like protein 3 OS=Homo sapiens GN=FMNL3 PE=1 SV=3 117138.9 2(2 0 0 0 0) 6.07E-11
Q81WE2 NXP20 HUMAN (Q81WE2) Protein NOXP20 OS=Homo sapiens GN=FAM114A1 PE=1 SV=1 60787.3 2 (2 0 0 0 0) 3.11E-10
Q81WX8 CHERP HUMAN (Q81WX8) Calcium homeostasis endoplasmic reticulum protein OS=Homo sapiens GN=CHE 103508.2 1 (1 0000 1.30E-05
Q81XI1 MIRO2 HUMAN (Q81XI1) Mitochondrial Rho GTPase 2 OS=Homo sapiens GN=RHOT2 PE=1 SV=2 68074.8 2 (20000 1.81E-05
Q81Y81 RRMJ3 HUMAN (Q81Y81) Putative rRNA methyltransferase 3 OS=Homo sapiens GN=FTSJ3 PE=1 SV=1 96516.2 3 (30000) 2.22E-12
Q81ZL9 CCRK HUMAN (Q81ZL9) Cell cycle-related kinase OS=Homo sapiens GN=CCRK PE=1 SV=1 38670.3 1(0 1 000) 1.87E-04
Q81ZQ5 SELH HUMAN (Q81ZQ5) Selenoprotein H OS=Homo sapiens GN=SELH PE=2 SV=2 23295.2 2 (2 0 0 0 0) 1.32E-07
Q8NOW4 NLGNX HUMAN (Q8NOW4) Neuroligin-4, X-linked OS=Homo sapiens GN=NLGN4X PE=1 SV=1 91857.0 1 (1 00 0 0) 2.07E-06
Q8NOX7 SPG20 HUMAN (Q8NOX7) Spartin OS=Homo sapiens GN=SPG20 PE=1 SV=1 72787.8 1 (1 0 0 0 0 1.57E-06
Q8N1C8 Q8N1C8 HUMAN (Q8N1C8) HSPA9 protein (Fragment) OS=Homo sapiens GN=HSPA9 PE=2 SV=1 73808.0 1 (1 0000) 3.53E-11
Q8N1F7 NUP93 HUMAN (Q8N1F7) Nuclear pore complex protein Nup93 OS=Homo sapiens GN=NUP93 PE=1 SV=2 93429.7 2 (20000 1.75E-07
Q8N1G4 LRC47 HUMAN (Q8N1G4) Leucine-rich repeat-containing protein 47 OS=Homo sapiens GN=LRRC47 PE=1 63433.9 9 (90000) 7.77E-15
Q8N2Q7 NLGN1 HUMAN (Q8N2Q7) Neuroligin-1 OS=Homo sapiens GN=NLGN1 PE=1 SV=2 93775.9 1(0 10 0 0) 7.36E-07
Q8N3R9 MPP5 HUMAN (Q8N3R9) MAGUK p55 subfamily member 5 OS=Homo sapiens GN=MPP5 PE=1 SV=3 77245.6 1 (1 0 0 0 0 3.44E-07
Q8N442 GUF1 HUMAN (Q8N442) GTP-binding protein GUF1 homolog OS=Homo sapiens GN=GUF1 PE=1 SV=1 74281.3 1 (1 0 0 0 0) 1.76E-07
Q8N5K1 CISD2 HUMAN (Q8N5K1) CDGSH iron sulfur domain-containing protein 2 OS=Homo sapiens GN=CISD2 PE 15268.5 2 (2 0 0 0 0) 1.21E-08
Q8N5L2 HUMAN (Q8N5L2)AXL receptor tyrosine kinase OS=Homo sapiens GN=AXL PE=2 SV=1 98302.2 1(1 0000 2.48E-05
Q8N6E1 Q8N6E1 HUMAN (Q8N6E1) Ribosomal protein L15 (Fragment) OS=Homo sapiens PE=2 SV=1 25646.0 2 (20000) 1.08E-10
Q8N7V9 Q8N7V9 HUMAN (Q8N7V9) cDNA FLJ40287 fis, clone TEST12027909, highly similar to 5'-AMP-ACTIVATED 38508.4 1 (1 0 0 0 0) 4.09E-06
Q8N999 CL029 HUMAN (Q8N999) Uncharacterized protein C12orf29 OS=Homo sapiens GN=C12orf29 PE=2 SV=2 37466.0 1 (1 00 000 2.42E-06
Q8N9N7 LRC57 HUMAN (Q8N9N7) Leucine-rich repeat-containing protein 57 OS=Homo sapiens GN=LRRC57 PE=2 26737.3 5 (5 0 0 0 0) 9.79E-07
Q8NB49 AT11C HUMAN (Q8NB49) Probable phospholipid-transporting ATPase IG OS=Homo sapiens GN=ATP11C P 129394.2 1(1 0 0 0 0) 4.76E-07
Q8NBU5 ATAD1 HUMAN (Q8NBU5) ATPase family AAA domain-containing protein 1 OS=Homo sapiens GN=ATAD1 P 40718.0 1 (1 0 0 0 0 5.05E-07
Q8NC51 PAIRB HUMAN (Q8NC51) Plasminogen activator inhibitor 1 RNA-binding protein OS=Homo sapiens GN=SEF 44938.5 9 (19 0 0 0 0) 1.30E-09
Q8NCN5 PDPR HUMAN (Q8NCN5) Pyruvate dehydrogenase phosphatase regulatory subunit, mitochondrial OS=Hom 99300.7 1 (1 0 0 0 0 7.92E-06
Q8NFJ5 RAI3 HUMAN (Q8NFJ5) Retinoic acid-induced protein 3 OS=Homo sapiens GN=GPRC5A PE=1 SV=2 40225.0 1 (1 0 0 0 0) 6.36E-07
Q8NFQ8 TOIP2 HUMAN (Q8NFQ8) Torsin-lA-interacting protein 2 OS=Homo sapiens GN=TOR1AIP2 PE=1 SV=1 51232.2 3(30000) 1.93E-10
Q8NFW8 NEUA HUMAN (Q8NFW8) N-acylneuraminate cytidylyltransferase OS=Homo sapiens GN=CMAS PE=1 SV=2 48348.7 3 (3 0 0 0 0 1.69E-08
Q8NG11 TSN14 HUMAN (Q8NG11) Tetraspanin-14 OS=Homo sapiens GN=TSPAN14 PE=2 SV=I 30670.6 3 (30000) 2.97E-06
Q8NHW5 RLAOL HUMAN (Q8NHW5) 60S acidic ribosomal protein PO-like OS=Homo sapiens PE=2 SV=1 34342.7 5 (5 0 0 0 0) 6.05E-08
Q8NHW5 RLAOL HUMAN (Q8NHW5) 60S acidic ribosomal protein PO-like OS=Homo sapiens PE=2 SV=1 34342.7 1 (1 0 0 0 0) 1.59E-05
Q8NI61 Q8N161 HUMAN (Q8NI61) Ribosomal protein S2 OS=Homo sapiens GN=OK/KNS-cl.7 PE=2 SV=1 21707.7 1(1 0000) 9.27E-08
Q8TAA3 PSA7L HUMAN (Q8TAA3) Proteasome subunit alpha type-7-like OS=Homo sapiens GN=PSMA8 PE=1 SV=3 28512.1 2 (2 0 00 0) 1.57E-05
Q8TAT6 NPL4 HUMAN (Q8TAT6) Nuclear protein localization protein 4 homolog OS=Homo sapiens GN=NPLOC4 PE- 68077.0 3 (30000 5.81E-08
Q8TD43 TRPM4 HUMAN (Q8TD43) Transient receptor potential cation channel subfamily M member 4 OS=Homo sap 134215.5 1(0 1 0 0 0) 1.16E-05
Q8TDB8 GTR14 HUMAN (Q8TDB8) Solute carrier family 2, facilitated glucose transporter member 14 OS=Homo sapie 56283.6 2 (20000) 1.78E-06
Q8TDN6 BXDC2 HUMAN (Q8TDN6) Brix domain-containing protein 2 0S=Homo sapiens GN=BXDC2 PE=1 SV=2 41375.0 3 (30000) 3.07E-06
Q8WTT2 NOC3L HUMAN (Q8WTT2) Nucleolar complex protein 3 homolog OS=Homo sapiens GN=NOC3L PE=1 SV= 92489.7 2 (2 0 0 0 0 1.00E-08
Q8WU19 Q8WU19 HUMAN (Q8WU19) TUBA1B protein OS=Homo sapiens GN=TUBA1B PE=2 SV=1 37194.1 2(20000) 5.50E-09
Q8WU19 Q8WU19 HUMAN (Q8WU19) TUBA1B protein OS=Homo sapiens GN=TUBA1B PE=2 SV=1 37194.1 2 (2000 0 5.83E-07
Q8WUD1 RAB2B HUMAN (Q8WUD1) Ras-related protein Rab-2B OS=Homo sapiens GN=RAB2B PE=1 SV=1 24199.2 1 (1 00 000 6.96E-07
Q8WUKO PTPM1 HUMAN (Q8WUKO) Protein-tyrosine phosphatase mitochondrial 1 OS=Homo sapiens GN=PTPMTI F 22829.2 1 (1 0 0 00) 1.01E-04
Q8WVC6 DCAKD HUMAN (Q8WVC6) Dephospho-CoA kinase domain-containing protein OS=Homo sapiens GN=DCAI 26533.3 1 (1 0 0 0 0 1.23E-05
Q8WVM8 SCFD1 HUMAN (Q8WVM8) Secl family domain-containing protein 1 OS=Homo sapiens GN=SCFD1 PE=1 S 72334.1 1 (1 0 0 0 0) 4.79E-08
Q8WVX7 Q8WVX7 HUMAN (Q8WVX7) Ribosomal protein S19 (Fragment) OS=Homo sapiens PE=2 SV=1 17271.2 7 (70000) 2.09E-09
Q8WVY7 UBCP1 HUMAN (Q8WVY7) Ubiguitin-like domain-containing CTD phosphatase 1 OS=Homo sapiens GN=UB 36781.2 1 (1 000 0 2.15E-05
Q8WW12 PCNP HUMAN (Q8WW12) PEST proteolytic signal-containing nuclear protein OS=Homo sapiens GN=PCNP 18913.4 1 (1 0 0 0 0) 6.58E-07
Q8WWC4 CB047 HUMAN (Q8WWC4) Uncharacterized protein C2orf47, mitochondrial OS=Homo sapiens GN=C2orf47 32524.0 4 (4 0 0 0 0 2.50E-06
Q8WW15 CTL1 HUMAN (Q8WW15) Choline transporter-like protein 1 OS=Homo sapiens GN=SLC44A1 PE=1 SV=1 73253.4 2 (2 0 0 0 0) 3.91E-09
Q8WWM7 ATX2L HUMAN (Q8WWM7)Ataxin-2-like protein OS=Homo sapiens GN=ATXN2L PE=1 SV=2 113303.8 2(20000) 1.62E-08
Q8WY22 BRI3B HUMAN (Q8WY22) BRI3-binding protein OS=Homo sapiens GN=BRI3BP PE=1 SV=1 27817.8 2(20000) 1.07E-12
Q92499 DDX1 HUMAN (Q92499) ATP-dependent RNA helicase DDX1 OS=Homo sapiens GN=DDX1 PE=1 SV=2 82379.9 3 (3 0 0 0 0) 1.43E-07
Q92520 FAM3C HUMAN (Q92520) Protein FAM3C OS=Homo sapiens GN=FAM3C PE=1 SV=1 24664.6 8 (7 1 00 0) 1.02E-10
Q92522 H1X HUMAN (Q92522) Histone Hlx OS=Homo sapiens GN=H1FX PE=1 SV=1 22473.6 2 (2 0 0 0 0) 3.97E-09
Q92542 NICA HUMAN (Q92542) Nicastrin OS=Homo sapiens GN=NCSTN PE=1 SV=2 78361.7 3 (3 0 0 0 0) 1.07E-06
Q92616 GCN1L HUMAN (Q92616) Translational activator GCN1 OS=Homo sapiens GN=GCN1L1 PE=1 SV=5 292555.8 2(2 0 0 0 0) 1.72E-09
Q92804 RBP56 HUMAN (Q92804) TATA-binding protein-associated factor 2N OS=Homo sapiens GN=TAF15 PE=1 S\ 61792.9 2(20000) 2.41E-08
Q92888 ARHG1 HUMAN (Q92888) Rho guanine nucleotide exchange factor 1 OS=Homo sapiens GN=ARHGEF1 PE 102371.5 5 (50000 1.96E-07
Q92979 NEP1 HUMAN (Q92979) Probable ribosome biogenesis protein NEP1 OS=Homo sapiens GN=EMG1 PE=1 S 26703.2 1 (1 0 0 0 0) 1.38E-05
Q93034 CUL5 HUMAN (Q93034) Cullin-5 OS=Homo sapiens GN=CUL5 PE=1 SV=4 90897.5 3(3 0 0 0 0) 1.96E-08
Q93096 TP4A1 HUMAN (Q93096) Protein tyrosine phosphatase type IVA 1 OS=Homo sapiens GN=PTP4A1 PE=1 S 19802.2 2 (2 0 0) 2.79E-10
Q969G5 PRDBP HUMAN (Q969G5) Protein kinase C delta-binding protein OS=Homo sapiens GN=PRKCDBP PE=1 S 27609.5 3(3 0 0 0 0) 1.02E-07
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Q969Q5 RAB24 HUMAN (Q969Q5) Ras-related protein Rab-24 OS=Homo sapiens GN=RAB24 PE=2 SV=1 23109.4 1 (1 0 0 0 0) 4.00E-05
Q969S9 EFG2 HUMAN (Q969S9) Elongation factor G 2, mitochondrial OS=Homo sapiens GN=GFM2 PE=2 SV=1 86546.3 1 (1 0 0 0 0) 7.63E-06
Q96A08 H2B1A HUMAN (Q96A08) Histone H2B type 1-A OS=Homo sapiens GN=HIST1H2BA PE=1 SV=3 14158.8 3(3 0 0 0 0) 1.02E-08
Q96A26 F162A HUMAN (Q96A26) UPF0389 protein FAM162A OS=Homo sapiens GN=FAM162A PE=1 SV=2 17331.2 2(2 0 0 0 0) 7.31E-07
Q96AG4 LRC59 HUMAN (Q96AG4) Leucine-rich repeat-containing protein 59 OS=Homo sapiens GN=LRRC59 PE=1 34908.9 2 (2 0 0 0 0) 1.32E-07
Q96AH8 RAB7B HUMAN (Q96AH8) Ras-related protein Rab-7b OS=Homo sapiens GN=RAB7B PE=2 SV=1 22496.6 1 1 0 0 0) 2.05E-05
Q96B97 SH3K1 HUMAN (Q96B97) SH3 domain-containing kinase-binding protein 1 OS=Homo sapiens GN=SH3KBP 73081.8 3 (30000) 7.20E-11
Q96C36 P5CR2 HUMAN (Q96C36) Pyrroline-5-carboxylate reductase 2 OS=Homo sapiens GN=PYCR2 PE=1 SV=1 33615.7 1 (1 0 0 0 0) 1.31E-07
Q96D71 REPS1 HUMAN (Q96D71) RalBP1-associated Eps domain-containing protein 1 O0S=Homo sapiens GN=REP 80720.4 2 (2 0 0 0 0) 4.07E-05
Q96DA0 YP003 HUMAN (Q96DA0) Uncharacterized protein UNQ773/PRO1567 OS=Homo sapiens GN=UNQ773/PR( 22724.6 1 (1 0 0 0 0) 1.95E-05
Q96DA6 TIM14 HUMAN (Q96DA6) Mitochondrial import inner membrane translocase subunit TIM14 OS=Homo sapien 12490.7 1 (1 0 0 0 0) 1.01E-04
Q96DB5 RMD1 HUMAN (Q96DB5) Regulator of microtubule dynamics protein 1 OS=Homo sapiens GN=FAM82B PE= 35785.4 1(1 0 0 0 0) 2.74E-07
Q96EK6 GNA1 HUMAN (Q96EK6) Glucosamine 6-phosphate N-acetyltransferase OS=Homo sapiens GN=GNPNAT1 20735.6 2 (2 00 0 0) 5.15E-06
Q96ER9 CCD51 HUMAN (Q96ER9) Coiled-coil domain-containing protein 51 OS=Homo sapiens GN=CCDC51 PE=2 45782.8 2 (2 0 0 0 0) 1.36E-07
Q96EY8 MMAB HUMAN (Q96EY8) Cob(I)yrinic acid a,c-diamide adenosyltransferase, mitochondrial OS=Homo sapien 27371.0 3 (3 0 0 0 0) 4.07E-08
Q96GQ7 DDX27 HUMAN (Q96GQ7) Probable ATP-dependent RNA helicase DDX27 OS=Homo sapiens GN=DDX27 P 89779.2 1 (1 0 0 0 0) 6.32E-06
Q96199 SUCB2 HUMAN (Q96199) Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial OS=Homo sapiens 46481.5 3 (3 0 0 0 0) 1.14E-12
Q961H1 Q961H1 HUMAN (Q961H1) FSCN1 protein (Fragment) OS=Homo sapiens GN=FSCN1 PE=2 SV=1 55101.4 6(60 0 0) 2.32E-07
Q96J84 KIRR1 HUMAN (Q96J84) Kin of IRRE-like protein 1 O0S=Homo sapiens GN=KIRREL PE=1 SV=2 83484.0 5 (5 0 0 00) 9.69E-07
Q96JB6 LOXL4 HUMAN (Q96JB6) Lysyl oxidase homolog 4 OS=Homo sapiens GN=LOXL4 PE=1 SV=1 84429.1 6 (6 0 0 0 0) 4.06E-08
Q96JJ7 TXD10 HUMAN (Q96JJ7) Protein disulfide-isomerase TXNDC10 OS=Homo sapiens GN=TXNDC10 PE=1 SV 51839.0 2 (2 00 0) 8.47E-07
Q96L92 SNX27 HUMAN (096L92) Sorting nexin-27 OS=Homo sapiens GN=SNX27 PE=1 SV=2 61226.6 11 0 00 0) 2.47E-07
Q96P70 IP09 HUMAN (Q96P70) Importin-9 OS=Homo sapiens GN=IPO9 PE=1 SV=3 115888.8 2 (2 0 000 2.74E-08
Q96PK6 RBM14 HUMAN (Q96PK6) RNA-binding protein 14 OS=Homo sapiens GN=RBM14 PE=1 SV=2 69449.0 1 (1 0 0 00) 4.03E-07
Q96PY5 FMNL2 HUMAN (Q96PY5) Formin-like protein 2 OS=Homo sapiens GN=FMNL2 PE=1 SV=2 123322.2 1 (1 0 0 00) 3.40E-09
Q96QK1 VPS35 HUMAN (Q96QK1) Vacuolar protein sorting-associated protein 35 OS=Homo sapiens GN=VPS35 PE: 91649.1 2 (2 0 0 0) 2.99E-07
Q96QV6 H2A1A HUMAN (Q96QV6) Histone H2Atype 1-AOS=Homo sapiens GN=HIST1H2AA PE=1 SV=3 14224.9 2 (20000) 3.60E-05
Q96RP9 EFG1 HUMAN (Q96RP9) Elongation factor G 1, mitochondrial OS=Homo sapiens GN=GFM1 PE=1 SV=2 83418.5 1(1 0 0 0) 6.70E-08
Q96RS2 Q96RS2 HUMAN (Q96RS2) Laminin receptor-like protein LAMRL5 O0S=Homo sapiens GN=LAMR1P15 PE=2 32975.5 3 (30 0 0 0) 4.62E-10
Q96S19 CP013 HUMAN (Q96S19) UPF0585 protein C16orfl3 OS=Homo sapiens GN=C16orfl3 PE=2 SV=2 22563.7 2 (20000) 2.15E-04
Q96S52 PIGS HUMAN (Q96S52) GPI transamidase component PIG-S OS=Homo sapiens GN=PIGS PE=1 SV=3 61617.3 2 (2 0 00 0) 6.36E-08
Q96S59 RANB9 HUMAN (Q96S59) Ran-binding protein 9 OS=Homo sapiens GN=RANBP9 PE=1 SV=1 77798.1 1 (1 0 0 00) 1.11E-07
Q96S97 MYADM HUMAN (Q96S97) Myeloid-associated differentiation marker OS=Homo sapiens GN=MYADM PE=1 35250.3 1 (1 000  0 09.03E-06
Q99456 K1C12 HUMAN (Q99456) Keratin, type I cytoskeletal 12 OS=Homo sapiens GN=KRT12 PE=1 SV=1 53478.5 1(0 1 000) 3.85E-05
Q99536 VAT1 HUMAN (Q99536) Synaptic vesicle membrane protein VAT-1 homolog OS=Homo sapiens GN=VAT1 PE 41893.5 2 (2 000 0) 6.87E-11
Q99569 PKP4 HUMAN (Q99569) Plakophilin-4 OS=Homo sapiens GN=PKP4 PE=1 SV=1 134186.1 1 (1 0 0 00) 1.79E-06
Q99575 POP1 HUMAN (Q99575) Ribonucleases P/MRP protein subunit POP1 OS=Homo sapiens GN=POP1 PE=1 S 114636.0 6 (6 0 00 0) 2.15E-08
Q99584 S0AD HUMAN (Q99584) Protein S100-A13 OS=Homo sapiens GN=S100A13 PE=1 SV=1 11464.1 4 (40000) 3.02E-06
Q99623 PHB2 HUMAN (Q99623) Prohibitin-2 OS=Homo sapiens GN=PHB2 PE=1 SV=2 33275.91111 ( 1 0 0 0) 1.22E-09
Q99643 C560 HUMAN (Q99643) Succinate dehydrogenase cytochrome b560 subunit, mitochondrial OS=Homo sapier 18597.8 2(2 0 0 00) 2.31E-05
Q99653 CHP1 HUMAN (Q99653) Calcium-binding protein p22 OS=Homo sapiens GN=CHP PE=1 SV=3 22442.4 3 (3 0 0 00) 6.27E-08
Q99700 ATX2 HUMAN (Q99700)Ataxin-2 OS=Homo sapiens GN=ATXN2 PE=1 SV=2 140195.9 1 (1 00 000 1.14E-05
Q99714 HCD2 HUMAN (Q99714) 3-hydroxyacyl-CoAdehydrogenase type-2 OS=Homo sapiens GN=HSD17B10 PE= 26906.1 3 (13 0 0 0 0) 2.92E-09
Q99798 ACON HUMAN (Q99798) Aconitate hydratase, mitochondrial OS=Homo sapiens GN=ACO2 PE=1 SV=2 85372.0 2 (2 0 0 0 0) 2.78E-07
Q99816 TS101 HUMAN (Q99816) Tumor susceptibility gene 101 protein OS=Homo sapiens GN=TSG101 PE=1 SV=2 43916.5 8 (8 00 0) 9.07E-09
Q99828 CIB1 HUMAN (Q99828) Calcium and integrin-binding protein 10S=Homo sapiens GN=CIB1 PE=1 SV=4 21689.9 2 (2 0 0 00) 5.16E-06
Q99832 TCPH HUMAN (Q99832) T-complex protein 1 subunit eta OS=Homo sapiens GN=CCT7 PE=1 SV=2 59329.0 2 (2 00 0 0) 1.18E-05
Q99848 EBP2 HUMAN (Q99848) Probable rRNA-processing protein EBP2 OS=Homo sapiens GN=EBNA1BP2 PE=1 34830.4 1 (1 000 0) 4.26E-05
Q99873 ANM1 HUMAN (Q99873) Protein arginine N-methyltransferase 10S=Homo sapiens GN=PRMT1 PE=1 SV=2 41488.5 3 (3 0 0 00) 3.99E-07
Q99986 VRK1 HUMAN (Q99986) Serine/threonine-protein kinase VRK1 OS=Homo sapiens GN=VRK1 PE=1 SV=1 45447.5 1 (1 0 0 0 0) 3.63E-05
Q9BPW8 NIPS1 HUMAN (Q9BPW8) Protein NipSnap homolog 1 O0S=Homo sapiens GN=NIPSNAP1 PE=I1 SV=1 33288.9 2 (2 0 0 00) 8.58E-06
Q9BQ61 CS043 HUMAN (Q9BQ61) Uncharacterized protein C19orf43 OS=Homo sapiens GN=C19orf43 PE=1 SV=1 18408.2 2(2 0 0 00) 1.54E-04
Q9BQC6 RT63 HUMAN (Q9BQC6) Ribosomal protein 63, mitochondrial OS=Homo sapiens GN=MRP63 PE=2 SV=1 12258.5 1 (1 0 0 0) 4.66E-08
Q9BQGO MBB1A HUMAN (Q9BQGO) Myb-binding protein 1A OS=Homo sapiens GN=MYBBP1A PE=1 SV=2 148761.2 7 (7 0 0 00) 3.78E-07
Q9BRG1 VPS25 HUMAN (Q9BRG1) Vacuolar protein-sorting-associated protein 25 OS=Homo sapiens GN=VPS25 PE 20734.5 3 3 0 0 0 0) 1.66E-05
Q9BRX8 CJ058 HUMAN (Q9BRX8) Uncharacterized protein C10orf58 OS=Homo sapiens GN=C10orf58 PE=1 SV=3 25747.4 6(60000) 2.09E-07
Q9BSD7 CA057 HUMAN (Q9BSD7) Nucleoside-triphosphatase Clorf57 OS=Homo sapiens GN=Clorf57 PE=1 SV=1 20700.1 4(4 0 000 6.83E-11
Q9BSJ8 ESYT1 HUMAN (Q9BSJ8) Extended synaptotagmin-10S=Homo sapiens GN=FAM62A PE=1 SV=1 122780.1 7 (17 0 0 00) 4.09E-11
Q9BTE7 DCNL5 HUMAN (Q9BTE7) DCN1-like protein 5 OS=Homo sapiens GN=DCUN1D5 PE=1 SV=1 27490.6 6(60000) 4.66E-11
Q9BTV4 TMM43 HUMAN (Q9BTV4) Transmembrane protein 43 OS=Homo sapiens GN=TMEM43 PE=1 SV=1 44847.3 4 (4 0 0 00) 5.10E-06
Q9BUL8 PDC10 HUMAN (Q9BUL8) Programmed cell death protein 10 OS=Homo sapiens GN=PDCD10 PE=1 SV=1 24685.8 3 (3 0 0 0) 3.36E-06
Q9BUQ8 DDX23 HUMAN (Q9BUQ8) Probable ATP-dependent RNA helicase DDX23 OS=Homo sapiens GN=DDX23 F 95524.0 1(1 0 000 7.41E-08
Q9BV20 EI2BL HUMAN (Q9BV20) Translation initiation factor elF-2B subunit alpha/beta/delta-like protein OS=Homo s, 39125.4 1 (1 0 0 00) 3.68E-07
Q9BVC6 TM109 HUMAN (Q9BVC6) Transmembrane protein 109 OS=Homo sapiens GN=TMEM109 PE=1 SV=1 26193.6 6(6 0 0 00) 1.74E-05
Q9BVK6 TMED9 HUMAN (Q9BVK6) Transmembrane emp24 domain-containing protein 9 OS=Homo sapiens GN=TME 25088.9 3 (2 1 0 0 0) 2.56E-05
Q9BVP2 GNL3 HUMAN (Q9BVP2) Guanine nucleotide-binding protein-like 3 OS=Homo sapiens GN=GNL3 PE=1 SV= 61958.5 3 (3 00 0) 3.45E-09
Q9BW27 NUP85 HUMAN (Q9BW27) Nucleoporin NUP85 OS=Homo sapiens GN=NUP85 PE=1 SV=1 74971.2 11 0 0 00) 6.55E-06
Q9BWH2 FUND2 HUMAN (Q9BWH2) FUN14 domain-containing protein 2 OS=Homo sapiens GN=FUNDC2 PE=1 SV= 20662.7 2 (2 0 0 0 0) 2.10E-07
Q9BX79 STRA6 HUMAN (Q9BX79) Stimulated by retinoic acid gene 6 protein homolog OS=Homo sapiens GN=STRA( 73455.9 3 (30000) 1.51E-07
Q9BY32 ITPA HUMAN (Q9BY32) Inosine triphosphate pyrophosphatase OS=Homo sapiens GN=ITPA PE=1 SV=2 21431.9 3 (3 0 0 0 0) 3.99E-11
Q9BZE4 NOG1 HUMAN (Q9BZE4) Nucleolar GTP-binding protein 1 OS=Homo sapiens GN=GTPBP4 PE=1 SV=3 73917.9 2 (2 0 000) 1.19E-06
Q9BZF9 UACA HUMAN (Q9BZF9) Uveal autoantigen with coiled-coil domains and ankyrin repeats OS=Homo sapiens 162403.8 1 (1 0 0 00) 3.95E-07
Q9BZK3 NACP1 HUMAN (Q9BZK3) Putative nascent polypeptide-associated complex subunit alpha-like protein OS=- 23291.9 1(0 1 000) 5.16E-07
Q9BZL1 UBL5 HUMAN (Q9BZL1) Ubiguitin-like protein 5 OS=Homo sapiens GN=UBL5 PE=1 SV=1 8541.4 2 (2000 0 4,.49E-05,
Q9C004 SPY4 HUMAN (Q9C004) Protein sprouty homolog 4 0S=Homo sapiens GN=SPRY4 PE=1 SV=2 32519.7 4 (4 0 0 00) 4.56E-07
Q9GZL7 WDR12 HUMAN (Q9GZL7) WD repeat-containing protein 12 OS=Homo sapiens GN=WDR12 PE=1 SV=2 47677.7 1 (1 00 000 1.96E-06
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Q9GZM7 TINAL HUMAN (Q9GZM7) Tubulointerstitial nephritis antigen-like OS=Homo sapiens GN=TINAGL1 PE=1 SV 52353.0 1 (1 0 0 0 0) 1.48E-09Q9GZT3 SLIRP HUMAN (Q9GZT3) SRA stem-loop-interacting RNA-binding protein, mitochondrial OS=Homo sapiens 12341.4 5(5 0 0 0 0) 1.48E-10
Q9GZT9 EGLN1 HUMAN (Q9GZT9) Egi nine homolog 1 OS=Homo sapiens GN=EGLN1 PE=1 SV=1 45991.9 2 (20000) 1.26E-07
Q9GZZ1 NAT13 HUMAN (Q9GZZ1) N-acetyltransferase 13 OS=Homo sapiens GN=NAT13 PE=1 SV=1 19386.0 5 (50 0 0 0) 8.40E-08
Q9H009 NACA2 HUMAN (Q9H009) Nascent polypeptide-associated complex subunit alpha-2 OS=Homo sapiens GN= 23208.8 1 (0 1 0 0 0) 1.62E-05
Q9H081 MIS12 HUMAN (Q9H081) Protein MIS12 homolog OS =Homo sapiens GN=MIS12 PE=1 SV=1 24124.3 4 (40000) 1.88E-07Q9HOA0 NAT10 HUMAN (Q9HOAO) N-acetyltransferase 10 OS=Homo sapiens GN=NAT10 PE=1 SV=l 115630.7 2 (2 0 0 00) 3.08E-08
Q9HOF7 ARL6 HUMAN (Q9HOF7)ADP-dbosylation factor-like protein 6 OS=Homo sapiens GN=ARL6 PE=1 SV=1 21084.2 1 (1 0 0 00) 6.23E-07
Q9HOS4 DDX47 HUMAN (Q9HOS4) Probable ATP-dependent RNA helicase DDX47 OS=Homo sapiens GN=DDX47 P 50614.8 2 (0 2 00 0) 2.12E-07
Q9H1C7 CE032 HUMAN (Q9H1C7) UPF0467 protein C5orf32 OS=Homo sapiens GN=C5orf32 PE=2 SV=1 10623.8 1(1 0 0 0) 3.02E-05
Q9H246 CA021 HUMAN (Q9H246) Uncharacterized protein Clorf21 OS=Homo sapiens GN=Clorf21 PE=1 SV=1 13856.7 1 (10 000) 4.13E-10
Q9H3Z4 DNJC5 HUMAN (Q9H3Z4) DnaJ homolog subfamily C member 5 OS=Homo sapiens GN=DNAJC5 PE=1 SV= 22134.3 2 (20000) 2.02E-08
Q9H488 OFUT1 HUMAN (Q9H488) GDP-fucose protein O-fucosyltransferase 1 OS=Homo sapiens GN=POFUT1 PE= 43927.2 5 (5 0 0 0 0) 2.35E-09
Q9H4B7 TBB1 HUMAN (Q9H4B7) Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1 50294.6 4 (4 0 0 0 0) 1.65E-07
Q9H4M9 EHD1 HUMAN (Q9H4M9) EH domain-containing protein 1 OS=Homo sapiens GN=EHD1 PE=1 SV=2 60588.8 3 (3 0 0 0 0) 8.21E-08
Q9H5V8 CDCP1 HUMAN (Q9H5V8) CUB domain-containing protein 1 OS=Homo sapiens GN=CDCP1 PE=1 SV=1 92815.5 2 (2 0 0) 2.51E-10
Q9H5Y7 SLIK6 HUMAN (Q9H5Y7) SLIT and NTRK-like protein 6 OS=Homo sapiens GN=SLITRK6 PE=2 SV=3 95048.9 3 (3 0 0 0 0) 1.97E-06
Q9H7B2 BXDC1 HUMAN (Q9H7B2) Brix domain-containing protein 1 OS=Homo sapiens GN=BXDC1 PE=1 SV=2 35560.2 2 (2 0 0 0 0) 9.07E-07
Q9H845 ACAD9 HUMAN (Q9H845) Acyl-CoA dehydrogenase family member 9, mitochondrial OS=Homo sapiens GN= 68716.8 3(30000) 6.17E-10
Q9H853 TBA4B HUMAN (Q9H853) Putative tubulin-like protein alpha-4B OS=Homo sapiens GN=TUBA4B PE=5 SV=' 27533.7 3 (3 0 0 0 0) 1.27E-07
Q9H8M5 CNNM2 HUMAN (Q9H8M5) Metal transporter CNNM2 OS=Homo sapiens GN=CNNM2 PE=2 SV=2 96561.8 1 (1 0 0 0 0) 9.75E-06
Q9H9B4 SFXN1 HUMAN (Q9H9B4) Sideroflexin-1 OS=Homo sapiens GN=SFXN1 PE=1 SV=4 35596.4 4 (4 00 0 0) 6.82E-09
Q9H9L3 120L2 HUMAN (Q9H9L3) Interferon-stimulated 20 kDa exonuclease-like 2 OS=Homo sapiens GN=ISG20L2 P 39129.6 2(2 0 0 00) 3.41E-10
Q9HAV7 GRPE1 HUMAN (Q9HAV7) GrpE protein homolog 1, mitochondrial OS=Homo sapiens GN=GRPEL1 PE=1 S 24263.9 2 (2 0 0 0 0) 4.82E-06
Q9HB66 Q9HB66 HUMAN (Q9HB66) McKusick-Kaufman syndrome, isoform CRA a OS=Homo sapiens GN=MKKS PI 7258.9 1 (1 0 0 0 0) 4.23E-05
Q9HB71 CYBP HUMAN (Q9HB71) Calcyclin-binding protein OS=Homo sapiens GN=CACYBP PE=1 SV=2 26193.7 2 (2 0000 2.35E-04
Q9HBAO TRPV4 HUMAN (Q9HBAO) Transient receptor potential cation channel subfamily V member 4 OS=Homo sapi 98218.6 2 (2 0 00 0) 1.10E-06
Q9HBB3 Q9HBB3 HUMAN (Q9HBB3) 60S ribosomal protein L6 OS=Homo sapiens PE=2 SV=1 32870.7 5 (5 0 0 0 0) 1.50E-09
Q9HCJ1 ANKH HUMAN (Q9HCJ1) Progressive ankylosis protein homolog OS=Homo sapiens GN=ANKH PE=1 SV=2 54205.5 2 (2 0 0 0 0) 4.35E-06
Q9HD33 RM47 HUMAN (Q9HD33) 39S ribosomal protein L47, mitochondrial OS=Homo sapiens GN=MRPL47 PE=2 S 29432.0 1(1 0 0 00 6.51E-05
Q9HDC9 APMAP HUMAN (Q9HDC9) Adipocyte plasma membrane-associated protein OS=Homo sapiens GN=APMAP 46450.9 2 (2 0 0 0 0) 1.06E-05
Q9NP72 RAB18 HUMAN (Q9NP72) Ras-related protein Rab-18 OS=Homo sapiens GN=RAB18 PE=1 SV=1 22962.6 2 (2 0 0 0 0) 1.01E-06
Q9NP90 RAB9B HUMAN (Q9NP90) Ras-related protein Rab-9B OS=Homo sapiens GN=RAB9B PE=1 SV=1 22705.0 2 (0 2 0 0 0) 1.09E-06
Q9NPAO C0024 HUMAN (Q9NPA0) UPF0480 protein C15orf24 OS=Homo sapiens GN=C15orf24 PE=1 SV=1 26453.5 1 (1 00 0) 4.63E-05
Q9NPD3 EXOS4 HUMAN (Q9NPD3) Exosome complex exonuclease RRP41 OS=Homo sapiens GN=EXOSC4 PE=1 26366.5 3 (3 0 0 0 0) 7.06E-06
Q9NPE3 NOP10 HUMAN (Q9NPE3) H/ACA ribonucleoprotein complex subunit 3 OS=Homo sapiens GN=NOP10 PE=' 7701.0 4(40000) 2.08E-07
Q9NPH3 IL1AP HUMAN (Q9NPH3) Interleukin-1 receptor accessory protein OS=Homo sapiens GN=IL1RAP PE=1 SV: 65376.8 1 (1 0 0 0 0) 4.73E-06
Q9NQ48 LZTL1 HUMAN (Q9NQ48) Leucine zipper transcription factor-like protein 1 OS=Homo sapiens GN=LZTFL1 P 34571.1 1 (1 0 0 0 0) 6.69E-09
Q9NQ88 CL005 HUMAN (Q9NQ88) Uncharacterized protein C12orf5 OS=Homo sapiens GN=Cl2orf5 PE=1 SV=1 30043.1 1 (1 0 0 0 0) 5.60E-06
Q9NQC3 RTN4 HUMAN (Q9NQC3) Reticulon-4 OS=Homo sapiens GN=RTN4 PE=1 SV=2 129851.2 2 (2 0 0 0 0) 3.20E-07
Q9NQG5 RPR1B HUMAN (Q9NQG5) Regulation of nuclear pre-mRNA domain-containing protein 18 OS=Homo sapien 36877.2 7 (70000) 7.34E-12
Q9NR30 DDX21 HUMAN (Q9NR30) Nucleolar RNA helicase 2 OS=Homo sapiens GN=DDX21 PE=1 SV=5 87290.5 7 (7 0 0 0 0) 1.26E-06
Q9NR31 SAR1A HUMAN (Q9NR31) GTP-binding protein SARla OS=Homo sapiens GN=SAR1A PE=1 SV=1 22352.5 1 (1 0 0 00) 2.36E-07
Q9NR45 SIAS HUMAN (Q9NR45) Sialic acid synthase OS=Homo sapiens GN=NANS PE=1 SV=2 40281.5 1 (1 0 0 00) 8.48E-05
Q9NSD9 SYFB HUMAN (Q9NSD9) Phenylalanyl-tRNAsynthetase beta chain OS=Homo sapiens GN=FARSB PE=1 S% 66087.7 1 (1 0 0 00) 7.60E-07
Q9NT62 ATG3 HUMAN (Q9NT62) Autophagy-related protein 3 OS=Homo sapiens GN=ATG3 PE=1 SV=1 35841.5 1 (1 0 0 00) 1.87E-07
Q9NT99 LRC4B HUMAN (Q9NT99) Leucine-rich repeat-containing protein 4B OS=Homo sapiens GN=LRRC4B PE=2 76385.8 2 (2 0 0 0 0) 2.78E-05
Q9NTJ4 MA2C1 HUMAN REVERSED - (Q9NTJ4)Alpha-mannosidase 2C1 OS=Homo sapiens GN=MAN2C1 PE=1 S 115761.7 1(0 1 000) 5.41E-07
Q9NTK5 OLA1 HUMAN (Q9NTK5) Obg-like ATPase 1 OS=Homo sapiens GN=OLA1 PE=1 SV=2 44715.4 1(10000) 4.62E-11
Q9NUJ3 TlL1, HUMAN (Q9NUJ3) T-complex protein 11-like protein 1 OS=Homo sapiens GN=TCP11L1 PE=2 SV=1 56998.8 1 (1 0000) 1.69E-05
Q9NUP9 LIN7C HUMAN (Q9NUP9) Lin-7 homolog C OS=Homo sapiens GN=LIN7C PE=1 SV=1 21820.5 1 (1 0 0 0 0) 7.23E-07
Q9NV31 IMP3 HUMAN (Q9NV31) U3 small nucleolar ribonudeoprotein protein IMP3 OS=Homo sapiens GN=IMP3 PE 21836.6 2 (20000) 3.83E-11
Q9NV96 CC50A HUMAN (Q9NV96) Cell cycle control protein 50A OS=Homo sapiens GN=TMEM30A PE=1 SV=1 40657.7 1 (1 0 0 0 0) 4.23E-05
Q9NVA1 UQCC HUMAN (Q9NVA1) Ubiquinol-cytochrome c reductase complex chaperone CBP3 homolog OS=Homo, 34549.6 1(1 00 0000 6.18E-05
Q9NVA2 SEP11 HUMAN (Q9NVA2),Septin-11 OS=Homo sapiens GN=SEPT11 PE=1 SV=3 49367.2 4 (4 0 0 00) 2.20E-10
Q9NVH1 DJC11 HUMAN (Q9NVH1) DnaJ homolog subfamily C member 11 OS=Homo sapiens GN=DNAJC11 PE=2 S 63238.9 1 (1 000 0) 2.03E-05
Q9NV17 ATD3A HUMAN (Q9NVI7) ATPase familyAAA domain-containing protein 3A OS=Homo sapiens GN=ATAD3A 71324.8 3 (30000) 8.86E-09
Q9NVT9 ARMC1 HUMAN (Q9NVT9) Armadillo repeat-containing protein 1 OS=Homo sapiens GN=ARMC1 PE=1 SV= 31260.8 2 (20000) 4.59E-07
Q9NW08 RPC2 HUMAN (Q9NW08) DNA-directed RNA polymerase III subunit RPC2 OS=Homo sapiens GN=POLR3B 127702.4 2 (20000) 8.59E-09
Q9NW13 RBM28 HUMAN (Q9NW13) RNA-binding protein 28 OS=Homo sapiens GN=RBM28 PE=1 SV=3 85684.8 1(1 00 00) 2.13E-08
Q9NX08 COMD8 HUMAN (Q9NX08) COMM domain-containing protein 8 OS=Homo sapiens GN=COMMD8 PE=1 SV 21077.0 2 (2 0 0 0 0) 2.55E-07
Q9NX24 NHP2 HUMAN (Q9NX24) H/ACA ribonucleoprotein complex subunit 2 OS=Homo sapiens GN=NHP2 PE=1 S 17189.9 3 (3 0 0 0 0) 5.06E-06
Q9NX58 LYAR HUMAN (Q9NX58) Cell growth-regulating nucleolar protein OS=Homo sapiens GN=LYAR PE=1 SV=2 43587.9 2 (2 0 0 0 0) 3.08E-06
Q9NX63 CHCH3 HUMAN (Q9NX63) Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, mitochondrial OS=F 26136.2 7 (70000) 1.09E-12
Q9NXF1 TEX10 HUMAN (Q9NXF1) Testis-expressed sequence 10 protein OS=Homo sapiens GN=TEX10 PE=1 SV=2 105607.8 2 (2 0 0 0 0) 4.41E-08
Q9NXR1 NDE1 HUMAN (Q9NXR1) Nuclear distribution protein nudE homolog 1 OS=Homo sapiens GN=NDE1 PE=1 S 38784.6 2 (2 0 0 0 0) 2.75E-07
Q9NXS2 QPCTL HUMAN (Q9NXS2) Glutaminyl-peptide cyclotransferase-like protein OS=Homo sapiens GN=QPCTL F 42837.2 1 (1 0 0 0 0) 1.07E-05
Q9NXU5 ARL15 HUMAN (Q9NXU5) ADP-ribosylation factor-like protein 15 OS=Homo sapiens GN=ARL15 PE=2 SV=1 22861.5 4 (4 0 0 0 0) 1.17E-08
Q9NXV6 CARF HUMAN (Q9NXV6) CDKN2A-interacting protein OS=Homo sapiens GN=CDKN2AIP PE=1 SV=2 61016.9 2 (20000) 1.92E-06
Q9NY12 GAR1 HUMAN (Q9NY12) H/ACA ribonucleoprotein complex subunit 1 OS=Homo sapiens GN=GAR1 PE=1 S 22334.2 4 (4 0 0 0 0) 4.40E-09
Q9NY35 CLDN1 HUMAN (Q9NY35) Claudin domain-containing protein 1 OS=Homo sapiens GN=CLDND1 PE=2 SV= 28584.1 2 (2 0 0 0 0) 5.05E-09
Q9NYL4 FKB11 HUMAN (Q9NYL4) FK506-binding protein 11 OS=Homo sapiens GN=FKBP11 PE=2 SV=1 22166.3 2 (2 0 0 00) 1.07E-06
Q9NZ45 CISD1 HUMAN (Q9NZ45) CDGSH iron sulfur domain-containing protein 1 OS=Homo sapiens GN=CISD1 PE 12191.2 3(30000) 1.83E-10
Q9NZI8 IF2B1 HUMAN (Q9NZI8) Insulin-like growth factor 2 mRNA-binding protein 1 OS=Homo sapiens GN=IGF2BP 63417.2 2 (2 0 0 0 0) 1.94E-08
Q9NZM1 MYOF HUMAN (Q9NZM1) Myoferlin OS=Homo sapiens GN=FER1L3 PE=1 SV=1 234558.8 7 (27 0 0 0 0) 2.99E-11
Q9NZU0 FLRT3 HUMAN (Q9NZU0) Leucine-rich repeat transmembrane protein FLRT3 OS=Homo sapiens GN=FLRTI 72957.6 2 (2 0 0 0 0) 1.07E-05
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Q9NZW5 MPP6 HUMAN (Q9NZW5) MAGUK p55 subfamily member 6 OS=Homo sapiens GN=MPP6 PE=1 SV=2 61078.9 (1 0 0 0 0) 2.41E-05
Q9P035 PTAD1 HUMAN (Q9P035) Protein tyrosine phosphatase-like protein PTPLAD1 OS=Homo sapiens GN=PTPL 43131.6 2 (2 0 0 0 0) 2.94E-10
Q9POLO VAPA HUMAN (Q9POLO) Vesicle-associated membrane protein-associated protein A OS=Homo sapiens GN=I 27875.2 2 (2 0 0 0 0) 9.81E-08
Q9POM6 H2AW HUMAN (Q9POM6) Core histone macro-H2A.2 OS=Homo sapiens GN=H2AFY2 PE=2 SV=3 40033.4 2 (20000) 1.38E-10
Q9P258 RCC2 HUMAN (Q9P258) Protein RCC2 OS=Homo sapiens GN=RCC2 PE=1 SV=2 56049.3 2 (2 0 0 0 0) 5.36E-07
Q9P273 TEN3 HUMAN (Q9P273) Teneurin-3 OS=Homo sapiens GN=ODZ3 PE=2 SV=3 300757.7 3 (3 0 0 0 0) 2.62E-08
Q9P2B2 FPRP HUMAN (Q9P2B2) Prostaglandin F2 receptor negative regulator OS=Homo sapiens GN=PTGFRN PE= 98494.7 6 (6 0 0 0 0) 1.98E-08
Q9P2J5 SYLC HUMAN (Q9P2J5) Leucyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=LARS PE=1 SV=2 134379.5 8 (80000) 1.24E-09
Q9P2J5 SYLC HUMAN (Q9P2J5) Leucyl-tRNA synthetase, cytoplasmic OS=Homo sapiens GN=LARS PE=1 SV=2 134379.5 1(1 0 0 0 0) 1.56E-07
Q9UBF2 COPG2 HUMAN (Q9UBF2) Coatomer subunit gamma-2 OS=Homo sapiens GN=COPG2 PE=1 SV=1 97559.7 2 (2 0 0 0 0) 8.24E-07
Q9UBGO MRC2 HUMAN (Q9UBGO) C-type mannose receptor 2 OS=Homo sapiens GN=MRC2 PE=1 SV=1 166548.2 1 (1 0 0 0 0) 6.87E-08
Q9UB16 GBG12 HUMAN (Q9UBI6) Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 OS=Homo 8001.2 3(30000) 7.14E-07
Q9UBP9 GULP1 HUMAN (Q9UBP9) PTB domain-containing engulfment adapter protein 1 OS=Homo sapiens GN=GU 34468.5 2 (2 0 0 0 0) 1.33E-05
Q9UBQ0 VPS29 HUMAN (Q9UBQO) Vacuolar protein sorting-associated protein 29 OS=Homo sapiens GN=VPS29 PE 20492.7 2 (2 0 0 0 0) 8.74E-05
Q9UBT2 SAE2 HUMAN (Q9UBT2) SUMO-activating enzyme subunit 2 OS=Homo sapiens GN=UBA2 PE=1 SV=2 71179.3 2 (20000) 8.66E-09
Q9UBU9 NXF1 HUMAN (Q9UBU9) Nuclear RNA export factor 1 OS=Homo sapiens GN=NXF1 PE=1 SV=1 70138.8 3 (3 0 0 0 0) 1.96E-07
Q9UBX3 DIC HUMAN (Q9UBX3) Mitochondrial dicarboxylate carrier OS=Homo sapiens GN=SLC25A10 PE=2 SV=2 31262.3 2 (2 00 0 0) 8.15E-07
Q9UDW1 QCR9 HUMAN (Q9UDW1) Cytochrome b-cl complex subunit 9 OS=Homo sapiens GN=UQCR10 PE=1 SV=, 7303.8 2 (20000) 3.63E-08
Q9UFW8 CGBP1 HUMAN (Q9UFW8) CGG triplet repeat-binding protein 1 OS=Homo sapiens GN=CGGBP1 PE=1 SV= 18808.6 2 (20000) 2.89E-05
Q9UGJO AAKG2 HUMAN (Q9UGJO) 5'-AMP-activated protein kinase subunit gamma-2 OS=Homo sapiens GN=PRKA( 63026.8 2 (2 0 0 0 0) 7.04E-07
Q9UHB9 SRP68 HUMAN (Q9UHB9) Signal recognition particle 68 kDa protein OS=Homo sapiens GN=SRP68 PE=1 S 70685.7 2 (2 0 0 0 0) 4.18E-07
Q9UHD1 CHRD1 HUMAN (Q9UHD1) Cysteine and histidine-rich domain-containing protein 10S=Homo sapiens GN=( 37465.7 4(40000) 1.51E-08
Q9UHD8 SEPT9 HUMAN (Q9UHD8) Septin-9 OS=Homo sapiens GN=SEPT9 PE=1 SV=2 65360.9 2 (2 0 0 0 0) 8.12E-08
Q9UHN6 TMEM2 HUMAN (Q9UHN6) Transmembrane protein 2 OS=Homo sapiens GN=TMEM2 PE=1 SV=1 154275.9 4(24 0 0 0 0) 2.21E-09
Q9U112 VATH HUMAN (Q9UI12) V-type proton ATPase subunit H OS=Homo sapiens GN=ATP6V1H PE=1 SV=1 55847.1 1(1 0000) 8.80E-06
Q9U114 PRAF1 HUMAN (Q9UI14) Prenylated Rab acceptor protein 1 OS=Homo sapiens GN=RABAC1 PE=1 SV=1 20634.8 2 (2 0 0 0 0) 2.83E-07
Q9U130 TR112 HUMAN (Q9U130) TRM112-like protein OS=Homo sapiens GN=AD-001 PE=1 SV=1 14190.3 4 (40000) 5.86E-10
Q9UIQ6 LCAP HUMAN (Q9UIQ6) Leucyl-cystinyl aminopeptidase OS=Homo sapiens GN=LNPEP PE=1 SV=3 117274.2 2 (2 00 00) 3.56E-07
Q9UIUO Q9UIUO HUMAN (Q9UIU0) Dihydropyridine receptor alpha 2 subunit OS=Homo sapiens GN=CACNA2D1 PE 125228.9 3 (3 0 0 0 0) 5.97E-07
Q9UJZ1 STML2 HUMAN (Q9UJZ1) Stomatin-like protein 2 OS=Homo sapiens GN=STOML2 PE=1 SV=1 38510.2 6 (60000) 2.15E-12
Q9UK41 VPS28 HUMAN (Q9UK41) Vacuolar protein sorting-associated protein 28 homolog OS=Homo sapiens GN=VI 25408.7 2 (20000) 5.61E-07
Q9UL25 RAB21 HUMAN (Q9UL25) Ras-related protein Rab-21 OS=Homo sapiens GN=RAB21 PE=1 SV=3 24332.3 9 (7 2 0 0 0) 3.74E-08
Q9UL26 RB22A HUMAN (Q9UL26) Ras-related protein Rab-22A OS=Homo sapiens GN=RAB22A PE=1 SV=2 21841.2 2 (20000) 2.31E-06
Q9ULL4 PLXB3 HUMAN (Q9ULL4) Plexin-B3 OS=Homo sapiens GN=PLXNB3 PE=1 SV=2 206714.5 1(1 00 0 0) 4.95E-07
Q9UMFO ICAM5 HUMAN (Q9UMFO) Intercellular adhesion molecule 5 OS=Homo sapiens GN=ICAM5 PE=1 SV=2 97270.1 2(2 0 0 0 0) 5.65E-08
Q9UMR2 DD19B HUMAN (Q9UMR2)ATP-dependent RNA helicase DDX19B OS=Homo sapiens GN=DDX19B PE=1 S 53892.9 2 (2 0 0 0 0) 2.44E-07
Q9UNKO STX8 HUMAN (Q9UNKO) Syntaxin-8 OS=Homo sapiens GN=STX8 PE=2 SV=2 26890.0 1 (1 0 0 0 0) 4.55E-07
Q9UNQ2 DIMT1 HUMAN (Q9UNQ2) Probable dimethyladenosine transferase OS=Homo sapiens GN=DIMT1L PE=1 S 35214.1 4(4000 0) 1.10E-07
Q9UPN3 MACF1 HUMAN (Q9UPN3) Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 OS=Homo sapiens GN=I 620038.5 5 (5 0 0 0 0) 1.32E-09
Q9UQQ2 SH2B3 HUMAN (Q9UQQ2) SH2B adapter protein 3 OS=Homo sapiens GN=SH2B3 PE=2 SV=2 63185.7 1 (1 0 0 0 0) 3.41E-08
Q9Y221 NIP7 HUMAN (Q9Y221) 60S ribosome subunit biogenesis protein NIP7 homolog OS=Homo sapiens GN=NIP 20449.5 1 (1 0 0 0 0) 1.70E-10
Q9Y224 CN166 HUMAN (Q9Y224) UPF0568 protein C14orf166 OS=Homo sapiens GN=C14orfl66 PE=1 SV=1 28050.7 9(9 0 0 0 0) 2.21E-09
Q9Y230 RUVB2 HUMAN (Q9Y230) RuvB-like 2 OS=Homo sapiens GN=RUVBL2 PE=1 SV=3 51124.6 5 (5 0 0 0 0) 2.64E-10
Q9Y265 RUVB1 HUMAN (Q9Y265) RuvB-like 1 OS=Homo sapiens GN=RUVBL1 PE=1 SV=1 50196.4 7 (7 0 0 0 0) 1.44E-08
Q9Y266 NUDC HUMAN (Q9Y266) Nuclear migration protein nudC OS=Homo sapiens GN=NUDC PE=1 SV=1 38219.1 4 (4 0 0 00) 7.43E-09
Q9Y277 VDAC3 HUMAN (Q9Y277) Voltage-dependent anion-selective channel protein 3 OS=Homo sapiens GN=VDA 30639.3 1 (1 0 0 0 0) 7.91E-07
Q9Y295 DRG1 HUMAN (Q9Y295) Developmentally-regulated GTP-binding protein 1 OS=Homo sapiens GN=DRG1 PI 40516.9 7 (70000) 9.91E-09
Q9Y2A7 NCKP1 HUMAN (Q9Y2A7) Nck-associated protein 1 OS=Homo sapiens GN=NCKAP1 PE=1 SV=1 128706.6 5(50000) 1.99E-07
Q9Y2L1 RRP44 HUMAN (Q9Y2L1) Exosome complex exonuclease RRP44 OS=Homo sapiens GN=DIS3 PE=1 SV=2 108934.0 1 (1 0 0 0 0) 5.03E-08
Q9Y2Q3 GSTK1 HUMAN (Q9Y2Q3) Glutathione S-transferase kappa 1 OS=Homo sapiens GN=GSTK1 PE=1 SV=3 25480.3 4 (4 0 0 0 0) 7.97E-09
Q9Y2R0 CCD56 HUMAN (Q9Y2RO) Coiled-coil domain-containing protein 56 OS=Homo sapiens GN=CCDC56 PE=1 , 11724.1 1 (1 0 0 0 0) 2.63E-05
Q9Y2V2 CHSP1 HUMAN (Q9Y2V2) Calcium-regulated heat stable protein 1 OS=Homo sapiens GN=CARHSP1 PE=1 15882.0 1 (1 0 0 00) 8.31E-11
Q9Y2W1 TR150 HUMAN (Q9Y2W1) Thyroid hormone receptor-associated protein 3 OS=Homo sapiens GN=THRAP3 108600.8 1 (1 0 0 0 0) 1.06E-07
Q9Y2X3 NOL5 HUMAN (Q9Y2X3) Nucleolar protein 5 OS=Homo sapiens GN=NOL5 PE=1 SV=1 59540.6 2 (2 0 0 0 0) 4.40E-07
Q9Y383 LC7L2 HUMAN (Q9Y383) Putative RNA-binding protein Luc7-like 2 OS=Homo sapiens GN=LUC7L2 PE=1 S\ 46485.6 1 (1 0 0 0 0) 2.89E-06
Q9Y3A5 SBDS HUMAN (Q9Y3A5) Ribosome maturation protein SBDS OS=Homo sapiens GN=SBDS PE=1 SV=4 28745.3 7 (7 00 00) 2.03E-12
Q9Y3A6 TMED5 HUMAN (Q9Y3A6) Transmembrane emp24 domain-containing protein 5 OS=Homo sapiens GN=TME 25988.2 4 (4 0 0 0 0) 1.29E-07
Q9Y3B4 PM14 HUMAN (Q9Y3B4) Pre-mRNA branch site protein p14 OS=Homo sapiens GN=SF3Bi4 PE=1 SV=1 14575.6 6(60 0 0 0) 3.10E-08
Q9Y3B7 RM11 HUMAN (Q9Y3B7) 39S ribosomal protein L11, mitochondrial OS=Homo sapiens GN=MRPL11 PE=2 S 20670.5 4(4 0 0 0 0) 1.10E-06
Q9Y3C1 NOP16 HUMAN (Q9Y3C1) Nucleolar protein 16 OS=Homo sapiens GN=NOP16 PE=1 SV=2 21175.1 4(40000) 1.02E-06
Q9Y310 CV028 HUMAN (Q9Y310) UPF0027 protein C22orf28 OS=Homo sapiens GN=C22orf28 PE=1 SV=1 55175.0 6 (60000) 1.62E-06
Q9Y3U8 RL36 HUMAN (Q9Y3U8) 60S ribosomal protein L36 OS=Homo sapiens GN=RPL36 PE=1 SV=3 12245.9 4 (40000) 1.59E-06
Q9Y490 TLN1 HUMAN (Q9Y490) Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 269596.3 0 (40 0 0 0 0) 1.13E-10
Q9Y4F1 FARP1 HUMAN (Q9Y4FI) FERM, RhoGEF and pieckstrin domain-containing protein 1 OS=Homo sapiens GI 118558.8 3(30000) 1.45E-08
Q9Y4L1 HYOU1 HUMAN (Q9Y4L1) Hypoxia up-regulated protein 1 OS=Homo sapiens GN=HYOU1 PE=1 SV=1 111266.2 3 (30000) 4.37E-07
Q9Y512 SAM50 HUMAN (Q9Y512) Sorting and assembly machinery component 50 homolog OS=Homo sapiens GN= 51943.4 1 (1 0 0 0 0) 1.21E-07
Q9Y584 TIM22 HUMAN (Q9Y584) Mitochondrial import inner membrane translocase subunit Tim22 OS=Homo sapienq 20017.9 2 (2 00 0 0) 8.75E-08
Q9Y5B9 SP16H HUMAN (Q9Y5B9) FACT complex subunit SPT16 OS=Homo sapiens GN=SUPT16H PE=1 SV=1 119838.3 4 (4 0 0 0) 4.73E-06
Q9Y5L4 TIM13 HUMAN (Q9Y5L4) Mitochondrial import inner membrane translocase subunit Tim13 OS=Homo sapien! 10493.0 2 (20000) 2.72E-08
Q9Y5M8 SRPRB HUMAN (Q9Y5M8) Signal recognition particle receptor subunit beta OS=Homo sapiens GN=SRPRB 29683.8 4 (4 0 0 0 0) 1.22E-07
Q9Y625 GPC6 HUMAN (Q9Y625) Glypican-6 OS=Homo sapiens GN=GPC6 PE=2 SV=1 62695.0 3 3 0 0 0 0) 6.08E-09
Q9Y639 NPTN HUMAN (Q9Y639) Neuroplastin OS=Homo sapiens GN=NPTN PE=1 SV=1 31271.9 3 (3 0 0 0 0) 4.99E-06
Q9Y696 CLIC4 HUMAN (Q9Y696) Chloride intracellular channel protein 4 OS=Homo sapiens GN=CLIC4 PE=1 SV=4 28753.8 1 (1 0 0 0 0) 1.98E-07
Q9Y6A4 CP080 HUMAN (Q9Y6A4) UPF0468 protein C16orf80O OS=Homo sapiens GN=C16orf80 PE=2 SV=1 22760.0 3 (3 0 00 0) 3.09E-08
Q9Y6E2 BZW2 HUMAN (Q9Y6E2) Basic leucine zipper and W2 domain-containing protein 2 OS=Homo sapiens GN= 48132.0 2 (2 0 0 0 0) 2.02E-10
Q9Y6M1 IF2B2 HUMAN (Q9Y6M1) Insulin-like growth factor 2 mRNA-binding protein 2 OS=Homo sapiens GN=IGF2BI 61804.5 1 (0 1 000) 5.52E-07
Appendix C
Q9Y6M4 KC1G3 HUMAN (Q9Y6M4) Casein kinase I isoform gamma-3 OS=Homo sapiens GN=CSNK1G3 PE=1 SV=2 51356.0 1 (1 0 0 0 )1 6.79E-09
Q9Y6W3 CAN7 HUMAN (Q9Y6W3) Calpain-7 OS=Homo sapiens GN=CAPN7 PE=1 SV=1 92593.9 1 (1 0 0 0 0)1 6.87E-06
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APPENDIX D.
MATERIALS AND METHODS
The content of this chapter were written by Hui Liu.
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MOLECULAR BIOLOGY PROTOCOLS
All molecular biology methods were performed according to standard molecular biology techniques.
All restriction enzymes were obtained from New England Biolabs.
Cloning of wild type CDCP1 and point mutants into retrovirus vector
1) Cloning of CDCP1 from cDNA derived from MA2 cells using primers:
Forward: 5'-CACGAATTCGCCACCATGGCCGGCCTGAACTGC-3'
Reverse: 5'-CAGATGCGGCCGCTTATTCTGCTGGCTCCATGGG-3'
PCR reactions is performed as the following using Pfu polymerase (Stratgene):
Stepl: 950C, 2min
Step2: 950C, 30 seconds
Step3: 590C, 30 seconds
Step4: 720C, 3min
Step5: RepTeat step 2 to 4 for a total 30 cycles
Step6: 72 C, 15min
Step7: 40C
PCR products were cloned into pcDNA3.1(+) vector via EcoRI and Notl and sequences were
confirmed using a set of three primers:
T7 primer: 5'-TAATACGACTCACTATAGGG-3'
CDCP1 F2 primer: 5'-GAGGTGTTCAAGCTGGAGGAC-3'
CDCP1 F3 primer: 5'-CTCTATCAAGCAGATCCAGGTG-3'
2) To clone CDCP1 into retrovirus vector, CDCP1 inserts were excised via EcoRI-Xhol and cloned
into pMIGw vector through EcoRI and Xhol sites. pMIGw vector was kindly provided by Dr. Patrick
Stern. To minimize recombination of the retrovirus, Stbl3 bacteria (Invitrogen) were used for
transformation and all bacteria were cultured at 300C.
3) Site-directed Mutagenesis using QuikChange XL kit (Stratagene)
Primers for Y734F point mutation:
Y734F- F: 5'- GAC TCC CAT GTG TTT GCA GTC ATG GAG GAC-3'
Y734F-R: 5'- GTC CTC CAT GAC TGC AAA CAC ATG GGA GTC-3'
Primers for Y743F point mutation:
Y743F-F: 5'- GAG GAC ACC ATG GTA TTT GGG CAT CTG CTA CAG-3'
Y743F-R: 5'- CTG TAG CAG ATG CCC AAA TAC CAT GGT GTC CTC -3'
Primers for Y762F point mutation:
Y762F-F: 5'- GAG GTG GAC ACC TTC CGG CCG TTC CAG -3'
Y762F-R: 5'- CTG GAA CGG CCG GAA GGT GTC CAC CTC -3
Primers for Y806F point mutation:
Y806F-F: 5'- CT GAG AGT GAA CCG TTC ACC TTC TCC CAT CCC-3'
Y806F-R: 5'- GGG ATG GGA GAA GGT GAA CGG TTC ACT CTC AG-3'
All mutagenses were performed in pcDNA3.1(+) vector, and sequences were confirmed
before excision of the insert via EcoRI and Xhol sites. Inserts were cloned into pMIGw vector via
EcoRI and Xhol sites.
Generation of CDCP1 knockdown constructs:
miR30-based RNAi constructs were developed for the Hannon-Elledge libraries (Stegmeier et al.
PNAS 102(37), p. 13212) and were obtained from Dr. Patrick Stern. The following primers
correspond to KD6 and KD10 described in the thesis.
KD6:
5'TGCTGTTGACAGTGAGCGACCTGTTACATCGTCATTTCTATAGTGAAGCCACAGATGTA
TAGAAATGACGATGTAACAGGGTGCCTACTGCCTCGGA-3'
KD10:
5'TGCTGTTGACAGTGAGCGCCCTGAGAATCACTTTGTCATATAGTGAAGCCACAGATGT
ATATGACAAAGTGATTCTCAGGATGCCTACTGCCTCGGA-3'
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PKC6 knockdown lentiviral constructs were obtained from OpenBiosystem (catalog number:
RHS4533).
Hairpin sequence for PKC6 KD7
CCGGGGCCGCTTTGAACTCTACCGTCTCGAGACGGTAGAGTTCAAAGCGGCCTTTTT
Hairpin sequence for PKC8 KD8
CCGGCAAGGCTACAAATGCAGGCAACTCGAGTTGCCTGCATTTGTAGCCTTGTTTTT
Hairpin sequence for PKC6 KD10
CCGGGCAGGGATTAAAGTGTGAAGACTCGAGTCTTCACACTTTAATCCCTGCTTTTT
CELL CULTURE
A375 cells and all derivatives were grown in E4Hg-10 medium, which contains basal E4Hg medium
and Glutamine and 10% fetal bovine serum. Cells were harvested in the absence of trypsin using
PBS/5mMEDTA.
Drug selections
MA2 cells infected with RNAi knockdown constructs were selected with 2.5pg/ml of puromycin two
days after virus infection. A375-vector control and A375-CDCP1 cells that harbor siRNA constructs
for PKC6 were selected with 5pg/ml of puromycin.
Retrovirus and Lentivirus Production
The day before transfection, 293 cells were plated into 6-well plate to approximately 25% confluence.
On the day of transfection, a total of 4pg of plasmids were used for each well, with 2ug being the
target vector, and 1.33pg of vector containing retrovirus or lentivirus Gag/Pol and 0.73pg of vector
containing virus Envelope. Transfection was performed using Fugene 6 (Roche) at ratio of 4:1
between Fugene 6 and vector. One day after transfection, the medium was changed and fresh 2ml of
E4Hg-10 were added. Two days and three days after transfection, virus particles in the supernatant
were collected by filtering through 2pm filter, and were used directly, or were stored at -800C till use.
Cell Infection
The day before cell injected, cells were plated in 6-well culture plates at approximately 25%
confluence. On the day of injection, 1ml of virus supernatant were add to the cell, with 1 pll of 5mg/ml
poBrene, and covered with Saran wrap. The plates were centrifuged in the table-top centrifuge at
30 C for 2 hours before returning to the incubator. The next day after infection, the supernatant
containing virus were removed and fresh medium were applied.
3-D Matrigel Culture -"on-top" method
We closely follow the protocol published by Debnath J, et al, Methods 30 (2003) 256-268. Briefly,
Matrigel (BD Biosciences) were thawed overnight on ice at 40C and mixed well using pre-chilled
pipette tips before use. Place 8-well glass chamber slides (NUNK, catalog # 177402) on ice, and
dispense 45pl1 of Matrigel in each well, spread with pipette tip till reaching all corners. Incubate the
glass slides at 370C for at least 30min. In the meanwhile, harvest and count cells and make single-
cell suspension of 25000cell/ml in E4Hg-10. Mix 200p1 of this cell suspension with 200pl of E4Hg-10
containing 4% Matrigel and dispense the whole 400pl into each well in 8-well chamber slides. Place
the chamber slides in 370C, 5% CO 2 incubator, change medium every 4 days and photograph on day
6 or day 10.
CELLULAR BIOLOGY PROTOCOLS
Adhesion Assay
96-well tissue culture plates were coated with 50pl of human plasma Fibronectin, vitronectin, or
20pg/ml poly-D-lysine diluted in PBS. The concentrations of each ECM proteins were indicated in the
296
Appendix D
experiments. After overnight coating at 40C, the plates were washed washed with PBS and blocked
with 5% BSA, before 50,000 cells were added to each well and incubated at 370C for indicated time
period. At the end of the adhesion assays, the plates were inverted on paper towel and allowed to
drain, and plates were washed carefully for three times with serum-free medium. Cells remain
adherent were fixed with formalin and stained with crystal violet before they were lysed in 0.1% Triton
X-100. Absorbance was recorded at A490 as indicator of cell numbers. In all cases, number of cells
remain adherent on poly-D-lysine (PLD)-coated wells were set as 100%.
Transwell Migration / Invasion Assay
Cells were serum-starved for 24 hours before harvesting using PBS/EDTA, and washed with serum-
free E4Hg and diluted to 5*10e5/ml in serum-free medium. 5001pI of E4Hg-10 (with 10% serum) were
added to the bottom of the transwell (8pm pore, Costar, catalog # 3422 for migration assay, BD
BioCoat Matrigel Invasion chamber, catalog #: 354480, 8um pore size for invasion assay) and 200pl
of cell suspension were added to the top of filter. The plates were returned to 370C incubator and
after 24 hours, cells on top of the filter were removed using cotton swap (QTip), and the cells were
fixed in formalin for 10min before staining with 0.1% crystal violet for 30min. Numbers of cells that
have migrated/invaded to the bottom of the filter were counted.
Scratch Miqration Assay
Cells were grown to confluent in 6-well plate and a scratch wound was made by attaching P20 pipette
tip to the vacuum line and aspirating cells, and the plates were washed three times with PBS and
replaced with E4Hg containing 2% serum. Pictures were taken at the time of scratching (time 0) and
after 24 hours (time24), distances of the open wounds were measured using OpenLab for time0 (DO)
and time 24 (D24). Distances migrated by the cells were calculated as (DO-D24)/2.
Soft Agar Colony Assay
In 24-weel plate, add 0.5ml of 0.4% agar diluted in E4Hg-10, and let cool to solidify (base agar).
Harvest cells and dilute to 1.2*lOe4cells/ml in E4Hg-10, and mix at 1:1 with 0.4% agar, and add 0.5ml
of the cell mixture to the top of base agar. After 7 days, number of colonies were counted under
microscope.
Anoikis Assay
Coat tissue culture plates with 12mg/ml of polyHEMA (Sigma) - for 24-well plate, add 100pI/well, and
for 6-well plate, add 500pl/well - and let evaporate in the hood till dry. The plates were washed with
PBS before 1*10e5 cells in 3ml serum-free E4Hg medium were added. The cells were returned to
37 0C incubator and after 24, 48, 72 hours, cells were harvested and resuspended in 100pI of Annexin
V binding buffer (BD PharmingenTM , Annexin V-PE Apoptosis Detection Kit I, Catalog # 559763), and
10 pl of 7- AAD and 5pl of Annexin V were added to the cells and incubated at room temperature for
15 minutes in dark. After that, 400pl of 1X binding buffer were added to the cells and analyzed by
flow cytometry within 30 minutes.
MOUSE INJECTION
Subcutaneous iniection
8- to 10-week-old NOD/SCID mice were anesthetized with an intraperitoneal injection of
Avertin/tribomethanol (Sigma). 200p1 of cell suspension (2.5*10e6 cells/ml) was injected to the
subcutaneous just above the pelvis of the mouse using 26G needle attached to 1 ml syringe.
Tail-Vein iniection
6- to 8-week-old NOD/SCID mice were kept in the mouse restraint, and 200pl of cell suspension
(5*10e6 cells/ml) was injected to the vein of the tail using 30G needle attached to 1 ml syringe.
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